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Abstract
A number of studies have reported that mast cells (MCs) play a critical role in 
host immune defence against bacterial infections. These studies have shown that mast 
cells have the ability to recognize and engulf bacteria. This project aimed to 
investigate the effect of MCs on selected microbial pathogens and the effect of these 
pathogen and their products on MCs and other cell types (RBL-2H3 and J774A.1 cell 
lines).
The phagocytic activity of sheep BMMC was studied by using bioluminescent 
strains of B. bronchiseptica and E. coli, and degranulation was followed by estimating 
|3-hexosaminidase release. The bioluminescent method is based on the assumption 
that the level of light output from bacteria is directly proportional to the number of 
viable bacterial cells. Comparison between light output of bioluminescent E. coli and 
B. bronchiseptica (Lux 95) in a short-run experiment (< 20 h) suggested that the 
correlation between bioluminescence output and optical density of the bioluminescent 
E. coli was not as good as with B. bronchiseptica (Lux 95). The difference is probably 
due to the fact that E, coli is a much more rapidly growing organism than B. 
bronchiseptica and will therefore reach stationary phase in a much shorter time.
A problem encountered in this study with B, bronchiseptica (Lux 95) was that 
it had been derived from a laboratory strain that may have partially lost its virulence 
attributes. Comparison of B. bronchiseptica (Lux 95) strain with B. bronchiseptica 
(Bvg" )^ and B. bronchiseptica (Bvg") strains revealed that it had more properties in 
common with the Bvg than the Bvg^ mode and may not, therefore, have been an ideal 
strain for this study. Construction of further bioluminescent derivatives of a wild-type 
(Bvg" )^ and avirulent (Bvg") strains should be considered for future work.
The bioluminescent method however, was shown to offer an easy and simple 
method of measuring the viability of the bacteria in real-time. Based on in vitro 
invasion assays, the kinetics of interaction between sheep BMMC and B. 
bronchiseptica (Lux 95) was followed. The data indicated for the first time, the 
presence of viable bioluminescent B. bronchiseptica within sheep BMMC, and this 
observation was confirmed by both viable count and TEM. For the first time, viable 
intracellular B. bronchiseptica (Lux 95) were shown within sheep BMMC. These 
results establish baseline data for individual and age-related variation in sheep 
BMMC phagocytic function, and form a basis for further evaluation of other functions 
such as chemotaxis, oxidative burst and clearance of bacterial infection by mast cells, 
either in sheep or other animal models.
Interaction of B. bronchiseptica strains with sheep BMMC was studied in vitro 
and their cytotoxicity was compared with that of other bacterial species. Virulence of 
B. bronchiseptica is controlled by the BvgAS genetic system which is shared with
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certain other species including B. pertussis. Comparison of B. bronchiseptica (Bvg^) 
and (Bvg') strains indicated that only the Bvg^ phase significantly reduced the 
viability of sheep BMMC and other cell types (RBL-2H3 and J774A. 1 cells). 
Furthermore, a significant p-hexosaminidase release was occurred after incubation of 
sheep BMMC with B. bronchiseptica (Bvg" )^ and this was much greater than the effect 
of the (Bvg") strain and certain other Bordetella species. However, it was observed for 
the first time, that B. trematum and B. hinzii could cause P-hexosaminidase release 
from RBL-2H3 cells, a model cell line for mucosal mast cells, similar to the effeet of 
B. bronchiseptica (Bvg^).
Cytotoxicity of different purified factors of Bordetella species (ACT, PRN, 
FHA and PT) towards sheep BMMC was investigated. The results showed that the 
cytotoxic effect of purified recombinant ACT depends on its enzymatic activity rather 
than on its cell-invasive activity alone. Inhibition of spontaneous p-hexosaminidase 
release was detected after incubation of RBL-2H3 cells with either rACT or PT. Also, 
both factors showed an increase in caspase-3/7 activity in RBL-2H3 cells, a novel 
finding. Caspase 3/7 and DNA fragmentation assays suggested that rACT could 
induce apoptosis in both sheep BMMC and RBL-2H3 cells, a novel finding.
The effect of rACT and PT on P-hexosaminidase release from RBL-2H3 cells 
induced by stimulation with B. bronchiseptica (Bvg"*") showed that these factors were 
working in different ways. rACT was able to inhibit P-hexosaminidase release from 
RBL-2H3 cells exposed to B. bronchiseptica (Bvg" )^, but this effect was temporary 
(i.e. it decreased with increasing time of incubation). In contrast, the effect of PT on 
P-hexosaminidsae release from RBL-2H3 cells exposed to B. bronchiseptica (Bvg" )^ 
appeared to be time-dependent. With increased time of pre-treatment a greater 
inhibitory effect was observed.
The J774A. 1 mouse macrophage-like cell line was used to study the effect of 
PT and rACT on survival of these J774A. 1 cells when infected by B. bronchiseptica. 
The results showed that pre-treatment with PT increased the survival of J774A.1 cells 
against B. bronchiseptica (Bvg" )^, but a similar concentration of rACT showed an 
enhanced cytotoxic effect. However, with lower doses of rACT, an increase in 
intracellular cAMP may cause impotence of phagocytic function in J774A.1 cells and 
then their ability to take up B. bronchiseptica (Bvg" )^ would be crippled and their 
survival enhanced.
The cytotoxic effect of B. bronchiseptica (Bvg" )^ on mast cells and other cell 
types, either directly or by inducing degranulation or apoptosis may suggest how this 
organisms overcome the natural defences of hosts and causes disease.
XXVII
C H A P T E R  O N E  
I N T R O D U C T I O N
1.1 Introduction to Bordetellae
1.1.1 The genus Bordetella
On the basis of several criteria including morphological, physiological and 
antigenic properties and DNA hybridization studies, nine species are recognized to be 
closely related and, accordingly, are classified in the genus Bordetella: B. pertussis, B. 
bronchiseptica, B. parapertussisim (human-adapted B. parapertussis), B. 
parapertussiSiyy, (ovine-adapted B. parapertussis), B. avium, B. hinzii, B. holmesii, B. 
trematum, B. petrii and B. ansorpii (Fig. 1.1) (Ko et a l, 2005; Mattoo and Cherry, 
2005). Members of these species are Gram-negative, minute (0,2 micron X 0.7 
micron) coccobacilli, which are strictly aerobic (except B. petrii) and have a 
respiratory but never exhibit fermentative metabolism. Their optimal growth 
temperature is between 35 and 37 °C (Gerlach et a l, 2001). B, avium, B. 
bronchiseptica and B. hinzii are motile by pertrichous flagella (Parton, 2005).
1.1.1.1 B. pertussis
B. pertussis causes whooping cough in human. Bordet and Gengou reported 
the isolation of B. pertussis in 1906, although they had observed the organism 
microscopically in the sputum of a patient with pertussis in 1900 (Bordet and Gengou 
1906, cited by Parton, 2005). The organism was originally classified as Haemophilus 
pertussis due to its growth requirement for blood but it was later found not to need the 
growth factors X (haemin) and V (nicotinamide adenine dinucleotide). The organism 
was later reclassified in its own genus Bordetella (Moreno-Lopez 1952, cited by 
Parton, 2005).
1.1.1.2 B, bronchiseptica
B. bronchiseptica was first isolated during the first decade of the 20th century 
(Ferry 1910, cited by Parton, 2005) from dogs suffering from distemper. It is also now 
known to infect many mammals, including humans, although infection in humans is 
relatively uncommon and usually occurs in immunocompromised hosts (Woolfrey 
and Moody, 1991). Some cases of humans infected with B. bronchiseptica have been 
related to contact with infected animals (Gueirard et a l, 1995).
.:;.Î
1.1.1.3 B. parapertussis hu or ov
B. parapertussis was isolated originally from a mild case of human pertussis
(Bradford and Slavin, 1937 cited by Parton 2005). More recently, ovine strains of B.
. . . .  parapertussis, distinct from human strains, have been identified from lambs showing
signs of pneumonia (Cullinane et a l, 1987). It has been reported that B. parapertussis 
is capable of causing typical whooping cough with paroxysmal coughing, whooping 
and vomiting (Hoppe, 1999).
IB. pertussis, B. parapertussis and B. bronchiseptica can cause similar diseases in the upper respiratory tract of man or animals. These disease involves the interaction 
of the bacteria with ciliated tracheal epithelial cells, resulting in ciliostasis and killing 
of the ciliated cells and damage to the respiratory epithelium (Preston, 2005). 
liowever, their host specificities vary dramatically. B. pertussis infects only humans; 
B. parapertussis strains can be classified in two groups, one of which infects only 
humans and one of which infects only sheep. B. bronchiseptica causes respiratory 
infections in a wide variety of mammals and birds but only rarely in humans (Mattoo 
and Cherry, 2005).
1.1.1.4 B. avium
B. avium is the aetiological agent of rhinotracheitis of birds, a disease of the
upper respiratory tract which resembles pertussis infection in humans. It was reported
that B. avium is similar to B. pertussis in that both species produce a dermonecrotic 
,toxin and a tracheal cytotoxin, and production of dermonecrotic toxin is regulated by 
nicotinamide and MgSO^ (Gentry-Weeks et a l, 1988).
1.1.1.5 B. hinzii
B. hinzii, a species similar to B. avium, can cause secondary or opportunistic 
respiratory infections in poultry. Bacteremia caused by B. hinzii has been described in 
an immunocompromised human without evidence of respiratory infection (Cookson et 
a l, 1994). B. hinzii was also isolated in four biliary specimens collected over 6 
months from a liver transplant recipient with cholangitis. The isolates were resistant to 
most beta-1 actam antibiotics and fluoroquinolones (Arvand et a l, 2004)
1.1.1.6 B. holmesii
B. holmesii isolates were originally classified as CDC non-oxidiser group 2 
(i.e. vernacular name given to gram-negative, non-oxidizing, brown soluble pigment 
producing rods), but were found to conform to the description of the family 
Alcaligenaceae and the genus Bordetella (Weyant et a i, 1995). The first isolates were 
from the blood of patients that had underlying clinical conditions but, more recently, 
this species has been isolated from the sputum of immunocompromised patients and 
from nasopharyngeal specimens of patients suspected to have pertussis (Mazengia et 
a l, 2000).
1.1.1.7 B. trematum
B. trematum has been isolated from ear infections and skin wounds in human. 
It was found to be more closely related to the type species of the genus Bordetella (B. 
pertussis) than to the type species of the genus Alcaligenes (Alcaligenes faecalis) and 
had the general characteristics of members of this family (Vandamme et al., 1996).
1.1.1.8 B. petrii
B. petrii strain was originally isolated from the environment and is capable of 
anaerobic growth (von Wintzingerode et a l, 2001). The only clinical isolate of B. 
petrii was from a patient with mandibular osteomyelitis (Fry et a l, 2005). B. petrii is 
suggested to be closely related to an environmental progenitor of Bordetellae and 
further characterisation of this species may provide interesting information on the 
early evolution of members of this genus (Gerlach et a l, 2001).
1.1.1.9 B. ansorpii
This is the most recently identified strain, based on the evaluated phenotypic 
and genotypic characteristics. It is a Gram-negative bacillus, originally designated 
SMC-8986^, which was isolated from the purulent exudate of an epidermal cyst and 
was classified as a new Bordetella species, namely Bordetella ansorpii although its 
pathogenic significance remains unknown (Ko et a l, 2005).
Figure 1.1 Phylogenetic relationships among nine known Bordetella species
Schematic presentation of phylogenetic relationships among nine of the known 
Bordetella species inferred from 16S rRNA sequences (Ko et a l, 2005).

1.1.2 G\'owi\\ oî Bordetellae
Bordetellae are aerobic (except B. petrii) with the growth optimum temperature 
ranging between 35-37”C. Exposure to a temperature of is lethal within 30 min 
and the heat-labile toxin is destroyed. They are non-fermentative to carbohydrates. 
Primary isolation of the whooping-cough bacillus was first achieved by Bordet and 
Gengou (1906) from sputum. It was cultured in a glycerol-potato-extract agar medium 
without peptone but containing 50% defibrinated horse blood. A similar medium 
(Bordet-Gengou medium) is still commonly used. Various solid and liquid media 
without blood have also been developed for bulk growth of cells, for the production of 
toxin-containing supernates and for genetic studies. The amount of blood in Bordet- 
Gengou medium may be reduced to 15 -  20 % for easier detection of haemolysis 
around the colonies (Parton, 2005).
Stainer and Scholte (1970) developed a chemically-defined liquid medium 
containing glutamic acid, proline and cystine together with ascorbic acid, niacin, 
glutathione, salts and Tris buffer. A modified Stainer-Scholte medium was used to 
induce B. pertussis to release substantial quantities of PT and FHA into culture 
supernates and thereby facilitate the manufacture of an acellular vaccine containing 
these components (Sato et a l,  1984). However, Stainer and Scholte medium did not 
permit growth from small inocula (Stainer and Scholte, 1970). Imaizumi et al (1983) 
overcame this difficulty by adding dimethyl-[3-cycIodextrin (DM(3CD) after which it 
was solidified with agarose to constitute the first defined medium for B. pertussis to 
allow reliable the growth of separated colonies from diluted inocula (Imaizumi et a i, 
1983).
Media suitable for B. pertussis growth are suitable for the other species. The 
time of visibility and size of the colonies differs between the species. For example, B. 
pertussis colonies appear after 3 days of growth on BG agar but B. bronchiseptica 
colonies become visible after 1 day (Parton, 2005). It was reported that both B. 
bronchiseptica and B. avium may be able to survive in the environment as they are 
capable of growing in low nutrient conditions such as natural waters or phosphate- 
buffered saline (Porter et a i, 1991). Modulation of many virulence factors of B. 
bronchiseptica in response to environmental signals has been shown (Passerini De 
Rossi et a l, 2001). For example, growth on nutrient agar and brain heart infusion 
broth induced the avirulent phase of B. bronchiseptica and growth on tryptic soy agar
induced an intermediate phase. Moreover, upon growth of the Bordetella in the 
laboratory, so-called phase variants may arise spontaneously with a strain-dependent 
frequency; these variants are no longer able to express the virulence factors owing to 
mutations in the virulence gene locus (Stibitz et a l  1988; Monack et a l  1989). 
Different Bordetella species can be distinguished from each other due to several 
phenotypic differences such as growth on blood-free peptone agar, motility, urease 
activity and nitrate reduction (Table 1.1).
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1.1.3 Properties of B. bronchiseptica cluster
Based on several criteria including morphological, physiological and antigenic 
properties, DNA hybridization studies and phage typing, B. pertussis, B. 
parapertussis and B. bronchiseptica were recognized to be closely related and, 
accordingly, were classified in the genus Bordetella as the B. bronchiseptica cluster 
(Gerlach et a l, 2001). All three species cause upper respiratory disease which 
involves the interaction of the bacteria with ciliated tracheal epithelial cells, resulting 
in ciliostasis and killing of the ciliated cells (Mallory and Horner 1913, cited by 
Gerlach 2001). The three species can be distinguished from each other due to several 
phenotypic differences such as growth conditions, urease activity and nitrate reduction 
(Table 1.1). Furthermore, it was reported that the genetic diversity between these three 
Bordetella species is quite limited (Gerlach et a l, 2001).
1.1.3.1 Genetic variation
Recently, the genome sequences of B. pertussis (Tohama-I), B. parapertussis 
(12822, human strain) and 5. bronchiseptica (RB50, rabbit strain) were successfully 
completed (Parkhill et a l, 2003). Comparison of these genomic sequences show that a 
large deletion event has occurred in the B. pertussis chromosome. A genetic locus in 
B. bronchiseptica which encodes several amino acid transporters is entirely missing in 
B. pertussis. In fact, in Southern blots this gene locus was found to be present in B. 
bronchiseptica, B. parapertussis and B. avium isolates, but no signal could be 
obtained with B. pertussis DNA (Schneider et a l, 2002). In addition, it has been 
reported that both B. pertussis and B. parapertussis are predominantly differentiated 
from B. bronchiseptica by large, species-specific regions of difference, many of 
which encode or direct synthesis of surface structures, including lipopolysaccharide 
which may be important determinants of host specificity (Cummings et a l, 2004). 
Importantly, the genomes of B. pertussis and B. bronchiseptica differ considerably in 
size and their size correlates with their gene coding capacities: B. bronchiseptica 
encodes 1191 more genes than B. pertussis. Pseudogenes, remnants of once active 
genes that have been silenced by mutation are common in B. pertussis. B. 
bronchiseptica has only 18 pseudogenes, whereas B. pertussis has 358. (Preston, 
2005). Furthermore, B. pertussis and B. bronchiseptica contain a largely identical core 
genome. The genome sequencing project identified 114 genes as being unique to B.
pertussis. But genome analysis by microarray-mediated genomic typing revealed that 
103 of the 114 genes were in fact found in other strains of B. bronchiseptica and only 
11 genes in B. pertussis have been found to be species-specific (Cummings et a i,
2004).
Many of the genes that are present in B. bronchiseptica but absent from B. 
pertussis appear to encode surface proteins (those located in the bacterial outer 
membrane and thus exposed to the bacterium's environment). In addition, others 
encode proteins involved with smal 1-molecule uptake and utilization; for example, a 
large number of proteins enable iron uptake. Both kinds of proteins are important for 
colonization of and persistence in a mammalian host, and it is likely that B. 
bronchiseptica has the ability to utilize a wide range of nutrients and to adhere to a 
wide repertoire of different molecules. This might explain the broad host range of B. 
bronchiseptica (Preston et a l, 2004).
It is well known that B. pertussis is a human pathogen and B. bronchiseptica is 
an animal pathogen. Indeed, B. bronchiseptica is rarely found associated with 
humans. Plowever, preliminary analysis of microrray-mediated genomotyping data 
(Cummings et a l, 2004) has shown that there are no genes associated with adaptation 
to humans in B. pertussis. It is possible that this species expresses certain genes 
differently than B. bronchiseptica and that this difference is responsible for infection 
in humans. Furthermore, the genes expressed in B. bronchiseptica that are 
pseudogenes in B. pertussis are presumably responsible for functions required for 
existence in the environment or in a non-human host (Preston, 2005).
1.1.3.2 Antigenic differences
Many of the virulence factors characterized in the Bordetellae are common to 
both B. pertussis and B. bronchiseptica. These include adhesins, such as filamentous 
haemagglutinin (FHA), pertactin (PRN), tracheal colonization factor and fimbriae, 
and toxins, such as adenylate cyclase hemolysin, dermonecrotic toxin and tracheal 
cytotoxin. Other virulence factors are expressed by just one species, such as pertussis 
toxin and serum-resistance protein expressed by B. pertussis or a type-HI secretion 
system expressed by B. bronchiseptica (Galan and Collmer, 1999; Smith et a l, 2001). 
The type-HI secretion systems (i.e. specific mechanisms for the export of virulence 
factors into host cells) in B. bronchiseptica. encode the full, intact operon, which is
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expressed and the operon in B. pertussis does not seem to be expressed (Stockbauer et 
a i, 2003). Comparisons of many of these virulence factors in either B. pertussis or B. 
bronchiseptica identify differences that might bear on the different host ranges and 
virulence profiles of these organisms.
O-antigens, i.e. the membrane-distal domains of some lipopolysaccharides are 
involved in many bacterial species in evasion of host innate and acquired immunity 
mechanisms. The genetic region of the biosynthetic locus probably directs differential 
modification of the lipopolysaccharide molecule, possibly forming the genetic basis 
for 0-antigenic variation. O-antigens have been reported to be expressed in B. 
bronchiseptica (Di Fabio et a l, 1992). The O-antigen biosynthesis locus is not 
expressed in B. pertussis (Preston et a l, 1999).
Regarding flagella (i.e. virulence factors for number of organisms), B. 
bronchiseptica is motile and encodes a full flagellar operon, whereas the flagellar 
operon of B. pertussis is inactivated by multiple pseudogenes, leading to a lack of 
motility (Parkhill et a l, 2003).
1.1.4 Phase variation
The variable expression of virulence factors in B. pertussis, known as phase 
variation, was originally divided into four phases. Phase I and phase II of B. pertussis 
were toxic for guinea pigs whereas phase III and IV were not (Leslie and Gardner, 
1931, cited by Parton, 2005). Nowadays, only phase I and phase IV are generally 
recognised. Phase IV strains are avirulent-phase mutants and no longer express the 
virulence factors associated with phase I strain of B. pertussis (Parton, 2005). Phase 
variation indicates a reversible alteration in the genotype caused by frame shift 
mutations in which the virulent bacteria simultaneously lose the ability to synthesize 
toxins and other factors associated with pathogenicity (Weiss and Falkow, 1984). 
Another type of variation by Borcletella has been termed antigenic modulation (Lacey, 
1960, cited by Lax, 1985). This involves changes similar to phase variation, but is 
readily reversed by changing the growth environment (Fzzell et a l, 1981). Thus phase 
I cells grown in the medium containing NaCl express all the above virulence 
characteristics and are termed X-mode; phase I cells grown in medium containing 
MgS0 4  do not express these characteristics and are termed C-mode. Therefore, 
expression of virulence factors in Borcletella is influenced by the growth conditions in
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vitro (Idigbe et a i, 1981) which is called antigenic modulation, or may be due to 
genetic mutation (Weiss and Falkow, 1984). In this regard, it was known the 
transposon Tn5 induces mutations by insertion of its DNA sequence into other DNA 
sequences. Tn5 has been shown to cause polar mutations, that is, it disrupts synthesis 
of all gene products encoded at sites distal from the insertion site when there is more 
than one gene product encoded in an operon (Berg et a l, 1980). Insertion into a 
structural gene usually results in a nonfunctional gene product (Kleckner, 1981, cited 
by Weiss et a l, 1983). Tn5 was introduced into B. pertussis by using a suicide 
plasmid vector (which is unable to replicate in this species). The advantage of 
transposon mutagenesis is that usually only a single gene is mutated and the site of the 
insertion is marked both physically by the transposon DNA and genetically with an 
antibiotic resistance. A transposon mutagen was used in order to produce a series of 
B. pertussis strains that were deficient in individual virulence factors including 
filamentous haemagglutinin, haemolysin and pertussis toxin and in a virulence 
regulatory locus (Weiss et a l, 1983). Hybridization experiments suggested that, with 
avirulent-phase mutants obtained by Tn5 mutagenesis, a single region located at a 
unique site in the B. pertussis chromosome controls the phase change. All 
recombinants which had reacquired the virulence-associated factors had also lost Tn5, 
indicating that loss of Tn5 was required to restore the virulent phenotype of B. 
pertussis. The Tn5 avirulent-phase mutants behave as if the insertion interrupted the 
function of a transacting gene product which is required for the expression of the 
other virulent-phase genes (Weiss and Falkow, 1984).
1.1.4.1 BvgAS signal-transduction system
Based on genetic analysis, evidence suggested that both phenotypic (antigenic) 
modulation and phase variation are under the control of a single genetic locus, which 
was originally designated as the vir (virulence) locus, that in turn was able to alter 
expression of virulence determinants. The vir locus was later termed the bordetella 
virulence gene (bvg) locus (Arico et a l, 1989; Stibitz and Yang, 1991). The predicted 
products of this locus are homologous to a family of regulatory proteins that transmit 
sensory signals using a conserved two-component motif. Originally bvgA, B and C 
were described. The bvgA gene encodes a transcriptional activator and, in the absence 
of modulating conditions, it was proposed that BvgC activated BvgA by
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phosphorylation (Arico et a l, 1989). It was later discovered that Bvg B and Bvg C 
were part of one larger protein and this was termed BvgS (sensor). BvgS is a 135-kDa 
membrane-bound protein with an N-terminal periplasmic region flanked by two 
transmembrane sequences that hold the protein in position within the cytoplasmic 
membrane (Stibitz and Yang, 1991). BvgA is a 23-kDa cytoplasmic protein. The 2- 
domain structure of BvgA (called the activator), consisting of a receiver at the N- 
terminus and C-terminal helix-turn-helix (HTH) motif, is characteristic of response 
regulators (Stibitz and Yang, 1991).
The BvgS periplasmic domains senses external stimuli (perhaps via 
dimerization) and triggers a series of phosphorylation steps starting with 
autophosphorylation in the transmitter domain at a conserved histidine residue. This is 
followed by the transfer of the phosphate group to a conserved aspartic acid in the 
receiver domain, which transfer it to a histidine at the C-terminal domain (Roy et a l, 
1990; Uhl and Miller, 1996). BvgA is activated by the transfer of a phosphate group 
from the C-terminus of the BvgS to conserved aspartic acid in the BvgA N-terminal 
receiver domain. Upon phosphorylation, BvgA positively regulates the bvgAS operon 
and other virulence factor promoters, including bvgR, by binding to a heptameric 
target sequence (Karimova and Ullmann, 1997). Phosphorylated BvgA can bind DNA 
via its HTH domain and it functions as a transcriptional activator and repressor 
resulting in the expression of distinct phenotypic phases (Cotter and DiRita, 2000). 
Similar regulation of virulence factors is also known to occur in B. parapertussis and 
B. bronchiseptica and B. avium (Parton 2005). A number of virulence-repressed genes 
{vrg) have now been identified but, in most cases, their functions are unknown. They 
are regulated by the bvg-locus in reciprocal fashion to the virulence-activated genes 
{vag) encoding the virulence factors (Parton, 2005). The regulation of virulence 
expression via the bvg locus is summarized in Fig. 1.2.
The virulent phenotype (Bvg^ phase) is characterised by the expression of all 
Bvg-activated adhesins and toxins. In contrast, the avirulent phase type (the Bvg" 
phase) is characterised by the absence of all Bvg-activated adhesins and toxins. The 
signals to which Bvg responds in vivo are unknown but, in vitro, the system is 
activated by growth at 37°C and silenced either by growth below 27°C or by adding 
sulphate ions or nicotinic acid to the growth medium, regardless of growth 
temperature (Coote, 2001).
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To directly address the role of Bvg-mediated signal transduction in B. 
pertussis pathogenesis, a Bvg ' phase-locked mutant was constructed and compared 
with the wild type for its ability to colonize the respiratory tracts of mice. This 
experiment showed that the Bvg phase of B. pertussis was necessary and sufficient 
for respiratory infection (Martinez de Tejada et a i, 1998). Therefore, the Bvg “ phase 
appears not to play a role in virulence at least in the mouse (Akerley et a l, 1995). 
However, there is some indication of the presence of a Bvg' (intermediate) phase and 
this has been assigned to wild type B. bronchiseptica able to grown in submodulating 
concentrations of magnesium sulphate or nicotinic acid. This phase is characterised by 
the absence of the Bvg-repressed phenotype and the presence of some but not all Bvg- 
activated virulence factors (Cotter and Miller, 1997; Cotter and DiRita, 2000).
The contribution of the BvgAS system to phenotypic differences in either B. 
pertussis or B. bronchiseptica was compared. Both B. pertussis and B. bronchiseptica 
contain a nearly identical BvgAS system that mediates a biphasic transition between 
virulent Bvg and avirulent Bvg ' phases. In the Bvg phase, the two species express 
a similar set of adhesins and toxins (except PT which is restricted to B. pertussis) 
(Matto and Cherry 2005). The Bvg “ phase of B. bronchiseptica is characterized by 
expression of motility and several metabolic processes invloved in redox reactions 
and amino acid transport (McMillan et a l, 1996) and survival under nutrient limiting 
conditions (Cotter and Miller, 1994). An environmental reservoir for B. pertussis 
seems less plausible, as these strains are more fastidious and appear to be confined to 
transmission by the respiratory droplet route (Mattoo and Cherry, 2005).
Recently, it was reported that the Bvg system also contributes to biofilm 
formation of B. bronchiseptica which is important for attachment of microorganisms 
to a surface (Irie et a l, 2004). It was shown that B. bronchiseptica forms the strongest 
biofilm phenotype in vitro in the intermediate (Bvg') phase. This was demonstrated by 
the formation of a strong biofilm phenotype by wild-type bacteria primarily in Bvg' 
mode growth conditions and also by the consistently high biofilm levels formed by a 
Bvg'-phase-locked mutant regardless of growth conditions. (Irie et a l, 2004).
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Figure 1.2 Borcletella virulence gene {bvg) structure
Bvg-mediated virulence regulation. The bvg locus encodes two proteins BvgS and 
BvgA with homology to 2-component signal-transduction proteins. BvgS is a sensor 
protein spanning the inner membrane and BvgA is a cytoplasmic response regulator 
protein able to bind to the DNA. The virulent mode (Bvg''') is due to incoming signals 
which are transmitted to the cytoplasmic portion of BvgS which autophosphorylates 
(P) and then activates BvgA. Then, allows transcription of the virulence-activated 
gene {vags) and causes repression of other, virulence-repressed gene (vrg.y). In the 
avirulent (Bvg ') mode, only the vrgs are expressed (adapted from Coote, 2001).
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1.1.5 Virulence factors of Bordetella
Numerous bacterial factors important in the pathogenicity of Bordetella 
species and the process of this disease have been characterized (Table 1.2).
1.1.5.1 Adhesin factors
1.1.5.1.1 Filamentous Haemagglutinin (FHA)
FHA appears to be the major adhesin of B. pertussis and similar but not 
identical proteins are present in B. bronchiseptica (Spears et a l, 2003). Genes 
encoding other FHA-like proteins have been identified in the genome sequences of B. 
bronchiseptica, B. pertussis and B. parapertussis (Parkhill et a l, 2003). Also, it has a 
filamentous structure, supported by electron microscopy studies, giving the 
dimensions of the molecule as 2 nm wide and 45-50 nm long (Makhov et a l, 1994). 
Mature FHA (220 kDa) derives from a larger precursor, FhaB (367 kDa) that 
undergoes post-translational maturation (Gnedin et a l, 2000).
FHA is both surface-associated and secreted from virulent Bordetella. It is 
efficiently secreted through a peptide-dependent pathway, with the help of one 
specific outer membrane accessory protein, FhaC (Guedin et a l, 2000). Most B. 
bronchiseptica isolates produce and secrete FHA at significantly lower levels than B. 
pertussis. This may reflect differences in strength of their respective FHA promoters, 
in the primary structure or function of FhaC accessory proteins, or in the overall cell 
envelop structure (Locht et a l, 1993).
Makhov and co-workers (1994) proposed that FHA consists of a polypeptide 
chain folded into a monomeric hairpin, comprising head, shaft and tail regions. The 
model predicts that whilst the head contains the terminal domains and the tail the 
important RGD (arginine-glycin-aspartic acid) sequence for adhesion, the shaft is 
composed of tandem 19-amino acid residue repeat regions R1 (38 cycles) and R2 (13 
cycles) which maintain the structural integrity of the molecules. FHA also possesses a 
carbohydrate recognition domain (CRD), which has a unique affinity for glycolipids, 
and mediates attachment to ciliated epithelial cells as well as cultured Chinese 
hamster ovary cells (Prasad et a l, 1993).
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1The tail region of FHA includes a binding moiety specific for complement 
receptor 3 (CR3) integrins present on the surface of macrophages. The RGD 
sequences in the tail region facilitates binding to CR3 and in turn leads to 
phagocytosis via CR3, which enables the bacteria to avoid triggering an oxidative 
burst and thereby permitting them to survive intracellulaiiy whilst evading the 
immune system (Reiman et a l, 1990). FHA is also known to bind the human serum 
protein C4BP. This protein is known as a regulator of complement activation and acts 
to inhibit the classical complement pathway, preventing the formation of the 
membrane attack complex (Berggard et a l, 1997).
A recent report suggested that FHA may be a critical virulence factor in 
facilitating pathogen persistence in the respiratory tract by suppressing or delaying the 
development of cell-mediated immunity (McGuirk and Mills, 2000). In this regard, it 
has been shown that purified FHA inhibited XL-12 secretion by a macrophage cell line f
or alveolar macrophages in response to E. coli or B. pertussis lipopolysaccharide.
Antibodies to FHA or dénaturation of FHA abrogated the inhibitory effect. The
suppressive effect of FHA was specific for XL-12, since the production of T F-a, XL- |
'3:6 and XL-10 was not suppressed, and production of XL-6 and XL-10 was up-regulated. AtAntibody-blocking studies revealed that the inhibitory effect of FHA on XL-12 S
'"V
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production was dependent on XL-10. Further work confirmed these findings by
showing that FHA was able to stimulate secretion of T Fa and may induce apoptosis f'Ï1
in human monocyte-like cells, macrophages and bronchial epithelial cells (Abramson -'p
et a l, 2001).
Recently, it has been demonstrated that FHA in B. bronchiseptica is both ;::r
necessary and sufficient for mediating adherence to a rat lung epithelial cell line, and 
necessary but insufficient for colonisation of the tracheas of anaesthetised rats (Cotter 
et a l,  1998). Cotter et a l  suggested that the role of FHA was to overcome the P:
clearance mechanism of the mucociliary escalator.
Xt was reported that FHA alone will protect against B. pertussis infection. Mice 
that were immunised with FHA by intraperitoneal or intramuscular inoculation, then pp
challenged with an aerosol of B. pertussis, had significantly reduced bacterial
colonisation in the lungs and trachea (Kimura et a l, 1990). FHA is currently included ;|
in multicomponent acellular pertussis vaceines. 2I
s
1.1.5.1.2 Fimbriae
Fimbriae (pili), also known as agglutinogens, are long filamentous protrusions 
whieh extend from the bacterial cell surface and facilitate a variety of binding 
capabilities. Bordetella species express fimbriae of at least four serotypes, Fim2, 
Fim3, FimX and FimA (Mattoo and Cherry, 2005). In both B. pertussis and B. 
bronchiseptica the required loeus for fimbriae secretion and assembly (fimB,JimC and 
fimD) is located between//înB and fhaC (Mattoo et a l, 2000). The BvgAS locus 
(Figure 1.2) encodes a two-component system which is responsible for the control of 
expression of fiin l and fin ii, Fimbrial phase variation is characterised by switching 
between a high and a low level of expression of a particular fim  gene. A region 
located 100 bp upstream of the fim3 gene is involved in the regulation, where a 
stretch of cytosines (Cs) upstream of \ho fim promoter would be subject to slip-strand 
mispairing during chromosome replication (Willems et a l, 1990).
It was suggested that fimbriae may mediate the binding of Bordetella to the 
respiratory epithelium via the major fimbrial subunits and to monocytes via the tip 
protein FimD. It was shown that purified B. pertussis fimbriae, with or without FimD, 
were able to bind to heparan sulphate, chondroitin sulphate, and dextran sulphate, 
sugars that are ubiquitously present in the mammalian respiratory tract (Geuijen et a l, 
1996). Heparin-binding domains within the Fim2 subunit were identified and found to 
be similar to those of the eukaryotic extracellular matrix protein, fibronectin. Studies 
by Hazenbos et al. suggest that FimD mediates the binding of non-opsonized B. 
pertussis to VLA-5 on the surface of monocytes, which then causes activation of CR3, 
thereby enhancing its ability to bind FHA (Hazenbos et a l, 1995).
The role of fimbriae in the pathogenesis of Bordetella species has been 
investigated using mutant strains. A B. bronchiseptica mutant that was unable to 
express fimbriae was defective in its ability for efficient establishment and persistent 
colonisation of the rat trachea (Mattoo et a l, 2000). However, the FimD deficient 
mutant strain was found to produce 75% less FHA than the wild type and this may 
have been partly responsible for the difference in colonisation behaviour. The FHA 
mutant was far less affected in its colonisation ability than the FimD deficient strain 
so it was assumed that colonisation defects were due to the lack of this minor subunit 
(Geuijen et a l, 1997). Moreover, the serum antibody profiles of animals infected with 
Fim deficient B. bronchiseptica differ qualitatively and quantitatively from those of 
animals infected with wild type B. bronchiseptica suggesting that fimbriae may play
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important roles, not only in adherence, but also in the nature and magnitude of the 
host immune response to B. bronchiseptica infection (Mattoo et a l, 2000).
Recently, it was demonstrated that the B. pertussis fimbriae protected mice 
against B. parapertussis infection although less efficiently than against B. pertussis 
infection. Furthermore, this result indicates that B. pertussis and B. parapertussis 
fimbriae are antigenically distinct (Willems et a l, 1998).
1.1.5.2 Autotransporters factors
Bordetella strains express a number of related surface-assoeiated proteins 
belonging to the autotransporter secretion system. The autotransporter family includes 
functionally diverse proteins such as pro teases, adhesins, toxins, invasins, and lipases, 
that appear to direct their own export to the outer membrane of the bacterium 
(Flenderson and ataro, 2001). Autotransporter proteins consist of an -terminal 
region (passenger domain), which confers the effector functions, and a conserved C- 
terminal region (8-barrel), which is required for the secretion of the passenger proteins 
across the membrane. It was reported that, after cleavage of the -terminal signal 
sequence in the periplasm, the C terminus folds into a 8-barrel in the outer membrane, 
forming an aqueous channel for transport of the passaged domain to the cell surface 
(Mattoo and Cherry, 2005). The autotransporters of Bordetella form a homologous 
family defined on the basis of their conserved C termini and the possession of RGD 
motifs of the type implicated in integrin binding (Henderson and ataro, 2001).
B. bronchiseptica encodes the greatest number of autotransporters and both B. 
pertussis and B. parapertussis have fewer au to transporter genes and more 
autotransporter pseudogenes (non-functional) than B. bronchiseptica (Parkhill et a l, 
2003). The autotransporter factors that have been best characterised are pertactin 
(PR), tracheal colonisation factor (Tcf), virulence-activated gene 8 (Vag8), 
bordetella resistance to killing protein A (BrkA) and Bordetella au to transporter 
protein C (BapC) (Figure 1.4).
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Figure 1.3: Bordetella autotransporters factors
Schematic diagram showing similarities between the autotransporter proteins in 
Bordetella. Numbering relates to the amino acid position and Arginine-Glycine- 
Aspartatic acid (RGD) sites are indicated. Pertactin is also shown with its 
immunodominant region 1 (GGXXP) and immunodominant region 2 (PQP)x, adapted 
from Packard, 2004.
PRN: Pertcatin
BrkA: Bordetella resistance to killing protein A 
VagS: Virulence-activated gene 8 
Tcf: Tracheal colonisation factor 
BapC: Bordetella autotransporter protein C 
RGD: arginine-glycine-aspartic acid
Outer membrane localisation signal
C-terminal region
Putative cleavage site
Signal sequence
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Figure 1.3: Different forms of Autotransporters factors. Adapted from Packard, 2004.
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1.1.5.2.1 Pertactin
Pertactin (PR) was the first autotransporter member of Bordetella species to 
be identified and studied. Mature pertactin is a 68- kDa protein in B. bronchiseptica 
(Montaraz et a l, 1985), a 69- kDa protein in B. pertussis (Charles et a l,  1989), a 70- 
kDa protein in B. parapertussis (Li et a l, 1991; Finn and Stevens, 1995). Pertactin 
has been proposed to play a role in attachment to mammalian cells such as Chinese 
hamster ovary (CFIO) cells and this attachment involved the participation of RGD 
(Arg-Gly-Asp)-containing sequence within the molecule (Leininger et a l, 1991; 
Emsley et a l,  1994). The gene prnA which encodes PR is controlled by the bvg 
locus (Charles et a l, 1994). Investigation of the role of pertactin in B. bronchiseptica. 
pathogenesis revealed that pertactin was involved in the cytotoxicity of this organism 
for mononuclear phagocytic cells (FIeckenstein et a l, 1996). Furthenuore, no 
evidence was found for the contribution of pertactin in B. pertussis adhesion to either 
bronchial or laryngeal cells (van den Berg et a l, 1999). PR is the only 
autotransporter for which the crystal structure has been determined (resolution, 2.5 
A). The protein comprises a 16-stranded parallel p-helix with a V-shaped cross- 
section and is the largest P-helix known to date (Emsley et a l, 1996).
Pertactin has been shown to be an immunoprotective antigen, being used in 
subunit vaccines to protect mice from respiratory challenge with virulent B. pertussis 
(ovotny et a l, 1991; Roberts et a l, 1993). Pertactin is included in some of the 
multicomponent acellular pertussis vaccines that are currently in use (van Loo et a l, 
2002).
1.1.5.2.2 Bordetella resistance to killing protein A
A B. pertussis mutant (BPM2041) which has Tn5 lac inserted in a bvg- 
regulated gene was found to be at least 10-fold more susceptible to human-serum 
killing than the wild type B. pertussis. This new locus was named brk {bordetella 
resistance to killing) (Fernandez and Weiss, 1994). The brk locus was cloned and 
sequenced, and it was found to encode two divergently transcribed open reading 
frames (ORFs), termed BrkA and BrkB and both ORFs were reported to be necessary 
for serum resistance. BrkA shows 29% identity to pertactin and has two RGD motifs 
in addition to a conserved proteolytic processing site and an outer membrane-targeting 
signal. Like pertactin, BrkA is involved in adherence and invasion (Fernandez and
22
Weiss, 1994). Despite the similarities, a pertactin mutant was found to be not as 
sensitive to serum killing as the BrkA or BrkB mutants.
In Southern blot analysis, brkAB sequences were found in B. bronchiseptica 
and B. parapertussis but not in B. avium. Clinical isolates of B. bronchiseptica and B. 
parapertussis were serum resistant, and wild-type strains possessing additional copies 
of the brk locus were two- to five fold more resistant to serum killing (Fernandez and 
Weiss, 1998). Although BrkA confers resistance to killing by complement in B. 
pertussis, interestingly, loss of BrkA in B. bronchiseptica did not confer sensitivity to 
complement-mediated killing (Rambow et a l, 1998).
1.1.5.2.3 Tracheal colonisation factor A
This protein is encoded by the tcfA gene. When a strain of B. pertussis 18323 
lacking this protein was used to infect mice by an aerosol challenge, the number of 
bacteria isolated from the tracheas was decreased 10-fold when compared with the 
parent 18323 (Finn and Stevens, 1995). Furthermore, by southern blot analysis of 
chromosomal DA from strains of B. bronchiseptica and B. parapertussis, using a 
probe derived from tcfA, strong hybridization was seen only to B. pertussis DA. 
Thus, Tcf appears to be a unique virulence factor of B. pertussis (Finn and Stevens, 
1995).
1.1.5.2.4 Virulence-activated gene 8
Vag 8 was initially discovered by transposon mutagenesis and shown to be 
positively controlled by the bvg locus (Finn and Amsbaugh, 1998). Vag-8 deficient B. 
pertussis was found to be significantly less able to colonise and persist in the lungs 
and tracheas of mice when compared to B. pertussis 18323^ (Finn and Amsbaugh,
1998). The complete gene is present in the B. parapertussis genome (Parkhill et a l, 
2003).
1.1.5.2.5 Bordetella autotransporter protein C
BapC is a newly identified member of the autotransporter family. BapC has 
properties in common with the other members of the autotransporter family 
particularly BrkA (Blackburn, 2000; Bokhari, 2002). The B. pertussis bapC gene 
sequence was originally submitted to GenBank as a putative autotransporter protein 
gene (accession number AF081494) named bap5 (Blackburn, 2000).
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The potential role of bapC was identified using a B. pertussis bapC mutant 
strain. The mutant strain was more susceptible to complement-mediated killing in 
vitro than the parent strain and was less able to colonise the respiratory tract in a 
mouse model when compared to the parent strain (Bokhari, 2002).
1.1.5.3 Toxins
1.1.5.3.1 Adenylate cyclase toxin (ACT)
It was shown for the first time that B. pertussis in phase I produce a factor able 
to inhibit phagocytosis of opsonized targets and chemotaxis of PM. The new factor 
was named PM-inhibitory factor (PIF) (Utsumi et a i, 1978). Then, it was showed 
that Bordetella species are able to produce a soluble, heat-stable, and highly active 
adenylate cyclase. This enzyme is internalized by phagocytic cells and catalyzes the 
unregulated formation of adenosine 3',5'-monophosphate (cyclic AMP), thereby 
disrupting normal cellular function (Confer and Eaton, 1982). Transposon Tn5 was 
used to isolate mutants of B. pertussis. One haemolysin mutant had no detectable 
adenylate cyclase activity. The new deficient strain of B. pertussis was avirulent in an 
infant mouse model of infection. (Weiss et a i, 1983). The adenylate cyclase (AC) of 
B. pertussis was first shown to be associated with toxic activity by its ability to 
attenuate neutrophil superoxide production and bactericidal capabilities (Galgiani et 
a i, 1988). However, immune effector cells such as neutrophils, monocytes, 
macrophages, dendritic cells and natural killer cells are thought to be the primary 
target (Mattoo and Cherry, 2005). B. parapertussis and B. bronchiseptica have AC 
activity similar to that of B. pertussis but the toxins are antigentically distinct (Parton,
2005).
1.1.5.3.1.1 ACT structure
The adenylate cyclase toxin (or CyaA) (Figure 1.5) is a bifunctional protein 
with the calmodulin-stimulated adenylate cyclase activity residing in the amino- 
terminal, and haemolytic and invasive activity located in the carboxy-terminus (Glaser 
et a l, 1991). CyaA is encoded by the cyaA gene, and the cya operon (Fig. 1.6) is 
composed of cyaA and three accessory genes cyaB, D and E, that are located 
downstream and are necessary for the secretion of CyaA (Goyard and Ullmann, 
1991). Furthermore, it was shown that the cyaC gene in B. pertussis, homologous to
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the the hlyC gene in E. coli (Figure 1.6) was required for the haemolytic activities of 
the cyaA gene product (Barry et al., 1991).
CyaA (or ACT) is a member of the repeats in toxin (RTX) family of calcium- 
dependent, pore-forming cytolysin (Coote, 1992). These toxins are characterised by a 
series of tandem repeats (41 repeats) that are rich in glycine (G) and aspartic acid (D) 
residues. The toxin (AC) has a molecular mass of 177 kDa, is a single polypeptide of 
1706 amino acids composed of a 400 amino acids -terminal domain, and responsible 
for the camodulin-simulated enzymatic activity (Ladant, 1988), and a 1307 amino 
acids C-terminal domain that is capable of forming pores, allowing the -terminus to 
enter many eukaryotic cells where it catalyses the conversion of endogenous ATP into 
cAMP. Within the AC domain there are two subdomains designated T25 and T18 
(Figure 1.4). The T25 domain contains the catalytic site where ATP is bound. T18 
contains the calmodulin binding site (Mock and Ullmann, 1993b).
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1.1.5.3.1.2 Activation of CyaA by CyaC
The cya locus of B. pertussis is composed of five genes: cyaA encodes the 
bifunctional CyaA protein, whose secretion requires the expression of the downstream 
cyaB, D and E genes. Activation of CyaA requires the expression of a fifth gene, cyaC 
located upstream from cyaA (Barry et a l, 1991). In this regard, mass spectrometry 
was used to study the activation of ACT from B. pertussis. It was shown that ACT 
requires the product of an accessory gene in order to express their biological 
activities. In this study, wild-type AC toxin was modified by amide-linked 
palmitoylation on the epsilon-amino group of lysine 983. This modification was 
absent from a mutant in which the accessory gene had been disrupted. A synthetic 
palmitoylated peptide corresponding to the tryptic fragment (glutamine 972 to 
arginine 984) that contained the acylation blocked AC toxin-induced accumulation of 
adenosine 3',5'-monophosphate, whereas the non-acylated peptide had no effect 
(Hackett et a l, 1994). These data suggest that palmitoylation at this site represents the 
modification that is required for the toxicity and haemolytic activity of CyaA.
Figure 1.4 Structural organisation of the B. pertussis adenylate cyclase toxin.
Structural organization of the B. pertussis adenylate cyclase (CyaA) toxin. umbers 
represent amino acid residues. The catalytic domain (AC) is enlarged to show the T25 
and TI8 subdomains. CBS corresponds to the main calmodulin-binding site, and 
boxes I, II and III represent regions involved in catalysis, (Ladant and Ullmann,
1999).
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Figure 1.5 Comparison of the B. pertussis {cya) locus and the E. coli (hly) operon 
The cya operon is composed of cyaA and three accessory genes cyaB, D and E, that 
are located downstream and are necessary for the secretion of CyaA, (Mock and 
Ullmann, 1993).
B. pertussis
cyaC cyaK cyàB cyàD cyaE
E, coli
hlyC hlyA hlyB hlyD
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1.1.5.3.1.3 Recombinant ACT production by E. coli
Production of active CyaA was achieved in a reconstructed E. coli system by 
cloning the 5 different genes of the cya locus on appropriate vectors under the control 
of promoters and E. co/Lspecific translation initiation signals. This step was necessary 
because B. pertussis is a slow growing organism and its genetic analysis was still 
limited at the time of this work. It was shown that CyaA produced alone in E. coli had 
no invasive or haemolytic activity and that the CyaC gene product was required to 
render the CyaA holotoxin invasive and haemolytic in the reconstructed system (Sebo 
et a i, 1991). The aggregation of the CyaA proteins enabled a simple purification 
procedure by extracting with 8 M urea (Glaser et a l, 1989).
In another study, an efficient T7 RA polymerase system was used for 
overexpression of cyaA and cyaC in E. coli (Westrop et a l, 1996). The E. coli host 
(BL21/DE3) strain was used for expression of different forms of AC. Generally, this 
strain contains chromosomally-located X.DA expressing the gene encoding T7RA 
polymerase under the control of the inducible lacUV5 promoter. Addition of 
isopropyl-1-thio-p-D galactoside (IPTG) to a growing culture induces the polymerase 
which, in turn, transcribes the target DNA in the plasmid via a T7 promoter. It was 
demonstrated that E. coli (BL21/DE3) which contain plasmids pGW44 and pGW54 
produced CyaA and CyaC in amounts that were similar to those obtained when the 
plasmids were carried separately (Westrop et a l, 1996). Furthermore, a third 
compatible plasmid (pGW 44/188) was constructed from pACM 188 (Ladant et a l, 
1992) and encoded the CyaA protoxin that lacked enzymic activity due to a dipeptide 
amino acid insertion in the N-terminal end. pGW44/188 was co-expressed with
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pGW54 to produce a full-length invasive toxin with little enzymic activity (pGW 
44/188,54). These constructs enabled the production of the different forms of AC (or 
CyaA) in E. coli without the inconvenience of growing B. pertussis and free from 
other B. pertussis components that could have displayed different effects.
Different forms of recombinant AC toxin produced in E. coli have been highly 
purified by using several methods. The most effective methods were a combination of 
DEAE sepharose column chromatography followed by phenyl sepharose column 
chromatography. Both methods were combined because it helped to remove 
contaminating proteins from E. coli (Lawrence et a l, 2002).
: :,2
1.1.5.3.1.4 Interaction of ACT with target cells
AC toxin (or CyaA) can penetrate a wide range of cell types, including 
mammalian erythrocytes that lack membrane trafficking (Gray et a l, 1999). Entry of 
AC toxin into target cells is a two-step process. In the first step, CyaA binds to the cell 
surface, possibly to gangliosides. This requires both the integrity of the carboxyl- 
terminal region of CyaA and the CyaC-dependent palmitoylation of Lys983. Binding 
of toxin to erythrocytes will eventually lead to cell lysis, due to ability of CyaA to 
form pores (Gray et a l, 1998). The second step comprises the actual translocation of 
the catalytic domain of the bound CyaA through the plasma membrane of the cells. 
This process is dependent upon the temperature (it only occurs above 15-20°C), the 
membrane potential of the target cells and the presence of millimolar concentrations 
of calcium ions (Mock and Ullmann, 1993a). It was shown that extracellular calcium 
was absolutely essential for ACT entry into target cells, and the penetration was 
blocked by neutralising, anti-adenylate cyclase antibodies (Rogel et a l,  1989).
AC toxin (or CyaA) of B. pertussis uses the MB2 integrin (CD! lb/CD 18) as a 
cell receptor. Binding of CyaA to the surface of various hematopoietic cell lines 
correlated with the presence of the MB2 integrin on these cells. Moreover, binding of 
CyaA to various murine cell lines and human neutrophils was specifically blocked by 
anti-CD 11b monoclonal antibodies (Guermonprez et a l, 2001). It was shown that 
increase of intracellular cAMP level and cell death triggered by CyaA intoxication 
was also specifically blocked by anti-CD I lb monoclonal antibodies.
Interaction of AC toxin and target cells requires a close association of live 
bacteria with target cells and the active secretion of AC toxin and is not dependent on 
the surface-associated AC toxin (Gray et a l, 2004). Wild type B. pertussis (BP338) 
treated without or with gentamicin for 2 h at 37°C were tested for their ability to 
intoxicate J774 cells and intracellular cAMP levels were assessed. Treatment with 
gentamicin reduced the number of viable organisms and intoxication by B. pertussis 
was reduced by 98% without affecting the binding of these bacteria to target cells. 
The amount of measurable AC enzymatic activity on intact gentamicin-treated 
bacteria was 80% of untreated bacteria. This modest reduction is most likely because 
of the fact that untreated bacteria were growing normally for an additional 2 h during 
the gentamicin treatment and accumulating more surface-associated AC toxin. Also, it 
was shown that gentamicin was not having a detrimental effect on AC toxin. In 
addition, irradiation was applied to B. pertussis (BP338). It was found to behave
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equivalently to those bacteria treated with gentamicin. Both numbers of viable 
bacteria and intoxication was decreased by 80%. However, there was no effect on 
binding of the bacteria to target cells or the amount of AC enzyme activity associated 
with the intact killed organism. These data show that viable bacteria are necessary for 
delivery of AC toxin to the target cell (Gray et a i, 2004).
Once inside the cell, AC toxin moiety is activated by the endogenous 
eukaryotic protein calmodulin, then causes unregulated synthesis of cAMP from 
adenosine triphosphate (ATP) which interfering with normal cell functions (Parton 
2005).
1.1.5.3.1.5 Role AC toxin
It is important to mention that both B. bronchiseptica and B. pertussis produce 
AC toxin. It was reported that both a virulent B. bronchiseptica (9.73H+) strain and a 
virulent B. pertussis (Tohama) strain possessed AC, hemolytic and invasive activities 
that were not significantly different (Gueirard and Guiso, 1993). Immunological 
properties, were tested by using Western bloting. Sera of B. pertussis infected mice 
collected 30 days post infection recognized the B. pertussis ACT but not the B. 
bronchiseptica ACT. Previous data suggest that immunological and protective 
properties of AC toxin from B. bronchiseptica are different from that of B. pertussis 
(Gueirard and Guiso, 1993).
The role that AC toxin may have in the pathogenicity of B. pertussis has been 
investigated. It was demonstrated that AC deficient B. pertussis had a reduced ability 
to cause lethal infection in infant mice (Weiss and Falkow, 1984). Furthermore, it was 
shown that an AC mutant B. pertussis 348, was rapidly cleared from mouse lungs 
with no viable bacteria remaining 10 days post challenge (Goodwin and Weiss, 1990). 
This observation suggested that AC toxin is critical for colonisation and initiation of 
infection. AC toxin may be involved in B. pertussis-mdwcod lung inflammation and in 
apoptotic death of alveolar macrophages. The resulting apoptosis may play a role in 
the initiation of infection (Gueirard et a i, 1998). It was determined that both domains. 
AC and haemolysin, were necessary to induce macrophage apoptosis as a mutated 
protein containing only the haemolysin domain was unable to induce apoptosis 
(Bachelet et a l, 2002). It was found that CyaA targets one or more aspects of innate 
immune response, one of which is probably neutrophils. This was further investigated 
and it was demonstrated that CyaA inhibits both Fc receptor-mediated attachment and
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phagocytosis of B. pertussis by neutrophil (Weingart et a l, 2000). Further study
■•f.ishowed that FHA mediates attachment of B. pertussis to neutrophils, but adenylate 
cyclase toxin blocks phagocytosis (Weingart and Weiss, 2000).
1.1.5.3.1.6 Protective role of AC toxin
It was demonstrated that immunization with specific anti-5, pertussis
adenylate cyclase antibodies or with purified B. pertussis secreted adenylate cyclase
protected mice against a lethal respiratory challenge with B. pertussis or B.
parapertussis (Guiso et a l, 1989). It has been shown that B. pertussis is killed
following phagocytosis by neutrophils. Therefore, identifying the antigens that
stimulate the immune response to promote phagocytosis and killing by neutrophils
could help to improve pertussis vaccines. In these regards, it was reported that
neutralizing antibodies to ACT, in conjunction with opsonzing antibodies, could be
beneficial in promoting immunity to pertussis by enhancing the phagocytic defence
mechanisms (Weingart et a l, 2000).
Unlike with most microorganisms, opsonization does not appear to promote
phagocytosis of wild-type B. pertussis by neutrophils and the bacteria remain
extracellular. Weingart et al. (2000) reported that opsonization with human immune
serum inhibited both attachment and phagocytosis of the wild-type B. pertussis to
neutrophils. But, when monoclonal antibodies (i.e. that had been demonstrated to be
most potent in neutralizing ACT activity) was added to the opsonized bacteria caused
a statistically significant increase in the number of extracellular bacteria attached to
the neutrophils as well as in the number of phagocytosed bacteria relative to the
number in opsonized controls. In contrast, monoclonal antibodies which inhibited 
.hemolysin activity but not adenylate cyclase toxin activity did not elicit a significant 
increase in the numbers of bacteria attached or phagocytosed. These results indicate 
that antibodies which neutralize adenylate cyclase toxin activity mediate a beneficial 
effect on phagocytosis by neutrophils but only when combined with human 
opsonizing antibodies.
The effect of co-administration to mice of the fully functional acyl ated CyaA 
toxin or a toxin lacking adenylate cyclase enzymic activity (CyaA*) with other 
antigens from B. pertussis (PT, pertussis toxoid (PTd), FHA and PRN). CyaA* 
enhanced the serum IgG antibody responses to each of these antigens whereas, with 
acylated CyaA, only anti-PRN antibody titres showed a modest increase. Peritoneal
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macrophages and spleen cells, collected at 2 weeks post-immunisation, were cultured 
and tested for nitric oxide (O) and IFgamma production, respectively, after 
stimulation in vitro with heat-killed B. pertussis cells or CyaA proteins. O and IF-y 
production were higher in cells collected from mice immunised with CyaA or CyaA* 
in combination with a PT, FHA and PR antigen mixture than from those taken from 
mice injected with antigen mixture alone, again with CyaA* acting as a better 
adjuvant than CyaA. The apparent enhancement of immune responses to the antigen 
mixture by CyaA* in particular was not paralleled by increased protection of mice 
against aerosol challenge with B. pertussis (Macdonald-Fyall et a l, 2004).
Recently, it was demonstrated that CyaA has adjuvant activity promoting Th2 
(T helper type 2) and Trl (T regulatory type 1) responses and the enhancement of 
antigen-specific IL-10 producing cells (Ross et a l,  2004). Furthermore, it was shown 
that acylated AC toxin (A-CyaA) and non acyl ated AC toxin (A-CyaA) enhanced T- 
lymphocyte receptor (TLR-ligand) induced IL-10 and inhibited IL-I2, and TF-alpha 
production by macrophages and DC. Furthermore, both A-CyaA and A-CyaA 
promoted the induction of murine IgGl antibody, Th2, and regulatory T cells against 
coadministered antigens in vivo (Boyd et a l, 2005). This report examined the 
influence of acylation and enzymatic activity on the adjuvant effect of CyaA in vivo 
and it demonstrated that A-CyaA and A-CyaA exert similar effects on innate cells 
and that CyaA with an inactive adenylate cyclase domain (iAC-CyaA), lacks 
immunomodulatory activity in vitro. BALB/c mice were immunized once or twice 
with keyhole limpet hemocyanin (KLH) alone or with A-CyaA, A-CyaA, or iAC- 
CyaA. Analysis of antibody titers revealed that A-CyaA and A-CyaA enhanced 
KLFI-specific IgG responses to the same extent, whereas iAC-CyaA had significantly 
reduced adjuvant activity. The adjuvant effeet was not thought to be due to residual 
LPS in the toxin preparations as enhancement of antibody response to KLH was also 
observed in TLR-4-defective C3H-HeJ mice. It was concluded from the data collected 
from this work that lack of acylation does not compromise the adjuvant properties of 
CyaA or its ability to direct the induction of T cell and antibody responses in vivo 
(Boyd et a l, 2005).
32
1.1.5.3.2 Pertussis Toxin
Pertussis toxin (PT) is an important virulence factor in B. pertussis and is 
actively secreted. Even if not expressed, the PT gene is also present in B. 
bronchiseptica and B. parapertussis but they appear to be transcriptionally silent due 
to defective promoters or activator (Bvg A) binding site (Arico and Rappuoli, 1987; 
Parkhill et a l, 2003). However, two atypical strains of B. bronchiseptica have been 
described that appeared to have produced the toxin during infection (Stefanelli et a l, 
1997).
PT is an ADP-ribosylating toxin, and is structured as a hex amer composed of 
five subunits, designated S1-S5 relative to their electrophoretic mobilities in 
denaturing gels (Locht and Keith, 1986). All the genes for PT subunits are closely 
linked in an operon and are probably expressed in a precise ratio which is similar to 
that of other AB5 toxins such as, cholera and E. coli heat-labile toxins (Locht and 
Keith, 1986). Secretion of PT across the outer membrane requires a specialized 
transport apparatus the pertussis foxin /iberation, ptl, locus (Farizo et a i, 1996). In 
this process, PT and Ptl proteins form a complex for spanning the inner and outer 
membranes and passing through the peptidoglycan layer (Burns, 1999).
PT is important for virulence of B. pertussis in mouse models of infection. 
One probable target is the phagocytic cells, in limiting their migration to the site of 
infection in the respiratory tract and in reducing their phagocytic potential and killing 
mechanisms (Schaeffer and Weiss, 2001). Upon receptor binding, PT is taken into the 
eukaryotic cell by receptors-mediated endocytosis and undergoes vesicular trafficking 
and membrane translocation to its target proteins on the inner surface of the plasma 
membrane. PT needs to be activated to exert its toxic effects. This requires ATP and 
the reduction of a disulphide bond in the S 1 subunit to liberate it from the B pentamer 
(Hazes et a l, 1996).
Many of the activities of PT depend on the enzymatic activity of the SI 
subunit. Based on extensive in vitro characterization of PT, the SI subunit in its 
reduced form has been shown to catalyze the transfer of ADP-ribose from NAD to the 
subunit of guanine nucleotide-binding proteins (G proteins) in eukaryotic cells. PT 
and their inactivation effects on G proteins such as Gi, Gt (transducin), and Go lead to 
different biological effects. Biological effects of PT attributed to the disruption of 
these signalling pathways include histamine sensitization, enhancement of insulin
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secretion in response to regulatory signals, and both suppressive and stimulatory 
immunological effects (Mattoo and Cherry, 2005).
The precise role of PT and its action in the host cells still remain obscure 
(Hewlett, 1997). It was reported that PT enzymic activity was necessary for full 
colonisation of B. pertussis in the mouse model (Carbonetti et a l, 2003). Chemically- 
detoxified PT has been demonstrated to be protective in the mouse model against 
intracellular and aerosol challenges of B. pertussis (Sato et a l, 1984) and this 
molecule has been included in all acellular pertussis vaccine preparations (Hewlett, 
1997). Plasmid D	A expressing PT (SI) subunit was evaluated for the ability to 
induce protection against PT challenge or B. pertussis infection in mice. This D	A 
vaccination induced anti-PT IgG production, inhibited leukocytosis-promoting 
activity and induced protection in mice against intracerebral challenge with B. 
pertussis (Kamachi e ta l ,  2003).
1.1.5.3.3 Dermonecrotic Toxin (DNT)
The dermonecrotic toxin is heat-labile at 56°C. The products of the dnt genes 
of B. pertussis and B. bronchiseptica are 1464 amino acids in length with a MW of
160.6 kD and there are only 11 residues different between the two polypeptides 
(Pullinger et a l, 1996). D	T activity is found in 4 species, and genetic studies 
showed that B. pertussis, B. parapertussis and B. bronchiseptica produce D	Ts 
which are essentially indistinguishable in their physicochemical, serological and 
biological properties whereas that of 5. avium is similar (Walker and Weiss, 1994).
D	T (heat-labile) toxin induces localized necrotic lesions in mice and other 
laboratory animals when injected intraderm all y and is lethal for mice at low doses 
when administered intravenously (Parton, 1985). A B. bronchiseptica strain deficient 
in D	T production was associated with considerably less turbinate atrophy and 
pneumonia in pigs compared to the wild-type parent and also had reduced ability to 
colonize the nasal cavity (Brockmeier et a l, 2002). The various effects of D	T on 
target cells include stimulation of D	A and protein synthesis and formation of actin 
stress fibres and focal adhesions. These effects are thought to be mediated by its 
activity as a transglutaminase catalyzing the deamidation or polyamination of GTP- 
binding protein Rho and other members of the Rho family involved in regulation of 
the cytoskeleton. These result in constitutive activation of the Rho proteins (Masuda 
et cd., 2002). Furthermore, Cys 1305 has been identified as an essential amino acid for
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the enzymatic activity of D
T, as the introduction of a mutation at Cys 1305 
eliminated the activity (Kashimoto et a i, 1999).
The role of D
T in the pathogenicity of B. pertussis is still unclear. However, 
the dermonecrotising activity appears to be due to a specific constrictory effect on 
vascular smooth muscle tissue. This effect on similar tissue in the respiratory tract 
could induce a local inflammatory reaction and could account for some of the 
pathology of pertussis (Hodgson et a l, 2005).
1.1.5.3.4 Endotoxin (Lipopolysaccharides)
Endotoxins, or lipopolysaccharides (LPSs), are major components of the outer 
membrane of Gram-negative bacteria. They generally consist of complex mixtures of 
related lipopolysaccharides of which the lipid region (lipid A) is covalently linked to a 
polysaccharide comprising a core region to which may be linked an O-chain having a 
variable number of subunits. Different species of Bordetella express different LPS 
molecules, which may be a factor in the high level of species specificity demonstrated 
within this genus (van den Akker, 1998).
The endotoxin of B. pertussis has been serologically characterized, and the 
structures of the constituent lipid A and cores have been documented (Caroff et a l, 
1994; Caroff et a l, 2000). B. pertussis endotoxin has no O-chains, unlike those of 
most other species of the Bordetella. Furthermore, LPS produced by Bordetella 
bronchiseptica is similar to that of B. parapertussis, as they both express temperature- 
dependent O antigen (Di Fabio et a l, 1992).
There is no clear understanding of the role of endotoxin in Bordetella 
infections although it may act in concert with other Bordetella toxins. However, its 
importance is suggested by the observation that changes in LPS structure in B. 
bronchiseptica are controlled by the BvgAS virulence regulatory system (van den 
Akker, 1998). B. bronchiseptica also produces host-specific LPS molecules, with 
isolates from dogs having more heterogeneous LPS structures than isolates from pigs 
(van den Akker, 1998). A human isolate of B. bronchiseptica displays a different LPS 
profile than that of a rabbit isolates. Subsequent isolation of B. bronchiseptica from 
the same human patient over 2 years has shown a variation in LPS profiles during the 
course of infection (Le Blay et a l, 1997).
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The role of lipopolysaccharide in virulence of Bordetella species was studied. 
It was well known that the wlb gene cluster which is composed of 12 genes, is 
required for biosynthesis and addition of the trisaccharide in B. pertussis and B. 
bronchiseptica and the O-antigen-like repeat in 5. bronchiseptica and B. 
parapertussis (Allen and Masked, 1996). So, deletion of the wlb locus results in the 
loss of membrane-distal polysaccharide domains in the three subspecies of 
bordetellae. Different species of the B. bronchiseptica cluster with mutantions in wlb 
genes were used to investigate the roles of distal LPS structures in respiratory tract 
infection by bordetellae. Each mutant was defective compared to its parent strain in 
colonization of the respiratory tracts of BALB/c mice by B. pertussis and B. 
parapertussis. Interestingly, the B. bronchiseptica De I taw lb strain was defective, 
compared to the wt strain, in colonization of the respiratory tracts of BALB/c mice, 
but did not differ from the wt strain in its ability to colonize the respiratory tracts of 
B-cell- and T-cel 1-deficient mice, suggesting that wlb-dependent LPS modifications in 
B. bronchiseptica modulate interactions with adaptive immunity. These data show 
that biosynthesis of a full-length LPS molecule by these three bordetellae is essential 
for the expression of full virulence for mice. In addition, the data indicate that the 
different distal structures modifying the LPS molecules on these three closely related 
subspecies serve different purposes in respiratory tract infection, highlighting the 
diversity of functions attributable to LPS of gram-negative bacteria (Harvill et a l, 
2000).
Mutants of B. bronchiseptica and B. parapertussis that were deficient in O- 
antigen biosynthesis both lacked the complement resistance associated with the wild 
type but only the B. parapertussis mutant had reduced ability to colonize the mouse 
respiratory tract (Burns et a l, 2003).
1.1.5.3.5 Tracheal cytotoxin
Tracheal cytotoxin (TCT) is released during log phase broth culture of B. 
pertussis and consists of 15 amino acid residues as well as two amino sugars. The 
selective biological activity of TCT has been studied in tracheal organ cultures by 
light and electron microscopy. A series of pathological changes precedes the eventual 
extrusion of ciliated cells, while all other epithelial cell types appear ultrastructurally 
normal. TCT also causes a dose-dependent inhibition of DA synthesis in cultured 
hamster trachea epithelial cells (Goldman and Herwaldt, 1985). Tracheal cytotoxin is
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an unusually small toxin with a mass of 921 Da. The toxin is known to be expressed 
by B. pertussis, B. parapertussis, B. bronchiseptica and B. avium. TCT is a 
disaccharide-terapeptide derived from gl y copeptide which is released from the cell 
envelope. Its structure is -acetylglucosaminykl ,6-anhydro--acetylmuramylalanyl- 
'y-glutaminyl-diaminopimelylalanine, which is identical to the Neisseria gonorrhoeae 
ciliostatic an h y dropepti dogl y can (Cookson et al., 1989).
The activities of TCT have been studied in vitro using in hamster tracheal 
epithelial cells. It has been demonstrated that the lactyl tetrapeptide part of the 
molecule is responsible for full toxic activity (Luker et a l, 1995). The abnormal 
release of large amounts of TCT by Bordetella spp. causes an exaggerated response 
that results in respiratory tract pathology (Flak et a l, 2000). The toxicity conferred by 
TCT is indirect, being caused by the induction of host cells to produce IL-1 which 
stimulates nitric oxide (O) production. This activated host cell O acts by 
destroying iron-dependent enzymes, eventually inhibiting mitochondrial function and 
DA synthesis in nearby host cells (Heiss et a l, 1994). TCT also has a toxic effect on 
other cells, impairing neutrophil function at low concentrations and conferring toxic 
activity in larger quantities (Cundell et a l, 1994).
1.1.6 Type III secretion system
A large number of gram-negative pathogenic bacteria secrete virulence factors 
via the type III secretion system (TTSS) during infection of host cells (Lee, 1997). 
Type III secretion system allow bacteria to translocate bacterial effector proteins 
directly into the plasma membrane or cytoplasm of eukaryotic cells through a needle­
like injection apparatus (Cornelis and Van Gijsegem, 2000), then these effector 
proteins alter normal host cell signalling cascades and other processes (Muller et a l, 
2001). The Bordetella TTSS locus, termed the bsc locus, includes 22 genes, which 
encode a secretion apparatus that spans the bacterial cytoplasmic and outer 
membranes, as well as translocator proteins that form pores in the eukaryotic cell 
membrane and a type III secretion-specific ATPase required for apparatus assembly 
and secretion (Kimbrough and Miller, 2002).
A functional type III secretion system has been discovered in B. 
bronchiseptica. Wild type B. bronchiseptica, but not the TTSS mutant, was shown to 
induce cytotoxicity against L2 cells that were established from rat lung epithelial cells
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(Yuk et a i, 1998). Biochemical and morphological analyses demonstrate that the B. 
bronchiseptica Type III secretion system induces a cell death pathway that resembles 
necrosis rather than apoptosis and is distinct from that of Yersinia, Shigella and 
Salmonella (Orth et a l, 1999). Furthermore, a TTSS mutant of 5. bronchiseptica was 
unable to colonise over the long term in the tracheas of immunocompetent mice and 
this mutant was unable to induce cell death in 1774 macrophage (Yuk et a l, 2000).
Recently, an additional locus consisting of four genes, btrS, btrU, btrW  and 
btrV {btr encode for "Bordetella type III regulation"), situated 3' to the bsc locus was 
identified and shown to encode regulatory proteins for the Bordetella Type III 
secretion system. Like the bsc genes, these new genes are also transcriptionally 
activated by BvgAS. Deletions in btrU and btrW  revealed an uncoupling of protein 
expression from secretion, since these mutants expressed type III proteins at normal 
levels but failed to secrete them (Mattoo et a l, 2004).
In addition, it was shown that TTSS in B. bronchiseptica participate in 
modulation of innate immune response (Legarda et a l, 2005). Wild type B. 
branchispetica express TTSS, shows suppression of the activation of the signalling 
pathway that is induced upon LPS (lipopolysaccharide) stimulation, whereas a TTSS- 
defective strain did not. These results suggest a mechanism for bacterial evasion of
the innate immune response in the airway, which could allow for the observed
persistent colonization of 5. bronchiseptica (Legarda et a l, 2005).
1.1.7 Bordetella infections
B. pertussis, B. parapertussis and B. bronchiseptica are highly related 
subspecies that colonize the respiratory tracts of mammals. B. pertussis has 
exclusively adapted to the human host while B. parapertussis comprises two distinct 
subspecies that infect either humans or sheep. In contrast to host-restricted members 
of the Bordetella genus, B. bronchiseptica, which appears to represent the 
evolutionary progenitor, infects the respiratory tracts of a broad range of mammals 
(Parton, 2005). B. bronchiseptica is associated with a variety of chronic respiratory 
diseases in laboratory animals. This contrasts with the acute human disease that 
results from B. pertussis and B. parapertussis infections.
Pertussis is primarily a disease of the respiratory tract and is a severe
debilitating disease in young children. It still afflicts up to 40 million children
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,worldwide (Ivanoff and Robertson, 1997). Infection with B. pertussis is initiated by 
the attachment of organisms to the cilia of epithelial cells of the upper respiratory tract 
(Weiss and Hewlett, 1986) and most patients with fatal cases of pertussis have 
bronchopneumonia. The initial stages of infection with B. pertussis entail congestion 
and infiltration of the mucosa by lymphocytes and polymorphonuclear leukocytes.
The lumens of the bronchi contain inflammatory debris. Various reports suggest that 
the initial pulmonary lesion in pertussis is a lymphoid hyperplasia of peribronchial 
and tracheobronchial lymph nodes (Lasfargues et a i, 1993). Pertussis or whooping 
cough is responsible for severe morbidity and mortality world wide mainly in 
unvaccinated communities. Fortunately, global immunization schemes are steadily 
reducing morbidity and mortality due to pertussis infection (WHO: 
www.who.int/vaccincs-diseases/diseases/pertussisvaccine.htm) (Parton, 2005).
1.1.7.1 Infection and the immune response
The aim of the immune response against extracellular pathogens is to destroy
and clear the pathogen and to neutralise its products. In vertebrates, immunity against
pathogens or against other foreign substances is divided into two categories; innate
immunity or acquired immunity (Roitt et a l, 1996). Innate immunity is present from
birth and includes such functions as physiological barriers, cellular defences and
inflammation, whereas acquired immunity develops as a consequence of an encounter
with a foreign substances. B (develop in bone marrow) and T (develop in thymus)
lymphocytes are responsible for the specificity exhibited by the acquired immune
response. B-cells produce antibodies (Ab) which recognises to foreign bodies called 
.antigens (Ag) and bind to them (i.e. humoral immunity). T-cells divided into different 
cells; cytotoxic T-cells which destroy the infected cells or helper T-cells which 
activate the infected cells by production of different chemical compounds such as 
cytokines (acquired immunity).
:
1.1.7.2 Immunity in pertussis
Immunity against pertussis infection could be developed either by natural 
infection or by vaccination. atural infection with B. pertussis is followed by an 
increase in the concentrations in serum of IgA, IgG, and IgM antibodies to specific 
antigens as well as to preparations of the whole organism (Mattoo and Cherry, 2005).
".I
Evidence of a role for antibodies has been shown in the murine model, particulary for 
PT and FHA. Early work showed the protective activities of FHA and FT and it was 
found that antisera containing antibodies to PT were able to protect mice against 
intracerebral challenge, whereas sera lacking anti-PT antibodies but containing anti- 
FHA antibodies was unable to protect mice (Munoz et a l, 1981). The role of 
antibodies in pertussis infection was studied by using Ig-defective mice (Ig 7“ mice)
(Mahon et a l, 1997). They demonstrated that B celFdeficient mice were unable to 
clear bacteria after aerosol infection when compared with the control mice. The Ig 7" 
mice failed to mount an IgG antibody response whereas the wild-type mice developed 
B. p e r t L i s s i s serum antibody by the day 24 after aerosol challenge. The 
evidence for the importance of T cells in immunity to B. pertussis was provided by 
the demonstration that mice devoid of T and B cells failed to clear the bacterium from 
the respiratory tract, whereas BALB/c mice (immunocompetent) cleared the infection 
after 5 weeks (Mills et a l, 1993). Further evidence for a role of T cells (i.e. classified 
according to their cluster of differentiation (CD) into CD4^ and CD8" )^, was provided 
by the demonstration that CD4"  ^T cell knockout mice could not be protected by intra- 
nasal challenge with inactivated bacteria whereas, in contrast, CD8^-depleted mice 
did not differ from wild-type mice in their ability to control aerosol pertussis 
challenge (Leef et a l, 2000).
1.1.7.3 Pertussis vaccines and immunity
Killed B. pertussis whole-cell vaccines (Pw) have played an essential role in 
the prevention of pertussis infection (1959). These vaccines consist of heat- or 
formalin-inactivated virulent B. pertussis. Widespread vaccination significantly 
decreased the number of pertussis cases, but publicity in the 1970s directed to the 
possible adverse reactions to Pw presented a serious social problem for vaccination 
against pertussis (Gustafsson et a l, 1996). Therefore, the development of more 
efficacious pertussis vaccine became an urgent need. A major effort was undertaken :to develop a new safer acellular pertussis (Pa) vaccine consisting of toxoided 
components of B. pertussis (formalinized pertussis toxin (PT) and filamentous 
haemagglutinin (FFIA)) (Sato et a l, 1984). Thus, combined vaccine which is 
consisting of diphtheria toxoid (D), tetanus toxoid (T) and acellular pertussis (Pa)
(Sato and Sato, 1999).
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Regarding immune response against due to either Pw or Pa vaecines, induction 
of T cells and Ab production have been studied. The immune responses induced in 
miee due to Pa and Pw induced distinct T cell populations as in children. Pw vaccines 
have been shown to induce Thl responses which are important for bacterial clearance. 
On the other hand, Pa has shown to produce Th2 responses and antibodies (IgG) 
which also play an important role in protective immunity against pertussis infection 
(Barnard et al., 1996). Furthermore, it was reported that acellular vaccine induced a 
high level of antibody to PR, Fim or PT and was associated with a lower risk of 
infection (Cherry et al., 1998) and with a reduction in reactogenicity compared with 
Pw vaccine (Donnelly et a i, 2001).
1.1.7.4 Pertussis and asthma
In several studies, an inverse relationship between asthma and the overall 
burden of respiratory infections has been reported. Asthma is a continuing and 
growing problem world-wide (Umetsu et a l, 2002). The asthma cascade is initiated 
by allergic sensitisation dependent on T-cell activation, IL-4 production, IgE antibody 
synthesis and mediator release from mast cells.
Mast cells are well known as effector cells in allergic reaction (see section 
1.2). They are widely distributed throughout the body especially at the host- 
environment interface and they can be activated to release various mediators in 
response to external stimuli via immunoglobulin E (IgE)-dependent or IgE- 
independent mechanisms.
Although pertussis is not generally viewed as an allergic disorder, pertussis- 
vaccinated animals have been used as models of allergic sensitisation, including 
asthma, and for investigating its pharmacological modulation (Nilsson et al., 1998). 
Furthermore, associations have been reported between a history of pertussis infection 
and allergic sensitisation (Wjst et al., 1994) and wheezing illness (Strachan et a l, 
1996) and between pertussis vaccination and a risk of bronchial asthma (Odent et a i,
1994).
1.1.7.4.1 Pertussis infection and development of asthma
A prospective study on this subject was performed in 25 children aged 0.8-
12.2 years. At the time of pertussis infection, the mean serum IgE concentration in the
study group was 62 +/- 30 kU/ml. At the follow-up visit, there was a significant 
increase in serum IgE to 137 +/- 51 kU/ml, which was also significantly higher than 
IgE in an age-matched control group. Children at a significantly higher risk for 
developing an IgE increase or new allergic sensitizations were those with a family 
history of allergy or potentially allergic disease in their personal history. These 
observations suggested that pertussis infection may induce IgE production in affected 
children (Schuster et. a l, 1993).
The role of previous pertussis infection and the prevalence of allergic 
sensitization and allergic rhinitis in children has also been studied. A study was 
carried out on 13,937 10-year-old children from Germany and data (questionnaire and 
skin prick tests with six different allergens) were analyzed. It was found that pertussis 
was much more common in the western than in the eastern part of Germany. The 
allergic sensitization after pertussis infection was slightly increased in western 
Germany than in eastern Germany. These results suggested that infection with 
pertussis may have had a weak influence on allergic sensitization (Wjst et a l, 1994).
Furthermore, in a study of wheezing illness, it was reported that the 
cumulative incidence was 18% by age 7, 24% by age 16, and 43% by age 33. The 
incidence during childhood was strongly and independently associated with 
pneumonia, hay fever, and eczema. There were weaker independent associations with 
male sex, whooping cough, recurrent abdominal pain, and migraine (Strachan et a l, 
1996). These results suggested that infection with pertussis seems may not have 
influence on wheezing illness.
1.1.7.4.2 Pertussis vaccine and development of asthma
It was reported in 1994 that, among 243 pertussis-vaccinated children at a 
mean age of 7.8 years, 10.7% were given a diagnosis of asthma compared with 1.97% 
of the 203 children who had not been immunized (Odent et a l, 1994). Furthermore, 
among a birth cohort of 1265 children that, at the age of 10 years, among those 23 
children who had not received the pertussis component of the triple (diphtheria- 
pertussis-tetanus) vaccine, none had asthma or other allergic diseases, whereas among 
children receiving diphtheria-pertussis-tetanus vaceine, 23% had asthma and 30% had 
consultations for other allergic diseases (Kemp et a l, 1997).
A prospective cohort study was designed to examine the relation between 
pertussis vaccination and the prevalence of wheezing illnesses in 9444 young children
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on whom data on wheezing symptoms and vaccination status was available. 
Unadjusted comparisons of the defined wheezing illnesses in vaccinated and non­
vaccinated children showed no significant association between pertussis vaccination 
and any of the wheezing outcomes regardless of stratification for parental asthma or 
allergy. Wheeze was more common in non-vaccinated children at 18 months, and 
there was a tendency for late onset wheezing to be associated with non-vaccination in 
children whose parents did not have asthma, but this was not significant. The data 
suggested that no evidence was found that pertussis vaccination increased the risk of 
wheezing illnesses in young children (Henderson et a i, 1999).
In another study, it was shown that DTP vaccination appeared to increase the 
risk of allergies and related respiratory symptoms in children and adolescents. The 
data used were from the Third National Health and Nutrition Examination Survey on 
infants aged 2 months through to adolescents aged 16 years (Hurwitz and 
Morgen stern, 2000). DTP vaccination, lifetime allergy history, and allergy symptoms 
were recorded. Logistic regression modelling was performed to estimate the effects of 
DTP on allergy. The odds of having a history of asthma were twice as great among 
vaccinated subjects than among un vaccinated subjeets. The odds of having had any 
allergy-related respiratory symptom was 63% greater among vaccinated subjects than 
unvaccinated subjects.
Recently, the effect of acellular pertussis vaccine Pa to enhance or prevent 
allergic sensitization was investigated. The effect of OVA sensitization upon the 
development of a protective response to B. pertussis infection in Pa-immunized and 
nonimmunized mice was also examined (Ennis et a l, 2005). BALB/c mice were used 
and divided into four groups; mice immunized with Pa only (group Pa); mice 
immunized with Pa and challenged with virulent B. pertussis via aerosol (group 
PaBp); mice immunized with Pa and sensitized with OVA (group PaOVA); and mice 
immunized with Pa, challenged with virulent B. pertussis via aerosol, and sensitized 
with OVA (group PaBpOVA). Sensitization with OVA did not impair the vaccine- 
mediated clearance of B. pertussis in this model. When the serum IgE responses of 
mice sensitized to OVA following Pa were examined, differences were observed in 
the induction of IgE antibodies to the different antigens, with the concentration of 
OVA-speeific IgE typically being greater than the concentration of IgE indueed to B. 
pertussis. Pa induced little B. pertussis~^pe.c\f\c IgE, and this was not altered by OVA 
sensitization. The only increase in B. pertussis-spQcïïxc IgE was observed when a
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combination of immunization and infection prior to OVA sensitization was used. 
These data demonstrate that immunization with Pa did not enhance ovalbumin- 
specific serum IgE production.
The above information have shown that possible links between pertussis 
infection or pertussis vaccination and the development of asthma are controversial and 
need further investigation. Therefore, this project was based on the assumption that B. 
pertussis infection and pertussis vaccination might be linked to development of 
asthma and allergic sensitization.
1.1.7.5 Pathogenesis of B. bronchiseptica
B. bronchiseptica infects the respiratory tract of wild, domestic and laboratory 
animals (Parton, 2005). For example, it causes kennel cough disease in dogs (Bemis 
and Kennedy, 1981). Kennel cough is characterized by congestion of the mucosal 
lining of the trachea and bronchi and a mucoid or mucopurulent exudate (Mattoo and 
Cherry, 2005). In young piglets, it causes atrophic rhinitis via an interaction with P. 
multocida (Magyar et a l, 1988), and in laboratory animals such as guinea pigs it 
causes lesions include mucopurulent or catarrhal exudates (Mattoo and Cherry, 2005). 
Infection with this bacterium has also been shown to increase the frequency and 
severity of respiratory disease due to other viral and bacterial pathogens (Brockmeier 
et a l, 2001). B. bronchiseptica and its importance as a human pathogen have been 
investigated. Evidence suggests that B. bronchiseptica may be rarely encountered as a 
commensal or colonizer of the respiratory tract of humans and rarely in association 
with disease (Woolfrey and Moody, 1991).
1.1.7.6 Prevention of B. bronchiseptica infection
Whole-cell, chemically-inactivated B. bronchiseptica vaccine containing 
adjuvant protected mice and guinea pigs against death and bronchopneumonia 
resulting from laboratory induced or natural B. bronchiseptica infections (Little, T.W., 
1975 cited by Goodnow, 1980). Furthermore, a group of guinea pigs were vaccinated 
with commercial porcine B. bronchiseptica vaccines, a human DPT vaccine (which 
includes a B. pertussis component), or an autogenous B. bronchiseptica bacterin. 21- 
days following vaccination, the animals were challenged with an intranasal dose of 
10^  virulent B. bronchiseptica cells. After a furher 15 days, the nares, nasopharynx.
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distal trachea and lungs were cultured. All non-vaccinated control animals developed 
acute signs of pneumonia, while none of the vaccinated animals developed clinical 
signs of disease or gross lesions. The frequency of B. bronchiseptica isolation from 
the lungs of animals in each vaccine group was reduced (Matherne et a l, 1987).
B. bronchiseptica produces a multiplicity of potential adhesins and toxins that 
may function as virulence factors. The outer membrane protein pertactin has been 
demonstrated to act as an adhesin. Extensive homology between the pertactin genes of 
B. pertussis and B. bronchiseptica (Li et a l, 1992), suggests that the proteins they 
encode may function similarly (Henderson and ataro, 2001). Both active 
immunization using purified pertactin, and passive immunization with a pertactin- 
specific monoclonal antibody, have been shown to provide protection against 
mortality and to reduce turbinate pathology and lung colonization in mice and pigs 
ehallenged with B. bronchiseptica (Kobisch and ovotny, 1990).
Filamentous haemagglutinin (FHA) is an outer-membrane associated adhesin 
conserved within the genus Bordetella. FHA provides protection against B. pertussis 
infections in humans and is a component of acellular whooping cough vaccines 
(Pichichero et a l, 1997). Furthermore, FHA serves as a protective antigen in several 
animal models of infection with B. bronchiseptica and may serve as a protective 
antigen of canine bordetellosis (Leininger et a l, 1997). Polyclonal anti-5, pertussis 
FHA anti serum was used to identify an immu noreactive clone from the genomic DA 
library of a canine B. bronchiseptica field isolate. The nucleotide and predicted amino 
acid sequences of the immunoreactive clone were compared to fhaB  and FhaB from 
B. pertussis, revealing 94% identity at the nucleic acid level, and 86% identity at the 
protein level. A truncated fusion protein (FHAt) was prepared which included a 
conserved domain homologous to the immunodominant region in the FHA of B. 
pertussis. FHAt was shown to be safe and antigenic in rabbits. FHAt induced the 
formation of antibodies that inhibit the haemagglutination associated with full length 
B. pertussis FHA, and inhibit adherence of B. bronchisepitca to canine fibroblasts by 
as much as 65%. This information may have implications for the development of safe 
and efficacious subunit vaccines for the prevention of canine bordetellosis and may 
contribute to future acellular whooping cough vaccines (Keil et a l, 1999).
Parenteral ly and intranasally administered vaccines containing B 
bronchiseptica to protect puppies from infection with B. bronchiseptica have been 
reported. Vaccinated puppies with this vaccine may provide substantial protection
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from clinical signs of respiratory tract disease associated with infection by this ‘I
bacterium (Ellis et a i, 2001).
One approach to attenuating a bacterial pathogen is to knock out the gene 
encoding for a known virulence factor. An attenuated B. bronchiseptica (aroA mutant) 
expressing the non-toxic fragment C (FrgC) of tetanus toxin was used to immunise A
mice intranasally. Upon challenge with wild-type B. bronchiseptica, immunised mice
rapidly reduced the numbers of B. bronchiseptica in their respiratory tract, although |
■ iclearance was more pronounced in the lower than in the upper respiratory tract 
(Stevenson and Roberts, 2002).
■.■If?
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1.2 Mast cells
Mast cells (MC) are mononuclear cells with distinctive cytoplasmic granules.
They reside in connective tissue matrices and at epithelial surfaces. MC are A
considered as critical effector cells because they play important roles in the elicitation 
of anaphylactic reactions (i.e. when two IgE antibodies bind allergen). IgE antibody i|
binds to high affinity receptors (FceRI) on the mast cell surface. This cross-linking 
will lead to a cascade of reactions in mast cells which undergo a dramatic 
degranulation, releasing a variety of inflammatory mediators (e.g. histamine) and 
cytokines. The effect of these products will result in a variety of clinical symptoms 
such as asthma, high fever and chronic inflammation (type I hypersensitivity)
(Yamaguchi e ta l ,  1997).
On the other hand, MC could represent a critical component of host defence in 71
natural immunity. MC could contribute in the initiation of host defence mechanisms 4;
against many different species of microorganisms. This new concept of mast cells 
functions can be explained by their ability to contribute to defence mechanisms either T
by phagocytic capabilities, or by contributing to the acquired immune responses of the 
host cells as a result of their ability to produce cytokines which are considered as 
essentials elements for other cells of the immune response (Galli, 1993; Echtenacher 
e ta l ,  1996; Malaviya c/a/., 1996a).
' ' t
'Mi1.2.1 Mast cell biology
Mast cells are resident in tissues throughout the body particularly those that 
interface with the external environment (Metcalfe et a l, 1997). They are seen in 
particularly high concentrations in the submucosal tissues lying just beneath body Î
surfaces, including those of the gastrointestinal and respiratory tract, and in 
connective tissues along blood vessels and especially in those layers called dermis i
that are located below the skin. It could be concluded from the distribution of mast 
cells throughout many different tissues that:
1- Their cell products are available to cells of the connective tissue, surface or 4
glandular epithelial cells, nerve, vascular endothelial cells and vascular, |
respiratory, gastrointestinal or genitourinary smooth muscle cells.
2- This distribution places mast cells near to pathogens as well as near environmental 
antigens that come in contact with the skin or mucosal surfaces.
I
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1.2.2 Mast cell progenitors and growth factors
MC originate from stem cell precursors (pluripotential haemopoietic), which 
depart from the bone marrow (BM) essentially as uncharacterised precursors and 
migrate into connective or mucosal tissues where they undergo differentiation and 
maturation (Kitamura et a l, 1978; Tsai et a l, 1991; Fodinger et a l, 1994). Then, MC 
proceed to synthesize their full complement of granules under the influence of many 
factors such as cytokines, acting on progenitors at early stages of development, 
including interleukin-3 (IL-3) (Small et a l, 1994), stem cell factor (SCF)(Macaldowie 
et a l, 1997a) and granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Saitoe/a/., 1996).
In the murine system, it has been elucidated that mast cells originate from 
hematopoietic stem cells in vivo (Kitamura et a l, 1981) or multipotential 
hematopoietic progenitors in vitro (Suda et a l, 1983). Cytokines such as SCF, IL-3, 
IL-4, 11-9 and IL-10 promote the development of immature mast cells into mature 
mast cells (Sawai et a l, 1999). In contrast with the murine mast cell system, in vitro 
development of human mast cells is different. In man, mast cell progenitors express 
CD34^, and SCF has been shown to act as a major growth and differentiation factor 
(Mitsui et a l,  1993; Kirshenbaum et a l, 1999). In sheep, increased generation of 
multipotential eosinophil, macrophage and mast cells/basophil cells in bone marrow 
has been demonstrated (Haig et a l, 1995).
1.2.3 Mast cell heterogeneity
Mast eells can be divided into two different kinds that can be visualized under 
light microscopy by using A lei an blue staining (Roitt, Brostoff and Male, 1996):
1“ Mast cells that are associated with mucosal tissue and called the mucosal mast 
cells (MMC) are located in the mucosa of the midgut and in the lung.
2- Mast cells that are associated with connective tissue (CTMC) are found around 
blood vessels in most tissues.
Mast cell mediators may be categorized into three groups; 1- granule-associated 
mediators such as histamine (ovak and Falus, 1997), polyanionic complex 
carbohydrates composed of repeating disaccharide units known as proteoglycans 
(heparin and chondroitin sulphate E)(Craig et a l, 1993) and proteases of the serine 
class (chymases, tryptases and carboxypeptidase)(Abe et a l, 2000).
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Heterogeneity of mast eells could be explained by the fact that mast cells migrate 
from bone marrow to particular sites in the body as uncharacterized precursors and, 
under the influence of various growth factors present in a particular site, will undergo 
differentiation and maturation. Thus, the character and responsiveness of mast cells 
and their mediator content depends on these growth factors (Abraham et a l, 1997; 
Metcalfe et a l, 1997). For example, biochemical analysis of mast cell granule 
constituents showed that there are two two types of proteases, rat mast cell protease I 
(RMCP-I) and rat mast cell protease II (RMCP-II) (Woodbury and eurath, 1980). In 
addition, it was demonstrated by using immunofluorescence technique that rat MMC 
and CTMC represent two approximately separate populations of mast cells containing 
RMCP-II and RMCP-I respectively (Gibson et a l, 1987). Furthermore, such 
observations of different mast cell population distinguished by their proteases have 
been observed in other species such as human (Irani et a l, 1989; Irani and Schwartz, 
1989) and mice (ewlands et a l, 1993). In addition, in sheep, MC heterogeneity may 
also occur based on the distribution of a sheep MC granule protease (SMCP) (Sture et 
a l, 1995b). In this study, it was observed that the majority of intestinal MMC stained 
positive for SMCP whilst only a small percentage of dermal and hepatic mast cells 
contained the enzyme.
Recent studies demonstrated that human mast cells are a source of several 
pleiotropic cytokines including IL-4, IL-5, IL-6, IL-8 and TF-a. But, not all mast 
cells contain all of these cytokines, suggesting that there is also functional 
heterogeneity with respect to cytokine content (Bradding et a l,  1995). Therefore, it 
could be concluded that heterogeneity of mast cells depends on many factors that 
affect their differentiation, proliferation, maturation and other characteristics.
Functional heterogeneity of mast cell sub-populations has been defined in both 
in vitro and in vivo derived mast cells from a number of species through their 
responses to chemieal secretogogues. This effect was initially demonstrated in vivo in 
the rat by injecting the polycationic secretogogue Compound 48/80 which depleted 
peritoneal CTMC but not MMC of their mediators (Enerback, 1966). The 
neuropeptide substance-P has been used to distinguish MMC from CTMC in a variety 
of species. It was observed that substance-P activates human cutaneous CTMC but not 
intestinal MMC via a cell receptor dependent pathway (Regoli et a l, 1994). In 
contrast, calcium ionophore A21387 acts by non-specifically increasing intracellular
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calcium levels in a variety of cell types activating calcium dependent cytoplasmic 
granule release mechanisms. Its effects are not entirely restricted to mast cells and has 
been shown to activate both CTMC and MMC populations present in laboratory 
animals (Pearce, 1986) and man (Cohan et a l, 1989).
Regarding ovine mast cells heterogeneity, it was reported that MC exhibit 
considerable structural, biochemical and functional heterogeneity dependent on the 
species and tissue location (Pluntley, 1992). Further studies were carried out regarding 
sheep mast cells and their tissue distribution has been described (Sture et a i, 1995a).
The presence or absence of the granule chymase, sheep mast cell proteinase (SMCP), 
was determined in trachea, bronchus, bronchial lymph node, lung, thymus, spleen, 
liver, flank skin, abomasum, duodenum, jejunum, ileum, colon and mesenteric lymph 
node by immunohistochemistry and by enzyme-linked immunosorbent assay using a 
polyclonal, affinity purified anti-SMCP antibody. It was confirmed by using reactivity 
to the anti-SMCP antibody that there are two populations of mast cells in sheep.
Those in gastrointestinal tissues (analogous to the mucosal mast cell subset) and those 
present in skin (the putative ovine connective tissue mast cell subset) (Sture et a l,
1995b). Currently, studies carried out in vitro on ovine bone marrow mast cell grown 
in the presence of reeombinant ovine interleukin-3 have shown that they are activated 
in the presence of calcium-ionophore A23187 (Huntley et al., 1992). Moreover, ovine 
bone marrow mast eell in the presence of recombinant ovine interleukin-3 is also 
relatively refractory to stimulation with compound 48/80 or substance-P (Sture, 1996 
PhD thesis). This, in combination with the fact that the majority of these cells contain 
SMCP (Huntley et al., 1992) indicates that they may possess MMC phenotype.
1.2.4 The development of sheep mucosal mast cells in vitro
Mucosal mast cell hyperplasia is a T cell-dependent process (Miller, 1996;
Mai bee et a l, 2004). Both mice and humans with T-cell immunodeficiencies lack 
mast cells in intraepithélial compartment of their intestines, even though numbers of 
mast cells in the adjacent submucosal connective tissues are normal (Irani et a l,
1987). As in mice, several cytokines (IL-3, IL-4, IL-5, IL-6, and IL-9) support the 
survival of cultured human mast cells in vitro (Yanagida et a l, 1995), or 
synergistically support mast cell proliferation when provided in combination with
i
SCF, also known as the c-kit ligand because it binds to c-kit tyrosine kinase receptors 
(Bischoff a/., 1999).
It was shown that mucosal mast cell development could be achieved in sheep 
by using recombinant ovine interleukin-3 (rOvIL-3) and recombinant ovine stem cell 
factor (rOvSCF) (Macaldowie et a l, 1997b). After approximately 2-3 weeks' growth 
in optimal concentrations of either rOvIL-3 alone or a combination of rOvIL-3 and 
rOvSCF, the majority of the cells produced in bone marrow culture were mast cells. 
The significant increase in the total numbers of cells and survival times of the cultures 
when both cytokines were present compared to either alone, indicated synergy 
between rOvIL-3 and rOvSCF on mast cell growth. Ovine and caprine cells cultured 
in rOvIL-3 alone produced a four-fold inerease in cell numbers compared with 
medium only controls. The resulting cultures contained up to 52% mast cells by day 
18 and had a lifespan of 3-4 weeks. In contrast, cells from both species grown in both 
rOvIL-3 and rOvSCF produced up to six times more cells than the equivalent rOvIL-3 
stimulated cultures, contained up to 69% mast cells by day 21 and could be 
maintained for at least 6 weeks. Ovine cells grown in rOvIL-3 alone or rOvIL-3 and 
rOvSCF contained significantly more aryl-sulfatase and serine protease but similar 
amounts of beta-hexosaminidase compared with caprine cells during the second week 
of culture. There were no significant differences in the granule-associated mediator 
content of cells from either individual species grown in rOvIL-3 alone compared with 
those grown in rOvIL-3 and rOvSCF during the first 21 days of culture (Macaldowie 
e ta l ,  1997b).
1.2.5 Mast celi activation and mediator release
MC plays an important role in allergic reactions (Taube et a l, 2004). 
Interaction of IgE antibodies with high affinity (FceRI) on mast cell surface, and 
aggregation of these FceRI by the reaction of cell-bound IgE with specific antigens 
induces mast cells to secrete different biologically active performed or lipid 
mediators, and cytokines (Williams and Galli, 2000). Recent results further suggest 
that mast cells, by also expressing Fey receptor I, Fey receptor III, Toll-like receptor 
(TLR) types 2 and 4 are the antennae of the microenvironment that direct the immune 
response (Mekori and Metcalfe, 2000; Frossi et a l, 2004).
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1.2.5.1 Coupling of different hypotheses in mast cell activation
Mast cell secretion is due to a cascade of reactions that end in the release of
■
:
jIt was reported that activation of MCs and release of their content of granules 
occur due to two mechanisms, which may operate individually or in parallel. The first 
mechanism is a rapid process of anaphylactic degranulation and second mechanisms 
is a slow process of piecemeal degranulation (Dvorak, 1992). Finally, the activated T
and degranulated mast cells reconstitute their lost preformed mediators through the T
rapid onset of de novo synthesis, becoming ready to participate in a new process of 
activation and degranulation (Dvorak et a i, 1986; Dvorak, 1992). Generally, 
preformed mediators are associated with the mast cell cytoplasmic granules. On the A
other hand, newly-synthesised mediators are produced at the time of cell activation 
(Bradding, 1996).
Regarding sheep mast cells and their contents, sheep mast cell chymase was 
first isolated from mucosal mast cells of ovine origin (Huntley et a l, 1986) and 
antibodies raised against the enzyme demonstrated its immunohistochemical 
localisation to mast cells in the ovine gut as well as other tissues (Sture et a l, 1995b).
Experiments involving isolated mucosal mast cells as well as in vitro derived ovine 
bone marrow mast cells have demonstrated that these cells also contain histamine, |
serotonin and dopamine (Huntley et a l, 1992) and in the case of the isolated cells are 
able to releases histamine on exposure of cells to larval antigens (Ben dix sen et a l, M
1995). Interaction of sheep mucosal mast cells with parasite antigen lead to release of 1
mediators following cross-linking of surface bound antigen specific IgE (Jones et a l,
1992).
contents, which include different chemical mediators (e.g. histamine and cytokines), 
into the surrounding medium. Different mechanisms, immunological stimulation A;
(IgE-dependent) and non-immunological (non-IgE dependent) provocation, under 
certain circumstances, cause mast cell activation:
1.2.5.1.1 The membrane stimulus
There are two possible ways to initiate mast cell activation, the IgE-dependent 
way and the IgE-independent way. The IgE-dependent way depends on interactions A
leading to cross-linking the high affinity IgE receptor (FeeRI) on mast cells and this
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initiates cascades of biochemical events leading to degranulation, membrane ruffling 
and other physiological responses (Rivera et a l, 2002). Activation of mast cells 
through the IgE-independent way occurs via a receptor-independent pathway. For 
example, adenosine and calcium ionophore are able to induce significant release of 
tryptase and histamine from mast cells (Stassen et a l, 2002).
1.2.5.1.2 Calcium hypothesis
It has been reported that histamine secretion due to stimulation of mast cells 
requires the presence of extracellular calcium (Johansen, 1980). Furthermore, it was 
reported that histamine secretion from rat mast cells previously incubated with a 
chelating agent and stimulated by compound 48/80, is dependent on extracellular 
calcium. If calcium is absent from the incubation medium, secretion is prevented 
(Chabot et a l, 1981). A rise in intracellular calcium ion concentration might be the 
link between membrane stimulus and histamine secretion. The principle evidence for 
this hypothesis came from the experiments with the calcium ionophore A23187 which 
transports calcium across the mast cell membrane from extracellular to intracellular 
compartments and thereby induces histamine secretion (Reed and Lardy, 1972).
1.2.5.1.3 Phospholipid metaholism
A close linkage between activated phospholipid metabolism and mast cell 
activation was reported. It has been shown that inhibition of mast cell secretion is 
associated with parallel inhibition of the phospholipid metabolism that occurs during 
mast cell activation (Kennerly et a l, 1979b; Kennerly et a l, 1979a). Mast cell 
degranulation has been shown to be potentiated by phosphatidyl serine. The action of 
phosphatidyl serine was related to the role of calcium in cell permeability. 
Phosphatidyl serine increases the membrane permeability to calcium in cells 
stimulated by a cross-linking stimulus (Martin and Lagunoff, 1979).
1.2.5.1.4 Cyclic AMP
It was identified that adenosine 3’,5’-monophosphate (cyclic AMP) is an 
intracellular second messenger of hepatic glycogenolysis (Sutherland and Rail, 1958 
cited by Bourne, et a l, 1974). The discovery of cAMP triggered a series of 
investigations which demonstrated that cAMP regulates leukocyte functions (Bourne 
et a l, 1974). Regarding the importance of cAMP in secretory events in MC, it was
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thus claimed that increase or decrease in levels of cAMP in mast cells either 
suppresses or enhances respectively the release of histamine (Kaliner and Austen, 
1974). Furthermore, it was shown that secretory events in cells are generally 
accompanied by increased levels of cAMP. But, in mast cells, the pattern is reversed 
(Aim and Bloom, 1982). It has been suggested that the lowered levels of cAMP lead 
to an increase in membrane permeability towards calcium and that an influx of such 
ions triggers the release mechanisms. It has further been reported that high levels of 
cAMP inhibit histamine release by decreasing the permeability (Aim and Bloom, 
1979). Stimulation of the mast cells is accompanied by falling levels of cAMP which 
ultimately results in increased membrane permeability to calcium. On the other hand, 
elevation on the eAMP level limits the permeability of the cell membrane to calcium, 
and histamine release dependent on extracellular calcium is inhibited (Foreman and 
Gomperts, 1975; Foreman et a l, 1975).
1.2.6 Importance of mast cells in immune response
The discovery that mast cells are a potential source of cytokines has suggested 
new ways in which mast-cell activation could lead to the development of late-phase 
reactions and influence other persistent inflammatory responses (Galli, 1993; 
Marshall et al., 2003b). It is now believed that mast cells are more central to innate 
and adaptive immune responses. They are known to phagocytose particles (Sher et a i, 
1979; Malaviya et al., 1994), process antigens, produce cytokines and release 
vasoactive substances (Gordon et al., 1990; Marshall et a l, 2003b).
1.2.6.1 Mast cells and phagocytic response
The possibility that mast cells are able to engulf bacteria was examined. 
Mixtures of mast cells and Fim'*' or Fim “ (E. coll) bacteria were incubated for Ih and 
then fixed and embedded and examined by EM of thin sections. It was observed that a 
high proportion (70%) of mast cells had at least one Fim’^ bacterium within distinct 
phagocytic vacuoles. In contrast, only 15% of mast cells exposed to Fim' E. coll, 
showed engulfed bacteria (Malaviya et a l, 1994). By using a model system in which a 
well-characterized T cell epitope is expressed within bacteria as a fusion protein, it 
was demonstrated that mast cells are capable of processing bacterial antigens for
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presentation through class I MHC molecules to T cell hybridomas after phagocytic 
uptake of live bacteria (Malaviya et a l, 1996b).
Cord blood-derived human mast cells (CBHMC) and their binding to various 
bacteria was also been examined. CBHMC bound the laboratory E. coli strain 
expressing recombinant type I fimbriae. The morphological aspects of the interaction 
between CBHMC and selected bacteria were examined by scanning and transmission 
electron microscopy and it was shown that mast cells employ protoplasmic 
protrusions on their surfaces to entrap bacteria. In addition, examination of cross- 
sections of mast cells after exposure to bacteria revealed a significant number of 
bacteria encased in vacuoles (Arock et a l, 1998).
Caveolae are pleomorphic membrane structures characterized biochemically 
by their buoyant density; resistance to nonionic detergents; and enrichment in 
cholesterol, glycolipids such as the glycosphingolipid GMl, and a specific protein, 
caveolin. Caveolae were detected in the microvilli and intracellular vesicles of 
cultured mouse bone marrow-derived mast cells (BMMCs). The involvement of 
caveolae in bacterial entry into BMMCs was indicated because caveolae-disrupting 
and -usurping agents specifieally blocked E. coli entry, and markers of caveolae were 
actively recruited to sites of bacterial entry. The formation of bacteria-encapsulating 
caveolar chambers in BMMCs represents a distinct mechanism of microbial entry into 
phagocytes (Shin et a l, 2000).
The interaction of B. pertussis with mast cells has been investigated using 
transmission electron microscopy (TEM). Phagocytosis of B. pertussis by mast cells 
was described as follows; B. pertussis adhered to mice BMMCs and were often 
surrounded by cytoplasmic protrusions expressed on the cell surface, probably 
reflecting a mechanism for entrapment of 5. pertussis. After contact, adherent bacteria 
were engulfed into invaginations of the mast cells. After 1 h, internalized bacteria 
were localized in membrane-bound intracytoplasmic vacuoles. In addition, BMMCs 
infected with virulent B. pertussis or a B. pertussis PT-deficient strain were equally 
able to present bacterial antigens to memory T cells isolated from the lungs of 
infected mice, as measured by the proliferation of the stimulated T cells. A dose- 
dependent increase in T-cell activation was observed when BMMCs were infected 
with a multiplicity of infection (MOI) of 1/100 compared with a MOI of 1/10. These 
data suggest that mast cells may play a role in the induction of immune responses
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against B. pertussis through the release of cytokines, especially TF-alpha (Mielcarek 
et a i, 2001).
1.2.6.2 Modulation of immune response by mast cell
An additional reason for attributing an important role for mast cells in various 
immune responses is the demonstration that mast cell mediators may have 
immunoregulatory or immunomodulatory effects(Marsha!l et a l, 2003b; Marshall and 
Jawdat, 2004). It was reported that cytokines proteins or glycoprotein molecules 
synthesized and secreted by mast cells have a broad spectrum of bioactivities (e.g. cell 
growth, repair, inflammation and the immune response) (Woolley and Tetlow, 2000; 
Marshall et a l, 2003a).
The recognition that non-Ig specific mechanisms are capable of causing 
mediators release from mast cells has increased recent interest in their role during the 
initiation and development of innate responses which may occur on initial exposure to 
parasites or bacteria (Mecheri and David, 1997). In this respect, innate mediator 
release from mast cells, including their ability to generate cytokines may have a direct 
effect on pathogens as well as being able to influence the development of subsequent 
acquired specific immune responses. This innate ability has been characterised most 
recently in experiments which demonstrate that the release of pre-formed mast cell- 
derived TFa is critical in vivo for promoting the clearance of virulent strains of K. 
pneumoniae from the lungs and peritoneal cavities of mice (Malaviya et a l, 1996a).
It was observed that the coupling of Fim H-expressing bacteria with CD48 
(glycosylphosphatidylinositol (GPI)-Iinked molecule) result in mast cell activation 
leading to the release of several proinflammatory mediators which can potentially 
play a role in determining the nature and intensity of the early inflammatory response 
to the infecting bacteria (Abraham and Malaviya, 2000).
Interaction of mast cells with B. pertussis was investigated (Mielcarek et a l,
2001). It was found that mast cells can take up the B. pertussis, present B. pertussis 
antigens to T cells, and induce the secretion of cytokines such as tumour necrosis 
factor alpha (TF-a), interleukin 6 (IL-6), IL-10 and IL-4. In this regard, The ability 
of MC to release TF-a and IL-6 following in vitro exposure to B. pertussis was 
investigated. It was found that, incubation with 5. pertussis, MC released significant 
levels of TF-a and IL-6 compared with BMMCs incubated with medium alone. To
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determine whether PT produced by B. pertussis may modulate the ability of mast cells 
to release these cytokines, The levels of TF-a and lL-6 released following exposure 
to wild-type B. pertussis (BPSM) was compared with the levels after incubation with 
PT-deficient strain (BPRA). The level of TF-a released by MC after contact with 
BPRA was not significantly different from that observed following exposure to 
BPSM. In contrast, the level of IL-6 was consistently found to be significantly higher 
following exposure to BPRA bacteria than to the virulent BPSM strain. Mast cells 
express IL-4 and IL-10. The ability of B. pertussis to stimulate the release of these 
two cytokines using MC was investigated. Significant levels of IL-4 were secreted by 
MC following exposure to the bacteria. This effect was independent of the production 
of PT. In contrast, while exposure to BPSM did not induce any detectable IL-10 
release by MC, an increased IL-10 production was observed following exposure to 
BPRA that was significantly different from the level of IL-10 released by BPSM- 
stimulated MC (Mielcarek et a i, 2001).
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1.3 Bioluminescence-based assay for detection of mammalian cell- 
bacterial interaction
Recent progress in molecular biology has made available several 
biotechnological tools that take advantage of the high detectability and rapidity of 
biological processes (e.g. gene expression). Reporter gene technology represents one 
of the major recent achievements of molecular biology and has been used in the 
present project to study host-pathogen interactions.
1.3.1 Reporter genes
Reporter genes are DA sequences that encode an easily detectable protein or 
enzyme (Alam and Cook, 1990). They can be artificially introduced into a cell to 
monitor gene expression, to obtain whole-cell biosensors or for cell-localization 
purposes. The principal advantage of reporter gene technology is based on their high 
sensitivity, reliability, convenience, and adaptability to large-scale measurements. The 
most common reporter genes used are; chloramphenicol acetyltransferase (CAT), (3- 
galactosidase, lueiferase (either firefly or bacterial), alkaline phosphatase and green 
fluorescent protein (GFP). Currently, bacterial luciferase genes {lux) as well as the 
eukaryotic lue and m e  genes from firefly and sea pansy represent the most widely 
used bioluminescence reporter genes (Lewis et a l, 1998). The following table (1.3) 
summarise of the advantages and disadvantages of the mostly used reporter genes 
(aylor, 1999).
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1.3.1.1 Luciferase
Luciferase is a generic name for any enzyme that catalyzes a light-emitting 
reaction (Baldwin et a l, 1995). The measurable release of visible light by organisms 
containing luciferase is termed bioluminescence. Bioluminescent organisms, 
including bacteria, algae, dinoflagellates, fungi, jellyfish, clams, fish, insects, shrimp, 
and squid, are ubiquitous and can be found in aquatic as well as terrestrial 
environments with the vast majority occurring in the marine communities (Meighen, 
1991). Among them, bacteria are the most abundant luminescent organisms and have 
been classified into three genera Vibrio, Photobacterium, and Xenorhabdus. The light- 
emitting (Lux) proteins of several of these bacterial species have been purified, and 
the ability to transfer the cDA coding for Lux proteins into prokaryotic and 
eukaryotic organisms has resulted in their common use as reporters of gene 
expression (Daunert et a l, 2000).
1.3.1.1.1 Bacterial luciferase
Bacterial luciferase is found in bioluminescent bacterial species and catalyses 
oxidation of a reduced flavin mononucleotide (FMH2) and a long-chain aliphatic 
aldehyde, such as dodecanal, with molecular oxygen:
FMNH2 + RCHO + 0 2 ^  FMN + RCOOH + H2O + light (490 nm)
Since FMH2 production depends on a functional electron transport system, 
only viable cells will produce light. Extensively studied procaryotic luminescent 
systems are those from marine bacteria (e.g.. Vibrio fischeri. Vibrio harveyi, and 
Photobacterium phosphoreum) (Francisco e ta l,  1993).
1.3.1.1.2 Firefly luciferases
Firefly luciferases used from either the firefly (Photinus pyralis) or the click 
beetle {Pyrophorus plagiophtalamus). The firefly luciferase [EC 1.13.12.7] uses 
luciferin, a heterocyclic carboxylic acid, as a substrate whose conversion depends 
upon the presence of ATP. According to the enzymatic mechanism (White et a l, 
1969), the beetle luciferases catalyze a sequence of reactions that convert firefly
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luciferin into an electronically excited state oxyluciferin product which then emits 
light:
luciferin + ATP + O2 —^ oxyluciferin + AMP + PPi + CO2  + light (560 nm)
In this case, luciferase activity is also linked to cellular physiology and viability, as 
the reaction depends on the ATP concentration in the cell (Hastings, 1996).
1.3.1.2 Lux Genes Involved in Bioluminescence
1.3.1.2.1 Bacterial luciferase [E.C 1.14.14.3]
This is a heterodimeric enzyme whose subunits (40 kDa) and (37 kDa) are 
encoded by the luxA. and luxQ genes, respectively, which are both required for 
luminescence. In addition to the structural genes (/wxAB), three other genes {luxC, D, 
and E) are found in all bacterial luminescence systems. These genes encode three 
proteins that associate to form a fatty acid reductase protein complex required for the 
synthesis and recycling of the aldehyde substrate (Meighen, 1991). The lux genes 
have now been transferred into a variety of different organisms to generate new 
luminescent species (e.g. B. bronchiseptica) (Forde et a i, 1998). aturally dark 
bacteria containing the luxCDABE and luxAB genes, respeetively, are luminescent or 
emit light on addition of aldehyde.
1.3.1.2.2 Eucaryotic luciferases
The most studied eucaryotic luminescence systems are those from the firefly 
and the click beetle, both possessing a luciferase encoded by the lue gene. In contrast 
to bacterial luciferases, the firefly enzyme is composed of a single polypeptide (62 
kDa) of 550 amino acids that is active in a monomeric form. In fireflies, the luciferase 
reaction occurs in the peroxysomes of a light organ, but the reaction can also occur in 
bacteria and in cell free extracts, and requires only the enzyme, ATP, Mg^ '*', O2 and 
the substrate luciferin (Billard and DuBow, 1998).
61
1.3.1.4 Biotechnological application of bioluminescence
1.3.1.3 Advantages of bioluminescence-based reporter systems
Several advantages of using a bioluminescence assay could be summarised as
follows:
1- Reliable reporter assay. A number of luminescent genes have been isolated from 
diverse luminescent organisms, sequenced, and are now available as cloning 
vectors.
2- When fused to appropriate genes from a host organism, they will produce light 
under defined conditions, a signal that can be accurately measured and with great 
sensitivity, as well as quickly (real-time) and without perturbation of the sample 
(nondestructive).
3- lux or lue genes can be detected on the basis of unique DA sequences by gene 
probing and PCR amplifieation, but the major advantage of luminescence-based 
systems is the ability to detect light emitted by marked organisms or by luciferase 
activity in cell-free extracts.
4- Luminescent colonies can be detected by eye, providing distinction from colonies 
of indigenous organisms. A number of methods have been developed to measure 
light emission. More sensitive techniques involving exposure of the sample to 
photographic or x-ray films, quantification using scintillation counting, or 
luminometry, are commonly used.
1.3.1.4.1 Use of bioluminescent bacteria for determination of phagocytosis and 
bacterial survival
Using bioluminescence to study phagocytic activity depends on the fact that 
the level of the in vivo luminescnce of luminous bacteria is directly proportional to the 
viability of the cells. Upon phagocytosis, the in vivo luminescence may decrease as a 
result of the intracellular killing of engulfed bacteria. Moreover, the bioluminescence 
assay being non-destructive to the experimental system, allows a continuous 
determination of the kinetics of the process (Barak et al., 1983; Forde et a i, 1998). 
Forde et al. (1998) developed an approach to evaluate survival of intracellular B. 
bronchiseptica within macrophage cells. The internalization and persistence of B. 
bronchiseptica was examined in a murine macrophage-like cell line and in murine
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1peritoneal phagocytes by using bioluminescence as a reporter of bacterial viability. In 
this work, A 7-kb EcoRI fragment bearing the intact lux operon (luxC, hixD, lux A,
The relationship between protozoa and internalised bacteria is an area which
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/mxB, and luxE) from P. luminescens Hb was isolated from plasmid pT7-3. Ligation ■smixes of pUTmini-Tn5km and the 7-kb EcoRI lux fragment were used to transform 
the E. coli host strain by electroporation. Recombinant plasmid pUTmini-TnSkm/wx 
was extracted from host E. coli, and used to transform E. coli donor strain SMlOpir
I:(which contain transfer vector) by electroporation. Lux+ {E. coli) transformants were
Iisolated by CCD imaging. Exponential cultures of B. bronchiseptica 5376 and E. coli
\donor strain SMlOpir (pUTmini-Tn5kmlux) were mixed for plate matings at 37°C on §
uf-BG plates for 16 h. The resulting growth was resuspended in 100-pl aliquots were 
spread on BG selective plates (with rifampin and kanamycin) and incubated overnight
■ '4at 37°C. Exconjugants of Lux strain of 5. bronchiseptica (Kan* R if AmpA were '
picked randomly to gridded BG plates and examined by CCD imaging. 
Bioluminescence is shown to act as a convenient real-time technique for monitoring If
of intracellular survival of B. bronchiseptica in vitro and may provide a suitable 
means for examining the role of long-term intracellular survival of the bacterium in 
the host. X
.
:,îhas been investigated by employing a bioluminescent bacterial strain in coculture with 4
the freshwater ciliate, Tetrahymena pyrifonnis (Nelson et al., 2003). A 
bioluminescent bacterial strain was developed that enabled real-time monitoring of 
the uptake and survival of bioluminescent E. coli (0157) within the freshwater ciliate 
Tetrahymena pyrifonnis. Constitutively bioluminescent E. coli (0157) pLITE27 was
cocultured with T. pyrifonnis in nutrient-deficient (Chalkley’s) and in nutrient-rich :(proteose peptone, yeast extract) media. Non-internalised bacteria were inactivated by 
addition of colistin, indicated by a decline in bioluminescence. Protozoa were A
subsequently lysed with Triton X-100 which lead to a further drop in 
bioluminescence, consistent with release of live internal bacteria from T. pyrifonnis A
into the colistin-containing environment. Bioluminescenee measurements for non- 
lysed cultures indicated that internalised E. coli (0157) pLITE27 cells were only 
slowly digested by T. pyrifonnis, in both media, over the time period studied. The
results suggest that bioluminescent bacteria are useful tools in the study of bacterial f
intra-protozoan survival.
a
1.3.1.4.2 Evaluation of antibiotics effect by bioluminescenee assay of bacterial 
ATP
Studies of the persistent suppression of bacterial growth after short 
antimicrobial exposure is called postantibiotic effects (PAE). The in vitro 
postantibiotic effects (PAE) of aztreonam, ceftazidime, cefuroxime, imipenem, and 
piperacillin on E. coli were studied by a bioluminescenee assay of bacterial ATP. The 
strain was exposed for 2 h to different concentrations of |3-lactam antibiotics. The 
antibiotic activity was eliminated by 10(-4) dilutions, and regrowth of bacteria was 
monitored hourly by the bioluminescent assay of bacterial ATP. The length of PAE 
was dose dependent for ceftazidime (0.5 to 2.6 h), cefuroxime (0.4 to 2.6 h), and 
imipenem (0.3 to 4.5 h). The long PAE for these antibiotics at higher concentrations 
was associated with a potent initial killing and the presence of spheroplasts. 
Aztreonam and piperacillin produced a short, non-dose-dependent PAE (0.4 to 0.95 
h). Short PAEs (below 1 h) were seen concomitantly with production of filaments, 
except in the case of imipenem, which only produced spheroplasts. The results of this 
work makes it possible to study PAE for (3 lactam antibiotics on Gram-negative 
bacteria with bioluminescenee (Hanberger et a l, 1990).
1.3.1.4.3 Use of ATP bioluminescenee as a measure of cell proliferation and 
cytotoxicity
The nucleotide adenosine triphosphate (ATP) plays a central role in energy 
exchanges in biological system. ATP is present in all metabolically active cells. Most 
ATP is found within living cells and links catabolic and anabolic processes. Cell 
injury or oxygen depletion results in a rapid decrease in cytoplasmic ATP. Therefore, 
measurement of ATP is important for study of living cells. This method has been used 
for ATP determination because of the sensitivity of the luciferin-luciferase 
bioluminescent assay (Higashi et a l, 1985 cited by Crouch, et al 1993). Adenosine 
triphosphate (ATP) bioluminescenee was used to determine whether there was a linear 
relationship between cultured cell number and measured luminescence using the 
luciferin-luciferase reaction (Crouch et a l, 1993). These investigations have been 
carried out using peripheral blood mononuclear cells in addition to a number of cell 
lines including MOLT-4, HL-60, TF-1 and FS-60 cells. The effect of granulocyte 
colony-stimulating factor (G-CSF) dependent proliferation on TF-1 cells was
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investigated. The cell lines MOLT-4, HL-60, TF-1 and FS-60 showed a strong 
correlation between thymidine uptake and ATP bioluminescence (p > 0.00001 for all 
cell types). Additionally the ATP method could detect the cytokine dependent 
proliferation on TF-1 and FS-60 cells by granulocyte-macrophage colony- 
stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF)
1.3.1.4.4 Investigation of quorum sensing by using bioluminescence assay using 
lux-based AHL on biolfim formation
autoinducers (Whitehead et a l, 2001). In Gram-negative bacteria, -acyl homoserine 
lactones (AHLs) are a common diffusible signal, controlling the expression of 
characteristics associated with virulence and secondary metabolism (Swift et a l, 
1996). AHL-mediated control of gene expression in quorum sensing occurs through 
the activity of proteins with homology to Lux I and LuxR, which control 
bioluminescence in the marine bacterium Vibrio {Photobacterium) fischeri (Chhabra 
et a l, 1993). To establish whether QS was occurring in Aeromonas biofilm, the 
presence of C4-HSL in biofilm samples was assayed using a bioluminescent AHL 
sensor strain E. coli strain JM109 (Lynch, 1999). It was shown that C4-HSL and the 
ahyl and ahyR genes are important in the differentiation of Aeromonas biofilm (Lynch 
et a l, 2002).
respectively. The tumour necrosis factor alpha (TF)-induced cytotoxic effect on L- 
929 cells could also be accurately detected using this method. It would therefore 
appear to be possible to use ATP bioluminescence in the detection of cytokine activity 
in a number of different bioassays.
6 ':::Quorum sensing (QS) is a process by which bacteria regulate gene expression 
through the production and detection of extracellular signalling molecules known as
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1.4 Aims of the project
In the light of recent findings about mast cell functions and their importance in 
the primary response of the immune system, the main aim of this study was to 
investigate their interaction with bacteria: their ability to recognize, engulf and kill 
bacteria and the effect of selected bacterial pathogens on the viability and 
degranulation of mast cells. The initial focus of interest was with the human pathogen 
B. pertussis, because of an apparent interaction with mast cells observed in a coughing 
rat model of pertussis, because of previous reports of the effects of B. pertussis and
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pertussis toxin on mast cells, and the possible links between pertussis and pertussis 
vaccination and allergic disorders. However, initial experiments failed to show that B. 
pertussis strains had any major effect of sheep bone marrow mast cells (sheep 
BMMC) that were available. Thus, attention was shifted to B. bronchiseptica, an 
important animal pathogen and possibly more relevant to study in conjunction with 
sheep BMMC. Other advantages of using this as the model organism were that it 
shares many of its virulence factors with B. pertussis but is less fastidious and easier 
to grow and also that a bioluminescent strain was available and thought to be highly 
suitable for monitoring bacterial-mast cell interactions.
Uptake of Borcletella bronchiseptica by sheep BMMC and other cell types will 
be studied by using a bioluminescent strain of B. bronchiseptica as a reporter strain.
As well as to assess intracellular survival of ingested B. bronchiseptica (Lux 95). This
‘.-Ibioluminescent strain has been used previously for studies on phagocytic uptake by, 
and intracellular survival in, mouse macrophage-like cells. Based on in vitro invasion 
assays, the kinetics of interaction between sheep BMMC and B. bronchiseptica will 
be followed.
B. bronchiseptica is an animal pathogen that can exist as virulent and avindent 
forms that are governed by the Bvg virulence-regulatory system. This study will 
compare the effects of wild-type B. bronchiseptica and a Bvg-phase-locked mutant on 
viability and degranulation of mast cells and other types of mammalian cells, namely 
the RBL-2H3 cell line and J774A.1 mouse macrophage-like cell line. At the same 
time, cytotoxicity of B. bronchiseptica will be compared with that of other Borcletella 
species and other unrelated bacteria toward mast cells and other cell types.
Adenylate cyclase toxin (or CyaA) is a putative virulence factor that is 
presumed to have a central role in the pathogenesis of B. bronchiseptica and B.
A
4:
pertussis infections. A main objective of this study was to compare the cytotoxic 
effect of different forms of purified recombinant ACT toward the mast cell population f
and, in addition, to specify the importance of either the enzymatic activity or pore- 
forming activity of adenylate cyclase toxin in its cytotoxicity towards sheep BMMC |
and other mammalian cells. Furthermore, the effect of other purified factors (PT, FHA 
and PRﬀ) from Borcletella species on viability and degranulation of different 
mammalian cells will be investigated. Finally, the importance of adenylate cyclase t
toxin and pertussis toxin in modulation of mouse macrophage cells functions toward |
B. bronchiseptica infection will be studied based on the ability of mouse macrophage 
cells pre-treated by CyaA to take-up bacteria.
I
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2.1 Bacteria and growth media
2.1.1 Gram negative bacteria
2.1.1.1 Bordetella bronchiseptica
Five different strains of B. bronchiseptica were used for assessing their effect 
on survival and degranulation of different mammalian cells. These strains are listed in 
table (2.1). All these strains were grown routinely on BG agar. Stocks were prepared 
as suspensions in 1% CAA-glycerol and aliquots were frozen at -70  °C and thawed 
for use.
Virulent-type B. bronchiseptica (BBC17) and avirulent-mutant type of B. 
bronchiseptica (Bvg" phase) were kindly donated by Professor Mark Roberts 
(Department of Veterinary Pathology, University of Glasgow). Both strains of B. 
bronchiseptica were received as BG agar plate cultures and converted into -70^C 
CAA-glycerol suspension.
A novel bioluminescent B. bronchiseptica strain (Lux 95) was received from 
departmental stock (Forde et a i, 1998) as CAA-glycerol suspension frozen at -70°C.
Two novel strains mutated in two-component systems (TCS), recently 
described, were created from B. bronchiseptica BBC 17 by Dr. Martin Lynch 
(Infection and Immunity Division, University of Glasgow). They were obtained from 
our department stocks. Both strains. Bag AS and BhoAS, were grown on BG agar and 
treated as previous strains.
Culture purity was checked by visual inspection and Gram stain. Virulence- 
related properties, adhesive and haemolytic effects of wild-type B. bronchiseptica 
BBC 17 and other mutant strains were checked by methods such as conductimetry 
assay (for ACT activity), haemagglutination assay (with sheep red blood cells) and 
haemolysis of sheep RBC on sandwich BG agar.
For storage (if previous tests were satisfactory), a loopful of a heavy inoculum 
was suspended in 1.6 ml of sterile casamino acids (CAA)(Difco) and 0.4 ml sterile 
glycerol (BDH) and put into washed, sterilized 2ml polypropylene screw-cap vials 
(Elkay Lab products UK LTD) and stored at -70 °C.
2.1.1.2 Bordetella pertussis
Four different strains of Bordetella. pertussis were received from departmental 
stocks as -70”C frozen suspensions and treated in same way as B. bronchiseptica (for
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example, purity and virulence). Originally, they were kindly donated by Dr. Alison 
Weiss (University of Cincinnati, USA). These four strains are: 338 (wild strain), 347 
(Bvg" phase), 357 (defective in pertussis toxin production) and 348 (defective in ACT 
production). All these strains are listed in Table (2.1). B. pertussis strains were grown 
routinely on BG agar and were placed in a humidified box and incubated for 2-3 days 
at 31°C.
2.1.1.3 Growth of different Bordetella species from frozen stock cultures
Frozen stock suspensions in 1% CAA-glycerol were thawed at room 
temperature. One loopful of the suspension was streaked on to each of two to three 
BG plates which were incubated in a moistened box in a 37^C. The resultant growth 
was checked by Gram stain to confirm the presence of Gram-negative coccobacilli 
and absence of contaminants.
2.1.1.4 Other Gram-negative bacteria
Pasteurella multocida strains 85020 and JRMT12 and bioluminescent strain of 
Escherichia coli (DH5apT7-3) were received as agar cultures from departmental 
stock. For stock, these strains were stored as CAA-glycerol suspensions at -70 °C. 
Culture purity was tested by visual inspection and Gram stain.
P. multocida was subcultured routinely on Brain-Heart Infusion (BHI) agar 
medium with the supplementation of 5% (v/v) defibrinated sheep blood. Liquid 
cultures were grown in the BHI broth medium in universal containers with shaking 
overnight on an orbital shaker at 150-200 rpm at 37°C.
The bioluminescent E. coli (DH5apT7-3) strain was grown with 50 |ig/ml 
ampicillin (Sigma) on LB agar or in 5ml LB broth media in Universal containers or 
dimpled flasks with shaking overnight on an orbital shaker (L.H. Engineering Co. 
LTD.) at 150-200 rpm at 3TC.
2.1.1.5 Construction of bioluminescent E. coli
The bioluminescent E. coli lux was strain DH5a containing plasmid pT7-3, 
which encodes ampicillin resistance and includes the lux CDABE genes from the 
naturally bioluminescent bacterium Xenorhabdus luminescens. In this plasmid, the lux 
genes are under the control of the phi-10 promoter for T7 RNA polymerase and are
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transcribed at a low level by E. coli RﬁA polymerase (Szittner and Meighen, 1990). 
This E. coli strain was kindly provided by Professor E. Meighen (Department of 
Biochemistry, McGill University, Montreal, Quebec H3G 1Y6, Canada).
2.1.1.6 Construction of bioluminescent B. bronchiseptica (Lux 95)
This particular strain was constructed by Forde et a l  (1998) in our laboratory 
by using a mini-Tn5 promoter probe carrying the lux operon {luxC, luxD, luxA, luxB, 
and luxE). Briefly, a 7-kb EcoRl fragment bearing the intact lux operon from X. 
luminescens was isolated from plasmid pT7-3 (see section 2.1.1.5) and blunt-ended 
with the Klenow fragment of DNA polymerase at 25°C for 15 min in the presence of 
4 pM deoxynucleoside triphosphates. Plasmid pUTmini-TnSkm was linearized with 
Notl and blunt-ended. Ligation mixes of AoB-linearized, blunt-ended pUTmini- 
Tn5km and the 7-kb EcoRl lux fragment were used to transform the E. coli host strain 
CC118Xp;r by electroporation, and transformants (Kan' Amp') were screened for 
bioluminescence with a charge-coupled device (CCD) luminescence imager (Photonic 
Science). Recombinant plasmids in which the lux genes were oriented divergently 
with regard to the kanamycin resistance marker were identified by their lack of 
bioluminescence. Recombinant plasmid pUTmini-Tn5kmfw% was extracted from host 
cells with Qiagen Mini-Prep columns, and used to transform E. coli donor strain 
SM107./?m by electroporation. Again Lux^ transformants (Kan' Amp') were isolated. 
B. bronchiseptica CBFl (Rif mutant of strain 5376) and E. coli donor strain 
SMlOXpir (pUTmini-Tn5km/ra) were resuspended in 10 mM MgS0 4 . Plate matings 
were performed at 37°C on BG plates for 16 h at a recipient-to-donor ratio of 3:1. 
Growth was resuspended in 1 ml of 10 mM MgS0 4 , and 100-pl aliquots were spread 
on BG selective plates (with rifampin and kanamycin) and incubated overnight at 
37°C. Exconjugants (Kan' R if Amp^) were picked randomly to gridded BG plates and 
examined by CCD imaging. The minitransposon pUTmini-Tn5kmZu% was used to 
generate a pool of 2,000 mutants of B. bronchiseptica CBFl (Forde et a l,  1998). From 
these, one strain, designated here as B. bronchiseptica (Lux 95) was chosen because it 
exhibited high light output under different growth conditions (i.e. constitutive 
expression of the lux genes)
Table 2.1: Different Gram-negative bacteria used in this project
Strain Description Growth media Source/Remarks
B. bronchiseptica Wild type (bvg"  ^phase)
BBC17
B, bronchiseptica Mulanl type (Bvg ” phase)
BBC17
B. bronchiseptica Bioluminescent strain 
Lux 95
B. bronchiseptica 
BagAS
B. bronchiseptica 
BhoAS
B. pertussis 
338
B. pertussis
347
B. pertussis 
357
B, pertussis
348
Mutant of BBC) 7
Mutant of BBC 17
Antibiotic resistance derivative 
of Tohania (Bvg + phase)
Transposon mutant (Bvg" phase) 
of B. pertussis 338
Transposon mutant (defective in 
pertussis toxin production) of B. 
pertussis 338
Transposon mutant (defective in 
ACT production) of B. pertussis 338
P. multocida 85020 Wild strain
P. multocida Mutant strain {aroA)
JRMT12
E.coli DH5apT7-3 Bioluminescent strain
BG agar, LB agar, LB 
broth, SS and CL 
media.
BG agar, LB agar, LB 
broth, SS and CL 
media.
BG agar, LB agar, LB 
broth, SS and CL 
media.
BG agar, LB agar, LB 
broth, SS and CL 
media.
BG agar, LB agar, LB 
broth, SS and CL 
media.
BG agar, SS and CL 
media.
BG agar, SS and CL 
media.
BG agar, SS and CL 
media.
BG agar, SS and CL 
media.
BHI agar and broth 
BHI agar and broth 
LB agar
Roberts, M.
Dept. Vet. Path. 
University of Glasgow 
Roberts, M.
Dept. Vet. Path. 
University of Glasgow 
Department stock
Department stock
Department stock
Weiss, A. Dept. 
Molecular Genetics, 
University of Cincinnati 
Weiss, A. Dept. 
Molecular Genetics, 
University of Cincinnati 
Weiss, A. Dept. 
Molecular Genetics, 
University of Cincinnati 
Weiss, A. Dept. 
Molecular Genetics, 
University of Cincinnati 
Veterinary research 
institute, SriLanka 
(Tabatabaei et a l,
2002)
(Herrero et a l, 1990; 
Forde et a l,  1998)
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Continued 
Strain_______  Description Growth media Source/Remarks
B. pertussis 18323 Wild-type
B. parapertussis ﬂCTC 5952
B. avium
B. holmesii
B. trematum
B. hinzii
ﬂCTC 12034
ﬂCTC 13202
ﬂCTC 13203
ﬂCTC 13200
BG ara, LB agar, LB 
broth, SS and CL media
BG ara, LB agar, LB 
broth, SS and CL media 
BG ara, LB agar, LB 
broth, SS and CL media 
BG ara, LB agar, LB 
broth, SS and CL media 
BG ara, LB agar, LB 
broth, SS and CL media 
BG ara, LB agar, LB 
broth, SS and CL media
Weiss, A. Dept. Molecular 
Genetics, University of 
Cincinnati 
RSIL
RSIL
RSIL
RSIL
RSIL
RSIL Respiratory and Systemic Infections Laboratory.
NCTC National Collection of type Cultures.
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2.2 Preparation of growth media
2.2.1 Bordet-Gengou (BG) agar
For routine growth and maintenance of Bordetella species, BG agar medium 
was used. 36 g of Bordet-Gengou Agar Base (Difco, Becton, Dickinson and company, 
France) and 1 % (v/v) glycerol were added to distilled water to give a final volume of 
850ml in 1000ml screw cap bottle. The mixture was heated in a steamer to dissolve 
the agar completely and then sterilised by autoclaving at 12UC for 15 minutes. The 
agar was allowed to cool to 45-50 °C in a thermostatically-controlled water bath. 
Fresh sterile defibrinated horse blood (Tissue Culture Service Ltd, Buckingham, UK.) 
was warmed up to 37 “C and 150 ml (15% of total volume) of the blood was added to 
BG agar aseptically.
2.1.2 Gram-positive bacteria
These were received as plate cultures and were converted into -70  '’C CAA- 
glycerol suspensions as done with previous strains, after growth in appropriate media 
as listed below.
2.1.2.1 Staphylococcus aureus \
S. aureus strain 24 (Rodgers et a i, 2001) is an avian isolate and was received I
originally from Dr. J. J McCullagh (Veterinary Science Division of Agriculture for j
Northern Ireland). It was cultured on 4% (w/v) Tryptone soya agar (TSA) (Oxoid). jI
!i2.1.2.2 Streptococcus pneumoniae I
Prof. Tim Mitchell, (Infection and Immunity Department, University of :
Glasgow) kindly provided two strains of S, pneumoniae, strain D39 (wild type) and I
strain D39 Aply (deficient in pneumolysin production) (Mitchell and Andrew, 1997).
Both strains were grown on BHI agar with the supplementation of 5% (v/v) 
defibrinated sheep blood with incubation overnight at 37“C.
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The mixture was rotated gently, avoiding the introduction of air bubbles, and 
was added aseptically into sterile petri dishes in a laminar flow cabinet. After cooling, 
the plates were stored at 4°C until required. Sandwich BG agar had a bottom layer of 
BG agar without blood (12 ml) and a top layer of BG with blood (12 ml). This aided 
the visualisation of haemolysis.
2.2.2 Luria Bertaiii (LB) agar
10 g of Tryptone powder (DUCHEFA, BIOCHEMIE, Netherlands) with 5g of 
yeast extract powder (DUCHEFA, BIOCHEMIE, Netherlands) and 5g of sodium 
chloride were dissolved into one litre of distilled water and mixed thoroughly, then 
heated with frequent agitation and boiled for 1 minute to completely dissolve the 
powder. For LB agar, 1.2% of Agar powder (Oxoid, CM3; 28g) was added. The 
mixture was heated to dissolve the agar and autoclaved at 12UC for 15 min. The 
medium was dispensed aseptically into sterile petri dishes in a laminar flow cabinet. 
The plates were stored at 4°C until required.
2.2.3 Cyclodextrin Liquid (CL) medium
CL-medium was prepared as described by Imaizumi et al (1983). 10.7g L- 
glutamic acid (Sigma), 2.5 g NaCl, 0.5 g KH2PO4, 0.1 g MgCC.ôHzO, 0.02 g CaCC, 
0.2 g KCl, 6.25 g Tris (Sigma), 10 g casein hydrolysate (Difco), 0.24 g L-proline 
(Sigma) and 1 g dimethyLp-cyclodextrin (J. Shimizu, Teijin Ltd, Tokyo, Japan) were 
dissolved in 1 litre of distilled water. The pH was adjusted to 7.4 with 1 N NaOPI. The 
CL-medium base was sterilised at 121 °C for 15 minutes and stored at 4°C until 
required.
A supplement was prepared by dissolving 0.01 g FeS0 4 , 0.04 g L-cysteine, 
0.004 g niacin, 0.15 g glutathione and 0.4g ascorbic acid (all from Sigma) in 10 ml 
distilled water, which was then sterilised by passage through a membrane (0.45 p,m 
pore size) filter (Sartorius). It was added to the CL-medium base immediately before 
use in a volume of 100 pi per 10 ml of medium. The supplement could be stored at -  
20"C, but was discarded after two months if not used.
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2.2.4 Modified Stainer-Scholte (SS) medium
Stainer and Scholte (1971) described a simple chemically-defined medium for 
the production of phase I B. pertussis. SS medium was prepared as follows; 10.7g L- 
glutamic acid (Sigma), 2.5 g ﬃaCl, 0.5 g KH2PO4, 0.1 g MgCl2.6H20, 0.02 g CaCC, 
0.2 g KCl, 6.25 g Tris (Sigma), 10 g casein hydrolysate (Difco) and 0.24 g L-proline 
(Sigma). The medium was sterilized at 121°C for 15 min and stored at 4°C until 
required.
A supplement was prepared by dissolving 0.01 g FeS0 4 , 0.04 g L-cysteine, 
0.004 g niacin, 0.15 g glutathione and 0.4 g ascorbic acid and 0.4 g ascorbic acid (all 
from Sigma) in 10ml distilled water, which was then sterilised by passage through a 
membrane (0.45 pm pore size) filter (Sartorius). It was added to the SS-medium base 
immediately before use in a volume of 50pl per 10 ml of medium. The supplement 
was stored at -20°C, and discarded after two months if not used.
2.2.5 Brain Heart Infusion (BHI) agar
37 g of Brain Heart Infusion powder (Oxoid) and 12 g of Agar powder were 
suspended into 1 litre of distilled water. The mixture was heated at 100°C to dissolve 
the powders and autoclaved at 121°C for 15 min. The agar was allowed to cool to 45- 
50°C in a thermostatically-controlled water bath. Fresh and sterile defibrinated horse 
blood (Tissue Culture Service Ltd, Buckingham, UK.) was warmed up to 37°C Media 
and was added slowly into mixture to a final concentration of 5%. The agar was 
mixed and dispensed aseptically into sterile petri dishes in a laminar flow cabinet. The 
plates were stored at 4°C until required.
2.2.6 Tryptone Soya Agar:
40 g of TSA powder and 12% of Agar powder (Oxoid, CM3; 28g) was added 
into one litre of H2O. The mixture was heated and autoclaved at 121 °C for 15 min. 
The medium was dispensed aseptically into sterile petri dishes in a laminar flow 
cabinet. The plates were stored at 4°C until required.
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2.3 Virulence related properties of B. bronchiseptica strains
2.3.1 Determination of AC enzymatic activity by conductimetry assay
2.3.1.1 Conductimetry apparatus
The adenylate cyclase (AC) toxin (or CyaA) is a product of the Bvg phase of 
certain Bordetella species. A conductimetry assay was used to detect the enzymatic
'^ '1
activity due to CyaA which determined whether the strains used for other purpose ywere in the Bvg"'' phase or Bvg ' phase. The assay measures a change in the electrical
conductance of the reaction solution (see next section). The conductimetry equipment f
was developed originally by Mezna and Lawrence (1994) and consists of an eight . Ï
glass-cell system. It has been modified recently for control from a computer, with
automatic balancing and calibration. The enclosed water bath where the glass cells are
suspended is allowed to heat to, and is maintained at, 37 °C and the stirrer inside
maintains constant water temperature.
The sampling period is 1 sec/cell, cycling through the cells from cell 1 through 
to cell 8, with each cell containing a magnetic flea. This allows continuous mixing of 
the contents of each cell. The conductivity of incomplete assay mixture (2ml) is |
allowed to balance before the reactions are initiated by the addition of sample contains a
AC enzyme. Data processing of results includes blank subtraction (removes |
background noise) and on-screen line drawing to measure tangents of progress curves A
and total change in the electrical conductance of the reaction solution. 7
2.3.1.2 Conductimetry assay of AC enzymic activity
Lawrence et al (2002) described the conductimetry assay. Buffer containing 
10 mM Bicine and 10 mM magnesium acetate (MgAc) was degassed by heating for 1- I
2 min to 90 C and placed under vacuum pressure for 30 s. It was then allowed to cool |
to room temperature before the addition of ATP. A volume of 2 ml of buffer, 1 pi of 1 f
mg/ml calmodulin (CaM) (Sigma) and ipl of 0.5 unit/pl of inorganic 
pyrophosphatase (PPiase) (Sigma) were added to each glass cell. Balancing of the 7
cells was allowed to occur before addition of samples containing AC enzyme. After T
three readings, 2 pi of 43 ng/pl of purified recombinant ACT was added as a positive
7control (provided by Dr. B. Orr, Infection and Immunity Division, University of
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Glasgow). The following reaction occurs in the cells where the buffer and reagents are 
present:
AC enzyme inorganic PPiase
(ATP.Mg)^' + Bicine ' ------- ► cAMF + (BicineH) + (PPiMg)^" ----- ► 2Pi^' + Mg^^
Calmodulin
This equation predicts no change in conductance unless the pyrophosphate product is 
cleaved to release the magnesium ion from chelation (Lawrence et al 2002). It is the 
release of the independently mobile ions, Pi and Mg that produces the change in 
conductance that is measured by the assay. Total conductance change and tangents to 
reaction curves were measured by an on-screen line drawing routine.
2.3.1.3 Detection of AC enzymic activity from B. bronchiseptica
The method developed for detection of AC enzymic activity from lysed cells 
of Bordetella species was described by Packard (PhD thesis, 2004).
Different B. bronchsieptica strains, wild-type B. bronchiseptica (Bvg phase), mutant 
strain (Bvg " phase) and bioluminescence B. bronchiseptica (Lux 95) were grown on 
BG agar plates and incubated overnight at 37 '^ C. Cell suspensions of bacteria from 
the overnight growth were prepared at 2 x 10  ^cfu/ml in saline, initially by comparison 
with an opacity rod, which was then later determined to be equivalent to OD6oonm = 
0.46.
1 ml of cell suspension was transferred to a 1.5ml eppendorf tube (Sarstedt), 
and centrifuged at 13000 rpm for 10 min (Biofuge pico, Heraeus). The supernatant 
was discarded and the pellet was solubilized by adding 300pl of 10% v/v solution of 
Triton X -100 (a non ionic detergents) and mixing at 4 °C on a rotary shaker for 20 
min. The conductimetry assay was carried out as described in 2.3.1.2, except that 100 
pi of lysate was added to glass cells to start the reaction.
2.3.2 Haemagglutination assay
The filamentous haemagglutinin of Bordetella species is another product of the 
Bvg phase (Mattoo and Cherry, 2005). Thus, a haemagglutination assay could be 
used to determine the phase of the strain used in this study. Purified FHA was used as 
a positive control in this work, and was serially diluted five times. The procedure
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involved the collection of different B. bronchiseptica strains from BG plates that had 
been incubated for 24h at 37 °C. Cell suspensions of bacteria were prepared to 2 x 10  ^
cfu/ml in saline, which was determined to be equivalent to ODfioonm = 0.46. A 100 pi 
volume of cell suspension was added to individual wells in a 96-well u-shaped plate 
(Greiner, UK) and for the following five wells, five serial dilutions were carried out 
(100 pi as a final volume in each well). Thereafter, lOOpl aliquots of 2% washed 
sheep red blood cells in saline were added to all wells. The plate was mixed for 15 
min on a shaker at room temperature. The plate was then incubated at 37 °C for Ih 
and thereafter at 4 °C for 24 h. At the end of the experiment, haemagglutination at the 
bottom of each well was determined.
2.4 Mammalian cells and culture
2.4.1 Sheep bone marrow mast cells
2.4.1.1 Bone marrow collection and preparation
Dr. John Huntley (Moredun Research Institute, Edinburgh) generously 
provided sheep bone marrow cells. Preparation of bone marrow cells was carried out 
using a modification of the teehnique of Haig et a l  (1988) for the collection of ovine 
sternal bone marrow. Suffolk-cross lambs, aged 6-12 months (the younger the animal 
the better, no older than 6 months if possible) were killed using captive bolt followed 
by exsanguination. Immediately post mortem, the sternum was removed and split 
longitudinally from the xiphoid cartilage to the manubrium with a surgical saw.
The marrow was extracted by squeezing the sternum in a vice and collecting 
the exudate from the cut surface with a sterile scalpel blade. The extracted marrow 
was resuspended in 20 ml of sterile Hanks balanced salt solution (HBSS) containing 
5% foetal calf serum (ECS), 1% penicillin/streptomycin (P/S) and 20 U/ml heparin. 
The cell suspension was removed from below the fat layer, filtered through two 
thicknesses of sterile lens tissue to remove fat and debris and washed twice in fresh 
HBSS + 5% PCS + P/S + heparin by centrifugation at 200 x g in a Beckman Model 
TJ-6 centrifuge at 4 °C for 5 min before re-suspending each preparation in 24 ml of 
the same medium. 4 ml aliquots of the washed cell suspension were carefully overlaid 
onto 6 ml of lymphoprep™ (Bayer, GmBH) for centrifugation at 400 x g for 30 min at 
room temperature. The resulting inter-phase cells were harvested, pooled and diluted
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in at least four volumes of HBSS + 5% PCS + P/S + heparin and washed three times 
as above, to remove any residual lymphoprep. After the final wash, the cells were f
resuspended in 20 ml of sterile Iscove’s Modified Dulbecco’s Media (IMDM, Gibco), A
containing 5 x 10 ' M mercaptoethanol (2-ME), 10 % PCS and P/S. A viable cell 
count was performed before adjusting the cell density to 2 or 3 x 10  ^ cells/ml in 
PVIDM and aliquoted into 75-225 cm^ canted neck sterile tissue culture flasks 
(Corning) for different studies.
]
2.4.1.2 Preparation of rOvIL-3 and rOvSCF
Dr John Huntley (MRI) generously provided cell supernatants containing 
recombinant ovine interleukin-3 (rOvIL-3) and recombinant ovine stem cell factor 
(rOvSCP). These factors were prepared as described by Mclnnes et al. (1993) for the 
production of rOvIL-3. Stable expression of rOvIL-3 and rOvSCP was achieved in 
Chinese Hamster Ovary (CHO) cells using the Celltech pEE14 vector (Cockett et al.,
1990). The gene for rOvIL-3 (Mclnnes et a l, 1993) and the cDA for the soluble 
form of rOvSCF (Mclnnes, unpublished, EMBL. O. Z50743) were ligated into 
separate vectors adjacent to the human cytomegalovirus immediate early promoter 
sequence. The vector contained the glutamine synthetase (GS) gene as an amplifiable 
marker in CHO cells. Pollowing transfection of ligated pEE14 IL-3/SCF plasmids into i
CHO cells, transfectants expressing elevated levels of GS were selected in the
■V [presence of 25-250 pM methionine sulphoxamine (Sigma). Expression of rOvIL-3 f
and rOvSCP mRA was checked by orthern blotting, and recombinant protein
expression by gel electrophoresis. Batches of supernatant were collected and assayed
for biological activity in 24-well plate bone marrow culture. 1;
2.4.1.3 In vitro growth of sheep bone marrow mast cells
All procedures of sheep bone marrow preparation and collection were carried 
out under aseptic conditions in a tissue culture hood (IC flow Gelaire® Class II j!BSB48, IC Pharmaceuticals LtD) using sterile media and equipment. 7These procedures were carried out according to the method of Macaldowie,
Huntley and Haig (1997). The recombinant growth factors, ovine interleukin-3
(rOvIL-3, Moredun batch no. 1H2 3/2/10/TP/1/C/9/2) and ovine stem cell factor y
(rOvSCP, Moredun batch no. 3/2/7/2/TP/2/A/3/12/3) were added in the appropriate I
I
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combination and concentrations for the current experiment. Then, the cells were 
incubated in an atmosphere of 5% CO2 in air at 37 °C in a tissue culture incubator 
(IC  Flow automatic CO2 incubator model 160, IC  Pharmaceuticals).
rOvIL-3 was added into bone marrow culture at 1:100 and rOvSCF were 
added at 1:50 (as final concentrations). For different studies, isolated bone marrow 
cells were set up at 1x10^ cells/ml in IMDM containing 10% PCS and 1% Penicillin / 
Streptomycin (P/S) in a 75 cm^ sterile tissue culture flask. The initial culture volume 
10ml was fixed during growth with observations of cell numbers during the growth.
Flask cultures were fed with both growth factors every 48h by adding the 
appropriate volume of fresh cytokine preparation to give the correct final dilution. 
Every seven days, the cells were centrifuged at 200 g for 5 min and resuspended in 
fresh IMDM + 10% PCS and 1% P/S. Throughout the culture period, the cells were 
monitored daily under a Leica DM IL inverted microscope (Leica microscopy) and 
by microscopic examination of Feishman’s cytosmear preparations.
2.4.1.4 Enumeration and staining of BMMC
Cytosmear preparations of sheep bone marrow mast cells were made using a 
Shan don Cytospin 2 cytocentrifuge (Shandon Southern Products LtD). Aliquots of 
200pl of cell suspension containing IxlO*^  cells/ml were centrifuged at 800 rpm for 5 
min. The slides (cytosmears) were stained immediately with Leishman’s stain.
2.4.1.5 Leishman’s staining of cytosmears
Cytosmears slides were laid out on a staining rack and flooded with 1 ml 
Leishman’s staining solution (BDH) for 2 min. 1 ml of tap water was then added and 
the mixture left for a further 5min. After rinsing thoroughly in tap water, the slides 
were air dried and mounted. Stained cells in the cytosmears were counted under a x40 
objective lens by normal microscopy. A minimum of 400 cells were randomly 
counted per slide with the final results expressed as the percentage of mast cells 
relative to the total cell population present in the cytosmear.
2.4.1.6 Cell fixation for electron microscopy
Aliquots of 1.5ml of cell suspension containing 1 x 10*^  cells/ml were 
transferred to eppendorffs and centrifuged at 1200 rpm for 5 min in a microcentrifuge 
(Biofuge, Heraeus). The supernatant was removed and the pellet resuspended in 1 ml 
of freshly made up fixative containing 3% glutaraldehyde (Sigma) and O.IM 
phosphate buffer. The cells were fixed for 24 h at 4°C before processing. The 
specimens were then rinsed in 0.1 M PBS for 3-10 min, and post-fixed in 2% osmium 
tetroxide (Sigma) in H2O for 2h. The specimens were then dehydrated through an 
ethanol series (30, 50, 70, 90 and 100%) for 10 min each. The specimens were then 
infiltrated with white resin (London Resin Comp.), (50:50 resin/absolute alcohol 
overnight), with the caps on the vials.
The caps were then removed and the ethanol allowed to evaporate overnight. 
The resin was then replaced with fresh resin and allowed to infiltrate for another 12- 
24 h. The specimens were then embedded in Beter Equipment Electron Microscopy 
B.E.E.M.) capsules, and polymerised at 60 °C for 24 h. Sections were cut at 60 
nanometeres on an L.K.B ultramicrotome, picked up on 100 mesh formvar coated 
grids, and stained with 2% methanolic uranyl acetate and lead citrate (5 min in each). 
The sections were visualized on a Zeiss 902 electron microscope at 80 KV. Images 
were captured digitally on an image slave software programme.
2.4.2 Cell lines and culture
2.4.2.1 Rat basophilic leukemia cell line (RBL-2H3)
RBL-2H3 (ATCC !o. CRL-2256) is a tumour analogue of mucosal mast cells 
and widely used as a model for mucosal mast cells (Gentile and Skoner, 1996). The 
cell line was isolated and cloned in 1978 from Wistar rat basophilic cells that were 
maintained as tumours. These cells have high affinity IgE receptors (FceRI). They can 
be activated to secrete histamine and other mediators by aggregation of these 
receptors or with calcium ionophore.
This cell line was received as frozen cells. All the following procedures were 
carried out under strict aseptic conditions in a tissue culture hood (IC! flow Gel aire® 
Class II BSB48, IC! Pharmaceuticals LtD) using sterile media and equipment. The 
cell line vial was thawed for 2 min by gentle agitation in a 37 '^C water bath. Then, the
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vial was decontaminated by dipping in 70 % ethanol. To remove the cryo protective 
agents, the cells were washed by transfer into a 30 ml Universal tube containing 15 ml 
of IMDM which contained 10 % PCS and 1% P/S. Then, the tube was centrifuged at 
125 xg for 5 min.
The supernatant was discarded and cells were resuspended in 20 ml of fresh 
IMDM containing 10% PCS + and 1% P/S. A viable cell count was performed before
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adjusting the cell density to 1 x 10 cells/ml in IMDM and aliquoting into 75 cm' 
canted neck sterile tissue culture flasks (Corning) for different studies. The cell line 
was then incubated in an atmosphere of 5% CO2 in air at 37 °C in a tissue culture 
incubator (ICN Flow automatic CO2 incubator model 160, ICN Pharmaceuticals).
Within the first week, the culture medium was not changed and the 
morphology changes of the cells were observed by inverted microscope (Olympus, 
CK2). When cell proliferation started, IMDM medium was renewed each 48h, old 
medium was discard and replaced by fresh IMDM containing 10% PCS and 1% P/S. 
Throughout the culture time, the cells were monitored daily by using an inverted 
microscope (Olympus, CK2).
After two-three weeks of observation, cells were passaged in a fresh IMDM 
containing 10% PCS and 1% P/S. Attached RBL-2H3 cells were collected by scraping 
and centrifugation at 125 xg for 5 min and resuspended in a fresh IMDM containing 
10% PCS and 1% P/S and viability was investigated by using trypan blue exclusion 
count. Then, the collected cells were passaged into four new 75 cm^ canted neck 
sterile tissue culture flasks, each flask containing 20 ml of cell suspension.
For cell cultures which would be used for further experiments, it was observed 
that more than 10 passages could not be useful and an increase of cell death was 
observed which was estimated by trypan blue exclusion count. This meant that a new 
stock vial from the frozen RBL-2H3 cell line should be used.
After the first passage, RBL-2H3 cells were kept as stock in liquid nitrogen for 
future use. For storage, after collection by centrifugation, 1ml of cell freezing medium 
-DMSO serum free (Sigma, C6295) was added to each cell pellet and transferred into 
sterilized 2-ml volume polypropylene plastic vials with O-ring screw-caps and 
labelled by writing the name of cell and date of collection. The vial was frozen in -70" 
C for 3-4 h and stored in liquid nitrogen for future use.
2.4.2.2 Macrophage cell lines
Three types of macrophage cell lines have been used in this study.
Table (2.2) Macrophage cell lines and sources
"o. Description Source
P338D1
J774A.
Mouse lymphoid macrophage
RAW.264.7 Mouse monocyte macrophage
Mouse monocyte macrophage
EC ACC 85011439 
(Departmental Stock) 
ECACC 91062702 
(Departmental Stock) 
ECACC 91051511 
(Departmental Stock)
All three cell lines were maintained as cell suspensions in 1ml of freezing 
medium -DMSO serum free (Sigma) and stored in liquid nitrogen. At the time of use, 
cells were washed twice with IMDM medium by centrifugation at 1200 rpm for 5 
min. and resuspended in a fresh IMDM containing 10% PCS and 1% P/S and 
aliquoting into 75 cm^ canted neck sterile tissue culture flasks (Corning) for different 
studies. Within the first week, the culture medium was not changed and proliferation 
was observed by inverted microscope (Olympus, CK2). When cell proliferation 
started, IMDM medium was renewed each 48h, the old medium was discarded and 
replaced by fresh IMDM containing 10 % PCS and 1% P/S.
After two to three weeks of observation, cells were passaged in a fresh IMDM 
containing 10% PCS and 1% P/S by using the method of Westrop et a l  (1994). 
Attached macrophage cells were collected by shaking the flask to detach the cells and 
centrifugation at 125 xg for 5 min. Cells were resuspended in a fresh IMDM 
containing 10% PCS and 1% P/S and viability was investigated by trypan blue 
exclusion count. Then, the collected cells were passaged into four new 75 cm^ canted 
neck sterile tissue culture flasks, each flask containing 20 ml of cell suspension.
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2.5 Automated luminometry method
2.5.1 Equipment
The lu mi nometer (Anthos lucy 1) is a bench-top luminescence photometer 
(Figure 2.1a) intended for the measurement of all types of luminescence (Anthos 
Labtec Instruments Ges.m.b.H, AUSTRIA, www.anthos-labtec.com). The sample 
holder was a 96-well fluorescence plate, black, with clear flat-bottom wells (Sigma- 
Aldrich) (Figure 2.1b). The luminometer was run on Stingray multi-use software 
(WWW.dazdaq.com), which controls the instrument and asseses bioluminescence 
emission data (Figure 2. Ic). Addition of reagents was done manually in the measuring 
plate. The cover of the sample holder was closed except when applying reagents, so as 
to avoid change of incubation temperature or quick evaporation of buffer. The sample 
volume in each well ranged from 200-250 pi to avoid any flooding from one well to
another well that could cause interference. The sample changing (moving the cursor) 
and luminescence measurement was done automatically. The light emitted from each 
well (sample) was detected and was converted into an electrical signal which was then
■-1amplified, recorded, saved and displayed on the computer screen in the form of digital 
data and graph output against time. The temperature in the luminometer was adjusted 
to 37 "C, and the time interval between each reading could be controlled and ranged 
from 0.1 sec to 900 sec (15 min).
Figure 2.1a: The luminometer (Anthos lucy 1) (Anthos Labtec Instruments 
Ges.m.b.H, AUSTRIA, www.anthos-labtec.com). A) Plate carrier which is suitable 
for 96-well plate, tranpsort in x/y direction. A certain position on the plate carrier is 
searched (hole) during transport. B) Control-board, containing keys for control of 
different functions. C) The luminometer was run on Stingray multi-use software, 
which is able to record, save and display on the computer screen.
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Figure 2.1b: 96-well Fluorescence plate, black, with clear flat-bottom wells (Sigma- 
Aldrich).
Figure 2.1c: The luminometer was run on Stingray multi-use software, which is able 
to record, save and display on the computer screen. Green circles indicate the wells 
which contain sample.
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2.6 Phagocytosis of different strains of B. bronchiseptica
Interaction of different strains of B. bronchiseptica and sheep BMMC (or RBL- 
2H3 or macrophage cell lines) was done based on the method described by Ford, 
Parton and Coote (1998) with some modifications. Sheep BMMCs (or RBL-2FI3 cell 
line or mouse-macrophage cells) routinely maintained in IMDM medium containing 
10% PCS and 1% P/S, were collected in a 30 ml Universal tube. Then, the collected 
cells were centrifuged at 1200 rpm for 5 min, the supernatant was discarded and 
replaced with fresh IMDM medium containing 10% PCS. This step was repeated 
twice to remove antibiotics from the surrounding medium and the cell pellet was then 
resuspended in fresh IMDM medium containing 10 % PCS only. Viability of cells 
was confirmed by trypan blue exclusion count and cell number was adjusted to 1 x 
10*" cells/ml.
Infection of sheep BMMC (or RBL-2H3 or mouse macrophage cells) with 
different bacterial strains was carried out at a ratio of 1:500 (one mammalian cell, 500 
bacterial cells) in 96-well plate in triplicate. The 96-well plate was then centrifuged at 
low speed, 150 rpm for 5 min, to accelerate interaction between the two cell types. 
Incubation times were varied from Ih to 3h at 37 ^C in 5% CO2.
2.6.1 Automated luminonietry of bioluminescent bacteria
Sheep BMMC or other cell lines were infected with the bioluminescent stain 
of B. bronchiseptica {lux 95) (or bioluminescent E. coli) at an infection ratio of 1:500 
and incubated for 1 -  3 h as described above (section2,6). Then, to some wells, 50 
|Ltg/ml (final concentration) of polymyxin B was added to kill extracellular bacteria. 
Preliminary experiments had shown that this concentration of polymyxin B killed 
>99.99% of 5 xlO^ cells/ml of B. bronchiseptica (Lux 95) (over the period of Ih). 
After a further incubation period of 1 h, 50 |Llg/ml (as a final concentration) of 
digitonin was added into some wells (to some of which polymyxin B had been added) 
to lyse the sheep BMMC (or other mammalian cells) and to expose any intracellular 
B, bronchiseptica (Lux 95) to the polymyxin B.
Killing or survival intracellulary of B. bronchiseptica (Lux 95) was assessed 
by comparison of the light emission from digitonin and polymyxin B treated, and 
polymyxin B only treated wells (see figure 2.2).
Figure 2.2: Invasion assay
Survival of B. bronchiseptica {lux 95) was assessed by comparison of the light 
emission from polymyxin B-only treated wells (A) and digitonin and polymyxin B 
treated wells (B).
Light
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2.6.2 Intracellular survival of different B. bronchiseptica strains
Intracellular B. bronchiseptica (Lux 95) within sheep BMMC was determined 
by luminometry. Furthermore, intracellular survival of the bioluminescent strain of B. 
bronchiseptica (Lux 95) was compared with intracellular survival of the virulent 
strain of B. bronchiseptica (Bvg phase), and the avirulent stain of B. bronchiseptica 
(Bvg “ phase) within either sheep BMMC or J774A.1 macrophage cells.
Bacterial suspensions prepared from growth for 24h on BG agar of different 
strains of B. bronchiseptica (Lux 95, Bvg^ phase or bvg ' phase) were made in IMDM 
medium containing 10% FCS only and bacterial number was adjusted at ODgoonm = 
0.46. Sheep BMMC (or other mammalian cells) were adjusted to 1x10® cells/ml in 
IMDM medium containing 10% FCS only. Infection of sheep BMMC (or other 
mammalian cells) with different strains B. bronchiseptica was carried out at MOI 
1:500 in a total volume of 6 ml. Each infection was carried out in duplicate in a 25cm^ 
cell culture flask with vent cap and incubated at 37°C in 5% CO2 After incubation for 
3h, culture flasks which contained sheep BMMC and bacterial suspensions were 
shaken to detach sheep BMMC (or other mammalian cells) and collected in a 30 ml 
Universal tube. Cell suspensions were centrifuged at 2000 rpm for 5 min in IMDM 
medium three times, old supernatants were discarded and antibiotic free IMDM 
medium containing 10% FCS was added.
The washing step was repeated 3 times. This was done to remove most of the 
extracellular bacteria because bacteria attached to the cell surface of mammalian cells 
could not be easily removed by washing. Due to this, sheep BMMC (or other 
mammalian cells) were resuspended in fresh IMDM medium containing 10% FCS 
and 1 |Lig/ml polymyxin B (as a final concentration) and incubated at 37°C in 5% CO2.
Finally, at the end of each incubation time (16 h, 24 h and 36 h), extracellular 
polymyxin B was removed by extensive washing by centrifugation at 2000 rpm for 5 
min and resuspeneded in fresh IMDM. At this point, viability of sheep BMMC (or 
other mammalian cells) was estimated by using trypan blue exclusion count. 
Intracellular bacteria within sheep BMMC (or mammalian cells) were released by 
adding 100 pg/ml of digitonin as a final concentration. Then, 100 pi of cell 
suspension was diluted 1:100 with PBS, another 100 ul (from the first dilution) 
diluted 1:100 with PBS. Finally, 100 pi of the second dilution was inoculated on a BG
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agar plate, which was incubated at 37°C for 48h. Colonies were counted and the #
number of viable bacteria per ml of the original suspension was estimated.
i2.7 Methods for assessing cytotoxicity of different bacterial strains
Sheep BMMC (or other cell lines) were mixed with different strains of B. 
bronchiseptica (or other related or unrelated bacteria) and loss of mammalian cells Iviability was estimated over time. A variety of assays were applied.
2.7.1 Trypan blue exclusion count
Cell numbers and viability were confirmed by diluting a sample of mammalian 4
cell suspensions with an equal volume of 0.1% trypan blue (Sigma). Then lOpl from 
the mixture was pipetted into an improved #eubauer haematocytometer cell counting 
chamber (Hawksley, England). Light microscopy used to assess cell viability. Viable 
cells were seen as bright cells whereas dead cells stained blue.
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2.7.2 CellTiter-Glo’^ ’ Luminescent cell viability assay (Promega)
The luciferin-luciferase-based ATP bioluminescence assay was designed for 1
determining adenosine triphosphate (ATP) present in metabolically-active cells 
(Crouch et al 1993). The amount of ATP present was estimated by adding 
homogeneous reagent (CellTiter-Glo™ Reagent) into a mammalian cell suspension.
This results in cell lysis and generation of a luminescent signal which is proportional »
to the number of metabolically-active cells. The luminescent signal was detected by %7'
using an Anthos lucy 1 luminometer (see 2.5.1). 100 pi of mammalian cell-bacterial A
suspension in IMDM medium was mixed with an equal volume of homogenous 
reagent in black, 96-well, flat- bottom microtitre plates in triplicate. All contents were
'f:mixed at 300-500 rpm for at least 2 minutes on an orbital shaker to induce cell lysis, 1
and left for 10 minutes to stabilize the luminescence signal. Bioluminescence 
emission was measured within 3 minutes. #on-infected sheep BMMCs were used as 
controls for ATP levels, and were compared with those of infected cells.
2.7.3 MTT Dye reduction assay
Cytotoxic activity of different strains of B. bronchiseptica and their extracts 
was determined by the MTT assay (Hussain et al 1993) using the cell titre assay 
(Promega) kit. This assay is based on the reduction of a yellow tétrazolium dye (3-[4, 
5-dimethylthiazole-2-yl]-2, 5-diphenyl tétrazolium bromide, MTT) into insoluble 
purple formazan by dehydrogenases in active mitochondria of living cells.
Sheep BMMC (or other mammalian cells) were maintained in IMDM medium
and adjusted to 1x10® cells/ml. Infection of sheep BMMC (or other mammalian cells) 
with different strains of B. bronchiseptica was carried out at infection ratio of 1:500. 
lOOpl of cell suspension was added into 96-well, flat-bottom microtitre plates 
($unclon) in triplicate. The plate was incubated at 37 °C in 5% CO2 for 3h before 
addition of 15 pl/well of MTT dye (Promega) and incubation continued at 37 °C in 
5% CO2 for another 4h. The solubilization / stop solution (100 pl/well) (Promega) 
was then added and incubation continued at 37 °C in the humidified box overnight.
An ELISA reader {rosys anthos 2001) was used to measure the optical denisty 
at a wavelength of 540nm. The percentage of cell death was calculated by applying 
the following formula:
Sample (OD 540 nm) -  Positive (OD 540nm)
% of cell death = ( -1 ) X 100
$egative (OD 540nm) -  Positive (OD 540nm)
Sample: test sample (mammalian cells infected with B. bronchiseptica)
Positive: lysed sample of sheep BMMC (or other mammal in cells), Sheep BMMCs 
were lysed by the method of rapid freeze-thawing at -70°C.
$egative: IMDM alone.
2.7.4 Estimation of caspase 3/7 activity
The cysteine aspartie acid-specific protease (caspase) family plays important 'roles in apoptosis in mammalian cells. Caspase-3 and caspase-7 are members of this
family, which can be detected by using the Apo-O$%& Homogenous Caspase-3/7 
.assay (Promega) kit. The caspase-3/7 assay kit consists of a profluorescent substrate
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rhodaminel 10, bis-('-CBZ-L-aspartyl-L-glutamyl-L-valyl-L-aspaitic acid amide)(Z- 
DEVD-RllO) which is diluted 1:100 with optimized bifunctional cell lysis buffer, A
prior to addition to mammalian cells. Upon sequential cleavage and removal of the 
DEVD peptides by caspase-3/7 activity, the rhodamine 110 leaving group becomes 7
intensely fluorescent. The amount of fluorescent product generated is proportional to 
the amount of caspase-3/7 cleavage activity present in the sample and can be detected 
by fluorimetry in a luminescence spectrometer LS55 reader (Perkin Elmer).
Different concentrations of purified factors were used to stimulate 5x10^ :
cells/ml of mammalian cell suspension in lOOp.1 IMDM medium supplemented with 
10% FCS dispensed in triplicate in black, 96-well plates and mixed with lOOpl of 
homogenous Caspase -3/7 reagent. The plate was gently mixed using a plate shaker at
.'k
300-500 rpm for different times (30 min -  4 h) at room temperature. The relative 
fluorescence light units (RFLU) of the products were measured at a wavelength of
7OD485nm. The following formula was used to calculate caspase activity: |
f:.7
Caspase activity = Test sample -  Negative control y
Î
. V
Test sample: sheep BMMC (or other mammalian cells) treated with different A
concentrations of purified factors.
Negative sample: sheep BMMC (or other mammalian cells) incubated with IMDM 
medium only.
■■i2.8 Degranulation assay for sheep BMMC (or other mammalian 
cells)
2.8.1 p-hexosaminidase Assay
Activity of the granule-associated acid hydrolase, P-hexosaminidase, was 
measured by hydrolysis of the substrate p-nitrophenyl-N-acteyl-P-D-glucosaminide 
(Sigma). It was reported that 1 unit of enzyme cleaves 1 jtimole of substrate per hour 7a'
at 37 “C (Schwartz, Austen and Wasserman 1979). Degranulation of sheep BMMC f
(or other mammalian cells) was estimated after treatment with different bacterial 
strains, different purified factors of Bordetella species, or treatment with chemical
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% of p-hexosaminidase release
sample supernatant (OD 405nm) -  spontaneous release supernatant (OD 405nm)
(   ) ( 1 0 0 )
total cell extract (OD 405 nm)
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stimulators such as calcium ionophore or substance-P in a total volume of 200|il 
which was added in triplicate in 96-well microtitre plates and the mixture plate was 
centrifuged (Multifuge 3 s -r , Hereaus) at 150 rpm for 5 min to accelerate interaction 
between mammalian cells, different bacteria, or factors.
After a certain period of treatment, lOOjitl of mixture supernatant (from each 
well) was transferred into clean wells. The 25 jil from mixed supernatant was mixed 
with 50 pi of aliquots of 5 mM substrate diluted in citrate buffer pH 4.5 (Appendix) in 
a 96"well microtitre ELISA plate (M l29A, Dynatech Laboratories Ltd). The last step 
was repeated in triplicate. The mixture was incubated at 37°C for 45 min then the 
reaction terminated with the addition of 100 pi of ice-cold glycine-(aOH buffer pH 
10.7 (Appendix). The resulting colour change was read at OD405 nm on an Anthos 
Labtech 2001 reader with the mean OD result being calculated by using the following 
formula:
I
Sample supernatant: The optical density of test sample supernatant.
Spontaneous release supernatant: The optical density of the supernatant of the 
negative control (cell incubated with IMDM only).
Total cell extract: The optical density due to the total available activity of {3- 
hexosaminidase from mammalian cells, obtained by freezing and thawing (3 times) to 
release all (3-hexosaminidase.
2.9 Effect of cell extracts of sheep BMMC on B. bronchiseptica (Lux 
95)
The effect of viable sheep BMMC (or other viable eell lines) was compared 
with the effect of cell extracts of sheep BMMC (or other cell line contents) on 
bioluminescence emission of B. bronchiseptica {lux 95). Different cell numbers of
. 1
sheep BMMC (or other cell lines) were adjusted and maintained in IMDM medium 
containing 10% FCS only. The method of rapid freeze-thawing at -70°C was used to 
lyse cell membranes and release cell contents. This step was repeated three times. The 
resulting extract was centrifuged at 4000 rpm for five minutes and the supernatant was 
removed into a sterilized universal tube. B. bronchiseptica (Lux 95) was grown and 
adjusted and maintained in IMDM. lOOpl of B. bronchiseptica (Lux 95) suspension 
was mixed with 100 pi of sheep BMMC contents. The luminescence out-put was 
measured as described previously.
2.10 Effect of different Bordetella extracts on sheep BMMC
Four different purified factors of Bordetella species were used to investigate 
their effects on sheep BMMC or other cell lines (RBL-2H3 or J774A.1).
2.10.1 Recombinant adenylate cyclase toxin (or Cya A)
The following toxin was produced in the Infection and Immunity Department, 
IBLS, University of Glasgow and was kindly provided from departmental stock. 
Three different forms of ACT were used, these forms being:
Table (2.3) different forms of rACT.
ACT Description Concentration Producer strain Activity
(pg/ml) AC Hly
44/188 Purified 2020 E. coli
44/54 Purified 4000 E. coli + +
44/54/188 Purified 2551 E. coli - +
AC: acylated and enzymatically active, Hly: haemolytic activity and pore-forming
2.10.2 Pertussis toxin (FT), filamentous haemagglutinin (FHA) and pertactin 
(PRN)
These purified B. pertussis proteins were generously provided Dr D. Xing 
(National Biological Standards Boards, NBSB) as freeze-dried preparations. The 
amount in each vial was 20 pg protein. Each of the extracts was dissolved in 5 ml of
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saline to a protein concentration of 4 pg/ml and immediately stored in small volumes 
at -20  °C.
remove traces of ethanol. The D)A pellet was rehydrated by adding 100 pi of 
rehydration solution (Promega) for 1 h at 65 ”C, or occasionally overnight at 4 °C. The 
D)A was aliquoted and stored at -20 °C for further steps.
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2.11 DNA extraction
The effect of different forms of rACT (44/54 and 44/54/188) and PT on 
genomic D)A structure of sheep BMMC (or cell lines) was investigated. 1x10® 
cells/ml of sheep BMMC stimulated with different concentrations of different forms 
of rACT or PT was incubated for 24 h at 37 ”C and in 5% CO2. At the end of 
incubation time, cells were collected and genomic D)A was purified.
y«
1
2.11.1 Genomic DNA of sheep BMMC (or other mammalian cells)
For isolation of genomic D)A from sheep BMMC, RBL-2H3 or J774A.1,
Promega's Wizard® genomic D)A purification kit was used. 10 ml of suspension of
■mammalian cells treated with different purified virulence factors were centrifuged at 
4000 rpm for 5 min. Supernatant was discarded and the pellet was resuspended in 1 
ml of fresh IMDM medium and collected in 1.5 ml eppendorf tubes by centrifugation 
at 13000 rpm for 2 min. To the pellet was added 600 pi of nuclei lysis solution 
(Promega) and the mixture was pipetted to completely mix and the sample was 
incubated at 37 ^C for 15 min and then cooled at room temperature. 3 pi of R)ase 
solution was then added and, after through mixing, the sample was incubated at 37 °C 
for 30 min and then cooled at room temperature. After cooling, 200 pi of protein 
precipitation solution was added, the mixture vortexed and incubated on ice for 5 min.
The sample was centrifuged at 13000 rpm for 3 min and the supernatant was carefully 
transferred to an eppendorf tube containing 600 pi of isopropanol and mixed 
thoroughly. The sample was centrifuged at 13000 rpm for 2 min and to the pellet was
added 600 pi of 70% ethanol. The sample was then mixed and centrifuged for 2 min 
at 13000 rpm. The supernatant was removed and the pellet was air dried to completely
2.12 Agarose gel electrophoresis
2.12.1 Sample preparation
The sample D*A (5-30 pi) was mixed with 6 x D*A loading buffer 
(Appendix) in a 5:1 (vol/vol) ratio prior to loading into the wells. Molecular weight 
markers (1 Kb ladder, Gibco BRL, UK) were utilised according to manufacturer’s 
instructions.
2.12.2 Gel preparation
Pre-weighed agarose (type II-A medium EEC, Sigma) was suspended in 0.5 x 
Tris-Borate-EDTA (TBE) buffer (appendix) and heated until the agarose solution 
became clear (completely dissolved). The solution was allowed to cool to the extent 
that it was still warm and ethidium bromide (Bio-Rad, UK) was added to a final 
concentration of 0.5 pg/ml. A gel tray was prepared by taping the edges with adhesive 
tape and the gel was cast to the desired thickness. Upon setting, the gel was immersed 
in 0.5 X TBE buffers containing ethidium bromide (0.5 pg/ml) in a horizontal 
submarine electrophoresis tank (E-C apparatus Corporation, USA). A power pack 
(model SL3655, Scotlab, UK) was used to provide a constant voltage corresponding 
to 1-5 volt/cm. Electrophoresis was carried out until the marker dye in the loading 
buffer migrated an appropriate distance.
2.12.3 Visualisation of DNA
The ethidium bromide-stained DNA was visualised using a UV 
transilluminator (model TM-40, UVP Inc, California, USA). Images were stored 
electronically as appropriate using the Gel Documentation System Image Store 5000, 
version 7.2 (Ultra Violet Products, Cambridge, UK), as well as being printed using a 
video graphic printer (model UP-860, Sony). Electronic images were edited using 
Adobe Photoshop 3.0 and images labelled with Microsoft Power point 4.0.
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C H A P T E R  T H R E E :  R E S U L T S  
S e c t i o n  O n e :  Differentiation of sheep bone
marrow mast cells (Sheep BMMC)
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The percentage of mast cells and other cell types were estimated. However,
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3.1.1 Differentiation of sheep bone marrow mast cells in vitro
Bone marrow cell cultures were grown in 25 cm^ tissue culture flasks in a total
of 10 ml volume of IMDM medium containing 10% FCS, 50pl of rOvSCF suspension if
and lOOpl of rOvIL-3 suspension. Feeding with both rOvSCF and rOvIL-3 started
from day zero and was done every 48 h (see Material and Methods). ?
■1:
Total viable cell numbers were estimated by trypan blue exclusion and mast ÿ
cell numbers were estimated by cytosmear preparation and staining cells by |
Leishman’s stain (Figure 3.1.1a). In most stem cell cultures, the initial viable cell
numbers were approximately 1x10® cells/ml and it was observed that total viable cell |
numbers and number of viable mast cells differentiated from primary stem cells were
highest at day 12. Subsequently, there was a gradual decrease in both total cell f
numbers and mast cell numbers.
the percentage of mast cells in cell cultures increased with time compared with other ■
,cell types in the culture (Figure 3.1.1b). 7
During the first week of culture, contamination of stem cells with red blood
cells (RBCs) was evident, but their numbers declined during the first week. Also, :t
contamination with other cell types like fibroblast cells and macrophages was 
observed. 7
f
It was difficult to differentiate mast cells from other cells in bone marrow 
culture by Leishman’s stain during the first 10 to 12 days. Some cells with empty 
granules or vacuoles were observed, so it was difficult to determine whether these 
were mast cells or not. Therefore, all observations were made after 12 days to enable 
identification and differentiation of mast cell from other cells
Figure 3.1.1a Differentiation of sheep bone marrow mast cells in vitro
Total ceil numbers and mast cell numbers for sheep bone marrow cell culture fed with 
rOvIL-3 and rOvSCF. Total cell numbers were estimated by trypan blue exclusion 
and mast cell numbers by Leishmain’s stain. Within the first 12 days it was difficult to 
differentiate between mast cells and other cells by Leishman’s stain (mean of 6 
observations ± SEM).
Figure 3.1.1b Percentage of mast cells in sheep bone marrow cell cultures with 
time
The graph shows that the pereentage of mast cells in the population increased, in 
comparison with other cell types, in sheep bone marrow cell cultures fed with rOvIL- 
3 and rOvSCF (mean of 6 observations ± SEM).
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3.1.2 Microscopic study of mast cell differentiation
Leishman’s stain was used to stain mast cell contents (Figure 3.1.2a). Light 
microscopy (original magnification x 600) was used to differentiate and count mast 
cell and other cells. As can be seen at day 30, most of the cells had the appearance of 
granulated mast cells. Some of these cells contained highly condensed granules. A 
small proportion of other cell types (macrophages and neutrophils) could also be 
observed.
Further microscopic studies were carried out by transmission electron 
microscopy (TEM). This method helped to observe mast cell differentiation. Mast 
cells differentiated from sheep bone marrow cells from different culture ages were 
examined by TEM. The images showed that there were differences in morphology, 
especially in their contents (in different cell cultures). The intracellular contents of 
mast cells differed and depended on the age of culture. Figure 3.1.2b shows a single 
mast cell from cell culture at 7 days. As can be seen, this mast cell has many 
pseudopodia and contains mainly empty cytoplasmic vacuoles. Figure 3.1.2c, shows a 
mast cell from culture at 15 days. It could be observed that the mast cell is again 
surrounded by pseudopodia but the proportion of empty cytoplasmic vacuoles was 
less than the previous figure and some intracytoplasmic dense granules were evident. 
Figure 3.1.2d shows a mast cell from culture at 29 days. Again, pseudopodia were 
evident on the mast cell surface but the number of dense granules was increased 
compared with the previous two figures (3.1.2b and 3.1.2c). These figures (3.1.2b,c, 
d) were typical of mast cells at these different ages of culture.
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Figure 3.1.2a A cytosmear specimen of mast cell culture
A cytosmear specimen of mast cell culture at 30-day stained by Leishman’s stain.
Both mature (A) and immature (B) mast cells were observed (  ) with other cell
types (C) ( — ) (X I000)
Figure 3.1.2b Section of sheep bone marrow mast cell (TEM)
Thin section of sheep bone marrow mast cell from 7-day culture obtained by TEM. 
The cell is surrounded by pseudopodia (A) and contain mainly empty cytoplasmic 
vacuoles (B). Scale bar = 10 pm
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Figure 3.1.2c TEM of sheep BMMC (15 day)
TEM of sheep bone marrow mast cell from 15-day culture. Scale bar = 10pm
Figure 3.1.2d TEM of sheep BMMC (29 day)
TEM of sheep bone marrow mast cell from 29-day culture. Scale bar = 10pm
1
Figure 3.1.2c
Figure 3.1.2d
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3.1.3 Characterisation of sheep BMMC
The ability of either calcium ionophore A23187 (carboxylic acid antibiotic) or 
substance-P (neuropeptide) to stimulate bone marrow mast cells at different ages of 
culture was tested, p-hexosaminidase was used as a marker for degranulation of 
differentiated mast cells from sheep bone marrow in cultures supplemented with both 
rOvIL-3 and rOvSCF. It is known that there are two mast cell types, connective tissue 
mast cells and mucosal mast cells. It has been reported that substance-P is not able to 
stimulate mucosal mast cells and release their contents (Stewart et a l, 1996). 
Therefore, the sensitivity of mast cells differentiated from sheep bone marrow to 
different concentrations of both substance-P or calcium ionophore was estimated.
Sheep bone marrow mast cells from two different cultures (at 18 days or 27 
days) were used. Viability and number of mast cells were estimated by the trypan blue 
exclusion count and adjusted to 10® cells/ml. Both cell suspensions were challenged 
for 30 min with different concentrations (10’"^ M, 10 ® M or 10'  ^ M) of calcium 
ionophore or substance-P. Control mast cells were treated with IMDM medium alone, 
to determine spontaneous P-hexosaminidase release. Other mast cells were frozen at 
-70°C and thawed three times, to release their total content of P-hexosaminidase.
As can be seen from Fig. 3.1.3a, lO'^ ^M or 10'®M of calcium ionophore 
A23187 caused significant release (15-25% of total) of p-hexosaminidase from the 
two ages of sheep BMMC culture compared with the effect of lO’^ M of calcium 
ionophore. Substance-P at any concentration failed to release a significant amount of 
p-hexosaminidase from any of these cultures. This indicates that mast cells 
differentiated from sheep bone marrow are relatively refractory to stimulation due to 
incubation with different concentrations of substance-P. This, in combination with the 
fact that the majority of their cell contents were released due to the effect of calcium 
ionophore, indicates that they may possess a mucosal mast cell phenotype.
p-hexosaminidase release from sheep BMMC was further examined after 
treatment with 10'®M of calcium ionophore. This step was done to investigate the 
timing of p-hexosaminidase release due to stimulation with calcium ionophore. As 
can be seen from Fig. 3.1.3b, there was a gradual increase in P-hexosaminidase 
release up to 30 min but after that, and apparently lower release of P-hexosaminidase 
was observed.
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Figure 3.1.3a Effect of substance-P or calcium ionophore on p-hexosaminidase 
release from sheep BMMC
Sheep BMMC from 18 day and 27 day cultures were incubated with different 
concentrations of either calcium ionophore (cal-ion) or substance-P (sub-P). p- 
hexosaminidase release, as a percentage of cell total content was calculated after 
incubation for 30 min (mean of 9 observations ± SEM).
1) lO'^ ^M on sheep BMMC (18 days)
2) 10'®M on sheep BMMC (18 days)
3) lO'^M on sheep BMMC (18 days)
4) 10'^ ^M on sheep BMMC (27 days)
5) 10'®M on sheep BMMC (27 days)
6) lO'^M on sheep BMMC (27 days)
Figure 3.1.3b Effect of time of incubation with calcium ionophore on p- 
hexosaminidase release from sheep BMMC (20 day culture)
Sheep BMMC was treated with 10'®M of calcium ionophore for different times (5 
min, 15 min, 30 min, 1 h and 3 h). p-hexosaminidase release, as a percentage of cell 
total content was estimated at the end of each treatment (mean of 9 observations ± 
SEM).
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3.1.4 Growth and maintenance of RBL-2H3 cells
RBL-2H3 cells (ATCC CRL-2256) were maintained in IMDM medium 
containing 10% heat inactivated FCS and 1% penicillin/streptomycin. Stock samples 
from liquid nitrogen required three weeks to recover and proliferate. The subsequent 
growth rate of RBL-2H3 cells was high (i.e. formation of a monolayer of RBL-2H3 
within 48 h). Therefore, it was important to change the IMDM medium every 48 h.
The morphology of RBL-2H3 cells was studied by both light microscopy and 
transmission electron microscopy (TEM). The growth rate of RBL-2H3 cells in tissue 
culture flask was investigated by light microscopy. As can be seen from figures 3.1.4a 
the appearance of these cells differed from that of mast cells, RBL-2H3 cells have 
longer pseudopodia (which could help these cells to attach to a substrate surface of a 
culture flask) that could be observed by light microscopy (Ohshiro et al, 2000). In 
contrast, by TEM the appearance of RBL-2H3 cells (Fig. 3.1.4b) resembled that of the 
sheep BMMC. They both have similar surface pseudopodia and cytoplasmic vacuoles 
were observed with granules of different densities.
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Figure 3.1.4a RBL-2H3 cell culture
RBL-2H3 cells show long pseudopodia that could be observed by light microscopy 
(XIOOO).
Figure 3.1.4b TEM of an RBL-2H3 cell
TEM of a single RBL-2H3 cell. Scale bar = 10pm.
Figure 3.1.4a
Figure 3.1.4b
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which was significantly (p-valiie < 0.001) higher than that caused by compared to 10’ 
W . But, as before, (section 3.1.3) substance-P failed to stimulate sheep BMMC to 
release a significant amount of p“hexosaminidase. In contrast, there was an apparently 
low P-hexosaminidase release from RBL-2H3 cells due to interaction with lO’^ M^ and
concluded that the effect of calcium ionophore A23187 on degranulation of sheep 
BMMC and RBL-2H3 cells was similar, and mast cells differentiated from sheep 
bone marrow cells had similar characteristics to those of a mucosal mast cell-type.
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3.1.4.1 Interaction of RBL-2H3 cells with different chemical stimulators
The RBL-2H3 cell line is a rat leukemia line that provides a model for the 
study of mucosal mast cell function. So, a comparison of the effects of calcium 3
ionophore and substance-P on stimulation of sheep BMMC and RBL-2H3 cell was 
performed. Figure 3.1.5 shows P-hexosaminidase release from either sheep BMMC or 
RBL-2H3 cells after incubation for 30 min with 10’"^ M or 10’'^ M of calcium ionophore
10"‘^ M of substance-P compared with the effect of similar concentrations of calcium |
ionophore (/7-value < 0.0001).
3
From these observations (section 3.1.3 and section 3.1.4.1), it could be
Figure 3.1.5 Effect of different concentrations of substance-P and calcium 
ionophore on P-hexosaminidase release from sheep BMMC and RBL-2H3 cells
ixlO^ cells/ml of sheep BMMC or RBL-2H3 cells were incubated with different 
concentrations 10'^ and 10'  ^M) of calcium ionophore or substance-P for 30 min. 
Substance-P failed to release P-hexosaminidase from sheep BMMC but with RBL- 
2H3 cells there was a slight P-hexosaminidase release. A similar concentration of 
calcium ionophore caused a significant p-hexosaminidase release from both sheep 
BMMC and RBL-2H3 cells (mean of 9 observations ± SEM).
1) Substance-P lO'"^  M
2) Substance-P 10’^  M
3) Substance-P 10’^  M
4) Calcium ionophore 10''^  M
5) Calcium ionophore 10'  ^M
6) Calcium ionophore 10’^  M
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S e c t i o n  T w o :  Application of bioluminescent
bacteria as an in vitro reporter of the interaction of 
B. bronchiseptica and sheep BMMC
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3.2.1 Characterisation of B. bronchiseptica (Lux 95)
3.2.1.1 Colony morphology
3.2.1.2 Haemolysis effect
BG sandwich agar plates were used to study the haemolytic effect of B. 
bronchiseptica (Lux 95) and compared with the haemolytic effect of both the virulent 
(Bvg phase) and the avirulent (Bvg “ phase) strains. It was observed visually that 
there was clear zone of haemolysis surrounding the colonies of the virulent strain 
(Bvg phase) after growth for 48h. +o zone of haemolysis surrounded the colonies of 
either the avirulent strain (Bvg “ phase) or the bioluminescent strain (Lux 95).
At the start of the present study, an attempt was made to determine whether 
the bioluminescent strain of B. bronchiseptica (Lux 95) had the typical virulent 
phenotype of bronchiseptica BBC17 (Bvg phase) or not. In addition, an avirulent 
(Bvg “ phase) mutant strain of B. bronchiseptica (BBC 17) was used as a control 
strain.
B. bronchiseptica (Lux 95) was compared with the virulent strain of B. 
bronchiseptica (Bvg phase) and avirulent strain of B. bronchsieptica (Bvg " phase) 
for a number of virulence-related properties.
%All three strains of B. bronchiseptica: the virulent strain (Bvg phase), the 
avirulent strain (Bvg “ phase) and the bioluminescent strain (Lux 95) were grown on 
BG agar plates and allowed to grow for 48 h in humid conditions at 37°C. Colonies on 
the plate were then observed with the naked eye and variation between colonies was 
recorded. After 24 h, it was observed that colonies of the avirulent strain (Bvg" phase) 
were visible. But both the virulent strain (Bvg phase) and the bioluminescent strain 
(Lux 95) needed more than 24 h to form colonies. It was observed that the avirulent 
strain (Bvg “ phase) colonies were large and flat compared with those of the virulent 
strain (Bvg  ^ phase) and of the bioluminescent strain (Lux 95) which could be 
characterised as small and domed.
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3.2.1.3 Haemagglutination assay
The haemagglutination assay was carried out to identify surface adhesion 
molecules of the bioluminescent strain (Lux 95) compared with the virulent strain 
(Bvg phase) and the avirulent (Bvg ” phase) strains. Purified filamentous 
haemagglutinin (FHA) was used as a positive control for haemagglutination and was 
received from a departmental stock. It was used at a net concentration of 45 pg/ml.
Growth of B. bronchiseptica (Bvg Bvg " and Lux 95) on BG agar for 24h 
was collected in phosphate buffered saline (PBS). Cell numbers were adjusted at 
OD6oonm= 0.46 equivalent (2x10^ cfu/ml) and diluted to 5x10^ cfu/ml in PBS.
There was a weak haemagglutination effect due to 5x10® cfu/ml of B. 
bronchiseptica (Bvg  ^phase), but this effect was not observed with greater dilution of 
the bacterial suspension. In contrast, no haemaggultination effect was observed for 
either mutant strain of B. bronchiseptica (Bvg " or Lux 95) at 5x10® cfu/ml. 
Haemagglutination of different strains B. bronchiseptica was compared with the effect 
of purified FHA (positive control) which gave a clear haemagglutination effect and 
IMDM medium (negative control) which gave no haemagglutination.
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3.2.1.4 Determination of AC enzymatic activity in B. bronchiseptica (Lnx 95)
Adenylate cyclase (AC) enzymatic activity of B. bronchiseptica (Lux 95) was 
estimated by a conductimetry assay (Chapter two; Materials and Methods) and 
compared with AC enzymatic activity of the virulent B. bronchiseptica (Bvg phase) 
or avirulent B. bronchiseptica (Bvg " phase). Growth of B. bronchiseptica- (Bvg 
Bvg" and Lux 95) on BG agar for 24h was collected in PBS and washed twice by 
centrifugation at 4000 rpm for 5 min. Cell numbers were adjusted to ODôoonm = 0.46 
(equivalent to 2x10^ cfu/ml) and diluted to 5x10® cfu/ml in PBS. 1% of Triton X I00 
was added to lyse the bacterial cells and released their contents.
Figure 3.2.1 shows that the AC enzymatic activity of B. bronchiseptica (Lux 
95) was low and similar to AC enzymatic activity of the avirulent strain of B. 
bronchiseptica (Bvg " phase), compared with the high enzymatic activity of the 
virulent strain of B. bronchiseptica (Bvg phase). These observations suggested that 
the contents of AC toxin in the bioluminescent strain of B. bronchiseptica (Lux 95) 
grown on BG agar is weak.
Furthermore, it is known that adenylate cyclase toxin, either as a soluble 
protein or when associated with whole bacteria, is a bi-functional molecule and, in 
addition to AC enzymic activity, is also able to lyse erythrocytes. The conductimetry 
assay is one way of characterization of ACT activity but it is also possible to estimate 
ACT activity in whole bacteria by observing haemolysis on sandwich BG agar 
(section 2.1.2). Thus, these were two estimates of ACT activity.
In conclusion, the findings with both the virulent strain of B. bronchiseptica 
(Bvg ''' phase) and avirulent B. bronchiseptica (Bvg " phase) agree with the known 
properties of these two strains. Furthermore, the bioluminescent strain of B. 
bronchiseptica (Lux 95) has a colony morphology like that of the virulent B. 
bronchiseptica (Bvg phase) but otherwise resembles the avirulent B. bronchiseptica 
(Bvg " phase). Thus, the bioluminescent B, bronchiseptica strain appears to be an 
intermediate phenotypic phase of B. bronchiseptica rather than a wild type (virulent 
Bvg  ^phase) strain.
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Figure 3.2.1 Comparison of the AC enzymatic activity in bioluminescent B. 
bronchiseptica {Lux 95) with AC activity in virulent and avirulent B. 
bronchiseptica by conductimetry assay
This graph shows a comparison between the AC enzymatic activity of B. 
bronchiseptica (Lux 95) that of B. bronchiseptica (Bvg"*") and (Bvg ') grown on BG 
agar. A represent the scale of conductivity of the reaction mixture (Y-axis) and B 
represents the scale of time (sec) (X-axis). AC enzymatic activity of both B. 
bronchiseptica (Lux 95) and B. bronchiseptica (Bvg “ phase) was low compared with 
the high AC enzymatic activity of B. bronchiseptica (Bvg phase).
Pure rACT 
(Positive control)
Cell extract from B. 
bronchiseptica (Bvg^ phase)
/
/
B
Cell extract from B. 
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Figure 3.2.1
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3.2.2 Bioluminescence activity of B. bronchiseptica (Lux 95)
3.2.2.1 Bioluminescence activity in different media
In order to study the interaction of B. bronchiseptica and mammalian cells, it 
was important to show that B. bronchsieptica (Lux 95) would survive, and its 
bioluminescence activity would be maintained, in the IMDM medium used routinely 
for culture of mammalian cells. It was assumed that the light output of live bacteria 
would be directly proportional to the viability of the bacteria cells (,elson et a i, 
2003). In addition, B. bronchiseptica can survive and even grow in natural waters and 
in PBS (Porter et a l, 1991). Therefore, bioluminescence activity of B. bronchiseptica 
(Lux 95) in IMDM was compared with that in PBS. The effect of adding heat- 
inactivated PCS to the media was also investigated. Growth of B. bronchiseptica (Lux 
95) for 24h on BG agar was collected in IMDM medium containing 10% PCS, IMDM 
medium only, PBS containing 10% PCS and PBS only. Bacterial cell numbers were 
adjusted to 5x10^ cfu/ml in the same medium or buffer. Bacterial suspension (200fxl) 
was then added in triplicate into 96-well plates and incubated at 37°C in the 
luminometer. Bioluminescence output as relative light units (RLU), of the bacterial 
cell suspension was measured with time.
Pigure (3.2.2a) shows that, within the first 0 -  6 h of incubation, there was 
only low bioluminescence activity of the Lux 95 suspension either in IMDM medium 
or in PBS. After 6 h, there was an increase in the bioluminescence activity of Lux 95 
suspension in IMDM medium, especially if the IMDM medium containing 10% heat- 
inactivated PCS. Bioluminescence activity in PBS only remained low. But, if PBS 
contained 10% heat-inactivated PCS, bioluminescence activity increased. Prom these 
observations, it could be concluded that IMDM medium containing 10% PCS helped 
B. bronchiseptica (Lux 95) to be more active in its bioluminescence emission 
presumably as a result of metabolic activity, growth and increase in cell numbers. 
Pigure 3.2.2b shows bioluminescence activity from different numbers of B. 
bronchiseptica (Lux 95) suspended in IMDM medium containing 10% PCS and 
measured immediately. There was a linear correlation between bioluminescence 
output (RLU) and cell numbers (cfu/ml). With an increase in cell numbers, there was 
increased bioluminescence activity.
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Figure 3.2.2a Bioluminescence output of B. bronchiseptica (Lux 95) in different 
media
B. bronchiseptica (Lux 95) was maintained in either IMDM medium or PBS in the 
presence or absence of 10% PCS. Bioluminescence output was measured and 
expressed as relative light units (RLU) (mean of 9 observations ± SD).
Figure 3.2.2b Bioluminescence output from different numbers B. bronchiseptica 
(Lux 95)
Different numbers of B. bronchiseptica (Lux 95) were prepared in IMDM medium 
and 10% PCS and bioluminescence output (RLU) was measured (means of 3 
observations)
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3.2.2.1.1 Bioluminescence activity of B. bronchiseptica (Lux 95) in a short-run 
experiment (20 h)
Bioluminescence activity in bacteria expressing lux genes is assumed to 
depend on metabolic activity. Therefore, it was important to investigate whether an 
increase in the bioluminescence activity of a B. bronchiseptica (Lux 95) culture 
correlated with an increase in cell numbers as determined by optical density (OD). 
Bacterial numbers of B. bronchiseptica (Lux 95) were adjusted to 5x10^ cfu/ml in 
IMDM medium containing 10% PCS. Bacterial suspension (200jal) was then added in 
triplicate into 96 -well plates and incubated at 37°C in the luminometer.
Figure 3,2.3a shows the overall measurement of both RLU and OD492nm 
estimated in a short-run (20 h) experiment. There was a parallel increase in both RLU 
and OD of B. bronchiseptica (Lux 95) culture over the first 10 h of incubation. From 
1 0 -2 0  h, there was a continued steady increase in RLU but only a gradual increase in 
OD and lack of correlation between the two curves.
The correlation between bioluminescence activity (RLU) of B. bronchiseptica 
(Lux 95) and optical density OD492nm was estimated by a regression plot (Figure 
3.2.3d). The following data shows output in the Session window of MINITAB that 
accompanied the graphical plot in Figure 3.2.3b.
Table 3.2.1; Analysis of variance of the regression between RLU and OD (short-run)
Regression Analysis: RLU versus OD
Predictor Coef SE Coef T P
Constant -45.084 5.500 -8.20 0.000
OD 132.606 7.685 17.26 0.000
Analysis of Variance
Source DF SS MS F P
Regression 1 14559 14559 297.75 0.000
Residual Error 19 929 49
Total 20 15489
DF: Degree of freedom, SS: sums of squares, MS: mean square, F: variance ratio,
T: Student’s f, P: null hypothesis, S: the error standard deviation, R-Sq: % of the 
variability (S and R-Sq are shown in Fig. 3.2.3b).
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Figure 3.2.3b shows the regression diagram between RLU and OD surrounded 
by additional dotted and dashed lines. The inner, dotted, lines are the 95% confidence 
bands of the regression itself. These are narrowest at the centre, indicating that the 
position of the regression line is known with greatest certainty in the middle region 
and with some wider uncertainty as the dotted lines flare out slightly at the ends.
With reference to figure 3.2.3b and table 3.2.1, and for 95% confidence bands 
and 95% prediction bands and p-value = 0.000 (< 0.001) which is very highly 
significant, it could be said that, over a short-run (20h) experiment, there was a good 
linear correlation between bioluminescence activity (RLU) and optical density (OD) 
of the 5. bronchiseptica (Lux 95). These observations suggested that bioluminescence 
output would be an easy and accurate measure of viable cell numbers.
Figure 3.2.3a Correlation between bioluminescence output and optical density of
B, bronchiseptica (Lux 95)
5x10® cfu/ml of B. bronchiseptica (Lux 95) were inoculated into IMDM medium 
containing 10% heat-inactivated PCS. Bioluminescence output (RLU) was measured 
in parallel with optical density (OD492nm) (means of 9 observations ± SD).
Figure 3.2.3b Regression plot of bioluminescence output and optical density
Regression of bioluminescence output (RLU) of B. bronchiseptica (Lux 95) and 
optical density (OD492nm) in IMDM medium containing 10% PCS. With 95% 
confidence bands (dotted lines) for the regression and 95% prediction bands (dashed 
line).
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3.2.2.1.2 Bioluminescence activity of B. bronchiseptica (Lux 95) in a long-run 
experiment ( >20 h)
Bioluminescence activity and optical density of B. bronchiseptica (Lux 95)
Régression Analysis: RLU versus OD
Predictor Coef SE Coef T P
Constant 113.25 46.86 2.42 0.024
OD -35.09 34.17 -1.03 0.315
Analysis of Variance
Source DF SS MS F P
Regression 1 2877 2877 1.05 0.315
Residual Error 24 65483 2728
Total 25 68361
DF: Degree of freedom, SS: sums of squares, MS: mean square, F:: variance ratio, T:
t
were monitored in a long-run experiment over 40 h. As can be seen from 3.2.3c there 
was a steady increase in both RLU and OD within the first 20 h (1199min). But, after 
20 h, it was observed that there was a sharp decline of bioluminescence output of B. 
bronchiseptica (Lux 95) and there was a slowing down of the rate of increase in OD. 
The correlation between bioluminescence activity (RLU) of B. bronchiseptica (Lux 
95) and optical density (OD492nm) was estimated by regression plot (Figure 3.2.3d). 
The following data shows output in the Session window of MINITAB that 
accompanied the graphical plot in Figure 3.2.3d.
Table 3.2.2: Analysis of variance of the regression between RLU and OD (long-run)
Student’s t, P: null hypothesis, S: the error standard deviation. (S is shown in Fig.
3.2.3d)
At the end of the 40 h incubation period in the luminometer, viability of B. 
bronchiseptica (Lux 95) was determined by viable counting on BG agar plates. A 
total of three samples was taken from each incubation well (n = 3) which had f
contained 5x10^ cfu/ml of B. bronchiseptica (Lux 95) at the start of experiment. These8 'Ucounts showed that there were not less than 1x10 cfu/ml in the 40h culture. From 
these observations it appears that, with increase in incubation time up to 40 h at 37°C 
in the luminometer, bioluminescence output (RLU) reduces in B. bronchiseptica (Lux 
95) culture but there is not a parallel reduction in bacterial viability. So, it appears 
that, in older cultures (> 20 h) of B. bronchiseptica (Lux 95), the linear relationship =r
between RLU and viable cell numbers breaks down.
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Figure 3.2.3c Bioluminescence output and optical density of B, bronchiseptica 
(Lux 95) in a long-run experiment
5x10^ cfu/ml of B. bronchiseptica (Lux 95) were incubated in IMDM medium 
containing 10% heat-inactivated FCS. Bioluminescence output (RLU) was measured 
along with optical density (OD) (means of 9 observations ± SEM). At the end of the 
run, viability of B. bronchiseptica (Lux 95) was determined by plating on BG agar.
Figure 3.2.3d Regression plot of bioluminescence output and optical density
Regression of bioluminescence output of B. bronchiseptica (Lux 95) and optical 
density in IMDM medium containing 10% FCS. With 95% confidence bands (dotted 
lines) for the regression and 95% prediction bands (dashed line).
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3.2.2.2 Effect of polymyxin B on bioluminescence activity
Polymyxin B is used to kill extracellular bacteria in studies of bacterial 
uptake/phagocytosis by mammalian cells. 10^  cfu/ml (lower number) and 5x10^ 
cfu/ml (higher number) of B. bronchiseptica (Lux 95) were prepared in IMDM 
medium containing 10% FCS and 200 pi volumes were incubated in 96-well plates at 
37°C in the luminometer. Bioluminescence output was monitored. After incubation 
for 3 h, 50 pg/ml of polymyxin B was added to some wells and other wells served as 
control wells which contained bacteria in IMDM medium only. As can be seen from 
Fig. 3.2.4, there was a sharp drop in bioluminescence output from low and high 
numbers of B. bronchiseptica (Lux 95) due to the addition of polymyxin B, compared 
with a gradual increase in bioluminescence output from B. bronchiseptica (Lux 95) in 
control wells. After incubation for 8 h in the luminometer, viability of B. 
bronchiseptica (Lux 95) was determined by viable counting on BG agar plates. In 
wells originally containing 10  ^ cfu/ml, and polymyxin B, it was observed that 50 
pg/ml polymyxin B killed > 99.99% of 10^  cfu/ml B. bronchiseptica (Lux 95). 
Whereas, without polymyxin B, the viable count was more than 1x10^ cfu/ml (number 
of observations = 6).
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Figure 3.2.4 Effect of polymyxin B on bioluminescence output from B.
bronchiseptica (Lux 95)
Bioluminescence output was monitored from 1x10^ and 5x10^ cfu/ml of B. 
bronchiseptica (Lux 95) in IMDM medium containing 10% FCS. After 3 h 
incubation, 50 pg/ml polymyxin B was added to some wells and other wells served as 
control wells (mean of 9 observations ± SD).
a) B. bronchiseptica 1x10^ cfu/ml in IMDM medium alone.
b) B. bronchiseptica 1x10^ cfu/ml and polymyxin B.
c) B. bronchiseptica 5x10^ cfu/ml in IMDM medium alone.
d) B. bronchiseptica 5x10^ cfu/ml and polymyxin B.
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3.2.2.3 Effect of digitoiiin on bioluminescence activity
Digitonin is a cholesterol-complexing agent soluble in water and dissolved by 
heating to 95 - 98°C. Pre-treatment of mammalian cells with digitonin results in rapid 
lysis of the cell membrane and release of intracellular contents. In these studies, it was 
used to disrupt the cell membrane of sheep BMMC and other mammalian cell lines, to 
determine whether bacteria are intracellular and for viable counts purpose (see section 
2.6.2, Materials and Methods). When digitonin was added to the mammalian 
cell/bacteria mixtures with polymyxin B, it allowed any intracellular bacteria to be 
released and killed by polymyxin B. The following study was planned to determine if 
digitonin itself had any effect on viability and bioluminescence activity of B. 
bronchiseptica (Lux 95).
B. bronchiseptica (Lux 95) was grown on BG agar for 24h, then 5x10^ cfu/ml 
was prepared in IMDM medium containing 10% FCS. 200pl of the bacterial 
suspension was then added in triplicate to 96 -well plates and incubated at 37°C in the 
luminometer. Bioluminescence output was measured and, after incubation for Ih in 
the luminometer, 50 jig/ml of digitonin and/or polymyxin B were added.
Figure 3.2.5 shows the mean of the bioluminescence output from B. 
bronchiseptica (Lux 95) under different conditions. As can be seen, there was a steady 
increase in bioluminescence output from B. bronchiseptica (Lux 95) in IMDM 
medium only. A similar increase in bioluminescence output from B. bronchiseptica 
(Lux 95) was observed when 50 pg/ml digitonin was present. However, 
biolumineseence output from B. bronchiseptica (Lux 95) declined due to the presence 
of 50 |0.g/ml polymyxin. A similar observation of decline in bioluminescence output 
was observed when both digitonin and polymyxin B were present. These observations 
suggested that this concentration of digitonin had no effect on viability of B. 
bronchiseptica (Lux 95) and could be used in invasion assays.
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Figure 3.2.5 Comparison of the effect of digitonin and polymyxin B on light 
output from B. bronchiseptica (Lux 95)
5x10^ cfu/ml of B. bronchiseptica (Lux 95) were maintained in IMDM medium 
containing 10% FCS. Bioluminescence output was measured at 37”C in a 
luminometer. After 60min, 50pg/ml digitonin and polymyxin B were added to some 
wells and IMDM medium was added to other wells (controls). Data are shown in 
relative light units (RLU) (means of 9 observations, error bars are omitted when SD 
of the mean do not exceed the dimensions of the symbols)
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3.2.2.4 Bioluminescent E. coli
A bioluminescent strain of E. coli, Hbl01pT7-3, was used in the study to 
compare its uptake and intracellular survival in mammalian cells with that of B. 
bronchiseptica (Lux 95). Its bioluminescence emission when maintained in IMDM 
medium containing 10% PCS was monitored. The E. coli was grown routinely in 5 ml 
LB broth with 50 fig/ml of ampicillin. Bacteria were harvested from LB broth, and 
suspended to 5x10^ cfu/ml in IMDM containing 10% PCS. 200 p.1 of cell suspension 
was added in triplicate in 96-well plates and incubated at 37°C in the luminometer. 
Pigure 3.2.6 shows the relationship between RLU and OD over 20 h at 37°C in the 
luminometer. There was a gradual increase in OD (up to 10 h), and then there was 
slower increase in OD (up to 20 h). Bioluminescence output shows a slow rise 
initially (up to 5h) then a more rapid increase (up to 10 h), and then there was a sharp 
decline in RLU down to baseline. At the end of the 20 h incubation time, viability of 
the E. coli was determined by viable counting on LB agar plates. A total of three 
samples was taken from each incubation well (n -  3) which contained 5x10^ cfu/ml of 
E. coli at the start of experiment. These counts showed that there were > 1x10^ cfu/ml 
in the 20 h culture. Prom these observations it appears that, with increase in 
incubation time up to 20h at 37°C in the luminometer, bioluminescence output RLU 
declines in the E. coli culture, but there is not a parallel reduction in bacterial 
viability. So, it appears that with E. coli, the linear relationship between RLU and 
viability breaks down.
Thus, the correlation between bioluminescence output and optical density or 
viability of the bioluminescent E. coli is not as good as with B. bronchiseptica (Lux 
95) even with a short incubation (up to 20 h). With a longer incubation time, 
presumably when the culture reaches stationary phase, the bacteria rapidly cease to 
emit light even though they remain viable. Such older cultures would therefore not be 
useful for invasion assays. This particular construct of E. coli is possibly less useful 
than B. bronchiseptica (Lux 95).
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Figure 3.2.6 Correlation between bioluminescence output and optical density of 
bioluminescent E. coli
5x10^ cfu/ml of bioluminescent E, coli (Hbl01pT7-3) was inoculated into IMDM 
medium containing 10% of heat-inactivated PCS. Bioluminescence output was 
measured in parallel with optical density (OD). Data are means of 9 observations ± 
SEM.
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3.2.3 Detection of intracellular B, bronchiseptica (Lux 95) within sheep BMMC
and P388D1 murine macrophage cell line
3.2.3.1 Luminometry method
Sheep BMMC (25 day culture) and murine macrophage-like cell line P388D1 
were maintained in IMDM medium and adjusted to 1x10^ cells/ml by using trypan 
blue exclusion. Infection of sheep BMMC or P388D1 by B. bronchiseptica (Lux 95) 
were carried out at on infection ratio of 1:500. Then, volumes of 200 |ll of cell- 
bacteria suspension were seeded in triplicate in 96-well micro-plates. To enhance 
bacterial uptake by sheep BMMC and P388D1 cells, the microtitre plates were 
centrifuged at low speed of 250 rpm for 10 min and then incubated at 37‘^ C in the 
luminometer. After incubation for 4 h at 37°C, extracellular bacteria were killed by 
adding polymyxin B sulfate (Sigma) to a final concentration of 50 pg/ml and 
incubation was continued. After 1 h, 50 pg/ml digitonin was added to some wells to 
lyse mammalian cells and to expose any intracellular bacteria to the polymyxin in the 
suspending medium.
Figure 3.2.7al (with P388D1 macrophage cell line) and figure 3.2.7 a2 (with 
sheep BMMC) show the overall light emissions at the infection ratio of 1:500. Figure 
3.2.7b (macrophage cell P388D1) and Fig. 3.2.7c (sheep BMMC) show light output in 
more detail after adding digitonin, using an expand scale for the Y-axis. In the two 
figures (3.2.7b and 3.2.7c), line A, represents the effect of polymyxin B on light 
emission of B. bronchiseptica (Lux 95) in IMDM medium only. A reduction in light 
output was observed and this had already reached baseline level at 390 min. In 
contrast, the difference in light output represented by line B {B. bronchiseptica (Lux 
95) in presence of mammalian cells and polymyxin only) and line C {B. 
bronchiseptica (Lux 95) in presence of mammalian cells and both polymyxin B and 
digitonin) shows the light emission from that is presumably from intracellular B. 
bronchiseptica (Lux 95) within either the sheep BMMC or the murine macrophage 
cells. With both cell types, in the absence of digitonin, internalized bacteria continued 
to emit a low level of light throughout the assay, demonstrating that some had retained 
viability and that polymyxin did not accumulate within these mammalian cells. 
However, addition of digitonin led to exposure of intracellular bacteria to the 
polymyxin in the suspending medium, and bacterial killing was shown by a rapid 
decrease in light output to reach the baseline level.
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Figure 3.2.7al Interaction of B. bronchiseptica (Lux 95) with P388D1 
macrophage cells
1x10^ cells/ml of P388D1 macrophage cell line maintained in IMDM medium 
containing 10% FCS were infected with B. bronchiseptica (Lux 95) at an infection 
ratio of 1:500 and incubated for 4 h. 50 jig/ml of polymyxin B was added to kill 
extracellular B. bronchiseptica (Lux 95) and after Ih, 50 jig/ml digitonin was added to 
some wells containing polymyxin B. The overall bioluminescence output was 
monitored (mean of 6 observations ± SD).
Figure 3.2.7a2 Interaction of B. bronchiseptica (Lux 95) with sheep BMMC
1x10^ cells/ml of sheep BMMC maintained in IMDM medium containing 10% FCS 
were infected with B. bronchiseptica (Lux 95) at an infection ratio of 1:500 and 
incubated for 4 h. 50 |4g/ml of polymyxin B was added to kill extracellular B. 
bronchiseptica (Lux 95) and after Ih, 50 |ig/ml digitonin was added to some wells 
containing polymyxin B. The overall bioluminescence output was monitored (mean of 
6 observations ± SD).
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Figure 3.2.7b Intracellular B. bronchiseptica (Lux 95) within macrophage cell 
P388D1
This graph shows enlargement of the previous graph (2.8a) after addition of digitonin. 
The light emission from intracellular B. bronchiseptica (Lux 95) in macrophage cells 
treated with of polymyxin B only, can be compared with light output from cells 
treated with both polymyxin B and digitonin. These data represent the mean of 6 
observations. The range of the error bars was between 0.01 and 0.1, therefore the bars 
were omitted to avoid exceed with other lines.
A) B. bronchiseptica (Lux 95) in IMDM medium containing 50 Ilg/ml of polymyxin 
B
B) P388D1 cell line and B. bronchiseptica (Lux 95) and 50 jag/ml of polymyxin B.
C) P388D1 cell line and B. bronchiseptica (Lux 95) and 50 p,g/ml of polymyxin B 
and 50 p.g/ml of digitonin.
Figure 3.2.7c Intracellular B. bronchiseptica (Lux 95) within sheep BMMC
This graph shows enlargement of the previous graph (2.8a) after addition of digitonin. 
The light emission from intracellular B. bronchiseptica (Lux 95) in macrophage cells 
treated with of polymyxin B only, can be compared with light output from cells 
treated with both polymyxin B and digitonin. These data represent the mean of 6 
observations. The range of the error bars was between 0.01 and 0.1, therefore the bars 
were omitted to avoid exceed with other lines.
A) B. bronchiseptica (Lux 95) in IMDM medium containing 50 ftg/ml of polymyxin 
B
B) Sheep BMMC and B. bronchiseptica (Lux 95) and 50 jLlg/ml of polymyxin B.
C) Sheep BMMC and B. bronchiseptica (Lux 95) and 50 flg/ml of polymyxin B and 
50 p.g/ml of digitonin.
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3.2.3.2 Microscopic study
,
j;
The presence of intracellular B. bronchiseptica (Lux 95) within sheep BMMC |
was investigated by using either light microscopy or electron microscopy. t
4'
V:
3.2.3.2.1 Light microscopy
At 4 h postinfection of sheep BMMC infected at MOI of 1:500, cytosmear 
samples of infected culture were stained by Leishman’s dye. As can be seen from 
figure 3.2.8, it was difficult to differentiate between bacterial cells and cytoplasmic 
granules within sheep BMMC.
3.2.3.2.2 Transmission electron microscopy
Transmission electron microscopy was used to investigate samples of sheep 
BMMC (Figure 3.2.9a and Figure 3.2.9b) and p388Dl macrophage cell line (Figure 
3.2.9c) infected at an MOI 1:500. Within sheep BMMC, bacteria were seen to be 
localized in the phagosomal vacuoles (Figure 3.2.9a and 3.2.9b) of the infected mast 
cells examined. The bacteria were present in low numbers in the phagosomes, usually 
a single bacterium was observed within each vacuole.
In contrast, transmission electron microscopy (TEM) of samples of P388D1 |
cultured macrophages infected at an MOI of 1:500 at 4h postinfection showed more 
bacteria localized within vacuoles (Figure 3.2.9c) and in around 90% of the infected 
cells examined. The bacteria were present in low numbers in the phagosomes, usually 
singly, although in some cells several bacteria could be observed within the same 
vacuole as shown in figure 3.2.9c. -o bacteria were observed free in the cytoplasm in 
the macrophage cells.
..9 ..
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Figure 3.2.8 Cytosmear of sheep BMMC infected with B. bronchiseptica (Lux
95).
At 4 h postinfection of sheep BMMC infected at MOI of 1:500, cytosmear samples of 
infected culture were stained by Leishman’s dye. The sheep BMMC contained highly 
condensed granules by Leishman’s stain (original magnifieation X600).
Figure 3.2.9a TEM of single sheep bone marrow mast cell infected with B. 
bronchiseptica (Lux 95). Arrows indicate bacteria in phagosomal vacuoles. Scale 
bar = 10pm .
Figure 3.2.8
Figure 3.2.9a
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Figure 3.2.9b TEM of single sheep bone marrow mast cell infected with B. 
bronchiseptica (Lux 95). Arrows indicate bacteria in phagosomal vacuoles. Scale 
bar = 10 pm.
Figure 3.2.9c TEM of single P388D1 macrophage cell infected with B. 
bronchiseptica (Lux 95). Arrows indicate bacteria in phagosomal vacuoles. Scale 
bar = 10 pm.
Figure 3.2.9b
%
Figure 3.2.9c
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3.2.4 Detection of intracellular B. bronchiseptica (Lux 95) within sheep BMMC 
depends on age of culture
It was observed that differentiation of the sheep bone marrow mast cells 
depends on the age of culture (section 3.1.2). Cells from the earliest age of culture 
(i.e. within the first two weeks) were devoid of cytoplasmic granules, but the number 
of dense granules within the eytoplasmic vaeuoles subsequently increased with the 
increasing of age culture. The aim of the following work was to investigate the ability 
of different ages of sheep BMMC to take-up bacteria.
The presence of intracellular B. bronchiseptica (Lux 95) within sheep BMMC 
was investigated with different ages of cell culture. From cell cultures at day 14 and at
batch of sheep bone marrow, cell numbers were adjusted to 1x10^ cells/ml using 7#
trypan blue exclusion. Infection of sheep BMMC with B. bronchiseptica (Lux 95) was 
carried out at MOI 1:500 (one mast cell to 500 bacterial cells) and bioluminescence 
output was monitored in the luminometer. To confirm intracellular B. bronchiseptica 
(Lux 95) within sheep BMMC, 50 pg/ml polymyxin B was added at 4 h post­
infection. A decline in bioluminescence output was observed (data not shown) due to 
killing of extracellular B. bronchiseptica (Lux 95). After a further 1 h, 50 pg/ml 
digitonin was added to selected wells to expose intracellular B. bronchiseptica (Lux 
95) to the polymyxin B. Bioluminescence output of B. bronchiseptica (Lux 95) with 
sheep BMMC (14 day culture) (Fig. 3.2.10a) and 29 day eulture (Fig. 3.2.10b) was 
compared. With the 29-day culture, there was a much higher bioluminescence output 
with polymyxin B alone (assumed to be from intracellular bacteria) than with 
polymyxin B and digitonin. This difference was not observed with the 14-day culture.
Therefore, bioluminescence output from intracellular B. bronchiseptica (Lux 95) 
demonstrated that only the mast cells which, by microscopy, appeared to be mature (at ÿ
29 days) seemed to be capable of take-up of the bacteria. An alternative but less likely 
explanation is that both ages of sheep BMMC were able to take-up the bacteria but 
that they only survived intracellulary in the mature mast cells.
The above observation was confirmed by a repeat experiment but with a new 
batch of sheep BMMC.
I
day 29 (mast cells more than 90% of total population in both eultures) from the same J;
4-
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For statistical analysis of the differences in bioluminescence output from 
intracellular 5. bonchiseptica (Lux 95) incubated with sheep BMMC from 14-day and 
29-day cultures with polymyxin B alone, the areas under the curves (Fig. 3.2.10a and 
3.2.10b) could be determined. Trendlines (Excel 98) may be used to analyze the 
problems of area under curves, such analysis is also called regression analysis. For 
this purpose, polynomial equation (calculates the least squares fit through points) may 
be used and the following equation may be applied:
In the case of the 29-day culture:
y= 2E-08x^ -  2E-06x'^ + 8E-05x'^ -0 .0 0 1 8x  ^+0.0215x^ -  0.1285x + 0.4015 
= 0.9663 (constant of polynomial equation)
(6,5...etc, refer to value)
In the case of the 14-day culture:
y= 2E-08x^ -  3E-06x^ + 0.0001 x  ^-  0.0024x^ + 0.0266x^ -  0 .1476x + 0.3196 
R^ = 0.9766 (constant of polynomial equation)
(6,5.. .etc, refer to R  ^value)
Then, integration of the following equation may be used for calculating the areas 
under the different curves:
Area (under curve) = /  ydxa-!
a 1 = lower time (e.g. at time 200 min) 
a 2 = higher time (e.g. at time 900 min) 
y = curve equation (polynomial equation) 
dx = a number raised to a power (value of R^).
In order to do this, a number of replicate observations would be required.
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Figure 3.2.10a Effect of sheep BMMC (14-day culture) on uptake of B.
bronchiseptica (Lux 95)
1x10^ cells/ml of sheep BMMC (14-day culture) was infected with B. bronchiseptica 
(Lux 95) at MOI 1:500. After 4h incubation, 50 pg/ml polymyxin B was added to kill 
extracellular B. bronchiseptica (Lux 95) and 1 h later 50 pg/ml digitonin was added to 
selected wells to lyse sheep BMMC and release intracellular B. bronchiseptica (Lux 
95). This graph shows light output (RLU) after adding polymyxin B and digitonin. 
These data represent the mean of 9 observations. The range of the error bars was 
between 0.01 and 0.1, therefore the bars were omitted to avoid exceed with other 
lines.
Figure 3.2.10b Effect of sheep BMMC (29-day culture) on uptake of B,
bronchiseptica (Lux 95)
1x10^ cell/ml of sheep BMMC (29-day culture) was infected with B. bronchiseptica 
(Lux 95) at MOI 1:500. After 4h incubation, 50 pg/ml polymyxin B was added to kill 
extracellular B. bronchiseptica (Lux 95) and 1 h later, 50 pg/ml digitonin was added 
to selected wells to lyse sheep BMMC and release intracellular B. bronchiseptica 
(Lux 95). This graph shows light output (RLU) after adding polymyxin B and 
digitonin. These data represent the mean of 6 observations. The range of the error bars 
was between 0.01 and 0.1, therefore the bars were omitted to avoid exceed with other 
lines.
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3.2.5 Effect of sheep BMMC culture fluid on B. bronchiseptica (Lux 95)
The following experiments were designed to investigate that the possibility of I
sheep BMMC releases any substances during normal growth into the surrounding 
medium which could be antimicrobial. Sheep BMMC (30-day culture) were 
maintained routinely in IMDM medium containing 10% FCS, 50 |l l 1 of rOvSCF and 
100 fxl of rOv IL-3. 1% of P/S suspension was usually added into IMDM medium to 
avoid any contamination. For these experiments, sheep BMMC was grown in 
antibiotic-free medium to avoid any possibility that antibiotics had an effect on 
viability of B. bronchiseptica (Lux 95). Three days before the experiment, fresh 
antibiotie-free IMDM medium containing 10% FCS and growth factors was used to 
replace the old IMDM culture medium and cells were incubated at 37°C under 5% 
CO2. Then, after 3 days, sheep BMMCs were collected in fresh IMDM medium 
containing 10% FCS and cell numbers were adjusted to 1x10^ cells/ml. Sheep BMMC 
culture fluid (3 days old) was collected in sterilised 30 ml universal tubes and kept in 
aseptic conditions at 37°C. B. bronchiseptica (Lux 95) grown for 24 h on BG agar 
were collected and cell numbers were adjusted to 1x10^ cfu/ml or 5x10^ cfu/ml in two 
different media: IMDM antibiotic-free medium containing 10% FCS only and three 
day old sheep BMMC culture fluid. Figure 3.2.11 shows the bioluminescence output 
from either lO^cfu/ml or 5x10^ cfu/ml under three different conditions. First, in 
IMDM antibiotic-free medium containing 10% FCS only. Second, in three day old 
sheep BMMC culture fluid. Finally, mixed with 1x10^ cells/ml sheep BMMC (in 
fresh IMDM medium). Each mixture was done in triplicate in 96-well plates and 
incubated at 37 *^C in the luminometer.
There was a gradual increase in bioluminescence output of B. bronchiseptica 
(Lux 95) (10^ cfu/ml and 5x10^ cfu/ml) in IMDM medium containing 10% FCS only 
and from B. bronchiseptica (Lux 95) maintained in sheep BMMC culture fluid. 
However, there was a decline in bioluminescence output from both concentrations of 
B. bronchiseptica (Lux 95) due to incubation with 1x10^ cells/ml of sheep BMMC. 
These observations suggest that mast cells had not released any substances during 
normal growth which were antimicrobial. It also suggests that the mast cells 
themselves were causing the decline in the bioluminescence output from B. 
bronchiseptica (Lux 95). This possible mechanism was further investigated in the 
next experiment.
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Figure 3.2.11 Effect of sheep BMMC and growth culture fluid on 
bioluminescence of B. bronchiseptica (Lux 95)
Bioluminescence output from 10  ^ cfu/ml or 5x10^ cfu/ml of B. bronchiseptica 
(Lux 95) was monitored in three different conditions: IMDM medium containing 10% 
FCS, sheep BMMC culture fluid and 1x10^ cells/ml of sheep BMMC). The data 
shown are the means of 3 observations ± SD.
a) lO^cfu/ml of B. bronchiseptica (Lux 95) in IMDM medium containing 10% FCS 
only
b) 1 O^cfu/ml of B. bronchiseptica (Lux 95) in sheep BMMC culture fluid (three days 
old).
c) lO^cfu/ml of B. bronchiseptica (Lux 95) co-cultured with 1x10^ cell/ml of sheep 
BMMC.
d) 5xl0^cfu/ml of B. bronchiseptica (Lux 95) in IMDM medium containing 10% 
FCS only
e) 5xl0^cfu/ml of B. bronchiseptica (Lux 95) in sheep BMMC culture fluid (three 
days old).
f) 5xI0^cfu/ml of B. bronchiseptica (Lux 95) co-cultured with 1x10^ cells/ml of 
sheep BMMC.
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3.2.6 Effect of sheep BMMC contents on B. bronchiseptica (Lux 95)
Sheep BMMC (32 day culture) was adjusted to 1x10^ cells/ml in fresh IMDM 
medium containing 10% FCS and lysed by the freeze/thaw method at -70°C. The cell 
contents of the lysed BMMC suspension was used to study the effect on 
bioluminescence output from B. bronchiseptica (Lux 95) and compared with the 
effect of viable sheep BMMC. Co-culture of B. bronchiseptica (Lux 95) with sheep 
BMMC was carried at MOI of 1:100 (one sheep BMMC to 100 B. bronchiseptica) or 
with the contents of an equivalent number of lysed cells. 200pl of each mixture was 
added in triplicate in 96-well plates and incubated at 37“C in the luminometer.
The bioluminescence output of B. bronchiseptica (Lux 95) in IMDM medium 
only was compared with the effect of either the contents of lysed sheep BMMC or 
viable sheep BMMC. All showed a gradual increase in bioluminescence, but the 
increases due to the effect of either lysed or viable sheep BMMC were lower than the 
increase in bioluminescence output from B. bronchiseptica (Lux 95) in IMDM 
medium only (Fig. 3.2.12a). These effects on bioluminescence output were compared 
with the sharp decline in bioluminescence output from B. bronchiseptica (Lux 95) 
killed due to addition of 50 pg/ml polymyxin B. At the same time, optical density 
(OD) of suspension of each mixture was measured. There was a gradual increase in 
OD of all cell suspensions, but a slight decline in OD of the B. bronchiseptica (Lux 
95) when polymyxin was added (Fig. 3.2.12b).
The above observations suggest that there are very similar effects of both viable 
sheep BMMC and the contents of lysed sheep BMMC on bioluminescence emission 
(RLU) from B. bronchiseptica (Lux 95). However, such effects were not observed on 
the optical density of the suspension containing both B. bronchiseptica (Lux 95) and 
sheep BMMC in IMDM medium. Thus, the bioluminescence method is more 
sensitive than the OD method for measuring changes in the B. bronchiseptica culture. 
Also, these observations suggest that further investigation should be done by 
estimating viable bacteria when mixed with viable sheep BMMC or contents of lysed 
cells at different times of incubation.
139
Figure 3.2.12a Effect of sheep BMMC contents on bioluminescence output from
B. bronchiseptica (Lux 95)
The effect of cell contents of 1x10^ cells/ml of lysed sheep BMMC on B. 
bronchiseptica (Lux 95) was compared with the effect of either viable sheep BMMC 
or IMDM medium containing 10% FCS only. These effects were compared with the 
effect of 50 ftg/ml polymyxin B. The data are means of three observations ± SD.
a) 10^  cfu/ml of B. bronchiseptica (Lux 95) in IMDM medium containing 10% FCS.
b) Effect of 50 p.g/ml polymyxin B on 10^  cfu/ml of B, bronchiseptica (Lux 95).
c) Effect of 1x10^ cells/ml of viable sheep BMMC on B. bronchiseptica (Lux 95).
(!) Effect of lysed sheep BMMC contents on B. bronchiseptica (Lux 95)
Figure 3.2.12b Effect of sheep BMMC contents on optical density of B.
bronchiseptica (Lux 95)
The effect of cell contents of IxlO^ cells/ml of lysed sheep BMMC on B. 
bronchiseptica (Lux 95) was compared with the effect of either viable sheep BMMC 
or IMDM medium containing 10% FCS only. These effects were compared with the 
effect of 50p.g/ml polymyxin B on B. bronchiseptica (Lux 95). The data are means of 
three observations.
a) 10^  efu/ml of B. bronchiseptica (Lux 95) in IMDM medium containing 10% FCS.
b) Effect of 50 pg/ml polymyxin B on 10  ^cfu/ml of B. bronchiseptica (Lux 95).
c) Effect of 1x10^ cells/ml of viable sheep BMMC on B. bronchiseptica (Lux 95).
d) Effect of lysed sheep BMMC contents on B. bronchiseptica (Lux 95)
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3.2.7 Comparing the effect of sheep BMMC on B. bronchiseptica (Lux 95) with 
the effect of RBL-2H3 cells and J774A.1 macrophage cells
The following work aimed to investigate the effect of different mammalian cells 
on bioluminescence output from B. bronchiseptica (Lux 95) and compare it with 
bioluminescence output of B. bronchiseptica in IMDM medium only.
3.2.7.1 Overall effect of different mammalian cells on bioluminescence output of 
B, bronchiseptica (Lux 95)
All three cell types: sheep BMMC (from 25 day culture), RBL-2H3 cells and 
J774A.1 macrophage cells were adjusted to 1x10^ cells/ml in IMDM medium 
containing 10% FCS only and treated as before to remove antibiotics. All three cell 
types were infected with B. bronchiseptica (Lux 95) at MOI 1:100 (one mammalian 
cells to 100 bacterial cells). A total of 200 p.1 of mixture was added in triplicate in 96- 
well micro-plates and incubated at 37°C in the luminometer. Bioluminescence output 
from B. bronchiseptica (Lux 95) in IMDM medium containing 10% FCS only was 
compared with bioluminescence output from B. bronchiseptica (Lux 95) co-cultured 
with the different cell types (Figure 3.2.13).
During the first 24 h (1440 min), there was a gradual increase in 
bioluminescence output (RLU) of B. bronchiseptica (Lux 95) mixed with different 
mammalian cell types and of B. bronchiseptica (Lux 95) in control wells, but at 
different rates. With sheep BMMC, bioluminescence output (RLU) of B. 
bronchiseptica (Lux 95) was slower than bioluminescence output from the control 
culture, as in previous observations (section 2.3 and section 2.7). On the other hand, 
bioluminescence output from B. bronchiseptica (Lux 95) co-cultured with J774A. 1 
cells was similar to bioluminescence output from the control. Bioluminescence output 
with the RBL-2H3 cell line was higher than the control, which could mean that RBL- 
2H3 cells could stimulate growth or metabolic activity of B. bronchiseptica (Lux 95) 
in some way. From 24 h - 48 h (2880 min) there was a gradual decline in 
bioluminescence output from all cell suspensions even from the control cultures of B. 
bronchiseptica (Lux 95) in IMDM medium alone. In addition, with RBL-2H3 cells, 
the decline in light output was slower than with the other cell types or the eontrol 
culture. These observations suggested that sheep BMMC have greater antibacterial 
activity than the two cell lines.
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Figure 3.2.13 Effect of different mammalian cells on bioluminescence output of
B. bronchiseptica (Lux 95)
1x10^ ce]]s/ml of different ce]l types were infected with B. bronchiseptica (Lux 95) at 
MOI 1:100. Bioluminescence output was monitored at 37“C in the luminometer. 
These data are the means of 3 observations ± SD. Error bars are omitted when 
standard errors of the mean do not exceed the dimension of the symbols.
a) 10^  cfu/ml of B. bronchiseptica (Lux 95) in BVIDM medium containing 10% PCS 
only.
b) Effect of sheep BMMC (25-day culture) on bioluminescence output of B. 
bronchiseptica (Lux 95).
c) Effect of sheep J774A.1 macrophage cell line on bioluminescence output of B. 
bronchiseptica (Lux 95).
d) Effect of RBL-2H3 cell line on bioluminescence output of B. bronchiseptica (Lux 
95).
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3.2.T.2 Comparing the internalization of B, bronchiseptica (Lux 95) by RBL- 
2H3 ceils and sheep BMMC 
3.2.7.2.1 Luniinometery assay
The ability of the RBL-2H3 cells was compared with the ability of sheep 
BMMC (from 29-day culture) for uptake of B. bronchiseptica (Lux 95). Both cell 
types were adjusted to 1x10^ cells/ml in IMDM medium containing 10% PCS and 
infected with B. bronchiseptica (Lux 95) at MOI 1:500. (one mammalian cell to 500 
B. bronchiseptica). 200 |ll volumes of the mixture were added in triplicate in 96-well 
plates. Contact between mammalian cells and B. bronchiseptica (Lux 96) was 
accelerated by centrifuging the micro-well plate at 250 ipm for 10 min. Then, the 
plate was incubated at 37°C and in 5% CO2 for 4 h. Polymyxin B 50 pg/ml was then 
added to kill extracellular B. bronchiseptica (Lux 95) and the micro-well plate was 
incubated at ?>TC in 5% CO2 for a further I h. 50 pg/ml digitonin was then added to 
some wells. Then, plates were incubated in 37°C in the luminometer and 
bioluminescence output was monitored (Figure 3.2.14a).
The effect of polymyxin B on B. bronchiseptica (Lux 95) in the absence of 
mammalian cells was used as a control for all other conditions. In the presence of 
mammalian cells (i.e. RBL-2H3 cell line or sheep BMMC) and 50 pg/ml polymyxin 
B, light output in the presence of sheep BMMC was higher than light output in the 
presence of RBL-2H3 cells which was similar to the control measurement. However, 
in the presence of 50 pg/ml digitonin, all RLU measurements were similar for light 
output of the control. From the above observations, it appeared either there was no 
evidence of internalization of B. bronchiseptica (Lux 95) by the RBL-2H3 cells, or 
that any internalized bacteria had been killed. Further investigation was done by TEM 
and viable counting.
3.2.7.2.2 TEM
Transmission electron microscopy (TEM) of sections of RBL-2H3 cells that 
had been mixed with B. bronchiseptica (Lux 95) at an MOI of 1:500 at 4 h 
postinfection did not show any bacteria localized within vacuoles of RBL-2H3 cells. 
Representative cells are shown in figure 3.2.14b. Extracellular bacteria were clearly
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visible (arrows). With sheep BMMC, internalized B. bronchiseptica (Lux 95) were 
clearly visible, as described in section (3.2.4.2.2).
3.2.7.2.3 Viable count
RBL-2H3 cells were infected with B. bronchiseptica (Lux 95) at MOI 1:500 
and incubated for 4 h at 37°C in 5% CO2. Then, extracellular B. bronchiseptica (Lux 
95) were removed by washing three times. Each time, the cell suspension was 
centrifuged at 2000 rpm for 5 min and fresh IMDM medium was added. At the third 
wash, the RBL-2H3 cell pellet was resuspended in a fresh IMDM medium containing 
50 |ig/ml polymyxin B as a final concentration and incubated for 1 h under the same 
conditions to kill any remaining extracellular B. bronchiseptica (Lux 95). To remove 
polymyxin B from the medium, the cell suspension was centrifuged twice at a speed f
of 2000 rpm for 5 min and fresh IMDM medium was added. 50 |Xg/ml digitonin was f
then added into the cell suspensions and incubated for Ih under the previous 
conditions. Then, 100 jil of cell suspension from each sample were diluted 1:10 in 
PBS and 100 fll of dilution were placed on BG agar. After incubation for 24 h at 37°C 1
in humid conditions, no colonies were observed. These observations supported the 
previous results in that there was no evidence of uptake of B. bronchiseptica by the 
RBL-2H3 cells.
144
Figure 3.2.14a Comparison of internalization of B. bronchiseptica (Lux 95) by 
RBL-2H3 cells and sbeep BMMC
This graph shows enlargement scale after addition of polymyxin B and digitonin. The 
light emission from intracellular B. bronchiseptica (Lux 95) in sheep BMMC and 
RBL-2H3 cells treated with of polymyxin B only, can be compared with light output 
from cells treated with both polymyxin B and digitonin. These data represent the 
mean of 6 observations. The range of the error bars was between 0.01 and 0.1, 
therefore the bars were omitted to avoid exceed with other lines.
A) B. bronchiseptica (Lux 95) in IMDM medium containing 50 jig/ml of polymyxin 
B
B) Sheep BMMC and B. bronchiseptica (Lux 95) and 50 Rg/ml of polymyxin B.
C) Sheep BMMC and B. bronchiseptica (Lux 95) and 50 p,g/ml of polymyxin B and 
50 p.g/ml of digitonin
D) RBL-2H3 cells and B. bronchiseptica (Lux 95) and 50 |Llg/ml of polymyxin B,
E) RBL-2H3 cells and B. bronchiseptica (Lux 95) and 50 |lg/ml of polymyxin B and 
50 p.g/ml of digitonin.
Figure 3.2.14b TEM of RBL-2H3 cells infected witb B. bronchiseptica (Lux 95)
TEM did not show any intracellular B. bronchiseptica (Lux 95) within RBL-2H3 
cells, only extracellular bacteria (arrows) are seen, scale bar =10|am.
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
100 130 160 190 220 250 280
T im e (m in)
-♦ -A  -B -B  -A-C -4K-E
310 340
Figure 3.2.14a
Figure 3.2.14b
145
3.2.8 Internalization of bioluminescent E. coli by sbeep BMMC
1x10^ cells/ml of sheep BMMC (28-day culture) were maintained in IMDM 
medium containing 10% FCS. Cell numbers and viability were confirmed by trypan 
blue exclusion counts. Infection of sheep BMMC with the E. coli strain (FlblOlpTV- 
3) was carried out at MOI 1:500 (one sheep BMMC to 500 bacterial cells). Volume of 
200 p,l of cell-bacteria suspension were added in triplicate in 96-well plates then 
incubated at 3TC  in the luminometer and bioluminescence output was monitored. At 
4 h postinfection, 50pg/ml polymyxin B sulphate (Sigma) was added to some wells to 
kill extracellular bacteria. After 1 h, 50 jttg/ml of digitonin was added to some wells to 
lyse sheep BMMC.
Figure 3.2.15a shows the overall light emission for the experiment. There was a 
gradual increase in bioluminescence output from E. coli maintained in IMDM 
medium only (over the first lOh of incubation). Then, there was a gradual decline in 
bioluminescence output. With sheep BMMC, there was an increase and decline in 
bioluminescence output similar to those in the control containing bacteria in IMDM 
medium only. But, the light outputof E. coli mixed with sheep BMMC was less than 
the light output of E. coli mixed with IMDM medium only. This obersvtion was 
similar to the light output of B. bronchiseptica (lux 95) mixed with sheep BMMC. A 
sharp decline in bioluminescence output from E. coli was observed due to addition of 
50|ig/ml polymyxin.
As can be seen from Fig 3.2.15b, the effect of polymyxin B on the light output 
from E. coli in absence of sheep BMMC was used as a control for light output 
measurement. In the presence of sheep BMMC and polymyxin B, light output 
measurement was higher than light output measurement in presence of sheep BMMC 
and digitonin. These differences could suggest that the light output in absence of 
digitonin could be due to intracellular viable bioluminescent E. coli (Fig. 3.2.15b). 
Unlike B. bronchiseptica (Lux 95) (Fig. 3.2.7c) there is a gradual decline in light 
output from assumed intracellular E. coli. This observations suggested that decline in 
light output of intracellular E. coli was due to either killing of intracellular E. coli by 
sheep BMMC or due to their lowering of light output as the culture age (see Fig. 
3.2.6).
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When digitonin was added, the intracellular E. coli were exposed to 
extracellular polymyxin B and bioluminescence output rapidaly declined to base level, 
even though there is not a good correlation between light output from bioluminescent 
E. coli and viable cell numbers in older cultures (section 3.2.2.4). The 
bioluminescence assay still provided evidence for uptake and survival for some time 
of E. coli in sheep BMMC.
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Figure 3.2.15a Overall effect of sheep BMMC on light output from 
bioluminescent E. coli
IxlO^ cells/ml of sheep BMMC maintained in IMDM medium containing 10% FCS 
were infected with E. coli (Hbl01pT7-3) at an infection ratio of 1:500 and incubated 
for 4 h. Polymyxin B was added to kill extracellular E. coli (Hbl01pT7-3) and after a 
further i h, digitonin was added to selected wells containing polymyxin B. The 
overall bioluminescence output (RLU) was monitored (mean of 6 observations ± SD).
A) E. coli maintained in IMDM only.
B) E. coli maintained in IMDM medium containing sheep BMMC.
C) The effect of polymyxin B on light output from E. coli.
D) The effect of polymyxin on light output from E. coli maintained in IMDM 
medium with sheep BMMC
E) The effect of digitonin and polymyxin on light output from E. coli maintained in 
IMDM medium with sheep BMMC.
Figure 3.2.15b Evidence for intracellular E. coli (DHot5pT7-3) within sheep 
BMMC
This graph shows an enlargement of the selected samples (Y-axis) for the previous 
graph (2.16a). The light emission in samples which containing polymyxin B only 
were compared with light emission in samples containing polymyxin B and digitonin. 
These differences could suggest that the light output in absence of digitonin could be 
due to intracellular viable bioluminescent E. coli (mean of 6 observations, the range 
of error bars was between 0.01 and 0.1, therefore error bars were omitted to avoid 
overlap with other lines).
A) E. coli in IMDM medium containing 50 pg/ml of polymyxin B.
B) Sheep BMMC and E. coli and 50 pg/ml of polymyxin B.
C) Sheep BMMC and E. coli and 50 pg/ml of polymyxin B and 50 pg/ml of 
digitonin.
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S e c t i o n  T h r e e :  Interaction of B. bronchiseptica 
and other bacteria with sheep BMMC and other 
cell types
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3.3.1 Effect of sheep BMMC and murine macrophage cell line (P388D1) on 
btouminescence output from B. bronchiseptica (Lux 95)
Bioluminescence output from B. bronchiseptica (Lux 95) was used as a reporter 
for the effect of either sheep BMMC or murine macrophage cell line (P388D1) on the 
bacteria. Two different infection ratios were used: 1:500 (one mammalian cell to 500 
bacterial eells) or 1:2500 (one mammalian cell to 2500 bacterial cells).
Viability of sheep BMMCs from a 25-day culture was investigated using trypan 
blue exclusion and cell numbers were adjusted to 1x10^ cell/ml in antibiotic-free 
IMDM medium containing 10% FCS. Viability and cell number of murine 
macrophage cells F388D1 were also adjusted to 1x10^ cell/ml in antibiotic-free 
IMDM medium containing 10% FCS. B. bronchiseptica (Lux 95) grown for 24 h on 
BG agar were collected. A suspension of pelleted bacteria was made in IMDM 
medium and cell numbers were adjusted to either 5x10^ cfu/ml or 25x10^ cfu/ml. 100 
jLil of sheep BMMC suspension (or P388D1) was mixed with lOOpl of bacterial 
suspension (total volume 200 jil) and was added in triplicate in 96-well plates and 
incubated at 37”C in the luminometer for 12 h. Bioluminescence output from the 
mixture of mammalian cell and bacteria was compared with bioluminescence output 
from control wells which contain B. bronchiseptica (Lux 95) in IMDM medium only. 
Figure 3.3.1a and Figure 3.3.1b show a comparison of the effect of sheep BMMC and 
P388D1 macrophage cell line on bioluminescence output from B. bronchiseptica (Lux 
95) at both infection ratios.
There was a gradual increase in bioluminescence output with time from the 
control well which contained B. bronchiseptica (Lux 95) in IMDM medium only. 
With sheep BMMC at either lower and higher infection ratios, there was only a slow 
increase in bioluminescence output from B. bronchiseptica (Lux 95). In contrast, there 
was increase in bioluminescence output from B. bronchiseptica (Lux 95) co-cultured 
with P388D1 macrophage cells compared with bioluminescence output in control 
wells. Thus, two different effects were observed. Co-culture of B. bronchiseptica (Lux 
95) with sheep BMMC appeared to reduce the growth rate of B. bronchiseptica (Lux 
95) in that there was a slow rate of increase in bioluminescence output. But, in the 
case of co-culture of B. bronchiseptica (Lux 95) with P388D1 macrophage cells there 
was an increase in bioluminescence output suggesting that there was enhancement of 
growth rate.
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Figure 3.3.1a Comparison of effects of sheep BMMC and P388D1 cells on B. 
bronchiseptica (Lux 95) (Low infection ratio)
5x10^ cfu/ml of B. bronchiseptica (Lux 95) were co-cultured with either sheep 
BMMC or P388D1 macrophage cell line at an infection ratio of 500:1 (500 bacteria to 
one mammalian cell) in IMDM medium containing 10% FCS and incubated at 37“C 
in the luminometer for 12h (mean of 9 observations ± SD).
a) Control wells containing 5x10^ cfu/ml B. bronchiseptica (Lux 95) in IMDM 
medium only.
b) 5x10® cfu/ml B. bronchiseptica (Lux 95) were co-cultured with 1x10^ cells/ml of 
P388D1 macrophage cells
c) 5x10® cfu/ml B. bronchiseptica (Lux 95) were co-cultured with 1x10^ cells/ml of 
sheep BMMC.
Figure 3.3.1b Comparison of effects of sheep BMMC and P388D1 cells on B. 
bronchiseptica (Lux 95)(High infection ratio)
25x10® cfu/ml of B. bronchiseptica (Lux 95) were co-cultured with either sheep 
BMMC or P388D1 macrophage cell line at infection ratio 2500:1 (2500 bacteria to 
one mammalian cell) in IMDM medium containing 10% FCS and incubated at 37”C 
in luminometer for 12 h (mean of 9 observations ± SD).
d) Control wells containing 25x10® cfu/ml B. bronchiseptica (Lux 95) in IMDM 
medium only.
e) 25x10® cfu/ml B. bronchiseptica (Lux 95) were co-cultured with 1x10^ cells/ml of 
P388D1 macrophage cell.
f) 25x10® cfu/ml B. bronchiseptica (Lux 95) were co-cultured with 1x10^ cells/ml of 
sheep BMMC.
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3.3.2 Interaction of different B. bronchiseptica strains with sheep BMMC and 
J774A.1 macrophage cells
In the previous experiments, interaction of sheep BMMC with B. bronchiseptica 
was studied by using a bioluminescent strain of B. bronchiseptica (Lux 95). 
Intracellular B. bronchiseptica (Lux 95) were observed within sheep BMMC at 4 h 
post-infection (section 3.2.3). As there was some doubt about the virulence mode of 
B. bronchiseptica (Lux 95) from preliminary characterisation tests (section 3.2.1), 
intracellular survival was compared with that of the virulent strain of B. 
bronchiseptica (Bvg phase) and an avirulent strain of B. bronchiseptica (Bvg 
phase) within sheep BMMC and the J774A. 1 macrophage cells.
Bacterial suspensions of different strains of B. bronchiseptica were prepared 
from 24 h BG agar plates. Bacterial numbers were adjusted to 5x10^ cfu/ml. Sheep 
BMMC (from 35-day culture) and J774A. 1 macrophage cells were adjusted to 1x10^ 
cells/ml in IMDM medium containing 10% FCS only. Infection of both cell types 
with different strains of B. bronchiseptica was carried out at MOI 1:500. Each 
infection was carried out in duplicate in 25cm^ cell culture flasks with vent caps and 
incubated at 37°C in 5% CO2. After incubation for 4 h, extracellular B. bronchiseptica 
were removed by centrifugation of the cell suspensions at 2000 rpm for 5 min, three i
times. Each time, fresh IMDM was added and the old IMDM medium was discarded. 
Pellets were resuspended in fresh IMDM medium containing 10% FCS and 1 pg/ml 
polymyxin B was added as a final concentration at zero time, and incubation 
continued at 3TC  in 5% CO2. At different times (12, 20 and 32 h) after zero time, 
extracellular polymyxin B was removed by extensive washing by centrifugation of the 
cell suspensions at 2000 rpm for 5 min and resuspension in fresh IMDM. This step 
was repeated twice. Then, the viability of sheep BMMC or J774A. 1 cells was 
estimated by using trypan blue exclusion count. Intracellular bacteria within sheep 
BMMC or J744A.1 cells were released by adding 100 |lg/ml of digitonin as a final 
concentration and dilution in PBS was carried out and plated on BG agar plate for 
viable counting.
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3.3.2.1 Comparison of survival of sheep BMMC and J774A.1 cells after 
infection with different B. bronchiseptica strains
The survival of sheep BMMC or J774A. 1 after infection with different strains 
of B. bronchiseptica was measured at different incubation times (Oh, 12 h, 20 h and 
32 h)(Fig. 3.3.2a). All cultures showed some loss of viability with time. Untreated 
cultures of both cell types showed around 20% loss of viability over 32 h. The most 
dramatic reduction in survival of both sheep BMMC and J774A. 1 cells was caused by 
the B. bronchiseptica (Bvg phase). At zero time (4 h after infecting mammalian cells 
with bacteria), there was 60 % survival of sheep BMMC and around 30 % survival of 
J774A.1. Furthermore, more reduction in percentage survival of both cell types due to 
the effect of B. bronchiseptica (Bvg"  ^ phase) was observed at 12 h incubation. Then, 
little further reduction was observed for both cell types at 20 h and 32 h incubation. In 
contrast, the avirulent strain of B. bronchiseptica (Bvg" phase) allowed around 85 % 
survival of sheep BMMC and similar percentage of survival of J774A. 1 cells at zero 
time. At 32 h, around 70% survival of sheep BMMC and 30% survival of J774A. 1 
cells were observed due to the effect of B. bronchiseptica (Bvg" phase). In contrast, 
the percentage survival of sheep BMMC due to the effect of B. bronchiseptica (Lux 
95) was higher than the percentage survival of sheep BMMC incubated with B. 
bronchiseptica (Bvg^ phase), but lower than the percentage survival of sheep BMMC 
due to the effect of B. bronchiseptica (Bvg" phase) at all incubation times. For 
example, there was around 75 % survival of sheep BMMC at zero time. At 32 h, 
around 60% survival of sheep BMMC was observed. At all incubation times, there 
was a statistically significant difference in percentage survival of sheep BMMC 
infected with biolumineseent B. bronchiseptica (Lux 95) strain when compared with 7sheep BMMC infected with the virulent B. bronchiseptica (Bvg phase) (Student t- 7
test, p-value < 0.001). Also, there was a significant difference between survival of
ÿsheep BMMC with avirulent B. bronchiseptica (Bvg phase) and with B. 
bronchiseptica (Lux 95) (p-value < 0.05). f
In contrast, the percentage survival of J774A. 1 at zero time, 12 h and 32 h due 
to the effect of B. bronchiseptica (Lux 95) were similar to the effect of B. 
bronchiseptica (Bvg" phase) which were higher than the percentage survival of 
J774A.1 cells due to the effect of B. bronchiseptica (Bvg^ phase). In general, the
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effects of the different strains of B. bronchiseptica on survival of J774A. 1 
macrophage cells (Fig. 3.3.2b) were similar to the pattern of reduction due to same 
strains on viability of sheep BMMC.
Therefore, the above observations, suggested that the cytotoxicity of the 
biolumineseent B. bronchiseptica (Lux 95) was intermediate between that of the Bvg^ 
phase and Bvg “ phase toward sheep BMMC which confirms the previous 
observations (section 3.2.1).
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Figure 3.3.2a Survival of sheep BMMC due to infection with different strains of
B. bronchiseptica
Sheep BMMC were infected with different strains of B. bronchiseptica (Lux 95), 
(Bvg phase) and (Bvg “ phase) at MOI 1:500. At different incubation times (0 h, 12 
h, 20 h and 32 h) survival of sheep BMMC was measured by trypan blue exclusion 
count (mean of 4 observations ± SEM).
Figure 3.3.2b Survival of J774A.1 macrophage cell line due to infection with 
different strains of B. bronchiseptica
J774A. 1 macrophage cell lines were infected with different strains of B. 
bronchiseptica (Lux 95), (Bvg phase) and (Bvg " phase) at MOI 1:500. At different 
incubation times (Oh, 12 h, 20 h and 32 h) survival of J774A.1 was measured by 
trypan blue exclusion count (mean of 4 observations ± SEM).
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3.3.2.2 Survival of different B. bronchiseptica strains within sheep BMMC or 
J774A.1 macrophage cells
Viable counts of the different B, bronchiseptica strains (Lux 95), (Evg"  ^phase) 
and (Bvg “ phase) were taken at different incubation times with the sheep BMMC and 
J774A. 1 cells (section 3.3.2.1). This step was done to confirm the previous suggestion 
that B. bronchiseptica (Lux 95) is at intermediate phase between the Bvg and Bvg" 
phase observations.
Figure 3.3.3a shows that, after 12 h, the avirulent B. bronchiseptica (Bvg' 
phase) showed a significantly higher survival rate than the virulent B. bronchiseptica 
(Bvg phase) (p-value < 0.001) within sheep BMMC or J774 macrophage cells 
(Figure 3.3.4a). But with increasing incubation time, survival of B. bronchiseptica 
(Bvg" phase) decreased within sheep BMMC (Fig. 3.3.3a) or J774A.1 cells (figure 
3.3.4a). A similar significant survival of B. bronchiseptica (Lux 95) was observed 
within both cell types, but within sheep BMMC at 20 h was lower than survival of B. 
bronchiseptica (Lux 95) within J774A. 1 cells. The numbers of viable intracellular B. 
bronchiseptica (Lux 95) or the avirulent strain (Bvg' phase) within sheep BMMC or 
J774A. 1 cells had declined by 20 h and 32 h when compared with numbers of 
intracellular survivors at 12 h. The last observation suggests that both strains of B. 
bronchiseptica (Bvg" phase) and (Lux 95) were eventually killed by the sheep BMMC 
and J774A. 1 cells (Fig. 3.3.3a and Fig. 3.3.4a) or that these strains eventually killed 
the sheep BMMC or J774A.1 cells and were then exposed to the extracellular 1 pg/ml 
polymyxin B. Another possibility is that polymyxin B eventually leaks into 
phagosoms of the mammalian cells to kill the intracellular bacteria.
In contrast, the number of viable intracellular B. bronchiseptica (Bvg phase) 
was low compared with other strains at all incubation times. These results indicate 
that the virulent strain of B. bronchiseptica (Bvg ’^ ) reduced the viability of the sheep 
BMMC or J774A.1 cells as shown in Fig. 3.3.3b and Fig. 3.3.4b and in turn any 
intracellular Bvg could be then killed by extracellular polymyxin B. With reference 
to the original infection number of different B. bronchiseptica strains (5x10^ cfu/ml), 
the percentage of intracellular B. bronchiseptica within either sheep BMMC or 
J774A.1 cell line was calculated at different incubation times. The percentages of
156
different strains of intracellular B. bronchiseptica declined with incubation time (Fig. 
3.3.3b and Fig. 3.3.4b).
The above observations suggested that B. bronchiseptica (Lux 95) may be as 
intermediate phase of B, bronchiseptica. Furthermore, the numbers of intracellular B. 
bronchiseptica (Bvg ' phase) and (Lux 95) within J774A.1 cells was higher than 
number within sheep BMMC which suggest that uptake of bacteria by sheep BMMC 
is less than the uptake ability of the professional phagocytic J774A.1 cells.
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Figure 3.3.3a Long-term intracellular survival of different strains of B. 
bronchiseptica within sheep BMMC
IxlO^ cells/ml of sheep BMMC were mixed with different strains of B. 
bronchiseptica at MOI 1:500 and incubated for 4 h. Extracellular bacteria were 
removed by washing and the cell suspension was incubated with 1 pg/ml of 
polymyxin. The time scale refers to the time point of washing and addition of 
polymyxin B to the cell suspension. At different times, the number of viable 
intracellular bacteria was determined by viable counting (means of 4 observations ± 
SEM).
Figure 3.3.3b Percentage of intracellular B. bronchiseptica (Lux 95), (Bvg"*") phase 
and (Bvg ") phase within sheep BMMC
Sheep BMMC were infected with different B. bronchiseptica strains at MOI 1:500 
and incubated for 4h. The time scale of viability of intracellular bacteria of different 
strains refers to the time point of washing and addition of polymyxin B to the cell 
suspension. Intracellular B. bronchiseptica at different incubation times calculated as 
a percentage of the original bacterial number.
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Figure 3.3.4a Long-term intracellular survival of different strains of B, 
bronchiseptica within J774A.1 cells
1x10^ cells/ml of J774A.1 were mixed with different strains of B. bronchiseptica at 
MOI 1:500 and incubated for 4 h. Extracellular bacteria were removed by washing 
and the cell suspension was incubated with 1 ftg/ml of polymyxin. The time scale 
refers to the time point of washing and addition of polymyxin B to the cell 
suspension. At different times, the number of viable intracellular bacteria was 
determined by viable counting (means of 4 observations ± SEM).
Figure 3.3.4b Percentage of intracellular B. bronchiseptica (Lux 95), (Bvg^) phase 
and (Bvg “) phase within J774A.1 cells
J774A. I were infected with different B. bronchiseptica strains at MOI 1:500 and 
incubated for 4 h. The time scale of viability of intracellular bacteria of different 
strains was refers to the time point of washing and addition of polymyxin B to the cell 
suspension. Intracellular B. bronchiseptica at different incubation times calculated as 
a percentage of the original bacterial number.
Ic  Q)IIa> oOQ
0)SI(0>
&E
3.5E+06 
3.0E+06 
2.5E+06 
2.0E+06 
1.5E+06 
1 .OE+06 
5.0E+05 
O.OE+00
12h
T-
20 h 
Incubation Time
32 h
Lux 95 □ Bvg + □ Bvg -
Figure 3.3.4a
0 .7
2
CL 0 .6
.2
ë 0 .5g-Q
CD 0.4
«3
S 0 .3gÇ
(D 0 .2
CO■>
“o 0.1
°
0
Lux 9 5 B v g  +
B. bronchisept ica
12 h 0 2 0  h «132 h
B v g  -
Figure 3.3.4b
159
3.3.3 ATP-bioluminescent assay and bioluminescence output strain from B. 
bronchiseptica (Lux 95)
The nucleotide adenosine triphosphate (ATP) plays a central role in energy 
exchange in biological systems. Many methods have been used for ATP 
determination, but now the most widely used, because of its sensitivity is the 
luciferin-luciferase bioluminescence assay which provides an assessment of viable 
cell numbers. The aim of this section was to further study the cytotoxic effect of 
different strains of B. bronchiseptica and to compare it with that of other related 
bacteria (i.e. different Bordetella species) and unrelated bacteria (i.e. Gram-positive 
bacteria). Therefore, different bacterial species were used and their effect on viability 
and degranulation of different mammalian cells was investigated. Viability of 
mammalian cells was assessed based on quantitation of the ATP present (by using the 
cellTiter-Glo™ luminescent cell viability assay), which signals the presence of 
metabolically-active cells by light output (RLU).
A preliminary study was set-up to examine the correlation between metabolic 
activities of different numbers of viable mammalian cells and light output (RLU).
RBL-2H3 cells were used as a model for the following study. Initially, different 
numbers of RBL-2H3 cells were adjusted in IMDM medium and the metabolic 
activities of these different cell numbers were estimated in IMDM medium only.
Figure 3.3.5a showed that there was a linear relationship between cell numbers and 
ATP levels (RLU). As the ATP-bioluminescent assay was to be used for estimation of 
metabolic activity of different mammalian cells in the presence of bacteria, therefore 
it was important to investigate the level of metabolic activity of bacterial cells (e.g. 
different strains of B. bronchiseptica) in the same assay. This would show whether 
there was any interference due to the ATP content of the bacterial cells themselves in 
the final readings. Figure 3.3.5b shows a comparison of the ATP levels of different 
mammalian cells and different strains of B. bronchiseptica.
■1As can be seen, there were different levels of ATP detected in the different 
mammalian and bacterial cells by using the cellTiter-Glo™ luminescent cell viability 
assay. But, in the case of B. bronchiseptica (Bvg"  ^ phase) and its mutants (Bvg " or
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Lux 95) at a cell concentration 5x10^ cfu/ml, the ATP-bioluminescent assay showed 
only very low light output from the bacterial cells compared with the different 
mammalian cells at 1x10^ cells/ml (p-value < 0.0001). These observations suggested 
that the ATP contents of the different strains of B. bronchiseptica would not interfere 
with measurment of ATP contents (and viability) of the different mammalian cells. In 
addition, the above results suggested that the bioluminescence output of B. 
bronchiseptica (Lux 95) did not interfere with the bioluminescence output (RLU) 
measured using the cellTiter-Glo™ luminescent cell viability assay at the same 
wavelength.
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Figure 3.3.5a The correlation between ATP measurement and mammalian viable 
cell numbers
The figure shows the correlation between bioluminescence output (RLU) detected by 
the ATP-bioluminescent assay and different viable cell numbers of RBL-2H3 cell line 
(mean of 9 observations and ± SEM).
Figure 3.3.5b ATP contents of different mammalian cells and different strains of 
B. bronchiseptica.
ATP contents of IxlO*^  cells/ml of different mammalian cells compared with ATP 
contents of different strains of B. bronchiseptica (5x10^ cfu/ml) by using the the ATP- 
bioluminescent assay (mean of 9 observations ± SEM).
MC: sheep BMMC
RBL-2H3 cell line
J774A.1 macrophage cell line
Bvg : virulent type of B. bronchiseptica
Bvg ■ : avirulent type of B. bronchiseptica
Lux 95; bioluminescent strain of R. bronchiseptica
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3.3.4 Im portance of growth medium on cytotoxic activity of B. bronchiseptica
3.3.4.1 Effect on cytotoxicity of B. bronchiseptica
To determine whether different growth media had an effect on the cytotoxicity 
of the virulent strain of B. bronchiseptica, cultures grown for 24 h on BG agar or in 
CL broth, on LB agar or other media were collected in IMDM medium containing 
10% PCS. Cell numbers were adjusted to OD^ oonm = 0.46 (equivalent to 2x10*^  cfu/ml) 
and diluted to 5x10^ cfu/ml. RBL-2H3 cells were adjusted to 1x10^ cells/ml in 
antibiotic-free IMDM and mixed with B. bronchiseptica at an infection ratio of 1:500 
(one RBL-2H3 cell to 500 bacterial cells). 200 (tl volumes of the mixture were added 
in triplicate in 96-well plates and incubated for 1 h at 37°C in 5% CO2. Viability of 
the RBL-2H3 cells was estimated by the ATP bioluminescence assay and the 
percentage of survival was estimated. Previous, degranulation of RBL-2H3 cells after 
incubation with lO'*^  M of calcium ionophore showed that (3-hexosaminidase release 
was highest after incubation for 3 h (data not shown). Therefore, estimation of (3- 
hexosaminidase release was used as a marker for RBL-2H3 cell degranulation after
incubation for 3h with different stimulators.
As can be seen from Figure 3.3.6a, the percentage of survival of the RBL-2H3 
cells infected with the virulent strain of B. bronchiseptica (Bvg"^ phase) grown on BG 
agar was low compared with the percentage of survival of RBL-2H3 cells infected 
with virulent strain of B. bronchiseptica (Bvg phase) grown in CL broth or on LB 
agar (p-value < 0.001). Figure 3.3.6b showed that there was statistically significant 13- 
hexosaminidase release from RBL-2H3 cells due to interaetion with B. bronchiseptica 
(Bvg '*') grown on BG agar compared with [3-hexosaminindase release from RBL-2H3 
cells due to the effect of B. bronchiseptica (Bvg”*”) grown on the other media including 
BG agra, CL broth, SS broth, LB agar or LB broth (p-value < 0.001). 10'  ^ M of 
calcium ionophore stimulated (3-hexosaminidase release from RBL-2H3 cells, but 10 ^^ 
M of substance-P did not show significant (3-hexosaminidase release from RBL-2H3 
cells, as shown previously.
Previously, it has been show that the medium cultur is an important factor in ÿ
modifying Bordetella virulence (Wardlaw et a l, 1976). Expression of all of the 
cytotoxic factors was reduced under phenotype-modulating growth conditions (Coote,
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2001) and in phase variants, demonstrating that their transcription was found to be 
affected by the growth conditions, with maximal expression being observed using BG 
agar. Therefore, these results suggest that BG agar is the preferred medium to grow B. 
bronchiseptica to obtain a cytotoxic effect.
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Figure 3.3.6a Effect of different growth media on cytotoxicity of B, 
bronchiseptica (Bvg for RBL-2h3 cells.
This figure shows the cytotoxicity of virulent strain of B. bronchiseptica (Bvg ’^ ) 
grown on BG agar, in CL broth or on LB agar. RBL-2H3 cells were infected at a ratio 
of 1:500 and incubated for 1 h. The percentage of survival of the RBL-2H3 was 
estimated by comparing the viability of RBL-2H3 cells treated in IMDM only with 
the viability of RBL-2H3 cells infected with B, bronchisetica grown in different 
growth media (mean of 9 observations ± SEM). Viability of RBL-2H3 cells was 
estimated by the ATP-bioluminescence assay.
Figure 3.3.6b Effect of cytotoxicity of B, bronchiseptica (Bvg )^ on degranulation 
ofRBL-2H3 cells.
The graph shows the percentage of P-hexosaminidase release from RBL-2H3 cells 
due to infection with B. bronchiseptica (Bvg" )^ grown on different media. Calcium 
ionophore and substance-P (lO'^^M) were used as controls. The results shown are the 
percentage of P-hexosaminidase release estimated after incubation for 3 h (mean of 9 
observations ± SEM).
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3.3.4.2 Effect of different media on enzymatic activity of adenylate cyclase toxin 
(ACT)
The previous observations suggested that growth media on BG agar gave 
greater cytotoxicity of the virulent strain of B. bronchiseptica towards RBL-2H3 cells 
than other growth media. Therefore, it was important to investigate the importance of 
growth medium on expression of different cytotoxic factors in B. bronchiseptica 
(Bvg'*'). For example, adenylate cyclase toxin (or CyaA) is a known Bvg-regulated 
virulence factor in B. bronchiseptica, and it is considered to be one of the most 
important virulence factors. Therefore, B. bronchiseptica (Bvg '"') was grown on 
different media (BG agar, LB agar and CL broth) for 24 h at 37°C and the resulting 
growth collected in PBS. Then, bacterial numbers were adjusted to OD6oonin=0.46 
(equivalent to 2x10^ cfu/ml). 1 % of Triton X I00 (Sigma) was added to lyse the 
bacterial cells. After 30 min, the mixture was centrifuged at 13000 rpm for 5 min and 
then the supernatant was placed in an ice bath. AC enzymic activity was detected in 
the supernatant by conductimetry assay (see Materials and Methods).
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Figure 3.3.7 shows that the AC enzymic activity of the virulent strain of B. |
bronchiseptica (Bvg '*') cells grown on BG agar was higher than the enzymic activity 
of B. bronchiseptica (Bvg '*') grown on LB agar or in CL broth. These observations 
again suggest that BG agar could maximise the cytotoxicity of B. bronchiseptica 
(Bvg'*') phase compared with the effect of other media. Therefore, in all future work,
BG agar was used as the growth medium for B. bronchiseptica.
Figure 3.3.7 Adenylate cyclase enzymatic activity from lysed B. bronchispetica 
(Bvg  ^phase) grown on different media.
B. bronchiseptica (Bvg phase) grown on different media were collected and 
bacterial numbers were adjusted to 2x10^ cfu/ml. 1 % of Triton XlOO was added to 
lyse the bacterial cells. AC activity was detected in the supernatant by conductimetry 
assay. This figure shows that the enzymic activity cells grown on BG agar was higher 
than when grown on LB agar or in CL broth. A) indicates an increase conductivity 
and B) is the time scale (sec).
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3.3.5 Importance of Bvg mode on cytotoxicity of B. bronchiseptica
Bvg-regulated factors are known to play a role in the virulence of B. 
bronchiseptica. Here, cytotoxicity of B. bronchiseptica towards different mammalian 
cells was investigated with regard to the Bvg mode of the bacteria. Two different 
strains of B. bronchiseptica were used, the virulent strain (Bvg and an avirulent 
strain (Bvg") to investigate their effects on the morphology, viability and 
degranulation of different mammalian cell types (sheep BMMC, RBL-2H3 cells and 
J774A. 1 cells).
3.3.5.1 Microscopic study of interaction of different strains of B. bronchiseptica 
with RBL-2H3 cells
RBL-2H3 cells were infected with either B. bronchiseptica (Bvg )^ or B. 
bronchiseptica (Bvg '). Both strains were grown on BG agar and the infection carried 
out at MCI 1:500 (one RBL-2H3 cell to 500 bacterial cells). The infection was carried 
out in tissue culture flasks (25 cm) and incubated for 3 h at 3TC  in 5% CO2. The cell 
suspension was then examined by using an inverted microscope (OLYMPUS CK2).
Figure 3.3.4a shows the effect of B. bronchiseptica on the morphology of 
RBL-2H3 cells after incubation for 3 h. Figure 3,3.8a.A. shows the normal appearance 
of RBL-2FI3 cells in IMDM medium only, with many pseudopodia that help RBL- 
2H3 cells to attach to the surface of the tissue culture flask. This appearance was 
similar to the appearance of RBL-2H3 cells when infected with B. bronchiseptica 
(Bvg ') strain (Fig. 3.3.8a.B) but the latter showed more vacuoles which were not 
apparent in RBL-2H3 cells maintained in IMDM only. However, the normal 
morphological appearance was completely changed due to infection with B. 
bronchiseptica (Bvg"*") (Fig. 3.3.8a.C). For example, they had lost most of their 
pseudopodia and also they appeared to be smaller with rounding up of cells which 
could suggest that they had lost their contents due to treatment with B. bronchiseptica 
(Bvg ^) mode.
Therefore, it was shown that infection of RBL-2H3 cells with B. 
bronchiseptica (Bvg "*") leads to dramatic changes in their morphological appearances, 
but such changes were not observed with B. bronchiseptica (Bvg ') mode.
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3.3.S.2 Effect of incubation time on the cytotoxic effect of B. bronchispetica 
(Bvg^ and Bvg ') toAvard RBL-2H3 cells
The cytotoxic effect of the different modes of B. bronchiseptica on the 
viability of RBL-2H3 cells was estimated at different incubation times (1 h, 3 h and 6 
h). The numbers of RBL-2H3 cells was adjusted to IxlO^ cells/ml and infected with 
different strains of B. bronchiseptica (Bvg or Bvg ') at an infection ratio of 1:500. 
The infection was carried out at 37°C in 5% CO2 condition and incubated for different 
times. At the end of each incubation time, the viability of RBL-2H3 cells was 
estimated by trypan blue exclusion and the percentage of survival was estimated 
compared with the control which contain RBL-2H3 cells in IMDM medium only (Fig. 
3.3.8b). It could be seen that B. bronchiseptica (Bvg "*") reduced the survival of RBL- 
2H3 cells more than B. bronchiseptica (Bvg " phase) (p-value < 0.001) at all three 
different incubation times. Also, it was observed that the effect of B. bronchiseptica 
(Bvg phase) on survival of RBL-2H3 cell was rapid and had occurred within 1 h. 
The effect of B. bronchiseptica (Bvg ' phase) on RBL-2H3 cells increased with 
increasing incubation times. There was around 90% survival of RBL-2H3 cells at 1 h 
but at 6 h the percentage of survival of RB-2H3 cells was reduced to 75%.
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Figure 3.3.8b Effect of different strains of B. bronchiseptica (Bvg  ^and Bvg ) on 
viability of RBL-2H3 cells.
The graph shows the percentage of survival of RBL-2H3 cells infected with different 
strains of B. bronchiseptica (Bvg or Bvg ') strains at MOI 1:500 and incubated for 
different times. The viability of RBL-2H3 cells was estimated by trypan blue 
exclusion (mean of 6 observations ± SEM).
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3.3.5.3 Effect of B. bronchiseptica (Bvg^ or Bvg ) on viability of different 
mammalian cell types (ATP-bioluminescent assay)
The previous results (section 3.3.5.2) were confirmed by estimating the effect 
of different strains of B. bronchiseptica on the ATP content of different mammalian 
cells. 1x10^ cells/ml of different mammalian cells (sheep BMMC, RBL-2H3 cells and 
J774A.1 cells) mainlined in IMDM containing 10 % PCS were infected with either B. 
bronchiseptica (Bvg'*') or (Bvg") strains at an MOI of 1:500. 200 jil volume of 
mixtures were added in triplicate in 96-well plates and incubated for 3 h at 37°C in 
5% CO2. The percentage of survival of all mammalian cells types were estimated by 
the ATP assay. Figure 3.3.8c shows the percentage of survival of different 
mammalian cells. As can be seen, there was a significant reduction in survival of 
different mammalian cells types after infection with B. bronchiseptica (Bvg'*') 
compared with B. bronchiseptica (Bvg ") (p-value < 0.001). For example, there was 
60% survival of sheep BMMC after incubation with B. bronchiseptica (Bvg" )^ and 
95% survival after incubation with B. bronchiseptica (Bvg" phase). Similar results 
were observed with RBL-2H3 cells and J774A. 1 cells, except that B. bronchiseptica 
(Bvg"*" phase) showed a greater killing effect with J774A.1 cell types than with the 
other cell types (sheep BMMC or RBL-2H3 cells) (p-value < 0.0001).
The above observations, confirm that the B. bronchiseptica (Bvg"*" phase) is 
more cytotoxic toward different mammalian cells than the Bvg “ phase, presumably 
due to one or more virulence factors produced by the virulent strain.
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Figure 3.3.8c The effect of B, bronchiseptica (Bvg^ and Bvg ) ou viability of 
different mammalian cell types.
The graph shows the effect of different strains of B. bronchiseptica (Bvg and Bvg ') 
on the viability of different mammalian cell types (sheep BMMC, RBL-2H3 and 
J774A. 1 cells) at an infection ratio of 1:500 and incubated for 3 h. The results shown 
are the percentage of survival of different cell types compared with the control group 
for each mammalian cell type maintained in IMDM only. The viability of different 
mammalian cells determined by using by using the ATP-bioluminescent assay (mean 
of 9 observations ± SEM).
Bvg +: B. bronchiseptica virulent strain.
Bvg -: B. bronchiseptica avirulent strain (mutant strain).
MC: sheep BMMC
RBL-2H3 cell line
J774A. 1 macrophage cell line.
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3.3.6 Cytotoxicity of two novel m utant strains of B. bronchiseptica (Bag and
Bho) on the viability of different mammalian cells
Dr. M. Lynch (Infection and Immunity Division, University of Glasgow) 
created two novel mutant strains. Bag and Bho, from a virulent strain of B. 
bronchiseptica (BBC17). He used comparative genomics to identify new putative 
two-component systems and then created mutants in two of these by using sequence 
probes (data not published). Furthermore, virulence experiments of the two new 
strains in a mouse model suggested that both new strains were attenuated their ability 
to colonise the mouse respiratory tract (personal communication). Cytotoxicity of 
both new strains on the viability of different mammalian cell types was investigated in 
vitro and compared with B. bronchiseptica (Bvg *") and (Bvg ') strains. 1x10^ cells/ml 
of different mammalian cells maintained in IMDM medium containing 10% FCS 
were infected with different strains of B. bronchiseptica (Bvg Bvg ", Lux 95, Bag 
and Bho) grown on BG agar for 24 h. Infection was carried out at MOI 1:500 and 
cells were incubated for 3 h at 37°C in 5% CO2.
The ATP-bioluminescent assay was used to estimate viability of different 
mammalian cells. Therefore, the ATP contents of different strains of B. 
bronchiseptica were estimated by the ATP-bioluminescent assay to avoid any 
interference with the assay of viability of different mammalian cells. Figure 3.3.9a 
shows the ATP content (RLU) of different strains of B. bronchiseptica compared with 
the ATP content (RLU) of different mammalian cells. Statistically, there was a highly 
significant difference between the ATP content of the B. bronchiseptica strains and 
the mammalian cell types (p-value < 0.0001). Thus, the ATP content of the B. 
bronchiseptica strains would not interfere with this cytotoxicity assay for mammalian 
cells.
The percentage of survival of different mammalian cells (sheep BMMC, RBL- 
2H3 cells and J774A.1 cells) was estimated after incubation for 3 h with different 
strains of B. bronchiseptica (Fig. 3.3.9b). As can be seen, there was a significant 
decrease in survival of different mammalian cells due to incubation with B. 
bronchiseptica (Bvg '*) compared with other strains of B. bronchiseptica.
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Cytotoxicity of the new mutant strains of B. bronchiseptica (Bag and Bho) was 
different towards the different mammalian cells. They caused a significant reduction 
in survival of J774A.1 cells, some reduction with sheep BMMC and had little effect 
on survival for RBL-2H3 cells. Furthermore, these results suggest that the new mutant 
strains (Bag and Bho) have a higher cytotoxic effect compared with the B. 
bronchiseptica (Bvg “ and Lux 95), but lower than that of B. bronchiseptica (Bvg "*"). 
Thus, cytotoxicity of B. bronchiseptica (Bag) and (Bho) may be intermediate between 
that of the Bvg'* mode and Bvg". lO '^M of calcium ionophore was used as a control to 
compare with the effect of different strains of B. bronchiseptica.
Furthermore, (3-hexosaminidase release was estimated from sheep BMMC and 
RBL-2H3 cells due to incubation with different strains of B. bronchiseptica. Figure 
3.3.9c shows that the percentage of (3-hexosaminidase release from both cell types 
were significantly high due to incubation with B. bronchiseptica (Bvg^) mode 
compared with the effect of other strains of B. bronchiseptica. There was a significant 
(3-hexosaminidase release from both cell types due to the effect of the new mutant B. 
bronchiseptica strains (Bag and Bho) comapred with the effect of B. bronchiseptica 
(Bvg ) mode, but it was lower than (3-hexosaminidase release from both mammalian 
cells due to the effect of B. bronchiseptica (Bvg"*"). Interestingly, B. bronchiseptica. 
(Bho) strain showed higher (3-hexosaminidase release from both cell types compared 
with effect of B. bronchiseptica (Bag) mode (p-value > 0.05).
The above observations showed that the new mutant strains of B. bronchiseptica 
(Bag and Bho) able to stimulate sheep BMMC and RBL-2H3 cell types to release its 
contents, but this effect was intermediate between those of the Bvg and Bvg ' strains.
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Figure 3.3.9a Comparison of ATP-content of different strains of B.
bronchiseptica with that of different mammalian cells
ATP contents of 1x10^ cells/ml of different mammalian cells was compared with the
ATP contents of different strains of B. bronchiseptica (5x10^ cfu/ml) by using the
ATP-bioluminescent assay (cellTiter-Glo™ luminescent cell viability assay (mean of 
9 observations ± SEM).
Sheep BMMC: sheep bone marrow mast cells
J774A. 1 macrophage cells
Bvg : virulent type of B. bronchiseptica
Bvg ■ : avirulent type of B. bronchiseptica
Lux 95: bioluminescent strain of B. bronchiseptica
Bag: mutant type of B. bronchiseptica
Bho: mutant type of B. bronchiseptica
Figure 3.3.9b Effect of different strains of B. bronchiseptica on viability of 
different mammalian cells
1x10^ cells/ml of different mammalian cells were treated with different strains of B. 
bronchiseptica at infection ratio of 1:500 and incubated for 3 h. Survival of treated 
mammalian cells were estimated by the ATP-bioluminescent assay (CellTiter-Glo™ 
luminescent cell viability) (mean of 9 observations ± SEM).
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Figure 3.3.9c Effect of different strains of B, bronchiseptica on degranulation of 
sheep BMMC and RBL-2H3 cells
IxlO*" cells/ml of sheep BMMC and RBL-2H3 cells were treated with different strains 
of B. bronchiseptica at an infection ratio of 1:500 and incubated for 3 h. 13- 
hexosaminidase release was estimated and lO'^M of calcium ionophore was used as a 
control (mean of 9 observations ± SEM).
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3.3.7 Influence of tem perature on cytotoxicity of B. hronchiseptica
The previous results (Fig. 3.3.8c) presented viability data for RBL-2H3 cells 
mixed with the virulent strain of B. hronchiseptica based on quantitation of the ATP 
levels by using the cellTiter-Glo™ luminescent cell viability assay. This assay signals 
the presence of metabolically active cells by light output (RLU). In further work, a 
tétrazolium salt reduction (MTT) assay was used in parallel with the ATP 
bioluminescence assay for measuring cell viability (see Materials and Methods). The 
following study aimed to determine the effect of temperature on cytotoxicity of 
different strains of 5. hronchiseptica. B. hronchiseptica (Bvg ’*') or (Bvg ') cells grown 
for 24 h on BG agar were collected and bacterial numbers adjusted to 5x10^ cfu/ml in 
IMDM medium. One sample was heated to 56°C for 10 min. The second sample was 
heated to 100°C for 10 min and the third sample was kept at room temperature. Then 
the contents of each were mixed with 10  ^ cells/ml of RBL-2H3 cells maintained in 
IMDM medium containing 10% PCS, equivalent to an infection ratio of 1:500 (one 
mammalian cells to 500 bacterial cells). 200pl volumes of mixture were added in 
triplicate in 96 -well plates and incubated for 3h at 37°C under 5% CO2. Survival of 
both RBL-2H3 cells and J774A.1 cells was estimated by both ATP-bioluminescence 
and MTT assays.
3.3.7.1 RBL-2H3 cells
Figure 3.3.10a shows survival of RBL-2H3 cells by ATP-bioluminescence 
assay after incubation with different samples of either B. hronchiseptica (Bvg or 
Bvg ') treated with different temperatures and figure. 3.3.10b shows survival of RBL- 
2H3 cells, measured by the MTT assay. Both assays (ATP-bioluminescence and 
MTT) sugggest that there was a statistically significant reduction in the percentage 
survival of RBL-2H3 cells due to infection with the untreated samples of B. 
hronchiseptica (Bvg '*') compared with other samples of B. hronchiseptica which were 
treated at different temperatures (p-value < 0.0001). The increase in survival of RBL- 
2H3 cells when mixed with B. hronchiseptica (Bvg "^ ) strain treated at 56°C suggested 
that cytotoxic factors were not totally destroyed at 56”C for 10 min.
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Interestingly, there was a statistically significant differences in survival of 
RBL-2H3 cells due to the effect of 10'*^ M of calcium ionophore. Less than 10 % 
survival of RBL-2H3 cells was observed according to the ATP-bioluminescent assay 
compared with 70 % survival by the MTT assay. Calcium ionophore presumably 
causes rapid depletion of ATP levels but has little effect on the dehydrogenase 
enzymes that are measured in the MTT assay.
Similar results were observed with J774A.1 macrophage cells (data not 
shown). Viability of J774A.1 macrophage cells treated with B. hronchiseptica 
suspension that had been treated to 56°C or 100°C for 10 min was higher than the 
viability of infected J774A.1 cells treated with B. hronchiseptica suspension kept at 
room temperature (p-value < 0.001). Degranulation of RBL-2H3 cells due to 
interaction with these B. hronchiseptica suspensions was also investigated and, as can 
be seen from figure. 3.3.10c, the ability of B. hronchiseptica (Bvg^) to cause 13- 
hexosaminidase release was also abolished at either 56”C or lOO'^ C for 10 min (p- 
value < 0.001).
The above observations demonstrated that the cytotoxic factor(s) of B,
hronchiseptica are heat-labile.
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Figure 3.3.10a The effect of temperature on cytotoxic effect of B. hronchiseptica 
(Bvg ").
The graph shows the percentage survival of RBL-2H3 cells mixed with B. 
hronchiseptica suspensions treated at different temperatures (not-treated (.T), 56°C 
or lOO^C (boil) for 10 min). Viability of the RBL-2H3 cells was estimated by the 
ATP-bioluminescence assay after incubation for 3 h (mean of 9 observations ± SEM).
Figure 3.3.10b The effect of temperature on cytotoxic effect of B. hronchiseptica 
(Bvg").
The graph shows the percentage survival of RBL-2H3 cells mixed with B. 
hronchiseptica suspensions treated at different temperatures (not-treated (.T), 56°C 
or 100°C (boil) for 10 min). Viability of the RBL-2H3 cells was estimated by the 
MTT assay after incubation for 3 h (mean of 9 observations ± SEM).
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Figure 3.3.10c Degranulation of RBL-2H3 cells treated with B. hronchiseptica 
(Bvg^) suspensions heated at different temperatures.
The graph shows percentage of p-hexosaminidase release (mean of 9 observations ± 
SEM) from RBL-2H3 cells treated with B. bronchiseptica suspensions that had been 
heated at different temperatures (not-treated (/T), 56°C or 100°) and incubated for 3 
h.
Bvg + (NT): B. bronchiseptica (Bvg )^ suspension kept at room temperature.
Bvg + (56°C): B. bronchiseptica (Bvg ‘^ ) suspension heated at 56°C for lOmin.
Bvg + (Boil.): B. bronchiseptica (Bvg '^ ) suspension heated at 100°C for lOmin.
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3.3.8 Comparison of the effect of different strains of Bordetella pertussis on 
viability of RBL-2H3 cells
The following strains of B. pertussis were grown on BG agar and cell 
numbers were adjusted to 5x10^ cfu/ml in IMDM medium containing 1% of PCS:
1) B. pertussis 338 (virulent strain)
2) B. pertussis 347 (avirulent strain)
3) B. pertussis 357 (pertussis toxin-deficient strain)
4) B. pertussis 348 (ACT-deficient strain)
10  ^ cells/ml of RBL-2H3 cells were maintained in IMDM medium containing 
10% PCS and infected with different strains of B. pertussis at an infection ratio of 
1:500. 200 pi volumes of mixtures was added in triplicate in 96-well plates and 
incubated for 3 h at 37°C in 5% COg. At the end of 3 h incubation, the percentage of 
survival of infected cells was estimated by the ATP-bioluminescent assay. It was 
important in the beginning to investigate any interference between the ATP content of 
RBL-2PI3 cells with that of the B. pertussis strains. Pigure 3.3.11a shows the ATP 
content of suspension of the different strains of B. pertussis compared with that of
RBL-2H3 cells estimated by the ATP-bioluminescent assay. This figure shows that
the ATP-bioluminescent assay would be a useful method to estimate the percentage of 
survival of RBL-2H3 cells treated with B. pertussis because there was little (non­
significant, p-value > 0.001) contribution to light output due to the ATP content of the 
B. pertussis.
Surprisingly, there was no effect of any strain of B. pertussis on the survival of 
RBL-2H3 cells. Pigure 3.3.11b shows the effect of different B. pertussis strains on 
survival of RBL-2H3 after incubation for 3 h compared with the effect of lO'^M of 
calcium ionophore. Purthermore, P-hexosaminidase release was estimated after 
incubation for 3 h. Pigure 3.3.11c shows no siginficant effect of any strain of B. 
pertussis on degranulation of RBL-2H3 cells compared with the effect of lO’^ M^ 
calcium ionophore.
The above observations suggest that to show any cytotoxic effect of different 
strains of B. pertussis, a higher infection ratio or longer incubation could be required.
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Figure 3.3.11a Comparison of ATP content of different strains of B. pertussis 
with that of RBL-2H3 cells
IxiO*^  cells/ml of RBL-2H3 cells and different strains of B. pertussis (5x10^ cfu/ml) 
were maintained in IMDM medium containing 10% FCS. Their ATP contents were 
compared by using ATP-bioluminescent method and expressed in RLU (mean of 9 
observations ± SEM).
Figure 3.3.11b Effect of different strains of B. pertussis on viability of RBL-2H3 
cells
1x10^ cells/ml of RBL-2H3 cells were infected with different strains of B. pertussis 
(5x10^ cfu/ml) at an infection ratio of 1:500. Survival of RBL-2H3 after 3 h 
incubation was estimated by the ATP-bioluminescent assay (mean of 9 observations ± 
SEM), lO'^M of calcium ionophore was used as a control.
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Figure 3.3.11c Effect of different strains of J5. pertussis on degranulation of RBL- 
2H3 cells
1x10^ cells/ml of RBL-2H3 cells were infected with different strains of B. pertussis 
(5x10^ cfu/ml) at an infection ratio of 1:500 and incubated for 3 h. p-hexosaminidase 
release was estimated after incubation for 3 h (mean of 9 observations ± SEM), lO'^M 
of calcium ionophore was used as control.
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3.3.9 Comparison of the cytotoxic effect of B. bronchiseptica with that other
Bordetella species
Different species of Bordetella were grown on BG agar, and bacterial numbers 
were adjusted to 5x10^ cfu/ml in IMDM medium containing 1% of FCS. 1x10^ 
cells/ml of RBL-2H3 or J774A. 1 cells were maintained in IMDM medium containing 
10% FCS and mixed with different Bordetella species at an infection ratio of 1:500. 
200 pi volumes of mixture were added in triplicate in 96-well plates and incubated for 
3 h at 37°C in 5% CO2. Survival of both infected cell types was estimated by the 
ATP-bioluminescent assay.
The percentage of survival of RBL-2H3 or J774A. 1 cells after infection with 
different Bordetella species was estimated (Fig. 3.3.12). There was a statistically 
significant reduction (p-value < 0.001) in survival of both RBL-2H3 and J774 A.l 
cells due to interaction with B, bronchiseptica (Bvg "^ ) compared with other Bordetella 
species. Furthermore, the J774A.1 cells showed slightly lower survival than RBL-2H3 
cells, but none of these species had any great effect on both cell types, unlike B. 
bronchiseptica (Bvg "^ ).
The effect of the different Bordetella species on survival of the two cell types 
was different. B. bronchiseptica (Bvg ) showed a low effect, less than 10% reduction 
in survival of RBL-2H3 cells but, with J774A.1 cells, there was around 15% 
reduction. B. bronchiseptica (Lux 95) reduced survival of RBL-2H3 cells by 15% but 
with J774A.1 cells there was 30 % reduction in the percentage of survival. In contrast, 
B. pertussis (18323) showed 15% reduction in survival of RBL-2H3 cells and 25% 
reduction of survival of J774A. 1 cells which were similar to the effect of B. 
bronchiseptica (Lux 95). Less cytotoxic effect of B. pertussis 338 toward RBL-2H3 
cells and around 10% reduction in survival of J774A. 1 cells. There was no significant 
difference between the cytotoxic effects of B. parapertussis and B. avium toward the 
percentage of survival of RBL-2H3 cells and J774A.1 cells. In contrast, a less 
cytotoxic effect towards RBL-2H3 cells and J774A.1 cells was observed with B. 
holmesii.
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B. trematum reduced the percentage of survival of RBL-2H3 cells as 
compared with the effect of other species of Bordetella but was less than the cytotoxic 
effect of 5. bronchiseptica (Bvg'*' phase). There was around 10% reduction in survival 
of RBL-2H3 and J774A.1 cells due to incubation with B. hinzii.
The above observations, suggested that B, bronchiseptica (Bvg" )^ mode 
showed the highst cytotoxic effect against both RBL-2H3 cells or J774A. 1 cells 
compared with other Bordetella species. With the other Bordetella species (i.e. B. 
pertussis 338, B. pertussis 18323, B. parapertussis, B. avium, B. holmesii, B. 
tretamutum and B, hinzii) higher infection ratios and longer incubation times could be 
used to show any killing effect on these mammalian cells.
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Figure 3.3.12 Effect of different Bordetella species on viability of RBL-2H3 and 
J774A.1 cells (ATP-bioluminescent assay)
The graph shows the percentage survival (mean of 9 observations ± SEM) of RBL- 
2H3 cells and J774A.1 cells treated with different Bordetella species grown on BG 
agar. Viability was estimated by the ATP-bioluminescent method after incubation for 
3 h at infection ratio of 1:500.
B.b (+): .6. bronchiseptica virulent (Bvg "*") strain.
B.b (-): B. bronchiseptica avirulent (Bvg ")strain 
Lux 95: B. bronchiseptica (bioluminescent strain)
Bp: B. pertussis, 338 and 18323 strains.
B.pp: B. parapertussis
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3.3.9.1 P-hexosaminidase release
All Bordetella species were grown on BG agar. Infection of RBL-2H3 cells 
was carried out at MCI 1:500 (one RBL-2H3 cell to 500 bacterial cells). 200 pi 
volumes of mixture were added in triplicate in 96-well plates and incubated at 37°C in 
5% CO] for 3 h. At the end of incubation, P-hexosaminidase release was estimated.
Figure 3.3.13 shows the effect of the different Bordetella species on 
degranulation of the RBL-3H3 cells, it is the difference between hexosaminidase 
release caused by different Bordetella species. A statistically significant release of p- 
hexosaminidase was detected from RBL-2H3 cells due to interaction with B. 
bronchiseptica (Bvg^) compared with either B. bronchiseptica (Bvg") or B. 
bronchiseptica (Lux 95) (P-value < 0.005). B. trematum and B. hinzii species showed 
a significant p-hexosaminidase release from RBL-2H3 cells compared with other 
species and similar to that caused by B. bronchiseptica (Bvg"*") (P-value < 0.005). B. 
holmesii showed very low p-hexosaminidase release compared with the effect of the 
B. bronchiseptica (Bvg '). Both strains of B. pertussis (338 and 18323) showed p- 
hexosaminidase from RBL-2H3 cells, although lower than the effect of B. 
bronchiseptica (Rvg"*"). The effect of B. parapertussis was similar to that of B. 
pertussis 18323. Also, B. avium show an effect similar to that of B. bronchiseptica 
(Bvg-)
These observations showed that degranulation effects differ from one species 
to another, which could suggest that more work is needed to investigate different 
factors (e.g. Type three secretion system (TTSS)) which could cause such different 
effects between different species, especially with B. trematum and B. hinzii, because 
both species showed an interesting effect on degranulation of RBL-2H3 cells but, 
unlike B. bronchiseptica (Bvg'*^ ) having a major cytotoxic effect on these cells.
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Figure 3.3.13 Effect of different Bordetella species on P-hexosaminidase release 
from RBL-2H3 cells
This graph shows P-hexosaminidase release from 1x10*^  cells/ml of RBL-2H3 cells 
due to the effect of different Bordetella species at MOI 1:500 and 3 h incubation 
(mean of 9 observations ± SEM).
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3.3.10 Comparison of the cytotoxicity of B. hronchiseptica with that of unrelated
bacteria
The effect of B. bronchiseptica (Bvg‘*‘ phase) on the viability of different 
mammalian cells was compared with the effect of different species of unrelated 
bacteria which were available in the laboratory. The ATP-bioluminescent assay was 
used and, as a preliminary step, it was important to avoid any interference between the 
light signals from the ATP content of the bacterial cells, therefore the ATP content of 
different bacterial strains was compared with the ATP contents of different i
mammalian cells. 1x10*^  cells/ml of different mammalian cells were maintained in 
IMDM medium containing 10% FCS. Also, different bacterial cells grown on 
different growth media were collected and adjusted to 5x10^ cfu/ml in IMDM 
medium containing 10% FCS. Figure 3.3.14a shows the bioluminescence output 
(RLU), which reflects the ATP levels of the different mammalian and bacterial cell 
suspensions. The graph shows the mean of RLU from 1x10^ cells/ml of sheep 
BMMC, RBL-2H3 cells and J774A.1 cells and from 5x10^ cfu/ml of the different
bacteria after incubation for 3 h in IMDM medium containing 10% FCS.
There was a statistically significant differences in light output from different 
mammalian cells compared with the light output of B. bronchiseptica (Bvg^) and most 
of the other bacterial species and these therefore would be unlikely to interfere with 
the estimate of viability of the mammalian cells in this particular assay. But, there was 
statistically significant increase in light output of Staphylococcus aureus (strain 24) 
compared with the other bacterial species (p-value < 0.001), equal to more than 50% 
of the RLU from sheep BMMC. This finding could suggest that the ATP- 
bioluminescence assay may not be useful with S. aureus (strain 24). It may be that 
Staphylococcus aureus (strain 24) has more rapid multiplication rate compared to the 
other bacteria in IMDM medium.
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Figure 3.3.14a ATP content of different bacteria compared with that of different 
mammalian cells
1x10^ cells/ml of different mammalian cells and 5x10^ cfu/ml of different bacteria 
were maintained in IMDM medium containing 10% FCS. The ATP content of 
different cell types was estimated by the ATP-bioluminescent assay (mean of 9 
observations ± SEM).
MC: sheep bone marrow mast cells 
B. bronchiseptica: wild-type strain 
S. pneumoniae: wild-type strain (D39)
S. pneumoniae: pneumolysin-deficient strain (Ply )
S. aureus: strain 24
P. multocida: strain 85020
P. multocida: mutant strain (JRMT/2)
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3.3.10.1 Effect of different bacterial species on viability of sheep BMMC and 
other cell types
The effect of B. bronchiseptica (Bvg^) on the viability of different mammalian 
cells was compared with the effect of different unrelated bacteria. Different 
mammalian cells were maintained in an antibiotic-free IMDM medium containing 
10% FCS and cell numbers were adjusted to 10*^  cells/ml. These cells were treated 
with different bacterial species (grown in the appropriate growth media) at an 
infection ratio of 1:500 and 200 pi volumes of total mixture were added in triplicate in 
96-well plates and incubated for 3 h at 37”C in 5% COg. At the end of the incubation 
time, the ATP levels (RLU) were determined by the ATP bioluminescent assay and 
the percentage survival of different mammalian cells was estimated. The effect of B. 
bronchiseptica (Bvg "*") on the viability of different mammalian cells was compared 
with the effect of virulent strains of Streptococcus pneumoniae (D39 wild-type) and 
P. multocida (85020). In addition, avirulent strains of Streptococcus pneumoniae 
(D39), which is pneumolysin-deficient (Ply") and P. multocida (JRMT/2) which is an 
avirulent aroA mutant, were used to compare their effect on survival of different 
mammalian cells.
As can be seen from figure 3.3.14b the virulent strains of Str. pneumoniae 
(D39) showed a highly cytotoxic effect towards all mammalian cell types compared 
with B. bronchiseptica (Bvg^) and both strains caused a statistically significant (p- 
value < 0.05) reduction in the viability of all three mammalian cells compared with 
the cytotoxic effect of the virulent P. multocida (85020) and other bacterial strains. 
Neither the virulent strain of P. multocida (85020) nor their avirulent mutant strain of 
P. multocida (JRMT) showed any significant reduction in the percentage survival of 
the three mammalian cells compared with the effect of B. bronchiseptica (Bvg"*").
The above observations suggest that pneumolysin (potent cytotoxic toxin) was 
the factor responsible for the dramatic reduction in the percentage survival of the three 
mammalian cells after incubation with Str. pneumoniae (D39) because the 
pneumolysin-deficient Str. pneumoniae strain did not show such a significant 
reduction in the percentage survival of different mammalian cells. In contrast, both 
virulent and mutant strain of P. multocida. did not show any reduction in the 
percentage survival of mammalian cells. Neither strain is known to produce cytotoxic 
toxins.
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Figure 3.3.14b: Effect of different bacteria on viability of sheep BMMC, RBL-
2H3 cells or J774A.1 cells.
IX10  ^ cells/ml of different mammalian cell types were infected with 5x10^ cfu/ml of 
different bacteria. The ATP content of sheep BMMC, RBL-2H3 and J774A. 1 cells 
was estimated by the ATP-bioluminescent method (RLU) after incubation for 3 h and 
the percentage of survival of the infected mammalian cells was estimated (mean of 9 
observations ± SEM). The effect on survival of different mammalian cells was 
compared with the effect of 10^ M of calcium ionophore, which was used as a 
control.
A) B. bronchiseptica (Evg"*")
B) S. pneumoniae (D39 wild-type)
C) S. pneumoniae (Ply' mutant type)
D) P. multocida (85020)
E) P. multocida (JRMT/2)
F) Calcium ionophore
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3.3.10.2 Effect of different bacteria on degranulation of sheep BMMC and RBL-
2H3 cells
The effect of previous bacterial strains on degranulation of sheep BMMC was 
investigated by estimating p-hexosaminidase release from sheep BMMC and RBL- 
2H3 cells treated with different bacterial strains at infection ratio of 1:500 and 
incubated for 3 h.
Previous observations (Fig. 3.3.9c and Fig 3.3.10c) had shown that B. 
bronchiseptica (Bvg'*' phase) caused significant p-hexosaminidase release from both 
sheep BMMC and RBL-2H3 cells after incubation for 3 h. But, as can seen from Fig 
3.3.14c, in this particular study that there was only around 6% of the total P- 
hexosaminidase released from sheep BMMC with this strain. This could be due to use 
of a different batch of sheep bone marrow (see discussion). In contrast, there was 
higher p-hexosaminidase release due to the effect of both Str. pneumoniae strains 
compared with the effect of B. bronchiseptica (Bvg'*’ phase). In fact, Str. pneumoniae 
has a gene for p-hexosaminidase production (www.tigr.net) and thus is unsuitable for 
use in this particular release assay. It would be necessary to use an assay to determine 
other release factors (e.g. histamine) to measure the effect of these bacterial strains on 
degranulation of sheep BMMC or RBL-2H3 cells. 2either strain of P. multocida 
stimulated P-hexosaminidase release from either sheep BMMC or RBL-2H3 cells.
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Figure 3,3.14c Effect of different bacteria on p-hexosaminidase release
IxIO^ cells/ml of sheep BMMC or RBL-2H3 cells were treated with 5x10^ cfu/ml of 
different bacteria. P-hexosaminidase release from sheep BMMC or RBL-2H3 cells 
was estimated after incubation for 3 h (mean of 9 observations ± SEM). 10'^ M of 
calcium ionophore, which was used as a control.
A) B. bronchiseptica (Bvg" )^
B) S. pneumoniae (D39 wild-type)
C) S. pneumoniae (Ply' mutant type)
D) P. multocida (85020)
E) P. multocida (JRMT/2)
F) Calcium ionophore
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S e c t i o n  F o u r :  Interaction of different purified 
factors of Bordetella species with sheep BMMC 
and other cell types
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3.4.1 Interaction of purified factors from Bordetella with sheep BMMC and 
other cell types
Previous observations (section 3 of Results) had shown that the virulent strain of 
B. bronchiseptica (Bvg^ phase) has a significant cytotoxic effect on viability and 
degranulation of different mammalian cells. Therefore, the next aim was to investigate 
the effect of different Bordetella extracts on viability and degranulation of different 
mammalian cells. Different purified factors of Bordetella species were used:
1- Adenylate cyclase toxin (or CyaA), an anti-phagocytic factor produced by certain 
Bordetella, including B. bronchiseptica and B. pertussis.
2- Pertussis toxin (PT), produced by B. pertussis only. A component of all acellular 
pertussis vaccine (in toxoided form).
3- Pertactin (PR3), an adhesin in Bordetella, including B. bronchiseptica and B. 
pertussis and a component of some acellular pertussis vaccines.
4- Filamentous haemagglutinin (FHA), an adhesin in Bordetella including B. 
bronchiseptica and B. pertussis and a component of some acellular pertussis 
vaccines.
The effect of these factors on different mammalian cells were studied in different 
assays: viability (ATP-bioluminescent assay, MTT assay and trypan blue exclusion), 
degranulation (p-hexosamindase release assays) and apoptosis (Caspase 3/7 activity 
and D3A fragmentation). Furthermore, it has been reported that adenylate cyclase 
toxin can modulate immune responses and inhibit phagocytosis (Weingart and Weiss, 
2000; Boyd et al., 2005). Therefore, it was important to study the effect of B. 
bronchiseptica (Bvg“^ mode) in J774A.1 macrophage cells pre-treated with different 
concentrations of ACT.
3.4.1.1 Interaction of recombinant adenylate cyclase toxin with sheep BMMC 
and other cell types
The cytotoxic effect of purified recombinant ACT from E. coli against sheep 
BMMC and other cell types was studied. Purification of recombinant ACT was done 
in 8M Urea/Tris buffer and steps were taken to reduce the amount of other factors 
such as lipopolysaccharide of E. coli in the purified preparation. Therefore, as a 
preliminary study, it was important to investigate the effect of different factors
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3.4.1.1.1 Effect of Urea/Tris buffer on viability of sheep BMMC
of 0.063 M of Urea/Tris buffer.
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-
(Urea/Tris buffer and LPS) on the interaction of ACT with sheep BMMC and other 
cell types.
The cytotoxic effect of Urea/Tris buffer on sheep BMMC was studied. Sheep 
BMMC were adjusted to IxlOf cells/ml in IMDM medium only (as a control for total 
survival) and IMDM medium containing different concentrations of Urea/Tris buffer 
in IMDM medium: 2 M, 1 M, 0.5 M, 0.25 M, 0.125 M and 0.063 M as a final Urea 
concentration. A total volume of (200 pi) of mixture was added in triplicate to 96-well 
plates and incubated for different times (30 min, 1 h, 3 h and 6 h) at 37°C in 5% CO2 
Viability of sheep BMMC was estimated by the ATP-bioluminescence assay and 
percentage survival was determined by comparison with controls of sheep BMMC in 
IMDM medium alone.
Figure 3.4.1a shows that statistically, there no significant effect on the 
percentage survival of sheep BMMC due to incubation with 0.063M of urea/Tris 
buffer at different incubation times, compared to cells in IMDM medium alone.
■IMDM medium containing 0.05-2 M Urea/Tris buffer showed a significant reduction 
in viability of sheep BMMC at all incubation times (p-value < 0.001) compared with 
cells in IMDM medium containing 0.063 M Urea/Tris buffer. In contrast, 0.0125 M 
and 0.25 M of Urea/Tris buffer showed no significant effect compared with the effect
The above results suggested that high concentrations of urea/Tris buffer in
■ ■ACT preparation may have an effect on viability of different mammalian cells.
Therefore, it was important to use Urea buffer in concentration equal to the content of 
urea/Tris buffer in the ACT preparation as controls to avoid any interference of the 
urea/Tris buffer in determining the effect of ACT on mammalian cells.
Figure 3.4.1a Effect of different concentrations of urea/Tris buffer on sheep 
BMMC viability
cells/mi of sheep BMMC were maintained in IMDM medium containing different
concentrations of urea/Tris buffer. Percentage survival of sheep BMMC was 
estimated by the ATP-bioluminescent assay. lO'^M of calcium ionophore (cal-ion) 
was used as control (mean of 9 observations ± SEM).
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3.4.1.1.2 Effect of lipopolysaccharide on cytotoxicity of rACT (44/54) for sheep 
BMMC
Recombinant ACT protein from E. coli is often contaminated with 
lipopolysaccharide (LPS) due to the high quantities of endotoxin in the cell envelope 
of this Gram-negative bacterium. This work aimed to investigate whether LPS which 
is heat-stable, might contribute to the cytotoxicity of rACT by examining the effect of 
heating on the cytotoxic activity of rACT. The probability of a cytotoxic effect due to 
LPS on sheep BMMC was examined by using rACT (44/54) which is enzymatically 
active and invasive at a final concentration of 0.156 qg.ml. One sample of rACT 
(44/54) suspension was kept at low temperature (icebox) and the another sample of 
rACT (44/54) at same concentration was heated to 100”C for 15 min. IxlO*" cells/ml 
of sheep BMMC suspension in IMDM medium containing 10 % PCS were treated 
with these two different rACT preparations. A total amount of 100 |ll1 of mixture was 
added in triplicate to 96-well plates and incubated for 1 h at 37°C in 5% CO2. The 
ATP content of sheep BMMC was estimated by the ATP-bioluminescent assay and 
the percentage survival was estimated by comparsion with sheep BMMC suspension 
in IMDM medium containing 10% PCS only. lO'^M of calcium ionophore was used 
as a control.
0.156 p-g/ml of rACT sample treated at lOO^C for 15 min gave around 85% 
survival of sheep BMMC, whereas same concentration of rACT sample kept at low 
temperature gave around 40% survival of sheep BMMC. 0.03M urea in Tris buffer 
which was equal to the concentration of the urea/Tris buffer in the rACT preparation 
gave around 93% survival of sheep BMMC (Pig. 3.4.1b). lO'^M of calcium ionophore 
was used as a control.
The above results suggested that the reduction in the percentage survival of 
sheep BMMC treated with unheated rACT (44/54) preparation temperature was 
significant compared with the reduction in survival of sheep BMMC treated with the 
heated rACT (44/54) sample. Therefore, these observations suggested either that there 
is no significant amount of LPS in the rACT sample preparation or there is no 
significant contribution of LPS to the cytotoxicity of rACT preparation.
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Figure 3.4.1b Effect of heating on cytotoxicity of rACT (44/54)
1x10^ cells/ml sheep BMMC were maintained in IMDM medium and treated with 
either heated rACT (to 100°C) for 15 min, unheated rACT or with the urea diluent for 
1 h. At the end of the treatment, survival of sheep BMMC was estimated by the ATP- 
bioluminescent assay. lO’^ M calcium ionophore was used as control (mean of 9 
observations ± SEM).
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3.4.1.2 Effect of rACT on viability of different mammalian cells
The aim of this study was to compare cytotoxic effects of two different forms of 
rACT on viability and degranulation of sheep BMMC, RBL-2H3 cells and J774A.1 
cells. These two forms of rACT:
1- rACT (44/54) which is enzymatically-active and invasive (AC '^/hly  ^ or wild 
type). Both plasmid GW44 (pro-cyaA) and GW54 {cyaC) are inserted in E. coli to 
produce enzymatically active and invasive ACT.
2- rACT (44-188/54) which is enzymatically-inactive and invasive (AC ' /hly or 
mutant type). Both plasmid GW44-188 (non-active pro-cyaA*) and GW54 {cyaC) 
are inserted in E. coli to produce enzymatically inactive and invasive ACT.
Any difference in the effects of rACT (44/54) and (44-188/54) could presumably be 
attributed to the AC enzymic activity of the toxin.
5x10^ cells/ml of sheep BMMC or other cell types (J774A.1 or RBL-2H3) were 
maintained in different IMDM media: IMDM containing 10% PCS only (as a 
control), IMDM containing 10% PCS and different concentrations of rACT (44/54) 
and finally IMDM containing 10% PCS and different concentrations of rACT (44- 
188/54). In addition, sheep BMMC (or other cell types) maintained in IMDM media 
containing 10 % PCS and Urea/Tris buffer at a concentration equivalent to that in 
highest concentration of rACT used in this experiment. Each cell mixture was 
incubated for 6 h at 37°C in 5 % CO2. Viability of different mammalian cells was 
estimated by the ATP-bioluminescence assay. Adenylate cyclase is well known as a 
toxin which depends for its activity on the conversion of intracellular ATP to cAMP 
and causes disruption to the cell functions. Therefore, interference of AC enzymic 
activity with the measurement of ATP levels of mammalian cells in the ATP- 
bioluminescent assay is possible. Thus, the MTT assay was also used to confirm the 
effect of ACT on viability of different mammalian cells.
3.4.1.2.1 Sheep BMMC
By the ATP-bioluminescent method, there appeal'd to be 100% survival of 
sheep BMMC treated with 0.02 pg/ml of rACT (44/54) which was similar to the 
effect of the urea buffer diluent used for rACT. A similar effect was obtained with
2 0 2
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rACT (44-188/54) (Fig. 3.4.2a). However, by this method of assessing cytotoxicity, 
the cytotoxic effect of rACT (44/54) toward sheep BMMC appeared to increase with 
increasing concentration of rACT (44/54). There appeared to be around 50% survival 
of sheep BMMC at 1.25p.g/ml of rACT (44/54). In contrast, there appeared to be 
around 85% survival of sheep BMMC at same concentration of rACT (44-188/54).
The above result of a cytotoxic effect of rACT (44/54) toward sheep BMMC 
by the ATP assay was estimated by MTT assay. It observed that sheep BMMC were 
not killed by different concentrations of rACT as determined by the ATP assay. There 
was around 99 % survival of sheep BMMC with rACT (44/54) at 1.25 jtlg/ml as 
estimated by the MTT assay compared with the apparent 50% survival of sheep 
BMMC by the ATP assay (Fig. 3.4.2b). This result suggested that rACT depleted the 
ATP levels of sheep BMMC without affecting the dehydrogenase enzyme activity 
which is measured by the MTT assay.
Figure 3.4.2a Effect of rACT (44/54) or rACT (44-188/54) on survival of sheep 
BMMC (ATP assay)
The graph shows a comparison of the effect of different concentrations (pg/ml) of 
rACT (44/54) and rACT (44-188/54) on survival of sheep BMMC after 6 h 
incubation. Percentage of survival was estimated by the ATP-bioluminescent assay 
(means of 6 observations ± SD).
Figure 3.4.2b Effect of rACT (44/54) on survival of sheep BMMC (ATP assay 
and MTT assay)
The graph shows a comparison of the effect of different concentrations (|ig/ml) of 
rACT (44/54) on survival of sheep BMMC after 6 h incubation. Percentage of 
survival was estimated by the ATP-bioluminescent assay and the MTT assay (means 
of 6 observations ± SD).
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3.4.1.2.2 RBL-2H3 cells
Survival of RBL-2H3 cells after incubation for 6 h with different forms of 
rACT was estimated by the ATP assay (Fig. 3.4.3a). There appeared to be 100% 
survival of RBL-2H3 cells treated in IMDM medium containing the urea buffer 
diluent for the rACT preparations. There was 90% survival of RBL-2H3 cells treated 
with 0.02 jxg/ml of rACT (44/54) and there was an apparent cytotoxic effect with 
increasing concentrations of rACT (44/54). There was apparently 45% survival of 
RBL-2H3 cells at 1.25 pg/ml of rACT (44/54). In contrast, there appeared 85% 
survival of sheep BMMC at the same concentration of rACT (44-188/54).
The above results result of an apparent cytotoxic effect of rACT (44/54) 
towards RBL-2H3 cells by the ATP assay was again not confirmed by the MTT assay. 
These results by MTT assay showed that survival of RBL-2H3 cells gradually 
declined with increasing concentrations of rACT (44/54) (Fig. 3.4.3b). There was 
appeal'd to be 80% survival of RBL-2H3 cells as estimated by the MTT assay at 
1.25pg/ml of rACT (44/54). In contrast, there was apparently around 45% survival of 
RBL-2H3 cells as estimated by the ATP assay. As in the previous section (4.1.2.1), 
the result suggests that rACT depleted the ATP levels of RBL-2H3 cells without 
affecting the dehydrogenase enzyme activity which is measured by the MTT assay.
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Figure 3.4.3a Effect of rACT (44/54) or rACT (44-188/54) on survival of RBL- 
2H3 cells (ATP assay)
The graph shows a comparison of the effect of different concentrations (|i.g/ml) of 
rACT (44/54) and rACT (44-188/54) on survival of RBL-2H3 cells after 6 h 
incubation. Percentage of survival was estimated by the ATP-bioluminescent assay 
(means of 6 observations ± SD).
Figure 3.4.3b Effect of rACT (44/54) on survival of RBL-2H3 cells (ATP assay 
and MTT assay)
The graph shows a comparison of the effect of different concentrations (|LLg/ml) of 
rACT (44/54) on survival of RBL-2H3 cells after 6 h incubation. Percentage of 
survival was estimated by the ATP-bioluminescent assay and the MTT assay (means 
of 6 observations ± SD).
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3.4.1.2.3 J774A.1 cells
The percentage of survival of J774A.1 cells was apparently dramatically 
reduced at lower concentrations of rACT (44/54) compared with the percentage of 
survival of both sheep BMMC and RBL-2H3 cells at the same concentrations of 
rACT (44/54) when estimated by the ATP assay. There was apparently around 15% 
survival of J774A.1 cells at 0.02 pg/ml of rACT (44/54) compared with more than 95 
% survival of sheep BMMC (Fig. 3.4.2a) and RBL-2PI3 cells (Fig. 3.4.3a) at the same 
concentrations of rACT (44/54). The percentage of survival of J744A.1 cells declined 
with increased in concentrations of rACT (44/54). On the other hand, there was 
around 75% survival of J774A.1 cells due to the effect of 0.02 jLtg/ml of rACT (44- 
188/54). The effect of rACT (44-188/54) on depleting ATP levels of J774A. 1 cells 
was increased with increasing of concentrations of rACT (44-188/54) (Fig. 3.4.4a).
The above effect of both rACT (44/54) and rACT (44-188/54) on viability of 
J774A. 1 cells was also determined by the MTT assay (Fig. 3.4.4b). There was around 
95 % survival of J774A. 1 cells at 0.02-0.078p.g/ml of rACT (44/54) estimated by 
MTT assay. Then, there was a dramatic decline in survival of J774A.1 cells at 0.156 
|Llg/ml of rACT (44/54) and there was around 10% survival of J774A.1 cells at 1.25 
pg/ml of rACT (44/54). In contrast, there was around 85 % survival of J774A.1 cells 
at 1.25 pg/ml of rACT (44-188/54).
The above observations suggest that rACT (44/54) had a significant effect on 
depletion of ATP levels of J774A. 1 cells at low concentrations, as estimated by ATP 
assay but, with the MTT assay, there was only a significant cytotoxic effect of rACT 
(44/54) at concentrations of rACT at 0.156 (ig/ml and above.
In all previous work (4.1.2.1, 4.1.2.2 and 4.1.2.3) the possibility that this 
killing effect may have been due to an effect of the Urea/Tris buffer diluent in the 
rACT preparations was excluded by using a concentration of Urea/Tris buffer equal to 
that in the highest concentration of rACT suspension. No significant reduction in 
viability of the different mammalian cell types was seen with this concentration.
These observations show that rACT (44/54) which is enzymatically-active and 
invasive had a much greater cytotoxic effect than rACT (44-188/54) and these effects 
were dose dependent. Thus, the enzymic activity of rACT is mainly responsible for its 
cytotoxicity, rather than its invasive (pore-forming) activity.
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Figure 3.4.4a Effect of rACT (44/54) or rACT (44-188/54) on survival of J774A.1 
cells (ATP assay)
The graph shows a comparison of the effect of different concentrations (jxg/ml) of 
rACT (44/54) and rACT (44-188/54) on the apparent survival of J774A.1 cells after 6 
h incubation. Percentage of survival was estimated by the ATP-bioluminescent assay 
(means of 6 observations ± SD).
Figure 3.4.4b Effect of different concentrations of rACT (44/54) or rACT (44- 
188/54) on survival of J774 cells estimated by the MTT assay
The graph shows a comparison of different concentrations of rACT (44/54) and rACT 
(44-188/54) on survival of J774A.1 cells at end of incubation for 6 h. Percentage of 
survival was estimated by the MTT assay (mean of 9 observations ± SD).
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3.4.1.3 Effect of rACT on caspase 3/7 activity
The ability of rACT (44/54) to activate caspase 3/7 in sheep BMMC was 
compared with other mammalian cells. Apoptosis (or cell-programmed death) was 
assessed by measuring the activity of caspase 3/7 (cysteinyl aspartate-specific 
proteinases) which have key effector roles in apoptosis. Briefly, caspase 3/7 present in 
apoptotic cells cleave a pro-fluorescent substrate to produce a fluorescent signal. The 
amount of fluorescent product generated is proportional to the amount of caspase 3/7 
cleavage activity present in the sample and therefore reflects apoptotic activity. 5x10^ 
cells/ml of sheep BMMC or other cell types (J774A.1 or RBL-2H3) were maintained 
in IMDM medium containing 10% PCS with different concentrations of either rACT 
(44/54) or rACT (44-188/54) and incubated for 6 h at 37°C in 5 % CO2. Also, sheep 
BMMC and other cell types were maintained in IMDM medium containing 10 % PCS 
as a control. At the end of the incubation time, the amount of fluorescent product 
generated, which is proportional to the amount of caspase 3/7 substrate cleavage was 
estimated as relative fluorescent light units (RFLU). Figures 3.4.5a (sheep BMMC), 
3.4.5b (RBL-2H3) and 3.4.5c (J774A. 1) show caspase 3/7 activity due to the effect of 
different forms of rACT activity.
Figure 3.4.5a shows little if any activity of caspase 3/7 in sheep BMMC after 
incubation with two different forms of rACT and no dose response effect with either 
form of rACT. Thus, this assay provided no evidence that rACT induces apoptosis in 
sheep BMMC (Fig. 3.4.5a). In contrast, rACT (44/54) showed a significant effect in 
activating caspase 3/7 activity cleavage in RBL-2H3 cells (Fig. 3.4.5b). It can be seen 
from this figure that there was very high induction of caspase 3/7 activity due to 
treatment with different concentrations of rACT (44/54) whereas, with rACT (44- 
188/54) there was a lower but significant effect. These observations suggested that the 
enzymatic activity of rACT is the most important factor to promote caspase 3/7 
activity in RBL-2H3 cells. The most important finding is that there is very high 
caspase activity with rACT (44/54) and it increased with increasing concentrations of 
rACT (44/54).
In contrast, the effect of different forms of rACT on caspase activity was very 
different on J774A.1 cells (Fig. 3.4.5c). The rACT (44/54) showed a peak effect at
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0.078 flg/ml, but this effect decreased with increasing concentrations of rACT 
(44/54). Similar to sheep BMMC and RBL-2H3 cells, rACT (44-188/54) showed a 
very low effect on caspase 3/7 activity of J774A. 1 cells and no dose response effect. 
These observations suggested that, at low concentration of rACT (44/54), there was 
an apoptotic effect in J774A.1 macrophage cells but, with increasing in concentrations 
of rACT (44/54), there was a possibility of necrotic effect.
These observations showed, three different effects on three cell types. The 
effect of rACT (44/54) in promoting caspase 3/7 activity (and possibility a poptosis) 
depends on cell type, and this activity was dose-dependent. Activation of caspase 3/7 
in RBL-2H3 cells and J774A.1 cells depended primarily on the enzymatic activity of 
rACT (possessed by 44/54), rather than on its pore-forming activity (a property of 
both forms). The possibility that this caspase 3/7 activity may have been due to an 
effect of the urea in the preparation was excluded by the results obtained by using the 
two forms of rACT which contained the same concentrations of Urea/Tris buffer.
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Figure 3.4.5a Effect of rACT on caspase 3/7 activity of sheep BMMC
The graph shows the effect of different concentrations of rACT (44/54) or rACT (44- 
188/54) on 5x10^ cells/ml of sheep BMMC after incubation for 6 h. Caspase 3/7 
activity was estimated as relative fluorescent light units (RFLU) (mean for 6 
observations ± SEM).
Figure 3.4.5b Effect of rACT on caspase 3/7 activity of RBL-2H3 cells
The graph shows the effect of different concentrations of rACT (44/54) or rACT (44- 
188/54) on 5x10^ cells/ml of RBL-2H3 cells after incubation for 6 h. Caspase 3/7 was 
estimated as relative fluorescent light units (RFLU) (mean for 6 observations ± SEM).
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Figure 3.4.5c Effect of rACT on caspase 3/7 activity of J774A.1 cells
The graph shows the effect of different concentrations of rACT (44/54) or rACT (44- 
188/54) on 5x10^ cells/ml of J774A.1 cells after incubation for 6 h. Caspase 3/7 was 
estimated as relative fluorescent light units (RFLU) (mean for 6 observations ± SEM).
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3.4.1.4 Effect of rACT on D4A fragm entation
Apoptosis was further assessed by studying the effect of the two different 
forms of rACT on genomic D4A and its fragmentation, which is another hallmark of 
apoptosis. 1x10^ cells/ml of sheep BMMC (or RBL-2H3 cells) were maintained in 
IMDM medium containing 10 % PCS and either 0.078 pg/ml or 0.39 p.g/ml (as final 
concentrations) of either rACT (44/54) or rACT (44-188/54). Cell mixtures were 
incubated for 6 h at 37°C in 5% CO2. At the end of the incubation, D4A was 
extracted and separated by agarose gel electrophoresis. D4A fragmentation was 
visualized by staining with ethidium bromide (Fig. 3.4.6a).
3.4.1.4.1 Sheep BMMC
There was evidence of D4A fragmentation with sheep BMMC after 
incubation with 0.078 p,g/ml of rACT (44/54) (Lane 8), but not with the higher 
concentration of rACT (44/54) (Lane 7). In contrast, there were similar, but faint 
bands with sheep BMMC after incubation with different concentrations of rACT (44- 
188/54) (Lanes 9 and 10). Little if any fragmentation effect due to the Urea/Tris 
buffer was observed (Lane 6) (Fig. 3.4.6a).
3.4.1.4.2 RBL-2H3 cells
0.39 pg/ml (lane 2) and 0.078 pg/ml (lane 3) of rACT (44/54) showed marked 
DNA fragmentations with RBL-2H3 cells. In contrast, similar concentrations of rACT 
(44-188/54) did not show any DNA fragmentation with RBL-2H3 cells (Lanes 4 and 
5). Also, the concentration of urea/Tis buffer which was equal to the Urea/Tris buffer 
present in the highest concentration of rACT (44/54) as used in this experiment did 
not show any DNA fragmentation with RBL-2H3 cells (Lane 1) (Fig. 3.4.6a).
3.4.1.4.3 J774A.1 cells
Furthermore, the effect of 0.078 pg/ml of rACT (44/54) on genomic DNA of
J774A. 1 macrophage cells was investigated and compared with that on genomic DNA 
of sheep BMMC. Figure 3.4.6b shows no evidence for genomic DNA fragmentation 
from J774A. 1 cells after incubation with 0.078 pg/ml of rACT (44/54) for 6 h (Lane
213
4) and no evidence for D5A fragmentation in J774A.1 cells due to the Urea/Tris 
buffer was observed (Lane 5). In contrast, there were faint bands (lane 2) in sheep 
BMMC after incubation with 0.078 ftg/ml of rACT (44/54) and no bands of DNA 
fragmentation in sheep BMMC due to the Urea/Tris buffer (Lane 3).
The above observations suggested that the enzymatic activity of rACT (44/54) 
is important factor to promoting caspase activity in RBL-2H3 cells and also genomic 
DNA fragmentation in RBL-2H3 cells compared with the effect of non-enzymatically 
active rACT (44-188/54). In contrast, with the low concentration of rACT (44/54), 
there was evidence for genomic DNA fragmentation in sheep BMMC, even though 
these cells gave little caspase activity. J774A.1 cells showed high caspase activity 
with low concentrations of rACT (44/54) but this was not reflected in strong DNA 
fragmentation activity after gel electrophoresis of genomic DNA.
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Figure 3.4.6a The effect of rACT (44/54) or (44-188/54) on genomic DNA of 
sheep BMMC or RBL-2H3 ceils
The following figures shows the effect of 0.078 |lg/ml or 0.39 pg/ml of rACT (44/54) 
or (44-54/188) for 6 h on the D6A structure of sheep BMMC or RBL-2H3 cells.
I : urea/Tris buffer on RBL-2H3
2: 0.39 pg/ml of rACT (44/54) on RBL-2H3 
3: 0.078 fxg/ml of rACT (44/54) on RBL-2H3 
4: 0.39 pg/ml of rACT (44-188/54) on RBL-2H3 
5: 0.078 pg/ml of rACT (44-188/54) on RBL-2H3 
6: urea/Tris buffer on Sheep BMMC 
7: 0.39 pg/ml of rACT (44/54) on Sheep BMMC 
8: 0.078 p.g/ml of rACT (44/54) on Sheep BMMC 
9: 0.39 pg/inl of rACT (44-188/54) on Sheep BMMC 
10: 0.078 p,g/ml of rACT (44-188/54) on Sheep BMMC
I I : D6A marker (control).
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Figure 3.4.6b Effect of rACT on genomic DNA of sheep BMMC and J774A.1 
cells
0.078 jlg/ml of rACT (44/54) was incubated for 6h with 10  ^cells/ml of sheep BMMC 
and J774 cells. D7A was extracted and separated by agarose gel electrophoresis and 
D7A fragmentation was visualized by staining with ethidium bromide.
1) D7A marker
2) 0.078 pg/ml of rACT (44/54) with sheep BMMC
3) urea buffer with sheep BMMC
4) 0.078 fxg/ml of rACT (44/54) with J774A.1 cell line
5) urea buffer with J774 cell line
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3.4.1.5 Effect of rACT on p-hexosaminidase release
Unfortunately, at this stage in the project, the supply of sheep BMMC was 
stopped and further observations had to be done with either RBL-2H3 or J774A.1 
cells. The effect of rACT on degranulation of RBL-2H3 cells was investigated. Three 
different forms of rACT were available:
44/54: enzymatically-active and invasive.
44-188/54: enzymatically-inactive and invasive.
44-188: enzymatically-inactive (AC ).
1x10^ cells/ml of RBL-2H3 were maintained in IMDM medium containing 10 
% FCS (as control) or were treated with different forms of rACT at O.lpg/ml. In 
addition, RBL-2H3 cells were treated with the Urea buffer diluent equivalent to that 
in the rACT (44/54) preparation. The RBL-2H3 cell suspensions were incubated for 3 
h at 37°C in 5% CO2. At the end of the incubation time, p-hexosaminidase release was 
estimated.
J
Figure 3.4.7 shows the effect of different forms of rACT. The spontaneous 
release of p-hexosaminidase was apparently inhibited from RBL-2H3 as a result of 
incubation with O.lpg/ml rACT 44/54 indicated by the negative value for this sample 
but there was spontaneous release from RBL-2H3 when incubated with other forms of 
rACT (44/188) or (44-188/54) or buffer containing the 0.04M Urea/Tris concentration 
equivalent to that in the rACT preparation. There was a statistically-significant 
difference between the inhibitory effect of rACT (44/54) and the effect of rACT 
(44/188) (student /-test, p-value < 0.05).
These observations again show the importance of enzymic activity of rACT 
(44/54) in inhibition of degranulation of the RBL-2H3 cells.
■Î
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Figure 3.4.7 Effect of different forms of rACT on release of p-hexosaminidase 
from RBL-2H3 cells
This graph shows the percentage release of P-hexosaminidase from RBL-2H3 cells
(1x10*  ^ cells/ml) in IMDM medium due to incubation with 0.1 pg/ml of different
forms of rACT for 3 h (mean of 9 observations ± SEM). These forms were
rACT (44/54): enzymatically-active and invasive
rACT (44-188): enzymatically-inactive and non-invasive
rACT (44-188/54): enzymatically-inactive and invasive
cal-ion : lO'^M of Calcium-ionophore
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3.4.2.1 RBL-2H3 cells
3.4.2 Cytotoxic effect of different purified virulence factors of Bordetella 
toward RBL-2H3 cells and J774A.1 cells
In these exeriments, RBL-2H3 cells were used as a model for mast cells and 
J774A. 1 macrophage cells were used as controls to study whether different purified 
Bordetella virulence factors have any cytotoxic effects on viability (by ATP
■ :bioluminescence assay and MTT assay), on apoptosis (caspase 3/7 activity and D8A 
fragmentation) or on degranulation (P-hexosaminidase release). RBL-2H3 cells (and 
J774A.1 cells) maintained in IMDM medium containing 10 % FCS were treated with 
0.1 jLlg/ml or 0,01 flg/ml (as a final concentrations) of FT or FHA or PR8 and the 
mixtures incubated for different times (3 h and 6 h) at 37”C in 5% CO2. In some 
experiments, the effect of these different Bordetella factors was compared with the 
effect of rACT (44/54) and lO '^M of calcium ionophore as controls.
'I
,1
Î
Figure 3.4.8a shows the effect of 0.01 pg/ml and 0.1 jlg/ml of PT, FHA or 
PR8 on the ATP content (by ATP-bioluminescent assay) of RBL-2H3 cells at end of 
incubation for 3 h and 6 h and compared with the effect of 10‘^ M of calcium 
ionophore. 8either concentrations of PT had any major influence on the ATP content 
of RBL-2H3 cells after incubation for 3 h and 6 h. With 0.1j.lg/ml FHA, there 
appeared to be 15 % reduction in the survival of RBL-2H3 cells at end of incubation 
for 3 h and appeared to be 13 % reduction in survival at end of incubation for 6 h. At 
0.1 j.tg/ml PR8, there appeared to be 10 % reduction survival of RBL-2H3 cells at end 
incubation for 3 h but, no major influence was appeared at end of incubation for 6 h. 
These observations with both FHA and PR8 on survival of RBL-2H3 cells could 
suggest that the initial apparent reduction was more an effect on metabolic activity of 
RBL-2H3 cells than killing.
The above results on RBL-2H3 cells were further investigated by MTT assay 
(Fig. 3.4.8b). As in the ATP assay, there was no major influence of 0.01 jig/ml of PT
on the percentage survival of RBL-2H3 cells at 3 h and 6 h. Both FHA and PR8 
showed similar effect (i.e. there was around 5-10 % reduction in the percentage
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survival of RBL-2H3 cells at 3 h with 0.01 jig/ml of both FHA and PR9, but these 
reductions were not observed at 6 h). With 0.1 jlg/ml of PT there was less than 10 % 
reduction in survival of RBL-2H3 cells at end of incubation for 3 h and 6 h. These 
results of PT suggested that a possible small killing effect of PT is dose and time 
dependent. There was no significant killing effect of either concentration of FHAor 
PR9 (0.1 pg/ml and 0.01|ig/ml) at 3 h and 6 h.
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Figure 3.4.8a Effect of different purified virulence Bordetella factors on ATP 
content of RBL-2H3 cells (ATP-assay)
RBL-2H3 cells were maintained in IMDM and treated with O.OI |ig/ml and 0.1 pg/ml 
of different purified Bordetella factors (PT, FHA and PR:) and incubated for 
different times (3 h and 6 h). ATP level of RBL-2H3 cells was estimated with ATP- 
bioluminescent assay and the percentage survival was calculated by comparison with 
RBL-2H3 cells in IMDM medium. lO'^M of calcium ionophore was used as a control, 
(mean of 9 observations ± SEM)
Figure 3.4.8b Effect of different purified virulence Bordetella factors on viability 
of RBL-2H3 cells (MTT-assay)
RBL-2H3 cells were maintained in IMDM and treated with 0.01 pg/ml and 0.1 pg/ml 
of different purified Bordetella factors (PT, FHA and PR:) and incubated for 
different times (3 h and 6 h). The percentage of survival of RBL-2H3 cells was 
calculated by comparison with RBL-2H3 cells in IMDM medium (MTT assay). lO'^M 
of calcium ionophore was used as a control, (mean of 9 observations ± SEM)
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3.4.2.2 J774A.1 cells
Figure 3.4.8c shows that 0.01 pg/ml of PT caused around 15 % reduction in 
the ATP level at both 3 h and 6 h. There was no effect observed at 0.01 pg/ml of FHA 
at 3 h incubation, but there was around 10 % reduction at 6 h. With PR;, there was 
around 20 % reduction in ATP contents 3 h and this reduction was increased to 30 % 
in 6 h. In contrast, 0.1 pg/ml of PT and PR; significantly reduced the ATP level 
compared with the effect of 0.1 pg/ml of FHA. These observations suggested that the 
effect of both PT and PR; is dose and time depndent. In contrast, 0.1 pg/ml of FHA 
showed similar observation to 0.01 pg/ml after 3 h and 6 h.
The above observations on J774A.1 cells were further investigated by the 
MTT assay (Fig. 3.4.8d). There was around 10 % reduction in the percentage survival 
at 3 h and 6 h due to 0.01 pg/ml of PT. 0.01 pg/ml and 0.1 pg/ml of FHA did not show 
any influence in survival of J774A.1 cells as determined by MTT assay. There 
appeared to be 20 % reduction in survival due to 0.01 pg/ml of PR;, but no effect was 
observed after 6 h. But, with 0.1 pg/ml PR;, there was 20 % reduction in survival 
after 3 h and 30 % reduction after 6 h. 10“^  M of calcium ionophore showed time 
dependent killing effect in the percentage survival of J774A.1 cells by both assays.
The above observations suggested that the effect of different purified 
Bordetella virulence factors (PT, FHA and PR;) in the survival of RBL-2H3 cells 
and J774A. 1 cells were different. These differences could be due to the availability of 
receptors on the cell surface of the two cell types and further work should be done to 
investigate such differences.
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Figure 3.4.8c Effect of different purified virulence Bordetella factors on ATP 
content of J774A.1 cells (ATP-assay)
J774A. 1 cells were maintained in IMDM and treated with 0.01 pg/ml and 0.1 pg/ml 
of different purified Bordetella factors (PT, FHA and PR<) and incubated for 
different times (3 h and 6 h). The ATP content of J774A.1 cells was estimated with 
the ATP-bioluminescent assay and the percentage survival of J774A.1 cells was 
calculated by comparison with J774A.1 cells in IMDM medium. lO'^M of calcium 
ionophore was used as a control, (mean of 9 observations ± SEM)
Figure 3.4.8d Effect of different purified virulence Bordetella factors on viability 
of J774A.1 cells (MTT-assay)
J774A.1 cells were maintained in IMDM and treated with O.OI pg/ml and 0.1 pg/ml 
of different purified Bordetella factors (PT, FHA and PR<) and incubated for 
different times (3 h and 6 h). The percentage of survival of J774A.1 cells was 
calculated by comparison with J774A.1 cells in IMDM medium estimated (MTT 
assay). lO'^M of calcium ionophore was used as a control, (mean of 9 observations ± 
SEM)
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3.4.2.3 Effects of different purified factors on caspase 3/7 activity
The effect of different concentrations 0.001 pg/ml, 0.01 pg/ml and 0.1 pg/ml 
of different purified virulence of Bordetella factors (PT, FHA and PR=) on activation 
of caspases 3/7, which drives the effector phase of apoptosis in different mammalian 
cells was studied. 5x10^ cells/ml of sheep BMMC, RBL-2H3 and J774A.1 were 
maintained in IMDM medium containing 0.001 pg/ml or 0.01 pg/ml or 0.1 pg/ml (as 
final concentrations) and incubated for 6 h at 37°C in 5% COg. At the end of 
incubation, caspase 3/7 activity was estimated as RLFU. Figure 3.4.9 shows PT 
increased caspase 3/7 activity only in the RBL-2H3 cells compared with sheep 
BMMC and J774A.1 cells. Sheep BMMC or J774A.1 cells showed only basal caspase 
3/7 activity with different concentrations of PT. The three cell types showed basal 
caspase 3/7 activity with different concentrations of FHA and PRN (data not shown).
3.4.2.4 Effect of PT on DNA structure of RBL-2H3 cells
#
In order to confirm the above findings, DNA fragmentation in RBL-2H3 cells
due to incubation with PT and rACT (44/54) was evaluated. 10  ^cells/ml of RBL-2H3 
cells were maintained in IMDM medium containing 10% FCS, mixed with 0.1 pg/ml 
of PT or 0.39 pg/ml of rACT (44/54) and incubated for 6 h. In addition, RBL-2H3 
cells mixed with 0.1 pg/ml of PT were incubated for 1 h, then 0.39 pg/ml of rACT 
(44/54) was added to the mixture and incubated for another 5 h (total incubation time 
was 6 h). At the end of incubation, DNA was extracted and separated by agarose gel 
electrophoresis and DNA fragmentation was visualized by staining with ethidium 
bromide. Figure 3.4.10, shows distinct nuclear DNA fragmentation in RBL-2H3 cells 
(Lane 4 and Lane 5) after incubation for 6 h with either concentration of PT or rACT 
(44/54) or both together. These observations suggest that PT activates caspase 3/7, 
which drives the effector phase of apoptosis of RBL-2H3 cells.
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Figure 3.4.9 Effect of PT on caspase 3/7 activity of different mammalian cells 
(apoptosis assay)
The graph shows the effect of different concentrations, 0.001, 0.01 and 0.1 pg/ml of 
PT on caspase 3/7 activity of sheep BMMC, RBL-2H3 and J774A.1 cells at 5x10^ 
cells/ml and incuabted for 6 h. (Mean of 9 observations ± SEM).
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Figure 3.4.10 Effect of PT and rACT on genomic DNA of RBL-2H3
10*^  cells/ml of RBL-2H3 cells were mixed with 0.1 pg/ml of PT or 0.39 pg/ml of 
rACT (44/54) and incubated for 6h. In addition, RBL-2H3 cells were mixed with 0.1 
pg/ml of PT and incubated for Ih, then 0.39 pg/ml of rACT (44/54) was added to the 
mixture and incubated for another 5h (total incubation time was 6h).
1 - D>A marker
2- RBL-2H3 with IMDM medium
3- RBL-2H3 with Urea/Tris buffer
4- RBL-2H3 with 0.39 pg/ml of rACT (44/54)
5- RBL-2H3 with 0.1 pg/ml of PT
6- RBL-2H3 with 0.1 pg/ml of PT then 0.39 pg/ml of rACT
4 5 6
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3.4.2.S Effects on degranulation (p-hexosaminidase assay)
In the following experiments and for the first time, p-hexosaminidase release 
was investigated in J774A. 1 cells due to the effect of different purified virulence 
factors of Bordetella. 5x10^ cell/ml of RBL-2H3 cells and J774A. 1 cells were 
maintained in IMDM medium containing 1% of FCS and either 0.01 pg/ml or 0.1 
pg/ml of different purified factors as a final concentrations. 200 pi volume of total 
mixtures was added in triplicate to 96-well plates. After incubation for 3 h at 37°C in 
5% CO2, p-hexosaminidase release was estimated. lO'^M of calcium ionophore was 
used as a control (Fig. 3.4.11).
3.4.2.5.1 RBL-2H3 cells
?one of the purified factors (PT, FHA and PR?) induced P-hexosaminidase 
releasefrom RBL-2H3 cells, unlike the effect of 10"'^ M of calcium ionophore seen here 
or with B. bronchiseptica (Bvg^ phase) in previous experiments. In fact, it appeared 
that all three factors (PT, FHA and PR?) inhibited spontaneous release from RBL- 
2H3 cells, as indicated by the negative values for percentage release in the figure.
3.4.2.5.2 J774A.1 cells
Surprisingly, both FHA and PR? induced a significant ampunt of P- 
hexosaminidase release from J774A. 1 cells in a dose-dependent manner. In contrast, 
0.01 pg/ml and 0.1 pg/ml of PT also inhibited P-hexosaminidase from J774A.1 cells. 
As with previous observation of lO'^M of calcium ionophore, there was little effect on 
J774A. 1 degranulation.
The above observations suggested that PT inhibited P-hexosaminidase release 
from both cell types. FHA and PR? do not stimulate p-hexosaminidase release and 
possibly may inhibit spontaneous release from RBL-2H3 cells. But, with J774A.1 
cells, both factors stimulate P-hexosaminidase release.
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Figure 3.4.11 Effect of different purified virulence factors of Bordetella on P- 
hexosaminidase release
RBL-2H3 cells and J774A.1 cells were maintained in IMDM medium containing 1% 
of FCS and either 0.01 pg/ml or 0.1 pg/ml of different purified factors and incubated 
for 3 h. P-hexosaminidase release was estimated at end of incubation time (mean of 9 
observations ± SEM)
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3.4.3 Effect of pre-treatment RBL-2H3 cells with rACT and PT on P-
hexosaminidase release due to calcium ionophore or B. bronchiseptica
The previous observations (Fig. 3.4.7b and Fig. 3.4.11) suggested that both PT 
and rACT were able to inhibit spontaneous P-hexosaminidase release from RBL-2H3 
cells. Therefore, it was of interest to investigate the influence of both factors in P~ 
hexosaminidase release from RBL-2H3 cells pre-treated with either PT or rACT and 
then treated with either calcium ionophore or B. bronchiseptica (Bvg"  ^phase), both of 
which are potent release agents.
3.4.3.1 Calcium ionophore
The effect of two different forms of rACT on the de granulation effect of 
calcium ionophore was studied. RBL-2H3 cells (1x10^ cells/ml) maintained in IMDM 
containing 10% FCS and 0.1 pg/ml of rACT (44/54) or rACT (44-188/45) and 
incubated for 3 h at 35°C in 5% CO2. 10'  ^M of calcium ionophore was added to the 
pre-treated RBL-2H3 cell suspensions and incubated for 1 h. Then, p-hexosaminidase 
release was estimated. 10‘^ M of calcium ionophore caused around 21% p- 
hexosaminidase release from untreated RBL-2H3 cells (Fig. 3.4.12a). 0.1 pg/ml of 
rACT (44/54) showed inhibition of spontaneous p-hexosaminidase release from RBL- 
2H3 as in previous observations (Fig. 3.4.7b). But, there was a significant p- 
hexosaminidase release from RBL-2F13 pre-treated with 0.1 pg/ml of rACT (44/54) 
for 3 h and challenged with lO'^M of calcium ionophore for 1 h compared with the 
effect of 10'  ^ M of calcium ionophore alone. In contrast, 0.1 fxg/ml of rACT (44- 
188/54) showed very little effect in spontaneous p-hexosaminidase release from RBL- 
2H3 cells after treatment for 3 h. But, there was a significant p-hexosaminidase 
release from pre-treated RBL-2H3 cells with 0.1 pg/ml of rACT (44-188/54) for 3 h 
and challenged with 10'  ^ M of calcium ionophore for 1 h compared with the effect of 
10'*^  M calcium ionophore alone (student f-test, p-value < 0.05).
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Similar experiments were done with using PT. 1x10^ cells/ml RBL-2H3 cells 
maintained in IMDM containing 1% FCS and 0.1 pg/ml of PT was incubated for 3 h 
at 35°C in 5% CO2. 10^ M of calcium ionophore was added to the pre-treated RBL- 
2H3 cell suspensions and incubated for 1 h then p-hexosaminidase release was 
estimated. 0.1 pg/ml of PT showed inhibition of spontaneous p-hexosaminidase 
release from RBL-2H3 as in previous observations (Fig. 3.4.11). But, there was a 
significant p-hexosaminidase release from RBL-2H3 cells pretreated with 0.1 jttg/ml of 
PT and then treated with lO '^ M calcium ionophore, similar to that from RBL-2H3 
cells treated with 10‘*^ M calcium ionophore only (student r-test, p-value > 0.05) (Fig. 
3.4.12b).
The above observations suggested that pretreatment with PT and rACT 
(44/54) failed to inhibit p-hexosaminidase release from RBL-2H3 cells treated with 
10'*^ M calcium ionophore.
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Figure 3.4.12a Effect of calcium ionophore on degranulation of RBL-2H3 pre- 
treated with rACT
1x10^ cells/ml RBL-2H3 cells were incubated in IMDM containing 10% FCS and 0.1 
pg/ml of rACT (44/54) or rACT (44-188/45) for 3 h at 35°C in 5% CO2. lO'^M of 
calcium ionophore was added to the pre-treated RBL-2H3 cell suspensions and 
incubated for 1 h then P-hexosaminidase release was estimated (mean of 9 
observations ± SEM)
Figure 3.4.12b Effect of calcium ionophore on degranulation of RBL-2H3 pre­
treated with PT
1x10^ cells/ml RBL-2H3 cells were incubated in IMDM containing 10% FCS and 0.1 
pg/ml of PT for 3 h a t 35°C in 5% CO2. lO'^M of calcium ionophore was added to the 
pre-treated RBL-2H3 cell suspensions and incubated for 1 h then p-hexosaminidase 
release was estimated (mean of 9 observations ± SEM)
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3.4.3.2 B. bronchiseptica (Bvg^ phase)
RBL-2H3 cells at 10  ^ cells/ml were maintained in IMDM medium containing 
either 0.1 pg/ml of rACT (44/54) or 0 .1 pg/ml PT and incubated for 1 h, 3 h and 6 h at 
35°C in 5% CO2. B. bronchiseptica (Bvg ‘^ ) grown on BG agar was then added at an 
infection ratio of 1:500 and reincubated for another 1 h under the previous conditions. 
At the end of incubation, P-hexosaminidase was estimated in the supernates of the 
different mixtures.
B. bronchiseptica (Bvg'*' phase) gave around 8% of total p-hexosaminidase 
release from RBL-2H3 cells after incubation for 1 h (Fig. 3.4.13a). Urea/Tris buffer at 
concentration equal to that in 0.1 pg/ml of rACT did not show any effect on P- 
hexosaminidase release. In contrast, 0.1 pg/ml of rACT (44/54) showed considerable 
inhibition of spontaneous p-hexosaminidase release from RBL-2H3 cells, which 
agrees with previous observations (Fig 3.4.12a). However, such an inhibitory effect 
on spontaneous P-hexosaminidase release appears to be temporary in that the effect 
decreased with increasing time of incubation. It has been reported that once rACT 
gets inside cells, it casues an increase in cAMP but it is degraded and (Hanski and 
Farfel, 1985). However, these observations suggested that rACT is able to inhibit p- 
hexosaminidase release induced by B. bronchiseptica from infected RBL-2H3 cells if 
cells are pre-treated just before (1 h or 3 h) expoure to B. bronchiseptica.
In addition, the effects of pretreated with PT on p-hexosaminidase release 
from RBL-2H3 cells by B. bronchiseptica (Bvg'*^  phase) was studied (Figure 3.4.13b). 
As in previous observations, O.lpg/ml PT showed inhibition of spontaneous P~ 
hexosaminidase release, but this was a slow-developing effect and was more evident 
with a longer (6 h) incubation period. When, pre-treated RBL-2H3 cells were infected 
with B. bronchiseptica (Bvg"*" phase), there was a statistically significant reduction in 
P-hexosaminidase release (student r-test, p-value < 0.05) compared with non-infected 
cells at all incubation times, but, this inhibitory effect was greatest after 6 h of pre­
treatment. Thus, the inhibitory effect of PT appeared to be time-dependent and, with 
increased incubation time, a greater inhibitory effect was observed.
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Figure 3.4.13a Effect of pre-treatment with rACT on p-hexosaminidase release 
from RBL-2H3 cells in the presence of B. bronchiseptica (Bvg
RBL-2H3 cells at 1x10^ cells/ml were pre-treated with 0.1 |lg/ml of rACT (44/54) for 
different time (1 h, 3 h and 6 h) and then infected with B. bronchiseptica (Bvg ^) for 1 
h. P-hexosaminidase release was then estimated (mean of 9 observations ± SEM)
A) Effect of B. bronchiseptica (Evg”*") on RBL-2H3 cells in IMDM alone.
B) Effeet of B. bronchiseptica (Bvg "*") on RBL-2H3 eells pre-treated with IMDM 
medium containing 0.04M urea/Tris buffer (urea control).
C) Effect of 0.1 pg/ml rACT (44/54) alone on spontaneous p-hexosaminidase release 
from RBL-2H3 cells.
D) Effect of B. bronchiseptica (Bvg"*") on RBL-2H3 cells pre-treated with IMDM 
medium containing 0.1 |ig/ml rACT (44/54).
Figure 3.4.13b Effect of pre-treatment with PT on P-hexosaminidase release 
from RBL-2H3 cells in the presence of B. bronchiseptica (Bvg )^
RBL-2H3 cells at 1x10^ cells/ml were pre-treated with 0.1 fig/ml of PT for different 
times and then infected with B. bronchiseptica (Bvg’*') for 1 h. p-hexosaminidase 
release was then estimated (mean of 9 observations ± SEM)
A) Effect of B. bronchiseptica (Bvg "*") on RBL-2H3 cells in IMDM alone.
B) Effect of 0.1 flg/ml PT alone on spontaneous P-hexosaminidase release from 
RBL-2H3 cells.
C) Effect of B. bronchiseptica (Bvg '*') on RBL-2H3 cells pre-treated with IMDM 
medium containing 0.1 jig/ml PT.
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3.4.4 Influence of rACT and PT on survival and phagocytic function of J774A.1
cells infected with B. bronchiseptica
The previous results determined different effects of ACT (normally present in 
B. bronchiseptica and B. pertussis) and PT (present only in B. pertussis). For 
example, a significant reduction in viability of different mammalian cell types have 
been observed after incubation with ACT but, there was no significant influence of PT 
on viability of these cell types. In addition, both purified factors have shown 
inhibitory effect on p-hexosaminidase release from RBL-2H3 but, such inhibitory 
effect was different when pre-treated RBL-2H3 eells infected with B. bronchiseptica 
(Bvg^ phase) (section 4.3.2). Therfore, it would be more useful to investigate the 
ability of both factors on phagocytic function of mouse macrophage cell line J774A.1. 
In this regards, it was reported that PT has been implicated in inhibiting a number of 
activities of human phagocytic cells including phagocytosis (Hiemstra et a i, 1992). 
Additionally, it was found that the B. pertussis ACT was important in crippling the 
phagocytic functions of neutrophils (Weingart and Weiss, 2000). Therefore, it was 
interesting to study the influence of both purified factors PT and rACT on survival of 
J774A. 1 cells and numbers of intracellular B. bronchiseptica. due to interaction with 
B. bronchiseptica (Bvg'*' phase). J774A. 1 macrophage cells were used in the following 
study. Previous observation had shown that RBL-2H3 cells did not take-up B. 
bronchiseptica (Lux 95) (Fig. 3.2.15a and Fig. 3.2.15b), so, these cells were not used.
3.4.4.1 Comparison of the effect of PT and rACT on survival of J774A.1 cells 
infected with B. bronchiseptica (Bvg^ phase)
0.1 pg/ml of either PT or rACT (44/54) as final concentrations were added 
into 1x10^ cell/ml J774A. 1 cells maintained in an antibiotic-free IMDM medium and 
incubated for 1 h at 37**C in 5% CO2. Then, B. bronchiseptica (Bvg'*') was added at an 
infection ratio of 1:500 (one J774A.1 cell to 500 bacterial cells) and incubated for 
another 3 h under 37°C in 5% CO2. At the end of the incubation period (total time 4 
h), the cell suspension was washed three times (to remove any extracellular bacteria) 
in an antibiotic-free IMDM medium. The viability of J774A. 1 cells was estimated by 
trypan blue exclusion and viability of bacterial cells was estimated by releasing the 
intracellular or adherent bacteria by adding 100 jig/ml of digitonin to the washed cell
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suspension, and plating out. Statistical analysis of the interaction of B. bronchiseptica 
(Bvg"*^  phase) with J774A.1 cells treated in different conditions containing 0.1 jig/ml 
PT or rACT was done by using Student r-test. Statistically, collected data were 
normally distributed, the variance of each sample was similar, and mean and variance 
were not correlated. A parametric test was chosen and, due to significant values of 
interaction observed by Student r-test, Tukey’s test was used (two way A@ OVA) to ■
confirm significance values which were done by using Xlstat (www.Xlstat.com) 
software.
Table 3.4.1, shows that, in general, the viability of J774A.1 cells (mean logio) 
was reduced due to the presence of B. bronchiseptica (Bvg"*") compared with the 
viability of J774A.1 cells (mean log to) in the absence of B. bronchiseptica (Bvg'*") 
phase (Tukey’s test: p-value < 0.0001) which agreed with previous observations (Fig.
3.2.17b). In the absence of bacteria, there was no statistically significant reduction in 
the viability of J774A.1 cells due to treatment in 0.1 pg/ml PT compared with 
J774A.1 cells in IMDM alone (Tukey’s test p-value > 0.05). But, there was a 
significant reduction in viability of J774A.1 cells treated with rACT compared with 
viability of J774A. 1 cells treated in IMDM medium alone or in the urea/Tris buffer 
diluent (Tukey’s test p-value < 0.0001). As expected, there was no effect observed in 
viability of J774A.1 cells due to treatment in Urea/Tris buffer compared with viability 
of J774A. 1 cells treated in IMDM medium only (Tukey’s test p-value > 0.05).
Interestingly, there was statistically significant increase in survival of J774A. 1 
cells pre-treated with 0.1 pg/ml of PT and then infected with B. bronchiseptica (Bvg"*" 
phase) compared with cells in IMDM only (Tukey’s test p-value < 0.0001). In 
contrast, there was a statistically significant decline in survival of J774A.1 cells pre­
treated with 0.1 pg/ml of rACT and then infected with B. bronchiseptica (Bvg "*" 
phase) compared with survival cells in IMDM only (Tukey’s test p-value < 0.0001).
The above observations suggested that pre-treatment of J774A. 1 macrophage 
cells with PT protected J774A.1 cells from the killing effect of B. bronchiseptica 
(Bvg'*' phase), but rACT enhances the killing effect of B. bronchiseptica (Bvg^ phase).
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'Table 3.4.1: Survival of J774A.1 cells pretreated with PT and rACT and infected 
with B. bronchiseptica (Bvg^ phase)
J774A.1 cells treated (for 1 h) in different conditions (containing EVIDM alone, 
Urea/Tris buffer, O.lpg/ml PT or rACT) and infected with B. bronchiseptica (Bvg'*' 
phase) for 3 h. Viability of infected J774A.1 cells (mean Logio) was estimated by 
trypan blue exclusion. IMDM: medium only. Urea: Urea buffer diluent for rACT, 
SD: Standard deviation (mean of 6 observations)
'
J774A.1 cells 
treatment in
Bacteria Mean (Logio) 
number of viable 
cells/ml
SD
IMDM Absent 5.854 0.043
Urea 5.831 0.047
0.1 |ig/ml (PT) 5.758 0.041
0.1 pg/m! (rACT) 5.091 0.175
IMDM Present 5.076 0.169
Urea 5.237 0.095
0.1 pg/ml (PT) 5.458 0.060
0.1 jag/ml (rACT) 4.659 0.169
:
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3.4.4.2 Effect of PT and rACT on uptake of B. bronchiseptica (Bvg  ^phase)
Previous observation suggested that 0.1 jLig/ml PT prevents killing of J774A, 1 
cells by B. bronchiseptica (Bvg phase). Therefore, it was interesting to investigate 
the ability of J774A.1 cells for uptake of or adherence to the surrounding B. 
bronchiseptica (Bvg'*' phase).
Figure 3.4.14 shows the total number of viable intracellular/adherent B. 
bronchiseptica. As can be seen, there was no significant differences between viability 
of B. bronchiseptica in the case of J774A. I cells maintained in IMDM alone or 
Urea/Tris buffer (Ftest: p-value > 0.05). Numbers were lower in J774A.1 cells treated 
with 0.1 pg/ml PT compared with J774A.1 cells in IMDM alone (r-test: p-value < 
0.05). In addition, numbers were much lower in J774A.1 cells treated with 0.1 pg/ml 
rACT compared with numbers in the Urea/Tris buffer diluent for the rACT 
preparation (r-test: p-value < 0.05).
Figure 3.4.15 shows the numbers of viable intracellulai7adherent B. 
bronchisptica per viable J774A.1 cell (i.e. Log lo number of intracellular B. 
bronchiseptica -  Log lo number of viable J774A. 1 cells). As can be seen, there was a 
decrease in the number of viable intracellular/adherent B. bronchiseptica per viable 
J774A. 1 cell pre-treated with 0.1 ftg/ml of PT compared with numbers in control cells 
or in cells pre-treated with 0.1 jttg/ml rACT (r-test: p-value > 0.05).
This observation could suggest that pre-treatment of J774A.1 cells with 
O.lpg/ml PT prevent killing of J774A. 1 eells and could prevent uptake of B. 
bronchiseptica by J774A.1 cells. ACT, however, was cytotoxic for the J774A.1 cells, 
hence there were fewer bacteria recovered. However, those J774A. 1 cells that had 
taken up bacteria contained similar numbers to those in the control, untreated cells.
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Figure 3.4.14 Intracellular survival of B. bronchiseptica in J774A.1 cells 
pretreated with PT or rACT
J774A.1 cells at 1x10*^  cells/ml were treated in different conditions (IMDM alone, 
urea/Tris buffer and 0.1 jig/ml PT or rACT) for 1 h and then infected with B. 
bronchiseptica (Bvg phase) at MOI of 1:500 for 3 h. At the end of incubation time 
(total 4 h), extracellular B. bronchiseptica were removed by washing and survival of 
intracellular/adherent B. bronchiseptica in J774A. 1 was determined by plating on BG 
agar (mean of 6 observations ± SEM)
Figure 3.4.15 Numbers of B. bronchiseptica per J774A.1 cell pretreated in 
different conditions
Survival of intracellular B. bronchiseptica per J774A.3 cell have been calculated by 
subtracting Log lo number of intracellular/adherent B. bronchiseptica from viable of 
Log 10 number of viable J774A.1 cell for each conditions.
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i3.4.4.3 Effect of B. bronchiseptica on viability of J774A.1 cells pre-treated with 
rACT
B. bronchiseptica (Bvg"*" phase) produces ACT, which is well known that 
causes an increase in intracellular cAMP in target cells. This increase in cAMP is 
thought to modulate cell functions, for example to inhibit the respiratory burst in 
neutrophils (Wang et a i, 1998). Therefore, it was of interest to study the effect of low 
doses of rACT (44/54) either to prevent the killing effect of B. bronchiseptica (Bvg^ 
phase) toward J774A.1 cells or to modulate the uptake of surrounding B. 
bronchiseptica.
J774A.1 cells at 1x10*^  cells/ml were maintained in antibiotic-free IMDM 
medium and treated with either; IMDM alone, urea buffer diluent, 0.025 jig/ml, 0.05 
pg/ml or 0.1 pg/ml of rACT and incubated for 1 h at 37°C in 5% CO2. Then each 
group of pre-treated J774A. 1 cells was infected with B. bronchiseptica (Bvg"*" phase) 
at an infection ratio of 1:500 (one J774A. 1 cell to 500 bacterial cells) and incubated 
for another 3 h under the previous conditions. At the end of incubation (total time 4 
h), bacteria-cell suspension was washed three times (to remove any extracellular 
bacteria) in an antibiotic-free IMDM medium. The viability of J774A.1 cells was 
estimated by trypan blue exclusion and the viability of bacterial cells was estimated 
by releasing the intracellular or adherent bacteria by adding 100 ftg/ml of digitonin 
into the washed cell suspension, and plating out. Statistical analysis of the interaction .
of B. bronchiseptica (Bvg'*' phase) with J774A.1 cells treated in different conditions 
was done by using Student /-test. Statistically, collected data were normally
distributed, the variance of each sample was similar, and mean and variance were not 
correlated. A parametric test was chosen and, due to significant values of interaction
...
observed by Student /-test, Tukey’s test was used (two way AAOVA) to confirm 
significance values which were done by using Xlstat (www.Xlstat.com) software.
Table 3.4.2, shows that, in general, viability of J774A.1 cells (mean logio) was 
reduced due to the presence of B. bronchisptica (Bvg"*") compared with the viability of 
J774A.I cells (mean logio) in the absence of B. bronchiseptica (Evg"*") phase (Tukey’s 
test: 77-value < 0.0001) which agreed with previous observations (Fig. 2.17b).
a
There was a significant reduction in viability of J774A.1 cells at all three 
concentrations of rACT (44/54) compared to the viability of J774A. 1 cells in urea 
bufer or IMDM medium only (Tukey’s test: p-value < 0.0001). These observations 
confirm the highly cytotoxic effect of the high doses of rACT (0.1 |LLg/ml) which 
confirmed our previous observation (Fig. 3.4.14).
As can be seen in Table 3.4.2, the viability of J774A.1 cells pre-treated with 
0.025 pg/ml of rACT and infected with B. bronchiseptica (Evg"*" phase) was high 
compared with the viability of J774A. 1 cells treated in urea buffer diluent in presence 
of B. bronchiseptica (Bvg'*' phase). This observation was significant (Student /-test p- 
value < 0.05), but, when analysed with Tukey’s test, it was not significant (p-value >
0.05). The last observations suggested that pre-treatment of J774A.1 cells with the 
lower concentrations of rACT (0.025 |lg/ml) may have prevented the killing effect of 
B. bronchiseptica (Evg"*" phase) toward J774A. 1 cells compared with higher doses.
.
1
I
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Table 3.4.2: Survival of pretreated J774A.1 cells with rACT and infected with B.
bronchiseptica (Bvg^ phase)
J774A. 1 cells treated (for 1 h) in different conditions (containing different 
concentrations of rACT) and infected with B. bronchiseptica (Bvg phase) for 3 h. 
Viability of infected J774A.1 cells (mean Logio) was estimated by trypan blue 
exclusion. IMDM: medium only, u: urea buffer diluent, 0.025, 0.05 and 0.1: 
different concentrations of rACT (|lg/ml) (mean of 6 observations).
Ceils
treatment in
Bacteria Mean (Logio) no. of 
viable cells/ml
SD
IMDM Absent 5.722 0.043
u/T 5.683 0.046
0.025 5.426 0.103
0.05 5.284 0.052
0.1 5.084 0.126
IMDM Present 4.476 0.105
u/T 4.449 0.094
0.025 4.591 0.064
0.05 4.370 0.106
0.1 4.128 0.139
241
bronchisptica per viable J774A. 1 cell (by substracting Log lo number of
This observation could suggest that pre-treatment of J774A.1 cells with low 
concentrations of rACT (0.025 pg/ml) reduced the cytotoxic effect of B. 
bronchiseptica (Bvg^ phase) towards J774A. 1 cells by reducing the ability of J774A. 1 
cells for uptake of surrounding B. bronchiseptica.
1
3.4.4.4 Effect of pre-treatment of J774A.1 cells with rACT (44/54) on survival of 
intracellular/adherent of B. bronchiseptica
The previous observation suggested that 0.025 pg/ml rACT may have reduced 
the killing effect of B. bronchiseptica (Bvg^ phase) towards J774A. 1 cells. Therefore, 
intracellular/adherent B. bronchiseptica (Bvg"*" phase) was investigated in each 
condition of J774A. 1 cells pretreated with different concentrations of ACT.
Figure 3.4.16 shows the total number of viable intracellular/adherent B. 
bronchiseptica. As can be seen, there was no significant difference between viability 
of B. bronchiseptica in the case of J774A.1 cells maintained in IMDM alone or 
Urea/Tris buffer (/-test: p-value > 0.05). Numbers were lower in J774A.1 cells treated 
with 0.025 pg/ml rACT compared with J774A.1 cells in IMDM alone (/-test: p-value 
> 0.05). In addition, numbers were much lower in J774A. 1 cells treated with higher 
doses of rACT compared with numbers in the Urea/Tris buffer diluent for the rACT 
preparation (/-test: p-value < 0.05).
Figure 3.4.17 shows the numbers of viable intracellular/adherent B.
intracellular/adherent B. bronchiseptica from the Log )o number of viable J774A.1 
cell). As can be seen, there was a decrease in the number of viable 
intracellular/adherent B. bronchiseptica per viable J774A.1 cell pre-treated with 0.025 
pg/ml of rACT compared with numbers in control cells or in cells pre-treated with 
other higher doses of rACT (/-test: p-value > 0.05).
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Figure 3.4.16 Intracellular survival of B. bronchiseptica in J774A.1 cells 
pretreated with different concentrations of rACT
J774A.1 cells at 1x10^ cells/ml were treated in different conditions (IMDM alone, 
urea/Tris buffer and different concentrations of rACT) for 1 h and infected with B. 
bronchiseptica (Bvg phase) at MOI of 1:500 for 3 h. At the end of incubation time 
(total 4 h) extracellular B. bronchiseptica were removed by washing and survival of 
intracellular/adherent B. bronchiseptica in J774A.1 was determined by plating on BG 
agar (mean of 6 observations ± SEM).
Figure 3.4.17 Numbers of B. bronchiseptica per J774A.1 cell pretreated in 
different conditions
Survival of intracellular B. bronchiseptica per J774A.3 cell were calculated by 
subtracting the Log lo number of intracellular/adherent B. bronchiseptica from viable 
of Log 10 number of viable J774A. 1 cell for each conditions.
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4.1 General Discussion
4.1.1 Advantages and limitation of methods used in this study
Different methods were applied to study the interaction of sheep BMMC and 
other mammalian cell types (RBL-2H3 and J774A.1) with B. bronchiseptica and 
different Bordetella purified factors. Uptake of bacteria by sheep BMMC was studied 
by using a bioluminescent construct of B. bronchiseptica (Lux 95) and a 
bioluminescent E. coli. The bioluminescent method was shown to offer an easy and 
simple method of measuring the viability of the bacteria in real-time. Based on in 
vitro invasion assays, the kinetics of interaction between sheep BMMC and B. 
bronchiseptica (Lux 95) was followed. The data indicated the presence of viable 
bioluminescent B. bronchiseptica within sheep BMMC, and this observation was 
confirmed by both viable count and TEM.
It is important to realise that intracellular bacteria within sheep BMMC might 
include both viable B. bronchiseptica surviving the invasion/phagocytic process and 
bacteria killed by the intracellular bactericidal mechanisms. Therefore, in future 
studies, it would be useful to apply a method which could help to detect and 
differentiate between viable and dead bacteria. For example, flow cytometry (FC) or 
fluorescence microscopy methods have the potential to measure the morphological 
and physiological characteristics of individual cells through labelling of cellular 
targets with organism-specific fluorescent dyes (lepras et a l, 1995). Several 
commercial DNA-intercalating fluorescent labels with various excitation and 
emission spectra have been developed to distinguish viable and non-viable bacteria on 
the basis of intact versus damaged cellular membranes.
These methods can measure the relative size, relative granularity, internal 
complexity and relative fluorescent intensity of individual cells. With its great speed, 
the FC method can individually evaluate several thousand cells per second. This 
method has been shown to be both sensitive and accurate in its rapid assessment of the 
viability of Gram-positive and Gram-negative bacteria (Wattanaphansak et a l, 2005).
Bordetella species interact with their mammalian hosts primarily at respiratory
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surfaces where they bind specifically to the cilia of the respiratory epithelium. In this 
study, interaction of B. bronchiseptica with sheep BMMC was studied in vitro and 
their cytotoxicity was compared with the effect of different bacterial species. 
Comparison of B. bronchiseptica (Bvg'*') and (Bvg') strains indicated that only the
Bvg^ phase B. bronchiseptica significantly reduced the viability of sheep BMMC and 
of other eell types (RBL-2H3 and J774A. 1 cells). Viability of mammalian cells was 
estimated by a bioluminescent assay for ATP which reflects the metabolic activity of 
the cells. Furthermore, degranulation of mammalian cells after incubation with B. 
bronchiseptica and other bacterial species was estimated. A significant 13- 
hexosaminidase release was estimated after incubation with B. bronchiseptica (Bvg"*") 
compared with the effect of the (Bvg') strain and certain other Bordetella species.
In their virulent phase, B. pertussis and B. bronchiseptica express a common 
set of surface-associated and secreted molecules involved in colonisation and 
virulence which include adhesins such as filamentous haemagglutinin (FHA) and 
pertactin (PRB), as well as the bifunctional adenylate cyclase toxin /haemolysin 
(ACT). B. pertussis also specifically expresses pertussis toxin (PT). Cytotoxicity of 
these different purified factors towards sheep BMMC were investigated by estimating 
their viability by MTT and ATP-bioluminescent assays, apoptosis (caspase-3 and -7 
and DBA fragmentation assays and by degranulation (p-hexosaminidase release 
assay).
The methods used in this study depend on studying the effect of a limited 
number of proteins produced by a limited number of genes in one experiment, for 
example, when assessing the viability or degranulation of sheep BMMC or other cell 
types. Thus, the throughput is very limited and the whole picture of alteration of 
protein production or gene function in sheep BMMC and other cell types is hard to 
obtain. The effect of B. bronchiseptica on sheep BMMC will alter the expression of a 
large number of proteins. Likewise, the effects of mammlian cells on B. 
bronchiseptica will be complex. For example, the production of most B. 
bronchiseptica virulence factors is under the control of BvgAS system, which is co­
regulated with other gene sets (i.e. vag genes and vrg genes) (Coote, 2001). Thus, 
monitoring the cascade of reactions and co-regulations that occur between different 
genes of B. bronchiseptica under different environmental conditions (or when 
interacting with different cell types) could be difficult by traditional methods. Thus, it 
would be useful to use a method which could monitor different gene sets either in the 
mammalian cells or in B. bronchiseptica at the same time under different conditions, 
either in vitro or in vivo. In this regards, the DBA micro array technique would be
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useful because it could help to follow many different gene functions in one 
experiment (Schoolnik, 2002; Call, 2005) (see Conclusions and future work).
4.1.2 Differences in cell types studied
In the present study, the focus of interest was the interaction between different 
bacterial species (mainly B. bronchiseptica) and sheep BMMC and other eell types 
(RBL-2H3 and J774A.1) in vitro, with view to some insight into how this interaction 
might influence the outcome of infection. Sheep BMMC were of prime interest used 
in this study (see 4.1.3). It is well known that they are multifunctional and they have 
been traditionally associated with the allergic response. They are found throughout the 
body, but are particularly prevalent at sites which interface with the environment such 
as the skin, airways and gastrointestinal tract and have been viewed as sentinel cells in 
host defence (Abraham and Malaviya, 2000). However, recent studies have suggested 
that these cells may be capable of regulating inflammation and innate immunity 
(Malaviya et a l, 2001). Furthermore, a number of studies have reported that MCs 
play a critical role in host immune defence against bacterial infections. These studies 
have shown that mast cells have the ability to recognize and engulf bacteria and 
release a number of inflammatory mediators (Marshall and Jawdat, 2004).
In contrast, the RBL-2H3 cell line is a tumour analogue of mucosal mast cells 
and widely used as a model for mucosal mast cells work. These cells have high 
affinity IgE receptors (FceRI). They can be activated to secrete histamine and other 
mediators by aggregation of these receptors or with calcium ionophore. This cell line 
was grown and readily available and easy to maintain, and could be grown in the same 
IMDM medium as sheep BMMC. It was observed that RBL-2H3 cells were 
metabolically very active and their multiplication rate was particularly high. When 
cell proliferation started, IMDM medium was renewed each 48h and replaced by fresh 
IMDM. For cell cultures which would be used for experiments, there was a limit of 
about 10 passages after which an increase of cell death was observed by trypan blue 
exclusion. This meant that a new stock culture should be preparedvial from the frozen 
RBL-2H3 stock.
In contrast, J744A. 1 cells are well known as a professional macrophage cell
'line. J774A. 1 is less metabolically active with a slow growth rate, compared with 
RBL-2H3 cells but higher than that of sheep BMMC. Therefore, when J774a. 1 cell
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proliferation started, IMDM medium was renewed twice per week and replaced with 
fresh IMDM. In contrast, the IMDM medium in the sheep BMMC culture was 
renewed once per week.
Despite these differences between RBL-2H3 and J774A. 1 cells, they were 
considered to be suitable for comparison with sheep BMMC in their interactions with 
bacteria. In the following sections (4.1.3 - 4.1.5) are described further properties of 
these cells and their advantages and limitations of their use are described.
4.1.3 Differentiation and characterisation of mast cells obtained from sheep 
bone marrow cells
The results presented in this study have shown that mast cells with the 
characteristics of mucosal mast cells proliferate to form the predominant cell type in 
sheep bone marrow cultures fed with the growth factors recombinant ovine SCF and 
IL-3. In earlier studies, the cell-free supernatant of conditioned medium has been used 
to stimulate mast cell growth in cultures of sheep bone marrow cells (Haig et a l, 
1988). The conditioned medium was prepared from lymphocytes recovered from 
sheep infected with the nematode Ostertagia circumcincta. Washed lymphocytes 
were maintained in IMDM containing 5x10''’ M 2-mercaptoethanol, 500 pg/ml bovine 
serum albumin, 25 pg/ml human transferrin, 1 |ig/ml palmitic, oleic and linoleic 
acids, 100 U/ml penicillin, 50 4 g/ml streptomycin and 7.5 pg/ml concanavalin A. 
Cultures were incubated for 1-5 days at 37°C. Then, lymphocytes were harvested by 
centrifugation and the cell-free supernatant was used. It was observed that mast cells 
developed rapidly after 2 weeks of culture and could persist for 2-3 months (Haig et 
a l, 1988).
Haig and his group later reported the effects of rat stem-cell factor (SCF) and 
interleukin-3 (IL-3), alone or in combination, on the in vitro growth of bone marrow- 
derived mast cells (BMMC). Rat SCF stimulated the growth of both rat connective 
tissue mast cells (CTMC) and rat bone marrow mast cells (BMMC). IL-3 stimulated 
BMMC growth to a lesser extent than did SCF, whereas CTMC numbers did not 
increase in IL-3 alone. These observations suggested that SCF and IL-3 can regulate 
the growth of rat BMMC and CTMC, and they had a synergistic effect on the growth 
of both BMMC and CTMC (Haig et a l,  1994).
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The growth of ovine and caprine mast cells in bone marrow cultures has been 
achieved using recombinant ovine interleukin-3 (rOvIL-3) and recombinant ovine 
stem cell factor (rOvSCF) (Macaldowie et a l, 1997). After growth for approximately 
2-3 weeks in optimal concentrations of either rOvIL-3 alone or a combination of 
rOvIL-3 and rOvSCF, the majority of the cells produced in bone marrow culture from 
both species were mast cells. The significant increase in the total numbers of cells and 
survival times of the cultures when both cytokines were present compared to either 
alone, indicated synergy between rOvIL-3 and rOvSCF on mast cell growth. Ovine 
eells grown in rOvIL-3 alone or rOvIL-3 and rOvSCF contained significantly more 
aryl-sulfatase and serine protease but similar amounts of beta-hexosaminidase 
compared with caprine cells during the second week of culture. There were no 
significant differences in the granule-associated mediator content of cells from either 
species grown in rOvIL-3 alone compared with those grown in rOvIL-3 and rOvSCF 
during the first 21 days of culture (Macaldowie et a l, 1997).
Investigations in the present study showed that the presence of both growth 
factors in sheep bone marrow cultures induced mast cell differentiation, but mast cell
development was slow in cultures over the first 12-14 days. However, over the next 2 
weeks, the proportion of mast cells in the cultures increased. In addition, batch-to- 
batch variation was observed in the quantity of bone marrow mast cells produced. 
Bone marrow cultures were obtained on different occasions from different lambs and 
then stimulated by adding rOvIL-3 and rOvSCF. Their differentiation was 
characterized by increased cytoplasmic granulation, which was observed by both 
Leishman’s stain and electron microscopic study. After 3 weeks, the percentage of 
mast cells varied from 50% for some cultures to 90% for other cultures of sheep bone 
marrow cells.
This variation could have been a reflection of the initial bone marrow cells 
themselves i.e. the differences were due to the animal from which the bone marrow 
cells were derived rather than the culture conditions. Unfortunately, the reason for this 
variation is not known, nor can it be predicted (e.g. it is not due to factors like age, 
breed, sex, or obvious past exposure to infection). So, perhaps the variation of mast 
cell numbers was just an extension or reflection of the variability of the cells in their 
mediator content or functional activity.
Isolated sheep mucosal mast cells (MMC) have been used to examine the 
ability of four neuropeptides, substance P, vasoactive intestinal peptide, beta-
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endorphin and somatostatin, to release mediators in the presence or absence of 
parasite antigen (Stewart et a l, 1996). Cone of the neuropeptides induced the release 
of sheep mast cell protease (SMCP) or histamine from MMC. The response of mast 
cells (MC) to non-IgE-mediated stimulation is critically dependent on the population 
of MC examined. The neuropeptide substance-P (SP) has been reported to activate 
connective tissue-type MC (CTMC), while MMC are not activated by SP (Karimi et 
a i, 2000). In comparison, the functional and biochemical characterization of rat bone 
marrow-derived mast cells was confirmed either by staining characteristics or release 
of the performed granule mediator (3-hexosaminidase in response to calcium 
ionophore A23187 and other secretagogues. It was reported that rat BMMC have the 
staining characteristics of mucosal mast cells and contain the mucosal mast cell 
protease. Rat BMMC released the preformed granule mediator beta-hexosaminidase 
in response to 1 pM calcium ionophore A23187 (net release 21.8 +/- 6 .8%), and 
neither compound 48/80 nor substance-P induced mast cell degranulation (Broide et 
a l, 1988).
The present observations showed that mast cells differentiated from sheep 
bone marrow in a culture containing both SCF and IL-3 did not react with substance-P 
whereas they did respond to calcium ionophore, which suggests that these mast cells 
were likely to be mucosal mast cell-like. For this reasons, these cells would seem to 
be highly appropriate as a model system to study the interaction of (mucosal) mast 
cells with the respiratory mucosal pathogen, B. bronchiseptica and related organisms.
Regarding culture medium, IMDM medium (Gibco BRL) which has Glutamax- 
1, has an advantage in that the glutamine is in a form that is not broken down 
immediately and used up by the cells. Also, IMDM medium contains several non- 
essential amino acids, thought to be necessary to support mast cell growth in bone 
marrow cultures. In the first 2 to 3 weeks, IMDM medium was changed every week 
because colour changes in the medium indicated an increase in acidity (red to yellow), 
although such changes in culture acidity was slower after 3 weeks.
Purification of sheep mast cells from other cells in bone marrow preparation 
was done by various procedures. First, centrifugation of the cell suspension at 250g 
for 5 mill helped to remove RBC. Also, RBCs died within the first 10 days of cell 
culture. Fibroblast cells and macrophages became attached to the plastic surface of the 
tissue culture flask. Purification by using percoll density gradient (Amersham
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Biosciences) was done with some cultures. However, it was observed that during the 
purification step many mast cells were lost and contamination of the cell culture with 
percoll was observed. Thus, in the experiments reported here, the cultures were not 
purified.
Working with sheep BMMC produced many problems. It was difficult to 
identify sheep BMMC during the first two weeks of growth by using either 
LeishmaiTs stain or electron microscopic study. But, with increase in culture age, the 
number of dense intracytoplasmic granules increased, which could be an indication of
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sheep BMMC maturation. It has been suggested that immature mast cells can be 
differentiated from other cells by staining with rabbit polyclonal antibodies raised 
against sheep mast cells protease (Macaldowie et a l, 1997).
In the present study, the development of mast cells was studied. It had been 
shown that IL-3 could give rise to mast cells. But, it was observed that other cell types 
such as monocytes, eosinophils and macrophages were present at low levels at 
different ages of the culture (< 5-20% of total population). The presence of these 
phagocytic cells could have had some influence on the results of the bacterial uptake
'■A
experiments, for example by luminometery and, for that reason the use of more
purified mast cell preparations could be explored further in future work. However, 
this possible influence was judged to be slight since, by electron microscopy (EM) 
intracellular bacteria were clearly evident within cells with typical mast cell 
morphology.
Use of the mast cell cultures in the present work was limited by availability 
because mast cell numbers in the BMMC cultures decreased after 35 days. It was 
advised that use be limited to mast cells within 35-40 days because it appeared that, as
.the older cells are fragile (i.e. centrifugation at low speed may lyse them), such cells 
may not be suitable for invasion and cytotoxicity studies (personal communication 
with Dr. John Huntley).
At times, there was a shortage of sheep bone marrow due to several problems.
The outbreak of foot and mouth disease (2001) which cut the supply of sheep bone 
marrow for a few months was one, and another was that the project on sheep bone 
marrow cells at the Moredun Research Institute was stopped (2004).
In view of the above problems it might have been better to have used a 
different source of bone marrow such as rats or mice because these are small animals ' Ï
and genetically homogenous strains are available, perhaps without such a great 
variation in granule contents as the sheep cells. B. bronchiseptica is a respiratory 
pathogen of many animals including rodents, therefore these types of mast cells would 
have been as appropriate as sheep cells.
4.1.4 RBL-2H3 cells as a mast cell model
In the present study, the RBL-2H3 cell line used. Rat basophilic leukemia cells 
(RBL-2H3), a tumour analogue of mucosal mast cells (i.e. homologous to mucosal 
mast cells) is a well known cell line (Seldiii et a l, 1985). RBL-2H3 cells can be 
activated to secrete histamine and other mediators, and have been used for the study 
of hematopoietic signalling and secretion (Oliver et a l, 1988). In the present study, 
RBL-2H3 cells had a similar pattern of interaction as sheep BMMC with different 
secretagogues (i.e. calcium ionophore and substance P). For example, there was 
around 30 % (3-hexosaminidase release due to interaction with lO'^M calcium 
ionophore, but little [3-hexosaminidase release (< 5%) was detected due to the effect 
of lO'^M substance-P (Fig. 3.1.5). Interaction of substance-P with RBL-2H3 cells 
however, has been reported. RBL-2H3 cells responded to substance-P when they had 
been primed with substance P (0.5 |xM) for one week (Furukawa et a l, 2001). In the 
present work, however interaction with lO'^M calcium ionophore was detected within 
5 min by estimating (3-hexosaminidase release and maximum release occurred after 
incubation for 3 h but then there was decline in release. In contrast, sheep BMMC 
showed a decline in |3-hexosaminidase release after incubation with calcium 
ionophore for more than 1 h. Therefore, RBL-2H3 cells may be used to study the 
effect of different bacterial and other stimuli on mast cell degranulation. The results of 
this study demonstrated the ability of B. bronchiseptica (Bvg" )^ to directly activate 
RBL-2H3 cells (a mucosal mast cell model) in vitro. The ability of B. bronchiseptica 
(Bvg‘*‘) to induce |3-hexosaininidase release from mast cells as a result of 
degranulation effect may offer a potential link between infection by the organism and 
pathogenesis of bacterial respiratory infectious diseases (see Section 4.1.4).
However, the use of the RBL-2H3 cells in the present work was limited and 
their ability to take up bacteria may need further investigation. In the present study, 
RBL-2H3 cells appeared to be unable to phagocytose B. bronchiseptica (Result,
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section 3.2.8 .2). Therefore, it was not possible to use RBL-2H3 cells with 
bioluminescent 5. bronchiseptica (Lux 95).
4.1.5 Advantages and limitation to the use of mast cells and other cell types in
this study
Despite the above problems (see section 4.1.1), mast cells were the focus of 
interest in this study for a variety of reasons. In the last few years, there has been a 
growing number of reports concerning the role of mast cells in host defence against 
bacterial infections (Malaviya and Abraham, 1995; Marshall and Jawdat, 2004). 
These studies have shown that mast cells have the ability to recognize and engulf 
bacteria and release a number of inflammatory mediators (Marshall et a l,  2003). In 
addition, studies have shown that the mast cell membrane is replete with many 
receptors/molecules, including those that promote the recognition and binding of 
bacteria. For example, mast cells exhibit two basic mechanisms of microbial 
recognition: opsonin-dependent (via Fc and C3 receptors) and opsonin-independent 
(via integrins, CD48 molecule and Toll-like receptors). Moreover, mast cells may 
phagocytose and kill adherent bacteria. Phagocytosis of bacteria results in the 
presentation of bacterial antigens via MHC class I to T cells (Malaviya et a l, 1996b).
B. bronchiseptica is well known as a respiratory tract pathogen of a wide 
range of animal species(see Introduction 1.1.7.5). Therefore, sheep BMMC were 
thought to be appropriate for this study. Also, sheep BMMC were conveniently 
available and kindly supplied by Dr. J. Huntley (M.R.I.).
In the present study, bacterial internalisation (e.g. Lux 95 of B. bronchiseptica) 
by sheep BMMC was compared with that by RBL-2H3 cells and macrophage cell 
lines (P388D1 and J774A. 1) (see 4.1.5.3). It was shown that sheep BMMC were 
indeed able to internalise the bacteria but uptake of Lux 95 was less than uptake by 
the macrophage cells, which are considered as professional phagocytic cells (Further 
discussion, see section 4.1.5). On the other hand, there was no evidence for bacterial 
internalisation by RBL-2H3 cells either by the bioluminescence technique or by TEM 
(see 4.1.2). Therefore, RBL-2H3 cells were not useful cell in the study of bacterial 
internalisation. But, the effect of different strains of B. bronchiseptica and of other 
related Bordetella species showed that RBL-2H3 cells could be a useful model for 
studying the degranulation effect of different bacterial cells and other stimuli.
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Previous studies have suggested that M. pneumoniae is capable of producing 
activation of the rodent mast cell line RBL-2H3. After 4 hours of coculture, 
morphologic changes indicative of activation were observed by means of electron 
microscopy, and M. pneumoniae was observed. Coculture of RBL-2H3 cells with M. 
pneumoniae for 4 hours resulted in release of p-hexosaminidase and serotonin into the 
supernatant. Live, but not heat-killed, organisms induced the release of IL-4 into the 
culture supernatant, with a peak at 4 hours. During coculture with M  pneumoniae, 
production of mRDA for IL-4, IL-6 , and TDF-alpha was upregulated after 2 hours and 
had returned to near baseline by 24 hours after infection (Hoek et a l,  2002).
p-hexosaminidase release was used as a marker for degranulation of sheep 
BMMC and RBL-2H3 cells due to interaction with B. bronchiseptica and other 
Bordetella species. P-hexosaminidase is well known as a granule-associated factor in 
mast cells and has been widely used as a marker for degranulation of mast cells by 
different chemicals (Stewart et a l, 1996; Mizota et a l, 2005) or bacteria (Munoz et 
a l, 2003). In the present study, there was a significant P-hexosaminidase release from 
sheep BMMC after incubation with wild type B. bronchiseptica (Bvg" )^ compared 
with the avirulent mutant B. bronchiseptica (Bvg‘). Furthermore, the effect of PT and 
rACT on RBL-2H3 cells was observed by estimating p-hexosaminidase release. In 
this study, it was shown that the inhibitory effect of PT was time-dependent and, with 
increased incubation time, a greater inhibitory effect was observed (see section 
3.4.3.2)
4.1.6 Relevance of mast cells to bacterial respiratory diseases
The firmly established role of mast cells and their products in allergic (type I) 
hypersensitivity contrasts with the comparatively sparse knowledge, until recently, of 
their physiological functions and their role in non-allergic diseases. The prominence 
of mast cells in lesions in multiple sclerosis (Ibrahim et a l,  1996) cardiomyopathy 
(Arbustini et a l, 1997) rheumatoid arthritis (Gotis-Graham and McDeil, 1997) and a 
number of other chronic inflammatory and fibrotic diseases in human subjects 
(Algermissen et a l,  1999) suggested mast cell involvement. The critical importance 
of mast cells in many of these diseases has recently been validated by animal models 
(Brightling et a l, 2002). It is now clear that mast cells receive and integrate a wide 
array of non-IgE-driven chemical signals from their environment, permitting
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mobilization of their effector properties. It has been suggested that the extent of mast 
cell involvement in both allergic and non-allergic disease pathophysiology, as well as 
host defence, is likely to be far greater than would be predicted strictly on the basis of 
studies of classical IgE-dependent immune responses (Galli, 1993; Boyce, 2003).
In this regard, mast cells are found particularly prevalent at sites which 
interface with the environment, such as airways and a number of studies have reported 
that mast cells play a critical role in host immune defence against bacterial infections. 
These studies have shown that mast cells have the ability to recognize and engulf 
bacteria and release a number of inflammatory mediators and there is an expanding 
list of microbes that can cuase their activity (Abraham et a l, 1997).
The function of mast cells as sensors of infection and injury through innate 
recognition receptors and their response to these signals both limits the potential 
spread of infection (by recruiting neutrophils) and facilitates wound healing, through 
actions on fibroblasts and other connective tissue elements (Malaviya et a l, 1996a).
In the context of TH2-polarized mucosal inflammation, cytokines transduce 
growth and survival signals to mast cells and their progenitors and alter their profile 
of gene expression. These alterations both expand the repertoire of mast cell effector 
mediators (cytokines) and lower their threshold for activation by both IgE-dependent 
and non-IgE-dependent mechanisms (Galli, 1993; Boyce, 2003). These mechanisms 
for phenotypic modification of mast cells might have evolved as a result of pressures 
exerted by helminth infection. They very likely contribute to functional alterations in 
mast cells in the tissues of allergic individuals. It is possible that these alterations 
render mast cells capable of triggering sustained or deleterious inflammatory 
responses to otherwise innocuous stimuli.
The potential for microbes to elicit or exacerbate allergic mucosal 
inflammation directly through activation of reactive phenotypically altered mast cells 
requires further investigation. Under such circumstances, the mast cell effector 
systems normally specialized to protect against pathogens and heal tissue could lead 
instead to prolonged inflammation and other damage such as fibrosis, angiogenesis, 
and tissue remodeling (Boyce, 2003).
There are, however, few reports or the role of mast cells in defence against or 
damage caused by bacterial respiratory diseases. For example, it was reported that 
mast cells are critical for the containment of and recovery from airway mycoplasma 
infection (Xu et a l, 2006). Mast cell-deficient mice had no apparent defects in
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adaptive immune responses but may mast cells contribute to innate defences against 
this important respiratory pathogen. If this is also the case in humans, than 
pharmaceutical strategies to eliminate mast cells in severely affected asthmatics may 
weaken defences against mycoplasma and lead to exaggerated inflammatory 
responses to infection (Xu et a l, 2006).
In term of their potential to cause damages mast cells produce histamine and 
are associated with the allergic response, and MCs lying below the mucosal surface 
can also stimulate neurons that innervate the gastrointestinal and respiratory tract. 
Such stimulation could result in increased peristalsis (gastrointestinal tract) or trigger 
the cough or sneeze response (respiratory tract), but this would have the benefit of 
aiding in expulsion of invading microorganisms (Salyers and Whitt, 1994).
In the present study, the Gram-negative bacterium B. bronchiseptica (Bvg"*") 
caused a significant cytotoxicity (ie. reduction in ATP content) in sheep BMMC, and 
p-hexosaminidase release. Such bacteria-indiiced cytotoxic effects and mediator 
release from superficially lying mast cells in the airways epithelium might be of great 
importance in respiratory tract infections. In fact, the balance between the potential 
beneficial and harmful effects of bacteria-mast cell interactions might have a pivotal 
role in determining the outcome of the infection. On the one hand, there is the 
beneficial phagocyte clearance of bacteria by mast cells and other cell types and, on 
the other hand, the potentially harmful effect resulting from mast cell destruction and 
mediator release. In this regard, mast cells have become recognised as essential in 
immune response as other cell types such as neutrophils and alveolar macrophages 
which are well-known defence mechanisms against bacterial infection (Malaviya and 
Abraham, 1995).
In the present study, phagocytic activity of MC was studied by using 
bioluminescent strains of B. bronchiseptica. and E. coli and degranulation was 
followed by estimating P-hexosaminidase release which is a granule-associated 
molecule. For the first time, viable intracellular B. bronchiseptica (Lux 95) were 
shown within sheep BMMC. These results establish baseline data for individual and 
age-related variation in sheep BMMC phagocytic function, and form a basis for 
further evaluation of other functions such as chemotaxis, oxidative burst and 
clearance of bacterial infection in mast cells, either in sheep or other animal models. 
In the present study, internalisation of B. bronchiseptica (Lux 95) by sheep BMMC
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was observed and P-hexosaminidase release was also detected due to interaction with i
B. bronchiseptica (Bvg ). These observations demonstrate the ability of sheep BMMC 
to recognise and take up surrounding bacteria.
B. bronchiseptica is a respiratory tract pathogen (Mattoo and Cherry, 2005). B. 
bronchiseptica is thought to achieve colonisation of this site by producing a variety of 
putative adhesins, such as filamentous haemagglutinin (FHA), pertactin (PRE) and 
adenylate cyclase toxin (CyaA) interfering with the normal phagocyte clearance 
mechanisms. The cytotoxicity of B. bronchiseptica toward sheep BMMC, RBL-2H3 
cells and macrophage cell lines was compared with that of different Bordetella 
species {B. pertussis and B. parapertussis) and unrelated bacteria {S. pneumoniae and 
P. multocida).
The effect of B. bronchiseptica in respiratory infection in swine has been
investigated (Brockmeier and Register, 2000). It was reported that bacteria were 
observed extracellularly as well as intracellulaiiy within swine alveolar macrophages 
by using immunofluorescent staining. However, more bacteria were found surviving 
intracellulaiiy after the macrophages were cultured with polymyxin B to kill 
extracellular bacteria. Similar results were seen in experiments performed with an 
isogenic Bvg' phase-locked mutant of B. bronchiseptica cultured at 37*^  or 23^ C, 
indicating that another temperature dependent mechanism in addition to Bvg may play 
a role in adhesion and intracellular survival. B. bronchiseptica was cytotoxic for 
swine alveolar macrophages in the Bvg"*" phase only. Furthermore, there was no doubt 
important to escape from immune clearance mechanisms and establish infection, and 
could leave the host susceptible to secondary respiratory pathogens (Brockmeier and 
Register, 2000).
In B. pertussis infections, there are no reports that mast cells have a role in 
clearance or pathology, but preliminary findings from a rat model of pertussis 
infection showed mastocytosis in the trachea, with evidence of mast cell 
degranulation (personal communication with J. Wastling and R. Parton). Likewise, 
there are no reports in the literature that mast cells have a role either in defence 
against B. bronchiseptica infection or in contributing to pathology of disease caused 
by these bacteria. However, in view of the present finding, where B. bronchiseptica
.(Bvg’^ ) strain and other Bordetella species caused a significant degranulation effect on
:g,
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mast cells (|3-hexosaminidase release) in vitro, this could suggest that similar effects 
could occur in vivo.
4.1.7 Use of bioluminescent bacteria as an in vitro reporter of the interaction
between B. bronchiseptica and sheep BMMC (mucosal mast cells) and
other cell types
4.1.7.1 Cytotoxic effect of B. bronchiseptica (Lux 95)
The bioluminescent mutant strain of B. bronchiseptica (Lux 95) used in this 
study (Forde et a l, 1998) had been created from a strain of B. bronchiseptica 5376 
that had been kept in the laboratory culture collection for many years. 
Characterisation of strain B. bronchiseptica (Lux 95) in the present study showed that 
it had some properties in common with the B. bronchiseptica. (Bvg" phase). These 
properties included a lack of haemolytic effect, lack of haemagglutination effect and 
lower enzymatic activity of the adenylate cyclase toxin (ACT) associated with the 
Bvg^ phase of growth of another B. bronchiseptica strain BBC 17 (F.B. Lux strain 
was derived from a different strain to the Bvg^ and Bvg " control strain). On the other 
hand, B. bronchiseptica (Lux 95) showed more of a cytotoxic effect than B. 
bronchiseptica (Bvg phase) (Fig. 3.3.12). For example, it was observed that there was 
around 80% survival of RBL-2H3 cells when incubated with B. bronchiseptica (Lux 
95), but 95% survival with an equal number of B. bronchiseptica (Bvg" phase) 
bacteria and 30 % survival with B. bronchiseptica (Bvg"  ^ phase) bacteria. 
Furthermore, it observed that there was greater |3-hexosaminidase release from RBL- 
2H3 cells due to incubation with B. bronchiseptica (Lux 95) compared with B. 
bronchiseptica (Bvg" phase), but less release compared with (Bvg"*" phase)(Fig. 
3.3.13). These observations suggested that B. bronchiseptica (Lux 95) used in the 
present study had some properties in common with both B. bronchiseptica (Bvg 
phase) and (Bvg" phase) and may have been in an intermediate phase (Bvg ' 
phase)(see Introduction).
The bacterium B. bronchiseptica in the Bvg  ^virulent phase or mode is known 
to be cytotoxic and the phase is characterized by the expression of adhesins such as 
fimbriae, filamentous haemagglutinin (FHA), and pertactin, and toxins such as 
adenylate cyclase toxin (ACT). The avirulent (or Bvg ") phase or mode is poorly 
cytotoxic and is characterized by motility and none of the known adhesins or toxins
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are present. Both phases are under the influence of the BvgAS signal transduction 
system (Coote, 2001) and modulation between the phases (the process known as 
antigenic modulation) can be induced by different factors. It has been reported that 
sulphate anion is a modulating agent for Bordetella and therefore addition into the 
growth media could shut off, very rapidly, the BvgAS signal transduction system and 
the kinetics of transcriptional pathway for production of different virulent factors. 
However, modulation is a freely-reversible process and, in the absence of MgS0 4  in 
the medium, the organism should readily revert to its original Bvg"  ^mode (Gross and 
Rappuoli, 1989; Martinez de Tejada et a l, 1996; Smith et a l, 2001). It was reported 
that B. bronchiseptica (Lux 95), used in the present study, was created in a condition 
containing 10 mM MgS0 4  (at the time of minitransposon mutagenesis, for plasmid 
transfer) (Forde et a l, 1998). In the present study, growth in the absence of the 
modulating agents (MgS0 4 ) in the culture medium (BG agar) did not help in 
resumption of transcription of virulence factors.
A more likely explanation for the loss of virulence of B. bronchiseptica (Lux 
95) is phase variation. Upon growth of Bordetella in the laboratory, phase variants 
arise spontaneously, with a strain-dependent frequency, and these variants are no 
longer able to express the virulence factors owing to spontaneous mutation in the bvg 
locus (Stibitz et a l, 1989). Thus, the laboratory strain used to create the B. 
bronchiseptica (Lux 95) strain could already have entered the Bvg" or Bvg' phase, or, 
for some reason, B. bronchiseptica Bvg" or Bvg' phase variants were selected during 
the transformation process. B. bronchseptica (Lux 95) used in the present work was 
grown routinely on BG agar to maximise its virulence factor expression, even though 
various lines of evidence suggested that it was not completely in the Bvg mode.
The phase variation of B. bronchiseptica (Lux 95) may suggest that B. 
bronchiseptica (Lux 95) may not have been ideal for study of interaction with 
different mammalian cells. In future studies, it would be better to create Lux strains 
from authentic B. bronchiseptica (Bvg'^ phase) and B. bronchiseptica (Bvg" phase), 
which would help to study their different interactions with different mammalian cells. 
This could be done by using the method of Forde et al. (1998) with the same 
minitransposon probe used to create strain Lux 95. Uptake of bioluminescent Bvg^ 
phase might kill the mammalian cells and then in turn the bacteria would be killed by 
polymyxin B. Uptake of the bioluminescent Bvg' phase could lead to possible 
intracellular survival for some time. By inserting the lux genes at different points in B.
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bronchiseptica chromosomes, under the control of promoters of known Bvg-activated 
or repressed genes, some insight would be gained into the role of these bvg-regulated 
factors when B. bronchiseptica interacts with, and is internalized by, different 
mammalian cells. Thus, the use of the bioluminescence technique may helping to 
understand better the intracellular survival of different phases of B. bronchiseptica 
and other bacteria.
4.1.7.2 Evaluation of using lux genes in this study
In the present study, the bioluminescent B. bronchiseptica (Lux 95) was one of 
2000 mutants of B. bronchiseptica constructed by Forde et al. (1998) with the aid of 
the minitransposon promoter probe vector pUTmini-Tn5km/wz. Forde et al (1998) 
observed that expression of bioluminescence varied considerably between the mutants 
and when they were grown under different conditions, as viewed by CCD imaging. 
Expression of bioluminescence in three very bright fusion strains was examined on 
BG agar and BG agar supplemented with MgS0 4  or nicotinic acid, because these 
stimuli are known to affect Bvg-dependent regulation of gene expression in vitro in 
Bordetella species. It was found that the level of light output in these three strains was 
unaffected by the growth medium. Expression of luminescence was also unaffected at 
low pH (pH 5.5) and in the presence of the superoxide generator methyl viologen. 
When levels of bioluminescence were measured by automated luminometry, the 
brightest strain showed light output greater than that found in X. luminescens, the 
original source of the lux genes or in E. coli DH5a carrying the multicopy plasmid 
pT7-3 containing the lux genes. Consequently, this B. bronchiseptica mutant strain 
(Lux 95) was chosen as a constitutively bioluminescent strain. However, the location 
of the lux genes in B. bronchiseptica (Lux 95) is unknown. With the availability of the 
B. bronchiseptica genome sequence (Parkhill et a i, 2003) this could be determined. 
Knowledge of the B. bronchiseptica genome sequence also opens up the possibility of 
a more rational approach to creating Lux strains in which the lux genes are placed 
under the control of different promoters of genes that are differentially (e.g. Bvg- 
regulated) or constitutively expressed.
In the present study, the bioluminescence level of B. bronchiseptica (Lux 95) 
maintained in different media (IMDM alone, IMDM containing 10% FCS, PBS alone 
and PBS containing 10% FCS) was monitored by luminometer. It was observed that 
the bioluminescence output was dependent on the presence of FCS in the different
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media. For example, the results in Figure 3.2.2a suggested that the addition of heat- 
inactivated fetal calf serum into IMDM growth medium increased light output. It 
could be that the presence in FCS of extra growth factors as exogenous substrate 
provides an ideal condition for the growth of B. bronchiseptica (Lux 95) in IMDM 
medium.
The correlation between bioluminescence output (RLU) and viability of B. 
bronchiseptica. (Lux 95) was monitored. It was observed that there was a linear 
correlation between the bioluminescent signal and viable numbers of B. 
bronchiseptica (Lux 95) (Figure 3.2.2b). When both relative light units (RLU) and 
optical density (OD) were monitored in a long-run experiment (> 20 h)(Figure 3.2.3c), 
it was observed that, within the first 2 0h, there was a good correlation between them. 
But, after that there was a poor correlation between the two factors (Figure 3.2.3d). At 
the end of a long-run experiment, viability of B. bronchiseptica (Lux 95) was 
determined by viable count on BG agar. The combination of reduction in 
bioluminescence output, recovery of viable B. bronchiseptica (Lux 95) suggests that 
B. bronchiseptica (Lux 95) can remain viable but without producing significant light 
output. In addition, bioluminescence output of B. bronchiseptica (Lux 95) was active 
up to 20 h, during the log phase of bacterial growth, but thereafter, B. bronchiseptica 
(Lux 95) showed reduced bioluminescence activity during the stationary and decline 
phases.
A bioluminescent E. coli was also used in this study and light output was 
monitored. When RLU and OD were monitored in a short-run experiment (20 h) 
(Figure 3.2.6), it was observed that, within the first 10 h, there was a good correlation 
between both bioluminescence output and optical density. But, after that, there was a 
poor correlation between the two factors. At the end of a short-run experiment (20 h) 
viability of E. coli was determined by viable count on LB agar and again, large 
numbers of viable cells were obtained but without significant light output.
Comparison between light output of bioluminescent E. coli and B. 
bronchiseptica (Lux 95) in a short-run experiment suggested that the correlation 
between bioluminescence output and optical density of the bioluminescent E. coli was 
not as good as with B. bronchiseptica (Lux 95). The difference is probably due to the 
fact that E. coli is a much more rapidly growing organism than B. bronchiseptica and 
will therefore reach stationary phase in a much shorter time. Even so, the differences
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in light output were a rapid decline in E. coli and a much slower decline in B. 
bronchiseptica.
Monitoring the light emission in bioluminescent bacteria may give an indication 
of bacterial growth phase. The latter phenomenon corresponds with the observations 
of other researchers working with reporter genes. For example, during mid to late 
logarithmic growth, depending on the species and the nutrient composition of the 
growth medium, light emission will increase dramatically. The increase in 
luminescence arises by activation of expression of the genes in the lux operon. 
Furthermore, it has been reported that upon entrance into stationary phase and during 
starvation, there is a decrease in luciferase activity that corresponded to a decrease in 
the metabolic activity of the population while the number of culturable cells remained 
relatively stable (Meighen, 1993; Unge et al., 1999).
In this regard, it was reported that the light emission from a bioluminescent 
Yersinia enterocolitica was partly dependent on the growth phase, and in stationary 
phase there was a significant reduction of light emission (Maoz et al., 2002). 
Accordingly, the observations in the present study suggest that, with a longer 
incubation time of B. bronchiseptica (Lux 95) or bioluminescent E. coli, presumably 
when the culture reaches stationary phase, the bacteria gradually crease to emit light 
even though they remain viable. Such older cultures would therefore not be useful for 
invasion assays.
In addition, it is known that the lux genes can rely on a promoter region of the 
host organism genome for their expression (Meighen, 1991). B. bronchiseptica was 
successfully mutagenized with a promoter probe suicide vector carrying the lux genes 
from P. luminescens on a mini-Tn5 derivative (Forde et a i, 1998). The lux genes 
were transferred to the chromosome of B. bronchiseptica whereas, in E. coli, the lux 
genes were carried on a plasmid. In the E. coli strain used in the present study, the lux 
genes were carried on plasmid pT7-3 and were under the control of the phi-10 
promoter for T7 RNA polymerase. They were transcribed only at a low level by the E. 
coli RNA polymerase (Szittner and Meighen, 1990). Chromosomal insertions of a 
transposon carrying the lux operon in bacteria would dictate the strength of light 
emission. As discussed previously the lux genes are used as reporters of gene 
expression and light output will depend on exactly where the lux genes have inserted 
in the chromosome. If the lux genes are inserted downstream of the promoter of a 
gene that is only active in the early stages of growth, light output may decline rapidly
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as the culture ages. If downstream of a gene that is constitutively expressed, light 
output may last longer. These differences may explain the differences in light 
emission of E. coli compared with B. bronchiseptica, but may need more 
investigation.
The use of reporter genes (lux genes) to study the interaction of mast cells with 
B. bronchiseptica showed that this technique was very sensitive, and there was a 
linear relationship between of light intensity and the viable numbers of bacteria, at 
least in short term experiments with actively growing bacteria. Furthermore, there was 
no need to add any exogenous substrates to observe the reaction, and, there was no 
biomedical hazard. Availability of a sensitive detector such as the Lucy luminometer 
used here enabled the direct measurement in vitro. Expression of the lux genes in 
different bacteria (B. bronchiseptica and E. coli) provided a simple and sensitive 
system for monitoring the growth and intracellular survival of bacteria, bearing in 
mind the various limitation of the system that are imposed by the growth phase of the 
bacterium as discussed above. Furthermore, use of lux genes under the control of 
appropriate promoters could indicate the different environmental conditions that the 
bacteria may be subjected to when interacting with different mammalian cells, either 
extracellulary or intracellulary.
The correlation between bioluminescence output and viability of B. 
bronchiseptica (Lux 95) and any new lux construct should be investigated thoroughly 
by viable counting at intervals throughout the growth cycle and in different media, 
and plotting light output against viable cell numbers. Optical density is a good 
indicator of viable cell numbers during the early stage of growth but does not 
distinguish between metabolically-active or inactive bacteria during later stages of 
growth. In addition, the results suggest that bioluminescence output could be a useful 
tool for short run experiments of up to 20 h for B. bronchiseptica (Lux 95). But, for 
longer term observations, for example for studying prolonged survival intracellulary a 
more accurate comparison of RLU and viable cell numbers, by using accurate plate 
counts would be necessary to confirm the relationship between light output and 
viability. Alternatively, new constructs might be useful when the lux genes might be 
controlled by promoters that are active in stationary phase.
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4.1.7.3 Intracellular B. bronchiseptica (Lux 95) within sheep BMMC
These studies with bioluminescent B. bronchiseptica (Lux 95) demonstrated 
that sheep BMMC are able to take-up bacteria. Furthermore, bioluminescence signals 
are indications of metabolic activity, and these studies demonstrated that both viable 
sheep BMMC and the contents of lysed sheep BMMC are able to reduce the 
metabolic activity of B. bronchiseptica (Lux 95).
Antimicrobial activity of polymyxin B sulphate was used to kill extracellular 
B. bronchiseptica. Polymyxin B sulphate is a cyclic decapeptide antibiotic with 
surfactant activity which disrupts the bacterial outer and cytoplasmic membranes by 
incorporation into the phospholipid bilayer (Ouderkirk et al., 2003). A cytolytic 
reagent, digitonin (C56H92O29), is also applied and, because of its mode of action for 
permeabilization of certain types of mammalian cells (e.g. blood platelets, 
hepatocytes, yeast, tumour cells and macrophage cell line), does not effect bacterial 
integrity and viability (Forde et a l, 1998). Both polymyxin B and digitonin were used 
for detection of intracellular B. bronchiseptica within sheep BMMC or other cell 
types. It was observed that 50 |ig/ml of polymyxin B killed more than 99.9% of B. 
bronchiseptica (Lux 95) within 2 h and, due to that, caused a sharp decline in 
bioluminescence output to basal levels where no mammalian cells were present. The 
optical density was not significantly altered by such treatment. Go effect on light 
output and viability of bacteria was observed with 50 jLtg/ml of digitonin (Figure 
3.2.5).
Some earlier reports have suggested that B. bronchiseptica can be found 
intracellulaiiy in HeLa cells (Savelkoul et a l, 1993) and in murine macrophages 
(Forde et a l, 1998). In the present study, the bioluminescent strain of B. 
bronchiseptica (Lux 95) was used to show that it could be found intracellulary in mast 
cells as well as in macrophage cell lines (P338D1 and J774A. 1). At 4 h postinfection 
of sheep BMMC with B. bronchiseptica (Lux 95), the results clearly showed a low 
level of light output recorded from infected sheep BMMC after polymyxin B 
treatment. Lysis of the sheep BMMC with digitonin, which has no effect on the 
viability of B. bronchiseptica, produced a rapid decline in this residual light output to 
basal levels as the internalized bacteria were exposed to the antibiotic polymyxin B in 
the surrounding medium and were killed. Furthermore, similar studies were done with 
bioluminescent E. coli (Result, section 2.9) and again showed light output from
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infected viable sheep BMMC after polymyxin B treatment. Lysis of the sheep BMMC 
with digitonin produced a rapid decline in this residual light output to basal levels as 
the internalized bacteria were exposed to the antibiotic polymyxin B in the 
surrounding medium and were killed.
In the present study, novel finding have been made by the use, for the first 
time of bioluminescent bacteria with mast cells. In the present study with sheep 
BMMC, their ability for uptake of B. bronchiseptica (Lux 95) increased with 
increased maturity of the sheep BMMC. Takeup of B. bronchiseptica (Lux 95) was 
observed with mast cell cultures aged between 14 and 30 days. It was observed that 
the bioluminescent signals from internalized B. bronchiseptica (Lux 95) were higher 
with 29-day cultures than with 14-day cultures.
In addition, a reduction in the bioluminescent signal from B. bronchiseptica 
(Lux 95) was observed due to co-culture with viable sheep BMMC or by mixing with 
the intracellular contents of lysed sheep BMMC. The results suggest that metabolic 
activity of bioluminescent B. bronchiseptica was reduced due to either the viable cells 
themselves or the contents of lysed mast cells. Furthermore, the effect of three day-old 
culture fluid from sheep BMMC (i.e. sheep BMMC grown in antibiotic-free IMDM 
medium) on B. bronchiseptica (Lux 95) was studied and there was no effect on 
viability, as judged by any alteration in light output compared with control B. 
bronchiseptica culture. The results suggested that there were no antimicrobial 
products secreted from sheep BMMC during their differentiation (Result, section 2.6).
An eventual reduction in bio luminescence signal was observed from 
intracellular B. bronchiseptica (Lux 95) within sheep BMMC (Figure 3.2.10b). This 
could be due to killing of the bacteria in the phagosomal vacuoles by fusion with 
antimicrobial granules or due to mast cells slowly dying under these assay conditions 
and therefore exposing B. bronchiseptica (Lux 95) to polymyxin B. Alternatively, 
polymyxin B could have been slowly leaking into the mast cells or being taken up by 
the mast cells and therefore exposing B. bronchiseptica (Lux 95) to polymyxin B. 
Another possibility is that the bacteria are simply becoming less metabolically-active 
in the intracellular environment even though they remain viable just as they do in old 
cultures.
The invasion experiments described here have shown that both phases of B. 
bronchiseptica (Bvg^ and Bvg ) as well as the bioluminescent strain (Lux 95) were 
able to invade or be taken up by sheep BMMC. Similar observations were detected
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with HeLa cells (Savelkoul et a l, 1993). Savelkoul and his group described that there 
was no difference in the invasiveness of B. bronchiseptica when the bacterium was 
not able to produce either FiraX or Fim2 fimbriae. The reason for this phenomenon 
was probably that B. bronchiseptica produces FHA which is the most important 
adhesin for B. pertussis (Saukkonen et a l, 1991). The present results showed that the 
bioluminescent strain of B. bronchisptica (Lux 95) was able to invade or be taken up 
by mast cells as well as the other two phases. Also, the results of the invasion assay 
had shown, for the first time, different phases of B. bronchiseptica within mast cells.
Pretreatment of sheep BMMC with either cytochalasin D (CD) or 
monodansylcadaverine (MDC) could help to understand whether the uptake of B. 
bronchiseptica by sheep BMMC occurred by microfilament-dependent phagocytosis 
rather than by invasion of B. bronchiseptica. (Forde et a l, 1998).
4.1.8 Interaction of B. bronchiseptica with different mammalian cells
These results of this study demonstrated that B. bronchiseptica is able to 
interact directly with sheep BMMC and other cell types (RBL-2H3, J774A. 1 cell 
lines) in a Bvg-dependent process.
B. bronchiseptica has been shown to exerted a strong cytotoxic effect on HeLa 
cells. When sulphate anions were added to the growth medium of B. bronchiseptica, 
this effect was not seen because sulphate anions inhibit the BvgAS response (van den 
Akker, 1997). In the present work, comparative analysis of the cytotoxicity of B. 
bronchiseptica (Bvg"'" phase) grown on BG agar and other media showed that 
cytoxticity and degranulation effects of B. bronchiseptica grown on BG agar were 
high compared with other media. In addition, activity of ACT from B. bronchiseptica 
grown on BG agar was high compared with CL broth or LB agar. These observations 
confirm the suggestion that growth medium is an important environmental factor in 
virulence modulation of B. bronchiseptica (Coote, 2001). In this regard, the BvgAS 
sensory transduction system activates the transcription of genes encoding all the 
known protein virulence factors expressed by Bordetella subspecies (Deora et a l, 
2001). Expression of different adhesins and toxins are presumably responsible for the 
cytotoxic effects of B. bronchiseptica (Bvg^ mode).
Cytotoxic factors of B. bronchiseptica were investigated by treating B. 
bronchiseptica (Bvg''') at different temperatures (Result, section 3.5). Survival of the
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different mammalian cell types was unaffected or less affected with B. bronchiseptica 
(Bvg''') treated to 56°C. These observations demonstrated that the cytotoxic factors of 
B. bronchiseptica (Bvg''') were heat labile and presumably protein in nature.
It was observed that B. bronchiseptica (Bvg"'' phase) has a degranulation effect 
toward sheep BMMC (and RBL-2H3 cells) causing the release of mast cell contents 
(e.g. p-hexosaminidase) into the surrounding medium.
4.1.8.1 Comparison of cytotoxicity of B. bronchiseptica with that of other 
Bordetella species
Many studies have evaluated virulence factor expression of B. bronchiseptica, 
and it was found to be similar to that of B. pertussis except for pertussis toxin (PT) 
which is specific to B. pertussis (Arico et a l, 1987; Martinez de Tejada et a l, 1996; 
Parkhill et a l, 2003). In the present study, different strains of 5. pertussis were used; 
wild-type {B. pertussis 338), avirulent strain (Bvg" phase) (B. pertussis 347), PT- 
deficient strain {B. pertussis 357) and ACT-deficient strain (B. pertussis 348). These 
strains were incubated with RBL-2H3 cells for 3 h. It was observed that none of the B. 
pertussis strains showed a reduction in the viability of RBL-2H3 cells or even a 
release of p-hexosaminidase. It was hoped that the wild type strain (338) would show 
cytotoxicity toward RBL-2H3 cells like B. bronchiseptica (Bvg''’) but, surprisingly, 
this was not observed. The transposon mutant strains (347, 357 and 348) could then 
have been used to identify whether certain virulence factors were responsible but 
again, no cytotoxic or degranulation effects were observed. These observations 
suggest that B. pertussis hss low cytotoxicity compared with that of B. bronchiseptica 
toward RBL-2H3 cells. More cytotoxic effect could perhaps have been observed with 
a higher infection ratio (more than 1:500) or longer incubation (> 3 h).
Cytotoxicity and the degranulation effects of different Bordetella species 
toward different cell types (RBL-2H3 and J774A.1 cells) were compared with B. 
bronchiseptica (Bvg^) and its mutants (Bvg" and Lux 95). As before, B. 
bronchiseptica (Bvg''') showed a more significant cytotoxic effect toward J774A.1 
cells than towards RBL-2H3 cells. Survival of both mammalian cell types was high (> 
70%) after incubation with different Bordetella species compared with B. 
bronchiseptica (Bvg'^) (Fig. 3.3.8). These species of Bordetella have not yet been well 
characterized (except B. pertussis), and it is not clear which virulence factors they
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possess. A recent paper has shown that B. hinzii produces ACT (Donato et a l, 2005). 
In contrast to B. pertussis ACT, however, ACT from B. hinzii is less extractable from 
whole bacteria, non-haemolytic, has a 50-fold reduction in adenylate cyclase enzymic 
activity, and is unable to elevate cyclic AMP levels in host macrophages. 
Furthermore, in the present work, B. trematum and B. hinzii showed a significant P- 
hexosaminidase release from RBL-2H3 cells similar to the effect of B. bronchiseptica 
(Bvg''') and greater than that of the other Bordetella species. Such observations have 
not been reported previously. These results suggest that it will be important to 
investigate whether these species produce TTSS and corresponding effector proteins 
like B. bronchiseptica (Bvg'''). Also, it would be useful to further investigate the 
different factors of B. trematum and B. hinzii that initiate p-hexosaminidase release. 
For this purpose, TTSS mutant strains should be generated, and secretion profiles be 
compared with that of the wild-type strain. For example, BopH, BopD, Bsp22 and 
BopB have been identified as type III secreted proteins in Bordetella. Severe 
cytotoxicity such as necrosis was induced in L2 cells by infection with the wild-type 
B. bronchiseptica. In contrast, this effect was not observed by the BopB mutant 
infection. These results demonstrate that Bordetella secretes BopB via a type III 
secretion system during infection. BopB may play a role in the formation of pores in 
the host plasma membrane which serve as a conduit for the translocation of effector 
proteins into host cells (Kuwae et a l, 2003).
4.1.8.2 Comparison of the cytotoxicity of B. bronchiseptica with that of 
unrelated bacteria
The cytotoxic and degranulation effects of B. bronchiseptica (Bvg )^ for 
different mammalian cell types were compared with the cytotoxic and degranulation 
effects of different unrelated bacteria, widely used in our laboratory to determine 
whether these effects were species specific. These bacteria included a virulent phase 
S. pneumoniae and a pneumolysin-deficient derivative. The virulent phase S. 
pneumoniae is a well-known pathogen for a number of diseases including pneumonia, 
otitis media, and meningitis in humans of all ages (Andersson et a i, 1981). 
Pneumolysin toxin has a range of biological activities such as lysis of mammalian 
cells in vitro (Ho 11 mann et a l,  2004). Other bacteria included P. multocida serotype 
B:2 which causes haemorrhagic septicemia (HS), a commonly fatal systemic disease
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of cattle and buffaloes in countries of South and Southeast Asia, and the wild-type 
strain 85020 compared with a derivative containing a deletion in the aroA gene (strain 
JRMT12) (Tabatabaei et a l, 2002).
It has been reported that significant differences were detected in survival time,
core body temperature, lung-associated and systemic bacterial loads, mast cell
numbers, magnitude and location of cytokine production, lung disruption, and ability
of isolated lung cells to release the cytokine tumor necrosis factor (TIF) alpha in
vitro following infection of (CBA/Ca) and resistant (BALB/c) inbred mouse strains
with S. pneumoniae (Kerr et a l, 2002). It was suggested that infection with S.
pneumoniae may be a factor in their elevated susceptibility to pneumococcal
pneumonia which reduced expression of TIF in lung airways during early infection.
This leads to reduced neutrophil influx, permitting pneumococcal numbers to increase
within the lung tissue, and to the initiation of systemic disease. In the present study,
there was a statistically significant differences in survival of sheep BMMC, RBL-2H3
cells and J774A.1 cells after incubation with wild-type and the pneumolysin deficient
strain of S. pneumoniae. The pneumolysin deficient strain caused little cytotoxicity
compared with both virulent strains of S. pneumoniae and B. bronchiseptica (Bvg''').
p-hexosaminidase release was also measured after exposure to both strains of S.
.pneumoniae. However, the P-hexosaminidase gene has been reported in the genome 
of S. pneumoniae (www.tigr.org) and p-hexosaminidase was detected in the culture 
supernatants of both strains of S. pneumoniae (data not shown). Thus, p- 
hexosaminidase is not a suitable marker for studying the effect of S. pneumoniae on 
degranulation of mast cells, and other degranulation markers such as histamine or 
mast cell proteases would be more appropriate.
Both strains of P. multocida showed little effect on survival of sheep BMMC, 
RBL-2H3 cells and J774A.1 cells compared with the cytotoxicity of B. bronchiseptica 
(Evg"*) (Figure 3.3.11b). In addition, both strains showed little effect on P-
hexosaminidase release from sheep BMMC and RBL-2H3 cells compared with the
,potent degranulation effect of B. bronchiseptica (Bvg ) on these cell types. These 
results suggest that wild-type of S. pneumoniae and P. multocida have different 
virulence factors and showed different cytotoxic effect toward sheep BMMC and 
other cell types. In these regards, it would be useful to study further the secretion
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systems in unrelated bacteria, for example in Gram-positive bacteria, and compare 
them with the TTSS system in B. bronchiseptica (Bvg''') (Mattoo et a l, 2004).
4.1.9 Interaction of different mammalian cells with purified factors of
Bordetella species
Adenylate cyclase toxin (or CyaA) of Bordetella species possesses both 
enzymatic activity and pore-forming activity. It can invade mammalian cells and 
catalyzes the unregulated production of cyclic adenosine 3',5'- monophosphate 
(cAMP) which disrupts the physiological functions of the cells and may cause cell 
death. The cytotoxic ability of ACT was investigated by using purified recombinant 
ACT produced in E. coli. This was achieved by comparing a rACT which was 
enzymatically active and invasive with different mutant forms of ACT.
Two different assays were used to assess cytotoxicity, the ATP 
bioluminescence assay which uses luciferase to measure ATP presence in cell and the 
MTT assay which relies on intact mitochondrial function to convert tétrazolium dye. 
In both the MTT and ATP assay, the wild-type rACT (44/54) was shown to be more 
cytotoxic than the rACT (44-188/54) which is enzymatically inactive (Table 4.1). This 
suggests that it is the adenylate cyclase conversion of ATP to cAMP that is 
responsible for cytotoxicity. However, rACT (44-188/54), it was still able to induce 
cell death in J774A.1 cells (50% survival by ATP assay and 85% survival by MTT 
assay), albeit at high concentration (0.625 pg/ml). These results suggest that the 
invasive, pore-forming activity of rACT (44-188/54) may be responsible for such 
deplation in the ATP contents of J774A. 1 cells. Such effects were not observed with 
other cell types (sheep BMMC or RBL-2H3 cells). When the results of both assays 
were compared, it appeard that rACT (44/54) affected the ATP content of the 
different mammalian cells more than the dehydrogenase enzymes measured in the 
ATP assay. Recombinant ACT (44/54) showed a high level of cytotoxic effect toward 
J774A. 1 cells compared with sheep BMMC and RBL-2H3 cells. These data suggest 
that sheep BMMC proliferated in vitro could express fewer CD 1 lb/CD 18 receptors 
on their surface compared with J774A. 1 cells which showed a high interaction with 
rACT (44/54).
The primary biological function of ACT is presumably to deliver its enzymatic 
activity into mammalian cells, ultimately resulting in their intoxication by the
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depletion of ATP rather than the formation of membrane channels. In addition, results 
of these studies suggested that the cytotoxic effect of rACT (44/54) on the viability of 
sheep BMMC and other cell types may depend either on the number or availability of 
cell receptors (C D lib). It has been reported that CyaA uses the 82 integrin Mac-1 
(CDl lb/CD 18, CR3) as a cell receptor in that binding of CyaA to various murine cell 
lines and human neutrophils was specifically blocked by anti-CD 1 lb monoclonal 
antibodies. The increase of intracellular cAMP level and cell death triggered by CyaA 
intoxication was also specifically blocked by anti-CD 1 lb monoclonal antibodies. 
(Guermonprez ei a l, 2001). The Mac-1 is present on neutrophils, monocytes, JK 
cells, eosinophils, and basophils. It has also been shown to be weakly expressed on a 
human leukemic MC line HMC-1 (Weber et a l, 1997), and in a small fraction (<5%) 
of in vitro-derived human MCs (Torn et a l, 1997), although Mac-1 has not been 
detected in mature MCs isolated from various human tissues (Valent, 1994). This 
could be determined by labelling the different cells with specific fluorescent 
monoclonal antibodies to the receptor (CDl lb/CD 18) and using FACS.
It has been shown previously that cell death in macrophage caused by ACT is 
due to the induction of apoptosis (Khelef et a l, 1993). It is possible that the AC 
activity may be responsible as the generation of high levels of cAMP can lead to 
alterations in protein phosphorylation and a reduction in ATP contents may deregulate 
protein kinase cascades and result in apoptosis (Duprez et a l, 1993). The results of 
these studies showed that the haemolytic property of ACT may be not mainly 
responsible for apoptosis, but it may cause a little apoptosis effect as pore formation 
results in changes in intracellular calcium level which can activate cell death 
(McConkey et a l, 1993). The results of these studies show that rACT (44/54), which 
is a cAMP elevating agent, induced a rapid increase in caspase 3/7 activity in RBL- 
2H3 cells which depends on the enzymic activity. rACT (44/54) showed only a low 
activity of caspase 3/7 in sheep BMMC similar to the effect of rACT (44-188/54) 
which suggested that these cells may not produce caspase 3/7 activity and may 
undergo apoptosis by a different mechanism. Further investigation of these 
mechanisms would be of interest. Also, this result suggests that RBL-2H3 cells appear 
useful for future studies of cAMP-dependent protein kinase involvement in biological 
processes. The results of these studies have shown three different types of activation 
of caspase 3/7 (apoptosis) on three cell types. The extent of DJA degradation in 
nuclei was investigated in three different cell types. Using the DNA fragmentation
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assay, rACT (44/54) was shown to induce cell death in RBL-2H3 cells via apoptosis 
and the enzymatic activity of ACT was important to induce such effects. In contrast, 
the rACT (44-188/54) with only pore forming activity did not show either caspase 3/7 
activity or DKA fragmentation in RBL-2H3 cells. There was a small effect on DKA 
fragmentation of sheep BMMC only at low doe of rACT (44/54) as determined after 
incubation for 6 h. In contrast, J774A. 1 cells cultured in IMDM medium containing 
both low (0.07 p,g/ml) and high (0.3 ftg/ml) concentrations of rACT failed to show 
DKA fragmentation. This is probably because all J774A. 1 cells die quickly within 6 h 
of incubation with low and high concentrations of rACT by necrosis rather apoptosis.
The result of these studies showed for the first time that the spontaneous 
release of ^-hexosaminidase was inhibited due to rACT (44/54). RBL-2H3 cells are 
well known as a tumour analogues of mucosal mast cells, therefore, the inhibitory 
mechanisms of ACT in RBL-2H3 cells may be similar to those mast cells because it 
had been reported that the increase in cAMP levels in mast cells lead to inhibition of 
release (see introduction) and such an effect is different from that in other mammalian 
cells. The effects of enzymatically-active and invasive rACT (44/54) on sheep 
BMMC and other cell types are summarized in Table 4.1. Some discrepancies were 
noted between the different effects. For example, there was evidence of DKA 
fragmentation at low concentration of rACT (44/54) in sheep BMMC but no caspase 
3/7 activity at either concentration. Also, with J774A. 1 cells, there was high induction 
of caspase 3/7 activity with the low concentration of rACT but no DKA fragmentation 
was seen at this dose.
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4.1.9.1 Interaction of PT, FHA or PRN with RBL-2H3 cells and J774A.1 cells
PT is an ADP-ribosylating toxin synthesized and secreted exclusively by B. 
pertussis and extensively studied for its effect on signalling mechanisms on 
mammalian cells in vitro (Smith et a l, 2001). PT binds to cell surface receptors and 
undergoes endocytosis via a cytochalasin Ddndependent pathway. The SI subunit 
(see introduction) in its reduced form has been shown to catalyze the transfer of ADP- 
ribose from MAD to the subunit of guanine nucleotide-binding proteins (G proteins) 
in eukaryotic cells (Bokoch and Gilman, 1984). The results of the present studies 
showed that with J774A. 1 cells, a significant reduction in ATP content was caused by 
incubation with 0.1 p,g/ml compared with 0.01 jttg/ml of PT. In addition, no significant 
cytotoxic effect was determined by the MTT assay. In contrast, no significant 
cytotoxic effect on RBL-2H3 cells, either by ATP or MTT assays, was determined at 
the end of incubation for 3 h and 6 h. But, there was an increase in caspase 3/7 
activity in RBL-2H3 cells and DMA fragmentation was determined at the end of 
incubation for 6 h. These results suggest that PT caused a depletion in ATP content of 
J774A.1 cells which may have a cytotoxic effect. In contrast, PT activates 
programmed cell death in RBL-2H3 cells. Also, PT caused an inhibitory effect on 
spontaneous |3-hexosaminidase release from RBL-2H3 cells. The last results suggest 
that further work should be done to determine the inhibitory mechanisms of PT in 
RBL-2H3 cells and whether an increase in cAMP content or to other factors.
The cytotoxic effect of PRM towards macrophage cells has been reported. A 
PRM mutant strain of B. bronchiseptica was less cytotoxic towards murine 
macrophage-like cells and on primary porcine alveolar macrophages compared with a 
significant cytotoxic effect of the wild type (Forde et a l, 1999) particularly where 
tight cell-to-cell contacts were established. The mechanism of eukaryotic cell death 
was examined, and cell death was found to occur primarily through a necrotic 
pathway, although a small proportion of the population underwent apoptosis. In 
another study, infection of monocyte-derived macrophages (MDM) with wild-type B. 
pertussis resulted in apoptosis within 6 h, while infection with an FHA-deficient 
derivative strain was only 50% as effective (Abramson et a i, 2001). The results of the 
present studies showed that 0.1 p.g/ml PRM had an effect on survival of J774A. 1 cells 
as determined by the ATP assay after incubation for 3 h and 6 h. Such effects of PRM 
have not been reported previously and deserve further investigation particularly as
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pertactin is a major component of some acellular pertussis vaccines. On the other 
hand, there was no significant cytotoxic effect on RBL-2H3 cells due to incubation 
with PRN. But, and for the first time, (3-hexosminidase release was determined in 
J774A. I cells due to treatment with PRN. Again, this effect deserve further study.
No significant cytotoxic effect of FHA toward RBL-2H3 and J774A. 1 cells 
was determined either by ATP or MTT assay. The effect of different concentrations of 
FHA on spontaneous p-hexosaminidase release from RBL-2H3 cells and J774A. 1 
cells was compared with the effect of PT and calcium ionophore.
4.1.9.2 Modulation of phagocytic function of J774A.1 cells treated with PT or 
ACT
It has been reported that B. bronchiseptica and certain other Bordetella species 
produce ACT. Also, it well known that ACT enters target cells to catalyze the 
production of supraphysiological levels of intracellular cAMP. The increase in 
intracellular cAMP levels in mammalian cells lead to disturbance of many biological 
functions. For example, early studies showed that partially purified ACT inhibited 
phagocytic functions by impairing chemotaxis, oxidative response, phagocytosis and 
superoxide generation (Confer and Eaton, 1982). In addition, it is known that B. 
pertussis mutants deficient in the expression of CyaA are impaired in their ability to 
cause a lethal infection in mice (Weiss and Goodwin, 1989).
To confirm the role of ACT in blocking phagocytosis, a GFP-labelled ACT 
mutant B. pertussis was added directly to neutrophils or mixed with an equal number 
of un labeled wild-type bacteria. In the absence of opsonization, neither the GFP- 
labelled wild-type strain, the GFP-labelled ACT mutant, nor the GFP-labelled ACT 
mutant mixed with the unlabeled wild-type strain was efficiently phagocytosed. 
Opsonization significantly increased the phagocytosis of the labelled ACT mutant but 
reduced phagocytosis of the wild-type strain as well as of the labelled ACT mutant 
mixed with the unlabeled wild-type strain. These results suggested that the presence 
of ACT blocks phagocytosis, even when bacteria are not expressing the toxin 
(Weingart et a l, 2000).
It also been reported that B. pertussis adenylate cyclase toxin can increase 
cAMP levels in monocytes without compromising target cell viability or impairing 
ingestion of particles and that the resultant accumulated cAMP is responsible for the
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inhibition of oxidative responses to a variety of stimuli (Pearson et a l, 1987). Other 
evidence for blocking of phagocytosis due to increase in cAMP has been obtained by 
using alveolar macrophages (AMs), which are critical participants in innate lung 
immunity, and their uptake of Klebsiella pneumoniae and E. coli. Prostaglandin E2 
(PGE2) suppression of phagocytosis was associated with enhanced intracellular 
cAMP production (Aronoff et a l, 2004).
On the other hand, PT pretreatment had no effect on the adherence of wild- 
type B. pertussis, BP338, to human monocytes, but incubation with PT at 1.0 ng/ml or 
greater caused a decrease in the phagocytic abilities. In these studies, B. pertussis 
were added at an MOI of 20. Oo differences in adherence or uptake following 
pretreatment of monocytes with PT occurred when experiments were conducted at an 
MOI of 5 (Schaeffer and Weiss, 2001).
In the present study, ACT was purified from a recombinant E. coli strain and 
not from B. bronchiseptica, although it is considered unlikely that this would affect its 
mode of action. Oative PT at a low dose was used in this in vitro study to compare 
with rACT at low dose. It was observed that a significant reduction in viability of 
J774A.1 cells after incubation with B. bronchiseptica alone but, at cause of pre­
treatment of J774A. 1 cells with 0.1 |ig/ml PT and mixed with B. bronchiseptica, there 
was a significant increase in survival of pretreated J774A.1 cells and infected with B. 
bronchiseptica (Bvg^) compared with non-pretreated J774A.1 cells (p-value < 0.05). 
In addition, there was a significant reduction in the number of intracellular B. 
bronchiseptica per viable J774A. 1 cells when pre-treated with 0.1 jttg/ml PT 
compared with the number in non-pretreated J774A.1 cells. Viability of pre-treated 
J774A. 1 with 0.1 dg/ml rACT for 1 h and infected with B. bronchiseptica (Bvg" )^ was 
significantly lower than viability of non-pretreated J774A.1 cells. In addition, there 
was no significant reduction in the number of intracellular B. bronchiseptica per 
viable J774A.1 cells when pre-treated with 0.1 qg/ml rACT compared with the 
number in pre-treated J774A. 1 cells with urea buffer diluent.
These observations suggest that rACT and PT work in different ways. PT 
appeared to protect J774A.1 cells from the killing effect of B. bronchiseptica (Bvg‘^ ) 
whereas rACT enhanced the killing effect of B. bronchiseptica. Also, 0.1 p.g/ml PT 
appeared to modulate phagocytic function of J774A.1 toward B. bronchiseptica.
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whereas rACT had no significant effect. Therefore, it was important to investigate the 
effect of lower doses of ACT in modulation of phagocytic function of J774A. 1 cells.
A significant reduction in viability of J774A. 1 cells was observed after 
incubation with B. bronchiseptica but, in the case of pre-treatment with 0.025 jttg/ml 
rACT, there was a non-significant increase in survival of J774A.1 cells treated with B. 
bronchiseptica (Bvg" )^ compared with non-pretreated J774A.1 cells. In addition, there 
was a little reduction in the number of intracellular B. bronchiseptica per viable 
J774A. 1 cells when pre-treated with 0.025 p,g/ml rACT compared with the number in 
non-pretreated J774A. 1 cells (Result, section 4.4.4).
These observations suggest that low concentrations of rACT (0.025 |ig/ml) 
could prevent cell death of J774A. 1 cells from the killing effect of B. bronchiseptica 
(Bvg" )^. In that case, ACT is well known in its ability to increase intracellular cAMP 
levels, and then lead to inhibition of several physiological functions in macrophage 
cells including superoxide production, chemotaxis and bacterial killing (Confer and 
Eaton, 1982). Therefore, increase in cAMP may cause impotence of phagocytic 
function in moue macrophage cell line J774A. 1. This may be how B, bronchiseptica 
overcomes natural defences and cause disease (i.e. colonization on surface of cilia of 
respiratory tract).
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4.2 Conclusions and future work
Certain microorganisms have been found to interact either directly or indirectly 
with mast cells. This interaction results in mast cell activation and mediator release 
which elicits an inflammatory response or direct killing leading to bacterial clearance. 
Recent studies, however, have shown that mast cells have the capacity to modulate the 
host's innate immune response to bacteria by their ability to phagocytose bacteria. 
These studies with bioluminescent B. bronchiseptica (Lux 95) demonstrated that 
sheep BMMC are able to take-up bacteria. Furthermore, bioluminescence signals are 
indications of metabolic activity, and these studies demonstrated that both viable 
sheep BMMC and the contents of lysed sheep BMMC are able to reduce the 
metabolic activity of B. bronchiseptica (Lux 95). However, production of 
antimicrobial agents and interaction of bone marrow derived mast cell with bacteria 
needs further investigations.
These results demonstrated that B. bronchiseptica is able to interact directly 
with sheep BMMC and other cell types (RBL-2H3, J774A.1 cell lines) in a Bvg- 
dependent process. The modulated Bvg“ phenotype of B. bronchiseptica, unable to 
express Bvg-activated gene products such as ACT, FHA and PRP, was clearly 
impaired in its ability to interact with sheep BMMC and other cell types. Since 
different virulence factors of B. bronchiseptica are controlled by BvgAS system, 
interactions of different purified factors of Bordetella with different cell types were 
examined. Recent advances have shown that some Gram-negative bacteria depend on 
type III secretion for delivering toxic proteins into the cytoplasm of host cells. 
Furthermore, as it has been shown that the Bvg virulence control system regulates 
type III secretion in B. bronchiseptica (Yuk et a l, 1998), it would be important to do 
a further study dealing with the importance of the type III secretion system on the 
interaction of B. bronchiseptica with sheep BMMC.
The cytotoxicity of recombinant ACT was investigated in the present work to 
show that the enzymic activity of rACT is important for cytotoxicity of rACT towards 
sheep BMMC, RBL-2H3 cells (mucosal mast model) as well as J774A. 1 macrophage­
like cells. Evidence for cytotoxicity of rACT was shown due to depletion of the ATP 
content of different mammalian cells. By this criterion, the killing effect of rACT 
towards J774A.1 cells was higher than for sheep BMMC or RBL-2H3 cells which 
could suggest that the availability of cell receptors (C D llb) on J774A.1 cells is
278
greater than on sheep BMMC or RBL-2H3 cells. In addition, it could be concluded 
that programmed host cell death (apoptosis of these cells) depends on the enzymatic 
activity of rACT rather than just the pore-forming activity. But, it could be assumed 
that ACT needs its pore-forming activity to get the enzymatic moiety into the 
mammalian cells.
It is well known that increases in intracellular cAMP would cripple many 
biological functions of mammalian cells. Spontaneous p-hexosaminidase release was 
inhibited in RBL-2H3 cells after incubation with enzymatically-active and invasive 
rACT. RBL-2H3 cells are well known as a tumour analogue of mucosal mast cells. 
The inhibitory mechanisms of rACT in RBL-2H3 cells may be therefore similar to 
that mast cells because it had been reported that an increase in cAMP levels in mast 
cells leads to inhibition of degranulation. For the first time, P-hexosaminidase release 
was determined in J774A. 1 macrophage cells after incubation with FHA and PRQ. 
Moreover, PRQ caused a depletion in the ATP content of J774A. 1 cells, and such 
observations require further investigations to determine their mechanisms.
The effect of RBL-2H3 cells pre-treated with either rACT or PT on p- 
hexosaminidase release induced by stimulation with B. bronchiseptica (Bvg'*') showed 
that these factors work in different ways. rACT was able to inhibit p-hexosaminidase 
release from RBL-2H3 cells exposed to B. bronchiseptica (Bvg'*'), but this effect was 
temporary (i.e. it decreased with increasing time of incubation). In contrast, the effect 
of PT on p-hexosaminidsae release from RBL-2H3 cells exposed to B. bronchiseptica 
(Bvg'*') appeared to be time-dependent. With increased time of pre-treatment, a greater 
inhibitory effect was observed.
Other evidence also suggested that rACT and PT work in different ways. PT 
appeared to protect J774A. 1 cells from the killing effect of B. bronchiseptica (Bvg'*') 
whereas rACT enhanced the killing effect of B. bronchiseptica. An increase in 
intracellular cAMP due to low doses of ACT may cause impotence of phagocytic 
function in J774A.1 cells and then their ability to take up B. bronchiseptica (Bvg^) 
would be crippled, as observed. This phenomenon suggests how B. bronchiseptica 
may overcome natural defences and cause disease or secondary bacterial infections.
These studies have shown the interaction of B. bronchiseptica and different 
factors (adhesins and toxins) with sheep BMMC and other cell types. Traditional 
methods, as used in this study, depend on studying the effect of one protein produced
279
by one gene in one experiment, for example, on the viability or degranulation of sheep 
BMMC or other cell types. Thus, the throughput is very limited and the whole picture 
of gene function in sheep BMMC and other cell types is hard to obtain. The effect of 
B. bronchiseptica on sheep BMMC depends on the expression and properties of a 
large number of proteins. Furthermore, the production and expression of most B. 
bronchiseptica virulence factors is under the control of a central two-component 
regulatory system (BvgAS), which is co-regulated with other gene sets (i.e. vag genes 
and vrg genes). The BvgS (sensor) protein and BvgA (activator) protein are able to 
induce the expression of the virulence genes {vag genes) which then lead to the 
repression of another set of genes, known as vrg genes (Coote, 2001). Thus, 
monitoring the cascade of reactions and co-regulations that occur between different 
genes of B. bronchiseptica under different environmental conditions (or when 
interacting with different cell types) could be difficult by traditional methods. Thus, it 
would be useful to use a method which could monitor different gene sets at the same 
time (i.e. which could provide information about what genes are OR (up-regulated) 
and OFF (down-regulated) under different environmental conditions) either in vitro or 
in vivo. In this regards, the DRA microarray technique would be useful because it 
could help to follow many different gene functions in one experiment (Schoolnik, 
2002; Call, 2005). For example, it could be used to monitor the activation (or 
inactivation) of vags and vrgs by BvgAS of B. bronchiseptica in the presence or 
absence of sheep BMMC or mouse macrophage cells (J774A. 1).
DRA microarrays exploit primary sequence data to measure transcript levels 
simultaneously for every gene which may play a role in the host-microbe interaction 
(Eskra et a l, 2003). This technology also offers the opportunity to examine the 
changes in gene expression in relation to specific stimuli (Boshoff et a l, 2004). DRA 
microarrays are composed of immobilized DRA probes that are complementary to the 
gene targets of interest, thus is important that gene sequences have been determined 
(Call, 2005). Row, that the whole genome sequences of B. pertussis, B. parapertussis 
and B. bronchiseptica have been completed (Parkhill et al., 2003), DRA microarrays 
could be applied to study the pathogenicity of B. pertussis and related specie such as
B. bronchiseptica (which has more than 95% homology to B. pertussis) toward mast 
cells (or any other mammalian cells) and their virulence mechanisms used to establish 
infection and cause disease.
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DSA microarrays have already led to the discovery of several new vags and 
vrgs (Hot et al., 2003). Two hundred selected B. pertussis genes have been analysed 
by using DSA microarray. These different genes were chosen for their potential 
involvement in virulence as possible members of the Bvg regulon. Also, it was found 
that some Bvg-regulated genes were modulated differentially by MgS0 4  and nieotinic 
acid, suggesting that the signal transduction triggered by these two modulators 
operates through two different initial molecular steps. In a similar way, DSA 
microarrays could be used to study the interaction between B. bronchiseptica and 
sheep BMMC or other cell types and precisely monitor the coregulation of different 
genes under different conditions of infection with these mammalian cells.
Therefore, it could suggest as a future work that DSA microarray could help to 
qualify bacterial killing as no attempt was made (in this project) to quantify total 
uptake of bacteria by sheep BMMC or J774A. 1 cells.
The use of DSA microarrays has uncovered two strongly Bvg A/S-activated 
gene in B pertussis, named hotA and hotB (for ‘homolog of toxin'), the products of 
which showed high sequence similarities to pertussis toxin subunits (Locht et a l, 
2004). It was suggested that such studies will help to identify the full array of 
virulence factors, as well as provide an integrated understanding of bacterial 
physiology, and to allow the design of attenuated B. pertussis strains useful for 
intranasal vaccination.
DSA microarrays might also be used to monitor modulation of expression of 
host cell genes stimulated by interaction with Bordetella (e.g. in human mast cells or 
mouse mast cells). For example, when human peripheral blood mononuelear cells 
(PBMCs) were exposed to live and heat-killed B. pertussis (Boldrick et a l, 2002), 
microarray analysis showed that there were distinct differences between PBMC 
responses to live and killed B. pertussis. For example, the genes encoding tumor 
necrosis factor (TSFa), macrophage inflammatory protein (MIPlp), interleukin-1 
(IL -la) and IL-lp were induced after exposure to either live or killed bacteria.
However, while the induction of these genes was sustained in PBMCs treated with 
killed bacteria, their transcripts rapidly diminished in the cells exposed to live B. 
pertussis. The ability of live B. pertussis to suppress expression of these important 
antimicrobial genes suggests active mechanisms used by the bacteria to influence the 
host response.
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Mast cells are responsible for immediate hypersensitivity responses. Their 
widespread distribution in the skin and respiratory tract suggests a role as for these 
cells as a first-line defence against invading pathogens. However, unregulated 
activation can result in deleterious effects. As such, understanding control of mast cell 
inflammatory activities is an area of increasing importance. Influences of B. pertussis 
or different purified factors (adhesins or toxins) on viability or degranulation of 
human mast cells could be investigated by using DTA micro arrays. For example, the 
DTA sequences of different cytokines secreted by mast cells and which influence 
recruitment of other cells of immune system could be investigated when under the 
influence of B. pertussis or other Bordetella factors.
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A) Media
A-1) Luria-Bertani 
A-1-1) LB (broth)
Tryptone 10 g
Yeast extract 5 g
Sodium chloride 5 g
Made up to 1 litre in distilled water 
Dissolved and autoclaved at 12UC for 15 min
A-1-2) LB (agar)
For previous, add 1.2% agar
Dissolved and autoclaved at 12UC for 15 min
A-2) Bordet-Gengou Agar (BG) (pH 7.4)
BG-Agar base (Gibco-BRL) 7.2 g
Glycerol 1% (v/v)
Distilled Water 160 ml
Dissolved and autoclaved at 12RC for 15 min. 15% (v/v) sterile defibrinated horse blood 
was added to the autoclaved BG agar cooled previously to 45°C.
A-3) Stainer Scholte (SS) liquid medium (pH 7.6)
L-glutamate 10.7 g
L-proline 0.24 g
Sodium chloride 2.5 g
Potassium di-hydrogen orthophosphate 0.5 g
Potassium chloride 0.2 g
Magnesium chloride (6H2O) 0.1 g
Calcium chloride 0.02 g
Tris 6.1 g
Made up to 1 litre in distilled water
A-3-1) Vitamin soIution/SS-supplements
L-cysteine 0.04 g
Iron sulphate (7H2O) 0.01 g
Nicotinic acid 0.004 g
Glutathione 0.15 g
Ascorbic acid 0.4 g
Dissolve in 10ml distilled water, sterile-filtered then added to 1 1 of CL medium.
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A-4) Cvdodextrin iquid (CL) medium
For CL medium, prepared solution as described above and supplemented with cas amino 
acids (10 g) (Difco) and methyle-|3-cyclodextrin 0.25 g.
Made up to 1 litre in distilled water. Solution is prepared to pH 7.6 then autoclaved.
B) DNA Solution 
B-1) Stop solution
Sodium dodecyl sulphate (SDS)
Tris
EDTA
0.5 % (w/v) 
50 mM 
0.4 M
B-2) Tris-Borate-EDTA (TBE) buffer (5X I D
Tris
Boric acid 
EDTA (0.5M)
54 g 
27.5 g 
20 ml
B-3) 6X DNA loading buffer
Tris
EDTA
Sucrose
Bromophenol blue
60 mM 
6 mM 
40 % (w/v) 
0.25%(w/v)
C) ACT enzymic assays 
C-1) Bicine buffer (pH to 8.0)
100 mM Bicine (pH 8)
100 mM Magnesium acetate 
100 mM ATP 
Made to 250 ml in deionised distilled water
25ml 
3.75 ml
(pH 71.25 ml (0.5 mM)/2.5 ml (ImM)
D) B-bexosaminidase assay buffers 
D-1) Citrate buffer for substrate (pH 4.5)
Solution A 
Citric acid
Sodium hydroxide (300ml)
Distilled water
3 L5 g
IM
700ml
317
Solution B
HCl O.IM
For use add together 67.8ml Solution A to 32.2ml Solution B.
P-2) 0.2M Glycine NaOH (pH 10.7)
Solution A
Glycine 7.5 g
Sodium Cholride 5.8 g
Distilled water 1000 ml
Solution B
Sodium hydroxide 0.2M
For use add together 52.8ml Solution A to 47.2 ml Solution B.
D“3) Substrate buffer
5mM p~nitrophenol-i-acetyl-(3-D-glucosamide in citrate buffer (pH 4.5)
Add 1.7mg of p-nitrophenol-i-acetyl-P-D-glucosamide (Sigma) to 1ml of citrate buffer 
(pH4.5).
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